High-resolution screening of metabolite-like lead libraries by Falck, D.
VRIJE UNIVERSITEIT
High-resolution screening 
of metabolite-like lead libraries
ACADEMISCH PROEFSCHRIFT
ter verkrijging van de graad Doctor aan
de Vrije Universiteit Amsterdam,
op gezag van de rector magnificus
prof.dr. F.A. van der Duyn Schouten,
in het openbaar te verdedigen
ten overstaan van de promotiecommissie
van de Faculteit der Exacte Wetenschappen
op donderdag 14 november 2013 om 13.45 uur
in de aula van de universiteit,
De Boelelaan 1105
door
David Falck
geboren te Haldensleben, Duitsland
promotoren: prof.dr. H. Irth
  prof.dr. W.M.A. Niessen
  prof.dr. M. Honing
copromotor: dr. J. Kool
Reading comittee: dr. F. Cuyckens
   prof.dr. U. Karst
   prof. dr. R. Leurs
   prof.dr. N. M. M. Nibbering
   dr. J. Wieling
   prof. dr. S. S. Wijmenga
The research described in this thesis was performed (partly) within the framework of the 
project D2-102 ‘Metabolic stability assessment as new tool in the Hit-to-Lead selection pro-
cess and the generation of new lead compound libraries’ of the Dutch Top Institute Pharma.
Shimadzu Benelux B.V. (’s-Hertogenbosch) and Antec (Zoeterwoude) are thanked for fi-
nancial support for the printing of this thesis. Printing was excecuted by Wöhrmann Print 
Services (Zutphen).
Copyright © 2013 David Falck, Amsterdam. All rights reserved. No part of this thesis may 
be reproduced in any form or by any means without permission from the author.
Table of Contents
1. Introduction       8
1.1 General Introduction     9
1.1.1 Discovery of new active pharmaceutical ingredients 10
a) Screening      10
b) Metabolite-like lead libraries    10
1.1.2 High-resolution screening    11
1.1.3 Modification methods in metabolism studies  15
a) Chemical oxidation     16
b) Electrochemistry     17
c) Biocatalytic approaches   17
d) Photochemistry     18
1.1.4 Structure elucidation in mixtures using mass spectrometry  
and nuclear magnetic resonance spectroscopy 18
a) Mass spectrometry    18
b) Nuclear Magnetic resonance spectroscopy 20
1.2 Scope       29
2. High-resolution screening platforms   34
2.1 A practical guide to high-resolution screening 35
2.1.1 The high-resolution screening platform   36
a) Separation      36
b) Flow splitting     39
c) Bioassay      39
d) MS detection     42
2.1.2 Data analysis      43
a) Differences between HTS and HRS   43
b) Validation      46
2.1.3 Conclusions      48
2.2	 Development	of	an	on-line	p38α	mitogen-activated	protein	
kinase binding assay and integration of LC–HR-MS 51
Introduction    52
Materials and Methods    53
Materials      53
Instrumentation     53
Plate Reader Assay     54
On-line Assay      54
Results and Discussion    56
Assay conditions optimization    56
Validation of the p38α binding assay   57
High resolution screening of mixtures  61
Semi-Quantitative affinity measurements  61
Applicability and binding modes  62
Conclusion    63
Supplementary Material   65
2.3 Development of on-line liquid chromatography– 
biochemical detection for soluble epoxide hydrolase  
inhibitors in mixtures    67
Introduction    68
Materials and Methods    69
Materials      69
Liquid chromatography – biochemical detection (LC–BCD) system     69
Determination of inhibitor potency   71
Metabolite identification using mass spectrometry  71
Buffer and compound solutions    71
Plate reader measurements    71
Microsomal incubations    72
Results and Discussion    72
Development of an LC–BCD system for the detection   
of sEH inhibitors    72
Characterization of the LC–BCD system   73
Application of LC-BCD on the analysis of metabolic mixtures   
of sEHis  75
Conclusion    77
Supplementary Material   79
3.	 Integration	of	modification	methods	and	HRS	work-flows		
for the study of metabolite-like lead libraries  80
3.1	 On-line	electrochemistry–bioaffinity	screening	with	parallel		
HR-LC–MS for the generation and characterization of  
modified	p38α	kinase	inhibitors	 81
Introduction    82
Materials and Methods    83
Chemicals      83
Instrumentation    83
Optimization of electrochemical conversion   85
Results and Discussion    85
Conclusion    91
Supplementary Material   93
3.2	 Combination	of	biotransformation	by	P450	BM3	mutants	with		
on-line	post-column	bioaffinity	and	mass	spectrometric		
profiling	as	a	novel	strategy	to	diversify	and	characterize		
p38α kinase inhibitors    97
Introduction    98
Materials and Methods    99
Chemicals      99
Expression and isolation of P450 BM3 mutants  99
Selection of the P450 BM3 mutant library   100
Biotransformation of TAK-715 by P450 BM3 mutants    
and human liver microsomes   100
HRS analysis of biotransformation products of TAK-715   
using the LC-p38α kinase affinity/MS platform  100
Large-scale production and isolation of biotransformation products  
by preparative HPLC     101
Results and Discussion    102
Biocatalysed synthesis of lead compounds from TAK-715   
by P450 BM3 mutants; comparison to human liver metabolism 102
Parallel on-line bioaffinity assay and mass spectrometry of   
TAK-715 biotransformation products produced    
by P450 BM3 M11 and HLM 103
Preparative scale biosynthesis of TAK-715    
biotransformation products    103
Structure elucidation of TAK-715 biotransformation products 105
Estimation of product affinity (IC50) 108
Conclusion    109
Supplementary Material   112
3.3 Comparison of (bio-)transformation methods for the generation  
of	metabolite-like	compound	libraries	of	p38α	MAP	kinase		
inhibitors using high-resolution screening   117
3.3.1. Introduction    118
3.3.2. Materials and Methods    119
1. Materials      119
2. Chemical oxidation     119
3. Photochemical modification    120
4. Microsomal incubations     120
5. HRS analysis      120
3.3.3 Results    121
1. Oxidation with hydrogen peroxide   123
2. Photochemical modification   126
3.3.4 Discussion    128
1. Comparison of compound modification methods  128
2. Conversion products as metabolite standards  130
3.3.5 Conclusion    131
Supplementary Material   135
4. Integrated structure elucidation approaches  
for high-resolution screening     144
4.1	 Tandem	mass	spectrometry	study	of	p38α	kinase	inhibitors		
and related substances     145
Introduction    146
Materials and Methods    147
Chemicals      147
Generation of related substances of p38α kinase inhibitors 147
HRS platform: LC with parallel bioaffinity screening and   
high-resolution MS     147
Results     149
Structure elucidation of DMPIP conversion products  150
Structure elucidation of SB203580 conversion products 153
Structure elucidation of BIRB796 conversion products 156
Structure elucidation of TAK-715 conversion products  158
Occurrence of homolytic cleavages  164
Conclusion    164
Supplementary Material   167
4.2 EC–SPE–stripline-NMR analysis of reactive products:  
A feasibility study  171
Introduction    172
Materials and Methods    174
Chemicals      174
Electrochemical conversion 174
On-line Solid Phase Extraction    174
Stripline chip, probe and microfluidics   174
Acquisition and processing    175
EC–SPE–stripline-NMR setup    176
Results and Discussion    176
Optimization of EC and SPE steps  176
SPE–stripline-NMR 177
EC–SPE–stripline-NMR 180
Conclusions and Perspectives    181
Supplementary Material   184
5.	 High	temperature	liquid	chromatography	hyphenated	with		
ESI–MS and ICP–MS detection for the structural  
characterization	and	quantification	of	halogen	containing	 	
drug metabolites      188
Introduction    190
Experimental    191
5.2.1 Materials      191
5.2.2 Methods  191
Results and Discussion    193
5.3.1 Solvent effect on electrospray ionization  193
5.3.2 Hyphenation of HTLC to ICP-MS  194
5.3.3 Profiling bromine containing MAPK inhibitor VIII products 195
5.3.4 Analysis of iodine containing SB-I and conversion products  
   195
5.3.5 Response comparison of ICP-MS and ESI-MS 199
Conclusion    201
Supplementary Material   202
6. Summary         204
6.1 Conclusions and Perspectives 205
6.2 Nederlandse Samenvatting 213
Appendix        218
I. List of Publications      219
II. Curriculum Vitae 221
III.	 Acknowledgements	 222
Chapter 1.1
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1.1.1	Discovery	of	new	active	pharmaceutical	ingredients
1.1.1.a) Screening
The vast majority of medicines work by modulating the activity of a target protein. Therefore, 
the discovery of an active pharmaceutical ingredient (API) involves finding molecules which 
interact with the chosen target protein. This process is called screening. Traditionally, this 
would be achieved by administering the molecules to diseased animals (animal models), 
a so-called phenotypic screening [1]. The high cost, limited throughput and increasing 
awareness of animal welfare, catalyzed by the emergence of biotechnology, have triggered 
the search for alternative in vitro methods [2]. In addition, it is easier to link an in vitro 
assay response to a molecular mechanism of action. In in vitro assays, the target protein 
is present either isolated or in individual living cells. The former is often the cheapest and 
simplest approach [3], which, in combination with the implementation of lab automation and 
robotics, has led to the emergence of high-throughput screening (HTS) [2]. Conceptually, 
HTS is based on the screening of large numbers, sometimes up to millions, of molecules 
(compound libraries) with the idea that APIs are discovered by pure chance [4]. However, 
even in HTS, there is a strong trend to reduce the chance element by designing focused 
compound libraries [5]. The technological platform consists of well plates, dispenser robots 
and specialized spectrophotometers, called plate readers [4]. With the extensive use of 
HTS within pharmaceutical companies, its limitations are becoming increasingly obvious 
[6]. A major issue is the quality of the hits (the compounds that show interaction with the 
target protein) [7]. The statistical approach used results in false positives which requires 
all hits to be re-screened for confirmation [6]. While HTS is unmatched for large libraries of 
compounds, it is not as useful for efficiently screening small numbers of compounds in the 
confirmation screening or at later stages like in lead optimization. Additionally, the purity of 
the compounds screened can have a significant influence on hit quality [7]. Thus, achieving 
sufficient purity of these libraries as well as maintaining them over years in different 
screening campaigns is challenging. Therefore, impurities and degradation products can 
lead to false assignment of active molecules as well. A significant effort has been put into 
improving, supplementing or even replacing HTS, for example with high-content screening 
[4], improved animal models [1] or in silico screening [8]. One of the key technologies in 
this thesis is high-resolution screening (HRS) [9,10] which can address some shortcomings 
of HTS in terms of flexibility and hit quality [Chapters 1.1.2 and 2.1]. Additionally, HRS 
is uniquely suited to screen mixtures and thus not limited to the use of pure compound 
libraries.
1.1.1.b) Metabolite-like lead libraries
The large compound libraries that are used in the initial screening preferably have a high 
chemical diversity [4], possibly within a predefined space [1]. After the hit confirmation 
and hit-to-lead selection [6], new libraries are created around the selected hit scaffold, 
the so-called lead libraries. Lead libraries are much smaller and incorporate a much 
narrower chemical space than the screening libraries [11]. However, both types of libraries 
traditionally consist of (more or less) pure compounds. An exception is presented by 
some combinatorial chemistry libraries [12] and natural extract libraries [13,14]. The latter 
originate from a wide variety of sources, including animal venoms [15] and plant extracts 
[16]. Due to their huge chemical complexity, these libraries mostly consist of mixtures of 
compounds, even if fractionation of the original sample was included. 
Not only chemists can generate molecules, but also our body itself is a complicated 
assortment of chemical reactions known as metabolism. Amongst others, this includes 
dealing with potentially harmful, foreign substances in our diet, the so-called xenobiotic 
metabolism. This consists of different enzymatically catalyzed reactions which are intended 
to increase the hydrophilicity of the xenobiotics with the ultimate goal of (renal or fecal) 
excretion. The main impact thereof is in pharmacotherapy, where the phenomenon is 
known as drug metabolism, because APIs are modified.
The metabolites of APIs are independent entities. In designing molecules, medicinal 
chemists often try to avoid metabolism as they fear unwanted side effects and a decreased 
therapeutic efficacy [17,18]. However, a metabolite may possibly show better therapeutic 
properties [18]. Even more so, the intrinsic tendency towards increased hydrophilicity is a 
real advantage. The molecules used in modern drug discovery often suffer from excessively 
low hydrophilicity which prevents them from entering the circulation or allows them to enter 
the brain [19,20]. Consequently, more polar compounds are more easily absorbed and 
more effectively excluded from the brain. An indirect advantage of hydrophilicity is found 
in the intended and unintended interactions with (target) proteins. Non-polar molecules 
mostly draw their affinity from van der Waals interactions which are undirected induced-
dipole interactions. The unspecific nature of those interactions increases the likelihood of 
affinity with multiple proteins which may lead to side effects [19]. In more polar molecules, 
amine, hydroxyl or carboxylic acid groups form interactions like hydrogen bonds, dipole-
dipole interactions or ionic interactions, requiring more specific partners in the protein. 
This may increase the specificity for the target, thus reducing side effects. In this context, 
specificity is defined as the relative affinity for the intended target versus other proteins. 
There are actually quite a number of examples where a metabolite ended up replacing the 
original active ingredient due to improved pharmacological properties [18]. 
Thus, the collection of metabolites derived from an active ingredient and a lead library 
derived from a hit are quite comparable. The scaffold is randomly (at least before 
establishing a pharmacophore model) modified by simple reactions yielding distinct but 
similar products. One aim of this thesis is, therefore, to investigate lead libraries which 
incorporate the positive bias of metabolism towards selectivity and hydrophilicity. Though 
the chemical space associated with metabolites is not easily accessed by classical 
synthetic approaches, there are a number of methods which are frequently employed for 
the generation of metabolite standards, some of which are discussed later. As our interest 
is not limited to actual metabolites, but extends to all products which show typical metabolic 
modifications, we use the term metabolite-like lead libraries. However, we use this term to 
describe the structural similarity of the molecules to drug metabolites and not (necessarily) 
to actual endogenous metabolites [21].
1.1.2 High-resolution screening
Although, the term high-resolution screening (HRS) was originally introduced for on-line 
post-column bioassays (see Figure 1A), we use HRS more generally to describe in vitro 
approaches which achieve the integration of a separation technique and a biological assay 
(bioassay) for screening purposes in drug discovery. The key benefit is that integrating 
separation and biological evaluation enables the HRS platform to handle mixtures of 
compounds and still be able to assess individual biological effects. Chapter 1.1.2 introduces 
important concepts and distinctions, and briefly discusses advantages and disadvantages 
of different HRS assay variants as well as of HRS over HTS assays. Examples are cited 
for the different concepts, preferably showing their use in HRS assays. A comprehensive 
overview of HRS methods is not attempted. The reader may refer to several recent reviews 
[24,25,10,9,23,26].
Although bioassays can also be set up to screen a single (or a limited number of) 
compound(s) for the interaction with multiple targets [27], we focus on the more common 
approach to develop a screening for a single target (or a small number of targets) [4].
An important distinction lies in the nature of the biological effect which is probed. This can 
be either biological affinity (bioaffinity) or biological activity (bioactivity). Bioaffinity assays 
measure the binding of an analyte to the target [Chapter 2.2]. Bioactivity assays can be 
further divided into biochemical assays which follow an enzymatic reaction [Chapter 2.3] 
and functional assays which visualize an indirect response to the analyte-target interaction 
[28]. Bioaffinity of an analyte is measured either by the displacement of a tracer molecule 
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[Chapter 2.2] or by directly visualizing the affinity of the analyte [29]. Bioaffinity assays 
either rely on affinity selection of the analyte using an immobilized protein [29-31], separate 
free and bound tracer [32] or utilize the difference between free tracer (or analyte) and 
tracer-target (or analyte-target) complex with regard to mass [33], spectroscopic properties 
[Chapter 2.2] [34,35] or Gibbs free energy [36]. Advantages are that the inactive form of 
a protein can be studied and no expensive co-factors are needed (see also Chapter 2.1) 
[Chapter 2.2]. However, though without affinity there is no activity, binding may potentially 
evoke different responses in the protein. Therefore, in bioaffinity assays the direction of 
activity remains unknown, for example whether a binder is an agonist or an antagonist. 
This is the domain of biochemical and functional assays. Biochemical assays measure a 
biocatalytic reaction by detection of a substrate and/or the product(s) and are therefore 
mostly applied to the study of enzymes [Chapter 2.3]. The difference in mass [16] or 
spectroscopic properties [Chapter 2.3] between the substrate and the product(s) is the key 
to this approach. Detection of multiple reaction partners (mainly substrates and products or 
reactants in short) usually increases the robustness of the assay, for example by revealing 
the influence of unexpected side reactions [37]. While, in principle, biochemical assays can 
be used to screen different substrates for the same (detected) product, the more common 
approach is to observe the effect of inhibitors, allosteric modulators, or competing substrates 
on a particular reaction. Given the use of the same detection technique, biochemical assays 
are usually more sensitive than bioaffinity assays, because of the signal amplification by 
reiterative, biocatalytical reaction cycles. In proteins, which do not catalyze a reaction, for 
example nuclear receptors or G-protein coupled receptors, functional assays are needed 
to investigate the nature of the biological effect [28]. These highly complex assays are often 
cell-based and mostly measure an effect of some signal cascade, like calcium release [38], 
labeled secondary messengers [39] or protein expression [28]. Because several signal 
amplification steps can be involved, functional assays are usually even more sensitive 
than biochemical assays. An endpoint has to be chosen beforehand, meaning that effects 
on the target leading to different signaling endpoints are not detected. However, in many 
studies, the effect of the analyte on the endpoint is more interesting than the mere effect on 
the target itself. This is both the advantage and the drawback of functional assays, because 
any effect of the analyte on the endpoint detected is merely assumed to be caused by 
the analyte-target interaction. In this respect, better certainty is achieved, if bioaffinity is 
established in addition to the specific bioactivity yielded by the functional assay [28].
An almost uncountable number of assay principles is currently available. Nonetheless, a brief 
overview is attempted referring to categories of principles rather than individual methods. 
The most desirable situation for bioaffinity assays is the direct measurement of the analyte. 
This is especially useful for novel targets with no or little known ligands [40]. However, it 
requires a detection technique capable of measuring all envisioned analytes or analyte-
target complexes. Though mass spectrometry (MS) [29] and surface plasmon resonance 
(SPR) [31] are well suited to achieve both the necessary selectivity for binders over non-
binders and the broad detection, even their application often requires at least additional 
purification steps. For example, it is very difficult to reliably ionize the intact analyte-target 
complex in MS which thus often requires prior separation of the unbound analytes [29]. 
Therefore, a tracer is often used for bioaffinity assays. This is a binder whose bound or 
unbound fraction can be easily monitored. Affinity of an analyte induces competition for 
Figure 1: Comparison of pre-column and post-column HRS setups. A) shows the specific setup used 
in Chapter 2.2 including an on-line post-column HRS bioaffinity assay and parallel HR-MSn detection. 
The setup is rather generic for on-line post-column assays and holds true for Chapter 2.3, by simply 
changing tracer to substrate. Variations are discussed in detail in Chapter 2.1. B) represents a unified 
schematic of pre-column affinity selection assays rather than a specific setup [12,22,23]. In the first 
step, protein and analytes are mixed so the binders form protein-analyte complexes. The proteins 
can be immobilized or can be free in solution during this step. Then, binders and non-binders are 
separated in a selection step, for example by SEC or by washing the immobilized proteins. Afterwards, 
the binders are released, trapped on an LC column and finally analyzed by LC–MS.
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the binding site and is thus detected as the signal change caused by reduction or increase 
of the bound or unbound fraction of the tracer, respectively. Focusing on the tracer allows 
a more selective detection method [Chapter 2.2] or an increased response [31]. Thus, it 
often improves the assay, e.g., through better signal-to-noise ratios (S/N) or less reagent 
consumption. In these respects, the detection of a tracer in bioaffinity assays has a similar 
function to the monitoring of a reactant in biochemical assays. The selection of either the 
tracer or the reactant(s) is of utmost importance. The tracer only probes the binding sites 
to which it binds itself, and, as for the reactant, the influence of the analyte might vary 
with different substrates. In pharmacology, for example, this choice might influence the 
translatability of the assay results to the desired efficacy in human. Therefore, a (relevant) 
natural reactant [16] or ligand is often desirable. Spectroscopic methods, like fluorescence 
[Chapters 2.2 and 2.3] or fluorescence polarization [35], promise excellent selectivity, 
sensitivity and robustness. Unfortunately, natural reactants or ligands rarely show the 
necessary optical properties or at least not at a wavelength allowing sufficient selectivity 
[16]. Therefore, synthetic substrates or tracers are often used which are either labeled 
versions of a natural reactant/ligand [28] or de novo designed compounds with some label-
like features [Chapter 2.2 and 2.3]. The label obviously depends mainly on the envisioned 
detection method, but it is important to establish that the target structure and the binding 
mode are as close as possible to the natural state which the assay is meant to probe. For 
some labels, like radioactive 3H or 14C labeling of natural substrates/ligands, this is the case 
almost by definition [28], while for others, like fluorescence labels, which can reach the size 
of proteins (for example green fluorescence protein), this has to be carefully investigated 
during assay development. Unfortunately, radioactive labeling is very costly, due to the 
necessary safety, synthesis and waste disposal efforts.
Perhaps, the most important distinction in HRS from a technical perspective is between pre-
column and post-column assays, that is, in whether the biological effect is probed before 
or after the separation step (see Figure 1). Pre-column assays rely entirely on bioaffinity 
measurements [23], while post-column assays are also open to biochemical [Chapter 2.3] 
and even functional readouts [28]. In pre-column assays, the first step is an affinity selection 
where the mixture of analytes is allowed to interact with the target which can be soluble or 
immobilized [23]. The bound fraction of analytes is then selected and, subsequently, either 
directly detected, for example with SPR [31], or released from the target, for example for 
MS [30] or liquid chromatography–MS (LC–MS) detection [12]. Because bioaffinity is not 
assessed on individual compounds, but from the mixture, an excess of one high-affinity 
analyte compared to the target concentration prevents lower-affinity analytes from being 
detected if they compete for the same binding site. Affinity selection is not biased towards 
a certain binding mode or region. On the one hand, this can lead to issues with nonspecific 
binding. On the other hand, compounds using new (allosteric) binding sites can be 
detected without prior knowledge of these sites. This, the relative ease of implementation 
and the potentially high throughput have made pre-column bioaffinity assays commercially 
attractive. Consequently, the Automated Ligand Identification System (ALIS), which is 
based on size exclusion chromatography–reversed phase LC–MS, has become the biggest 
commercial success in HRS so far [12]. In post-column assays, the separation is the first 
step. Consequently, all following steps are applied to the pre-separated analytes meaning 
that they affect each analyte individually. This means that, in principle, a separate signal is 
obtained for every compound with a (sufficiently large) biological effect. Due to the fact that, 
assuming sufficient separation, every analyte enters the post-column assay separately, 
every HTS assay is theoretically convertible into a post-column assay. For more details on 
post-column assays, refer to Chapter 2.1.
A distinction which only applies to post-column assays is whether the binder, tracer or 
detected reactant is separated from other molecules before the actual detection step. This 
is necessary when the assay principle does not allow to distinguish bound and unbound 
tracer (or binders) or substrate and product(s) solely on basis of their detected properties. 
If this is indeed necessary, the assay is called heterogeneous. A prime example are assays 
based on radioactively labeled tracers where bound and unbound fraction need to be 
separated because they show no difference in radioactivity [28]. Due to the highly dynamic 
nature of bioaffinity, washing away the unbound fraction, while retaining all bound tracer, 
is not trivial. Additionally, heterogeneous assay are usually much more labor intensive and 
error prone than their homogeneous counterparts [32]. Consequently, state-of-the-art post-
column HRS assays are usually homogeneous assays.
Assays can also be distinguished on whether the separation step is operated in the same 
flow system as the bioassay. If this is the case, we speak of an on-line or continuous-flow 
assay [9]. The (virtually) closed system and the retention of a peak shape for the effect signal 
result in many advantages. Chapter 2.1 deals extensively with on-line assays. On the other 
end of the spectrum stands the classical HTS assay were each separate step involves 
liquid handling [4]. However, next to on-line approaches, HRS also utilizes hybrids called 
at-line assays [9]. These are based on post-column high-resolution micro-fractionation. 
After separation, the effluent is mixed with the bioassay reagents and the mixture is then 
micro-fractionated into 96-, 384- or 1536-well plates [28,41,42]. Incubation and readout of 
the well plates are conducted like in HTS. If the fractionation is conducted at sufficiently high 
resolution, the chromatographic peak shape of the effect signal is retained. The greatest 
advantage of the at-line approach is that long incubation times can be achieved with limited 
compromise on the chromatographic resolution in the effect signal. This advantage is 
accompanied by the drawbacks of an open system and a major increase in time and effort. 
However, in cell-based assays, the at-line HRS approach may be preferred, because of the 
long incubation times or because of the need to use adhesive cells. To avoid the physical 
stress on the cells or to enable solvent evaporation, the mixing is sometimes postponed 
to after the fractionation. However, in this way, the efficient mixing of the on-line system 
is lost and solvent evaporation is also not without risks. For example, we developed an 
HRS platform where parallel MS detection was coupled at-line via microfractionation to 
three parallel bioassays; a functional assay for the human histamine H4 receptor and two 
radioligand binding assays which assessed selectivity of the H4 ligands over histamine H3 
receptor binding [28,43].
MS has become an integral part of state-of-the-art HRS platforms [9]. Next to exploiting the 
excellent flexibility of MS between general and specific detection for the effect detection in 
bioassays, MS is used as a means of implementing rapid structure elucidation into HRS 
platforms [Chapter 4.1]. It additionally allows the detection of analytes without biological 
effect, though this ability is limited to certain HRS setups [Chapter 2.2]. For example, the 
necessary selection step between bound and unbound analytes in pre-column assays 
prevents detection of analytes without bioaffinity [30]. Though this can be advantageous 
with MS based bioassay readouts, because it significantly reduces the complexity of the 
mixture prior to analysis, it limits the usefulness of these assays for mixtures of unknown 
analytes.
1.1.3	Modification	methods	in	metabolism	studies
For the study of the metabolism of an API, different model systems are used to predict the 
changes of an API after ingestion by patients or healthy volunteers. Most commonly, this is 
attempted by the use of animal models, cultured human hepatocytes or in vitro incubations 
with (human) liver fractions [44,45]. However, none of these methods is particularly suitable 
to produce sufficient amounts of material to further investigate the chemical and biological 
properties of the metabolites. Therefore, an increasing number of methods is proposed to 
augment metabolic studies by producing metabolite standards. This is necessary, because 
the many reactions observed in metabolism are not easily reproduced by classic organic 
synthesis approaches. Oxidative metabolism yields a broad variety of reactions, depending 
on the structure of the active ingredient. Mainly aromatic and aliphatic hydroxylation, N- and 
O-dealkylation, dehalogenation, epoxidation, carbonyl oxidation and N- and S-oxidation 
are observed [46]. Especially the introduction of hydroxyl groups to non-activated carbon 
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moieties is a great synthetic challenge. Because the methods, used for metabolite standard 
synthesis, offer access to a unique chemical space and are often scalable to preparative 
dimensions, this thesis applies some of them to the generation of metabolite-like lead 
libraries (see Chapter 1.1.1.b).
As mentioned, an increasing number of these modification methods are available and this 
section gives some examples, mainly focused on the methods actually used in this thesis 
(see Figure 2). For a better overview, the methods are divided into chemical, electrochemical, 
biocatalytic and photochemical approaches. Though the methods are logically separated 
by the nature of the (initial) redox agent, with respect to other aspects such as reactions, 
driving forces or even the ultimate redox species, the division may be artificial.
1.1.3.a) Chemical oxidation
Organic synthesis knows many oxidizing agents and some of them have been used in 
metabolism studies such as hydrogen peroxide [47], potassium permanganate [48] or 
sodium hypochlorite [49]. In classic synthesis, the oxidation aims at an existing functional 
group and the power of the oxidizing agent is tightly controlled in order to direct the 
modification to this site. However, enzymatic catalysis, which underlies metabolism, is much 
more controlled by proximity to the catalytic groups, e.g., the heme group in cytochrome 
P450s (CYPs), than by redox potentials [50]. Therefore, for the generation of metabolite-
like lead libraries, the side reactions obtained with strong and thus less selective oxidizing 
agents can be of great interest.
Though hydrogen peroxide by itself is not a strong oxidizing agent, it can be activated, 
for example thermally, photochemically or by metal catalysis [51]. The reactive species is 
the hydroxyl radical. Additionally, hydrogen peroxide can yield epoxidation of electrophilic 
alkenes under basic conditions [52]. In the context of drug metabolism studies, hydrogen 
peroxide has been used, amongst others, to achieve S-oxidation [47,53,54], aromatic and 
aliphatic hydroxylation [55], formation of aliphatic ketones [55], N-oxdidation [56-58], N- 
and O-dealkylation [57,58] and carboxylic acid formation [58].
Furthermore, metallo-organic catalysts have been employed for the generation of 
metabolites [59]. These metalloporphyrins are meant to mimic the active state of the CYP 
coenzyme Protoporphyrin IX. They can be operated with molecular oxygen and reducing 
co-factors, but are often also used in combination with chemical oxidants like hydrogen 
peroxide or sodium hypochlorite. This opens a grey area between catalytic activation 
of hydrogen peroxide and catalytic, metallo-organic oxidation with hydrogen peroxide 
regeneration.
1.1.3.b) Electrochemistry
Electrochemical conversion (EC) has been extensively explored [60] and in recent years 
has found increasing use in metabolic studies. Due to the low matrix content of the reactions 
in EC, it has become very popular in combination with MS and LC–MS, and has even lead 
to hyphenated EC–MS and EC–LC–MS systems. The field has been extensively reviewed 
by the groups of Karst [59,61-63], Bischoff/Bruins [64,65] and Jurva [66]. EC can mimic 
a wide range of metabolic reactions, such as aromatic and aliphatic hydroxylation, N-, P- 
and S-oxidation, N- and O-dealkylation, alcohol oxidation, dehydrogenation, epoxidation 
and dehalogenation [61,64]. Additionally, it has been used for the generation and study of 
reactive metabolites, such as quinones and quinoneimines. Prominent examples are N-(4-
hydroxyphenyl)acetamid (Paracetamol), amodiaquine and clozapine [67]. 
The EC reaction is driven by adding (reduction) or removing (oxidation) electrons to/from 
the substrate at the electrode surface. Two reaction classifications are distinguished in 
EC as well as with CYP reactions: single electron transfer oxidation and hydrogen atom 
transfer/abstraction [64]. Additionally, ozonolysis might occur at high voltages [68].
1.1.3.c) Biocatalytic approaches
Because in enzymes the catalytic group is presented in the context of a complex, three-
dimensional active site in which the substrate has to fit in one (or a limited number of) 
specific orientation(s) [50], biosynthetic approaches offer an unmatched product selectivity, 
especially when it comes to chiral synthesis [69]. A variety of enzyme classes has been 
employed for biocatalytic purposes including aldolases, lyases, dehydrogenases, reductases, 
transaminases, esterases, oxidases, proteases and lipases [69-74]. Viewed as “by far the 
most dominant and important” enzymes in drug metabolism, the CYP superfamily has 
received specific attention in drug metabolism studies [46]. CYPs are capable of catalyzing 
most of the reactions of oxidative metabolism (see above). Very promising in biocatalysis 
is a CYP from Bacillus megaterium, named BM3, which shows a wide substrate spectrum, 
a high solubility, high expression levels in E. coli and a high catalytic efficiency [75,76]. 
The latter is especially important, because CYPs use the expensive co-factor nicotinamide 
adenine dinucleotide phosphate (reduced form: NADPH). Although its consumption can 
be reduced from stoichiometric to catalytic amounts by employing a co-factor regenerating 
Figure 2: Generation of metabolite-like lead libraries. A schematic representation of the four 
modification methods (see Chapter 1.1.3), used to generate metabolite-like lead libraries (see 
Chapter 1.1.1.b), is shown. As substrates, we employed p38 mitogen-activated protein kinase α (p38α) 
inhibitors (either common molecular probes or clinical candidates) which were very hydrophobic but 
had high affinity. We aimed at generating more hydrophilic conversion products which retain p38α 
affinity, as is visualized in the right column. Though HRS platforms have been reported that allow 
selectivity determination, we did not include this feature in either of the two HRS platforms developed 
in this thesis.
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system based on glucose or glucose-6-phospate and their corresponding dehydrogenases, 
this presents a significant hurdle in large-scale application [77].
The versatility of employing CYP BM3 for the biocatalytic conversion of APIs is demonstrated 
in a recent review [76].
1.1.3.d) Photochemistry
Photochemistry, meaning the use of light to activate chemical reactions, mainly acts 
through the formation of radicals by homolytic cleavage [78]. While visible (VIS) light with 
between 167 kJ•mol-1 (red) and 293 kJ•mol-1 (blue) is limited to weak bonds, ultraviolet 
(UV) light at 586 kJ•mol-1 strongly decomposes organic molecules. For this reason, most 
applications use visible light. Next to radical mechanisms, light can induce electrocyclic 
reactions. Light- and thermally-induced electrocyclic reactions start from an exited state or 
the ground state, respectively. The difference in orbital geometry between the two states 
results in a different stereochemistry [79]. Classical, synthetic applications of photochemistry 
include polymerization, halogenation of alkanes and carbon-carbon bond formation using 
organo-tin reagents [78]. In the pharmaceutical industry, another important aspect of 
photochemistry is known as photostability which refers to the light-induced degradation of 
active ingredients during production and storage of a drug [80,81]. Similar to metabolism, 
degradation can have a huge influence on efficacy and side effects of a formulation. In 
addition, light-induced degradation can also occur in vivo during the use of cosmetics [82] 
or pharmaceuticals [83].
With respect to the radical mechanism, photochemistry [78] shares some common ground 
with hydrogen peroxide [51], electrochemical and CYP oxidation [64]. Light and EC have 
the advantage that the energy input is tunable by changing the wavelength or the voltage, 
respectively. The radical and electrocyclic reaction mechanisms in photochemistry allow 
rearrangements in the scaffold of the molecule which are not accessible by the other 
methods [84].
1.1.4 Structure elucidation in mixtures using mass 
spectrometry and nuclear magnetic resonance 
spectroscopy
For the structure elucidation of small, organic molecules a wide variety of methods is 
available [85,86]. This includes the classical spectrophotometric techniques like UV/VIS 
absorption, fluorescence and phosphorescence emission spectroscopy, and vibrational 
approaches like infra-red and Raman spectroscopy. Additionally, scattering techniques like 
X-ray or neutron scattering are used. However, the focus is on mass spectrometry (MS) 
and nuclear magnetic resonance spectroscopy (NMR) which dominate today’s routine 
structure elucidation of small molecules. Special attention is paid to structure elucidation in 
mixtures which is one of the main challenges in this thesis.
1.1.4.a) Mass spectrometry
For MS, mainly two developments have enabled structure elucidation. Firstly, the high 
mass accuracy of the high-resolution (HR) mass analyzers [87], i.e., sector field, time-of-
flight (TOF), Orbitrap [88,89], and Fourier-transform ion cyclotron resonance, allows the 
determination of the elemental composition of ions [90,91] [92]. Secondly, fragmentation 
reveals functional groups and residues by observing specific neutral losses and allows 
interpretation of their connectivity. Classically, fragmentation was achieved during electron 
ionization (EI) with the risk of missing the molecular ion [87]. After the introduction of the 
soft ionization techniques, especially electrospray ionization (ESI), fragmentation of the 
protonated molecule had to be achieved in the mass analyzer. This fueled the development 
of tandem MS and ion trap MSn. Tandem MS instruments can be divided into unit-resolution 
instruments, like quadrupole–linear ion trap and triple-quadrupole, and (hybrid) HR 
instruments, like quadrupole–TOF, ion trap–TOF, linear ion trap–orbitrap, quadrupole–
orbitrap, and quadrupole– or linear ion trap–Fourier-transform ion cyclotron resonance 
instruments [92] [93]. Obviously, the combination of high mass accuracy and fragmentation 
makes the HR tandem MS instruments ideally suited for structure elucidation. Nowadays, 
a kaleidoscope of fragmentation techniques is being developed, but for small molecules 
collision induced dissociation (CID) is still applied almost exclusively [94]. However, 
uncertainty in the fundamental understanding of the ESI process [95] and the reactions 
governing CID-fragmentation (especially for small molecules), as opposed to the thoroughly 
elucidated main fragmentation reactions of the radical ions, for example the α-cleavage 
and the McLafferty rearrangement [85], present a serious hurdle in modern MS structure 
elucidation. Additionally, there is a large variation between different instruments in the 
actual energy deposited to the ions by CID, which varies between 1 and 100 eV for ion trap 
and quadrupole based fragmentation [94], while in EI a standard setting of 70 eV is applied. 
Therefore, almost every ESI instrument produces different MS/MS spectra of the same 
analyte, especially with respect to the relative abundance of product ions. A fundamental 
difference is found between ion trap geometry collision cells and those with quadrupole 
geometry. Quadrupole geometries are limited to one collision experiment per cell while ion 
traps can perform iterative fragmentation cycles until the number of ions falls below the 
detection limit. Therefore, ion trap instruments allow a much more reliable interpretation of 
precursor-product ion relationships [96].
The advent of tandem MS required the development of various data acquisition strategies 
to fully exploit its possibilities. The most straightforward is the product-ion analysis mode. 
Herein, a precursor ion is selected, fragmented and a mass spectrum of the fragments 
collected. Two other widespread strategies have greatly contributed to the success of 
triple-quadrupole instruments. Selected reaction monitoring (SRM) follows one or multiple 
specific CID-reactions by selecting one precursor ion in Q1 and one fragment ion in Q3 for 
each reaction. It is the most popular method for targeted quantitation, probably because 
of the dramatically increased speed, selectivity, and data reduction compared to a full-
spectrum analysis. The neutral loss analysis mode searches for a specific m/z difference 
between the precursor and the product ion, thus for a neutral loss. It is often used to monitor 
classes of molecules which show the same specific neutral loss. Because neutral loss 
analysis shows all class compounds regardless of the precursor m/z, as long as the neutral 
loss is retained, it can also detect (some) unknown molecules. Nowadays, product-ion 
analysis is becoming increasingly fast and sensitive, e.g., in quadrupole–TOF instruments. 
CID-reactions and neutral losses may also be monitored by data interpretation of product-
ion analysis spectra. Thus, combining the strength of HR-(tandem)MS in structure 
elucidation with the quantitative interpretation of CID-reactions or neutral losses is an 
emerging approach [97]. A powerful tandem MS data acquisition strategy for monitoring 
unknowns is data-dependent acquisition. First, a full spectrum without fragmentation is 
collected and processed in real-time. Based on pre-selected criteria, the software selects 
the most abundant ions to be fragmented and collects their MS/MS spectra. For ion trap 
fragmentation this can be an iterative process (MSn). In this way, the process of identifying 
unknown ions and collecting fragmentation data for structure elucidation can be greatly 
automated.
The most important breakthrough with respect to MS analysis of mixtures was certainly the 
hyphenation of MS to separation techniques [98,99], most importantly gas chromatography 
(GC) using EI and LC using ESI. This hyphenation does not only enable the detection of 
individual isobaric and isomeric compounds, but it also significantly reduces the occurrence 
of ionization suppression issues in ESI. Fortunately, modern (reversed phase (RP)) LC and 
ESI-MS are very well compatible [99]. In addition, LC–HR-MS resolves isobaric compounds 
which have not been separated, but issues with isomers and ionization suppression cannot 
be elevated by HR-MS alone. In some cases, fragmentation can help in the discrimination of 
isomers. When standards are available, fragmentation patterns on the same MS instrument 
can be compared to that of the unknown. Recently, the hyphenation of ion mobility 
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spectrometry and MS has received increasing attention accompanied by the introduction 
of new commercial instrumentation [100]. Because the drift-time is usually on the scale of 
the MS experiment or even shorter and separation is based on size and shape rather than 
on the physicochemical properties employed in GC and LC, IMS might offer an interesting 
secondary separation dimension. However, in contrast to separation techniques, IMS does 
not reduce ionization suppression as it is positioned after the ionization step.
There are a number of data interpretation methods which were specifically developed for 
the analysis of unknown mixtures of related compounds such as they occur, for example, in 
metabolism studies. The profile group approach [101,102] assumes that the identity of one 
compound in the mixture is known and that this compound is related by simple chemical 
modifications to the other compounds in the mixture, for example an active ingredient and 
its metabolites [102] or a substrate and its multiple products from a shotgun synthesis 
approach [42]. Firstly, the fragmentation of the standard (parent drug) is thoroughly 
analyzed on the MS instrument intended for the study, the data are interpreted, and a 
fragmentation tree is established. A number of structurally informative fragment ions are 
selected as profile groups. Then, the fragmentation trees of all analytes are measured 
and compared to that of the standard, following mainly the profile groups. The difference 
in elemental composition between the analyte and the standard is found back in some 
profile groups, which is evidence that the molecule is modified in the corresponding part 
of the molecule. The difference depends on the modification, for example, oxygenation 
and dehydrogenation result in +O (+16 Da) or –H2 (–2 Da), respectively. Thus, the site of 
modification can be narrowed down. In addition, changes in (relative) retention time in RPLC 
can be used to distinguish the isomeric modifications of common metabolic reactions, like 
hydroxylation and N-oxidation [90].
MS is one of the most sensitive techniques for structure elucidation and fast enough for real-
time collection of structural data in LC–MSn combinations. LC–MS or GC–MS are therefore 
often employed as the first line of structure elucidation/confirmation [103]. Unfortunately, 
modifications can rarely be pinpointed with single atom accuracy. As a result, NMR is often 
employed at a later stage to elucidate the exact position of the modifications [Chapter 3.2] 
[104]. However, NMR requires much more material than MS. 
1.1.4.b) Nuclear magnetic resonance spectroscopy
The basis of the structure elucidation of a small, organic molecule by NMR is usually a 
proton spectrum (1H-NMR) [85,105,106]. This can already reveal a lot of information about 
the structure of the molecule. The chemical shift of a proton indicates the hybridization 
of the connected carbon atom and the proximity to a heteroatom. Integration reveals the 
relative number of chemically equivalent protons which, combined with the hybridization 
information from the chemical shift, establishes the connectivity of the associated carbon 
atom. Analysis of the J-coupling pattern hints to the number of neighboring protons while 
J-coupling strength indicates their distance and steric features, such as E/Z isomerism, and 
can be used to match J-coupling partners. The signals of exchangeable protons are usually 
broader than the other signals, if they are not eliminated completely by efficient exchange 
with the deuterated solvent.
For the structural analysis of more complex molecules, homonuclear 1H correlation (2D-1H-
NMR) spectra are often useful [85,105,106]. They can reveal more structural information, 
but are less sensitive or require longer measurement time. Correlation spectroscopy 
(COSY) reveals the interaction of J-coupling partners which is especially useful when 
several J-couplings of similar strength were observed in the 1H spectrum. As a variation 
of COSY, total correlation spectroscopy (TOCSY) reveals not only direct coupling, but 
also interactions of couplings, thus revealing so-called spin systems. Instead J-coupling 
interactions, nuclear Overhauser effect spectroscopy (NOESY) and rotating-frame nuclear 
Overhauser effect spectroscopy (ROESY) reveal spacial proximity of protons by employing 
dipole-dipole interactions.
Protons are not the only nuclei which can be followed by NMR. Not surprisingly, carbon, 
the backbone atom of organic molecules, is the second most commonly detected element 
[85,105,106]. However, its most abundant natural isotope 12C is not NMR active, leaving 
only 13C with ca. 1% natural abundance. Consequentially, 13C-NMR is much less sensitive 
than 1H-NMR. However, chemical shifts are more widely distributed, leading to higher 
resolution, and quaternary carbon atoms are revealed which are obviously hidden in 
1H-NMR. Heteronuclear 13C-1H correlation NMR also suffers from the low 13C abundance 
and is therefore even less sensitive than 2D-1H-NMR. Examples are heteronuclear single-
quantum correlation (HSQC) and heteronuclear multi-bond correlation (HMBC) which 
reveal short-range or long-range 13C-1H J-coupling partners, respectively.
Heteroatoms are also used in NMR of small molecules, mainly 15N, 19F and 31P [85], and 
sometimes employed in correlation experiments like 19F-1H [107], 19F-13C, 19F-19F [108], and 
15N-1H [109].
LC–NMR is certainly an important development in mixture analysis by NMR though the less 
straightforward hyphenation has so far prevented the same widespread use which LC–MS 
has seen [110]. The sensitivity issue usually also prevents real-time NMR detection of LC. 
LC–NMR systems often operate with a stopped-flow approach and/or with an intermediate 
solid-phase extraction (SPE) step, decoupling the chromatographic from the detection time 
scale and (in SPE) additionally allowing solvent exchange and analyte pre-concentration 
[111,112]. The increasing resolution of NMR instruments has also enabled the direct 
detection of mixtures by NMR. Today, it is possible to analyze even complex biological 
samples [113]. Simplification of the complex spectra by specialized pulse methods can 
contribute to resolving overlapping signals. The effect is similar to the transition from EI to 
ESI in the way that information is sacrificed in order to strengthen the data that remains. 
Simplification is achieved by canceling the influence of J-coupling on the spectra which 
ideally yields singlet peaks and thus greatly simplifies the determination of chemical shifts 
in complex samples. It is routine to decouple different nuclei (heteronuclear decoupling) 
[114], for example protons in 13C-NMR. However, the decoupling of the same nuclei 
(homonuclear decoupling), for example protons in 1H-NMR, is subject to ongoing study 
[115] and especially interesting for the NMR analysis of mixtures. 
Miniaturization is a promising approach to enhance the sensitivity of NMR. By reducing 
the detection volume without equally reducing the concentration sensitivity, an increase in 
mass sensitivity is achieved. While sample pre-concentration, e.g., by SPE, becomes even 
more crucial, the total amount of sample material used can be decreased by ca. 100-fold 
in some cases. Different geometries have been proposed to achieve a well focus rf-field 
[116,117].
Despite all the structural information that can be obtained from the various NMR 
experiments, the input of information obtained with MS experiments greatly complements 
NMR data [111]. The simplest example is the calculation of the elemental composition 
from HR-MS experiments which amongst many other advantages is a much faster way of 
revealing heteroatoms than any method available to NMR [118]. Especially, sulfur, chlorine 
and bromine are readily followed by MS while their NMR detection has to be called exotic at 
the least. Even if all structural information can be obtained by NMR alone, MS can provide 
a second independent confirmation and exclude symmetric dimeric structures. Additionally, 
because MS is generally faster and more sensitive than NMR, the same information can 
be obtained by MS earlier on and more economically in a structure elucidation procedure. 
Due to the more straightforward hyphenation of LC and ESI-MS, this is especially true were 
separation is needed, thus for LC–MS vs. LC–NMR [110]. However, because NMR has 
much more possibilities to elucidate structural details and even conformational questions, 
LC–MS and NMR have become a dream team of structural analysis for small, organic 
molecules [104,111,112].
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Figure 3: The HRS workflow integrating modification, separation, affinity assessment and structure 
determination. This approach is used in different forms throughout Chapter 3. The library generation 
was explained in Chapter 1.1.3. Sample preparation beyond HPLC was only necessary for biocatalysis 
[Chapter 3.2]. Different forms of pre-screening were applied to select only potentially interesting 
libraries. The compromise between information content and sample throughput varied due to varying 
sample numbers. The heart of the strategy is the HRS system allowing simultaneous separation, 
affinity measurement and structural analysis [Chapter 2.2]. Also included are the example steps for 
further evaluation of the new leads demonstrated for the biocatalysis libraries [Chapter 3.2]. Upscaling 
and purification allow additional structural information from NMR and a quantitative comparison of 
affinities, for example by IC50 values.
The aim of this thesis is to investigate the possibilities for the integration of innovative 
synthetic methods into analytical platforms for drug discovery (see Figure 3). A strong 
focus of this work is the advancement of existing and the development of novel analytical 
methodology which would be demanded and inspired by this challenging objective. More 
specifically, we studied workflows and developed platforms which integrate innovative, 
analytical-scale analyte modification methods with HRS technology, MS structure 
elucidation and (miniaturized) NMR. This will make neglected chemical space available 
early on in lead optimization and might contribute to a more efficient drug discovery cycle, 
if boldly implemented in novel screening paradigms.
Chapter 1.1 introduces important concepts starting with general aspects of the discovery 
of API, for example screening. At the core, it introduces several approaches to HRS and 
rationalizes the focus of this thesis on on-line post-column assay formats. As structure 
elucidation has become an integral part of state-of-the-art HRS platforms, structure 
elucidation by MS and NMR is introduced with a special attention to the analysis of 
mixtures. Building on the introduction of these concepts, Chapter 2.1 describes how to set 
up a state-of-the-art HRS platform and a successful HRS campaign. It gives practical tips 
on optimization and validation of such platforms, warns of common pitfalls, and introduces 
specialized concepts of data analysis.
Chapter 2 is dedicated to the development of HRS assays for the drug targets encountered 
in this thesis, being p38 mitogen-activated protein kinase α (p38α) and soluble epoxide 
hydrolase (sEH). The former is widely investigated as anti-inflammatory and analgesic 
target, and the latter presents an emerging target for therapy of inflammation, pain and 
cardiovascular disease. Chapter 2.2 describes the development of the first reported on-
line post-column bioaffinity assay for an enzyme target. Decreased stability as compared 
to more robust protein targets presented a challenge and the generally high lipophilicity of 
p38α inhibitors inspired novel solutions. While for sEH a more classical approach, based 
on homogeneous detection of a fluorescent product, was chosen, the benefits of HRS in 
the analysis of metabolic mixtures catalyzed the development of this assay [Chapter 2.3].
Chapter 3 deals with the integration of the innovative synthetic methods described in 
Chapter 1.1.3. Chapter 3.1 reports on the direct integration of flow-through EC into the HRS 
setup described in Chapter 2.2. This promises superior reproducibility of the combined 
modification, separation, affinity assessment, and structure elucidation approach. As a 
significant number of samples either lacking conversion or showing redundant product 
profiles were expected, a suitable pre-screening preceded all HRS analysis in Chapter 3. 
Implementation of LC–MS for pre-screening (Chapter 3.1) provides more information, but is 
more resource intensive than (UP)LC–UV (Chapter 3.2 and 3.3). The compound modification 
with BM3, described in Chapter 3.2, offered the largest potential sample variation due 
to the number of tested BM3 mutants. Therefore, UPLC–UV pre-screening was applied. 
After selection of some favorable biocatalysts by HRS, BM3 catalyzed production was 
scaled up and the main products further probed for structural details and IC50-values by 
NMR and HRS, respectively. Chapter 3.3 expands the combined modification, separation, 
affinity assessment, and structure elucidation approach to the application of chemical 
(hydrogen peroxide) and photochemical (visible light) conversion. It also compares the 
different techniques, identifies strengths and weaknesses, and discusses the usefulness of 
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the approach in lead optimization and generation of metabolite standards.
Chapter 4 is dedicated to structure analysis in HRS. While Chapter 4.1 deals with MS 
as an integral part of HRS platforms, Chapter 4.2 explores an interesting solution to the 
sensitivity gap between HRS and the desirable structural refinement by NMR. Chapter 4.1 
describes in detail the structure elucidation of the kinase inhibitor drug-like lead libraries 
by MS. On the basis of examples, general aspects related to MS structure elucidation in 
HRS are discussed as well as interesting observations of fragmentation pathways and gas-
phase ion and radical chemistry. Chapter 4.2 shows the evaluation of EC hyphenated via 
SPE to stripline-NMR, the latter being a novel, miniaturized NMR approach with nanoliter 
sample volume detection. Next to compatibility with analytical scale samples, the integration 
achieves advantages in the detection of reactive products, as demonstrated in Chapter 3.1.
Finally, Chapter 5 describes the quantitation and structure elucidation of APIs and their 
conversion products by high-temperature liquid chromatography (HTLC) – inductively 
coupled plasma (ICP) MS (HTLC–ICP-MS) and HTLC–ESI-MS, respectively. Although, 
ICP-MS has not been employed in HRS so far, the technique is an interesting candidate 
for integration into novel HRS platforms. The integration of analyte quantitation into HRS, 
for example by ICP-MS, would complete the information package desired in many types 
of studies [1]. The low and constant organic modifier content of HTLC is beneficial for both 
ICP-MS [Chapter 5] and HRS assays [2], promising an interesting synergy. We report the 
sensitive quantitation of bromine or chlorine containing conversion products produced by 
HLM, BM3 and EC from two kinase inhibitors, including a complete mass balance for EC 
derived samples. Furthermore, ESI-MSn structure elucidation was achieved and correlated 
to the quantitation results.
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In this chapter, we want to shed light on the different aspects that are involved in a success-
ful high-resolution screening (HRS) campaign. We limit the discussion to homogeneous 
on-line post-column assays, but many of the aspects are interesting to users of at-line as-
says as well. As discussed in Chapter 1.1.2, heterogeneous assays are very laborious and 
should thus be avoided. We use certain terms like bioassay or biochemical assay in the 
way defined in Chapter 1.1.2 despite their much broader meaning. The most obvious re-
quirement for HRS is a suitable, robust and sufficiently sensitive analytical platform. There-
fore, the setup of such a platform is the first topic [Chapter 2.1.1]. It includes practical tips 
to design a state-of-the-art analytical system for HRS. The second part [Chapter 2.1.2] is 
dedicated to data analysis which needs special attention due to the innate complexity of the 
data obtained in HRS. Furthermore, certain concepts in HRS data analysis, some of which 
are still under development, are just a bit different than in high-throughput screening (HTS) 
or in conventional chromatographic detection. These concepts are needed to fully harness 
the advantages of HRS platforms over HTS platforms, but awareness of sources of error is 
critical, especially where the concepts are not fully developed yet [Chapter 2.1.2]. Screen-
ing campaigns at the scale realized in HTS have rarely been realized for HRS (except [1]), 
in fact to the best of our knowledge none including post-column HRS assays. Therefore, 
many lessons remain to be learned.
2.1.1. The high-resolution screening platform
An HRS platform consists of four essential parts, as exemplified in Figure 1. At the core is 
a separation setup which allows the different analytes of a mixture to be detected individ-
ually by separating them in time. In order to allow two parallel detection techniques, one 
for structure and one for effect analysis (affinity, activity or functional), the effluent of the 
separation step has to be divided. This is achieved by a flow split in the second part. The 
third and fourth part constitutes the two parallel detection techniques being the bioassay 
detection and mass spectrometry (MS), respectively. The bioassay detection reports the 
effect, by which we mean the bioactivity or bioaffinity towards the target protein. MS gives 
information about the chemical composition and structure of the analytes. These four stag-
es are scrutinized subsequently.
2.1.1.a) Separation
We identified the purpose of the separation step as being the separation of the different 
analytes in a mixture on the time scale. In other words, we seek to obtain a virtual chro-
matogram, virtual because we do not (necessarily) subject the eluent to a detection method 
yet. An efficient separation is desired meaning as many fully separated compounds in as 
little time as possible. Thus, standard state-of-the-art chromatographic or electrophoretic 
equipment should be utilized. While this point is of course true for any separation, there are 
significant differences to separations with more classical detectors like ultra-violet/visible 
spectrophotometers (UV) which can mainly be attributed to the very specialized bioassay 
detection. We focus on high-performance liquid chromatography (LC) as other separation 
techniques, e.g., incorporating electrophoretic separations, are still rare [3]. 
The most important stepping stone is the innate incompatibility of many classical LC mobile 
phase constituents (and flow rates) with the bioassay detection. The main reason for this 
incompatibility is the unfolding/denaturation of the target protein which is triggered by ex-
cessive concentrations of organic modifiers after post-column mixing of effluent and protein 
[4]. Additionally, extreme acid, salt or base content or immiscibility of non-polar solvents 
with the aqueous buffers used in the bioassay detection could interfere when using for 
example ion-exchange [5] or normal-phase LC, respectively. Fortunately, standard RP-LC 
solvents like acetonitrile and especially methanol usually only produce unfolding at higher 
concentrations [6]. Thus, compatibility can often be achieved by suitable dilution of the 
eluent with the bioassay reagent solutions. If several reagent addition steps are involved, 
the compatibility has to be achieved in the step in which the target protein is added, usually 
the first, as once unfolded protein molecules often remain denatured even after additional 
dilution. For example, the sEH bioassay features a ca. 1:11 dilution in the first enzyme 
mixing step, but only a 1:0.15 dilution when the substrate is mixed in [Chapter 2.3]. In the 
p38α bioassay, the influence of the gradient on the baseline is much more pronounced, be-
cause the first mixing step is 1:5 though the total mixing dilution (DM) is with 1:9 similar that 
in the sEH assay (Attention: The baselines are straightened by background subtraction.) 
[Chapter 2.2].
However, dilution is often an important challenge in HRS. Dilution reduces the final con-
centration at the point of detection and thereby reduces the sensitivity of the HRS platform. 
There are two dilution steps involved for the bioassay detection. The first one is chromato-
graphic dilution (DC). It is a result of diffusion and convection which transforms the initially 
homogeneous injection plug into a concentration gradient by mixing with the solvent flow. 
The result is the (nearly) Gaussian signal distribution so typical for chromatographic sepa-
rations. Depending on the interplay between injection volume (Vi), flow rate in the bioassay 
detector (uBio) and void volume, the maximum concentration of the analyte is diluted and 
the signal height is reduced. Though we can consider increasing the ratio of Vi to uBio, 
this has a negative influence on the separation due to the consequential increase in peak 
width. The second dilution DM was already mentioned above. It is exactly the same dilution 
that appears when sample and reagents are mixed in a beaker or well plate, for example 
in HTS. DM exclusively occurs in the bioassay detection. Firstly, electrospray ionization 
(ESI) MS does not usually need reagents or suffers as much from incompatibility with LC. 
Secondly, even if a makeup flow is desired, the reduced ionization efficiency at higher flow 
rates can be more than compensated by suitable additives and/or an increased organic 
modifier concentration. We have a more quantitative look at dilution in the respective data 
analysis section (Chapter 2.1.2.a)). Suffice it to say for now that total dilution is usually in 
the order of 50 to 100 times, therefore thus far impairing the HRS measurements of low 
concentration samples, for example from clinical or animal studies.
We have discussed compatibility of the separation with the biochemical detection, but 
compatibility with MS is equally important, though usually easier to achieve. Surely, it is 
superfluous to recap here the hyphenation of HPLC and MS as there are excellent books 
and reviews on that topic [7,8]. However, one has to be aware of the many mobile phase 
Figure 1: Example of an HRS setup. A typical single assay HRS platform is depicted like 
the ones developed in Chapters 2.2 and 2.3, where detailed descriptions can be found. 
Fluorescence is probably the most widely used bioassay detection in HRS, but other tech-
niques such as fluorescence polarization have been employed as well. When using MS 
for both structure and affinity measurements, these two detections are usually combined 
in one instrument [2]. As discussed in Chapter 1.1.4.a), MS instruments offering both frag-
mentation as well as high mass accuracy provide the most useful data for structure eluci-
dation.
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additives that are used to enhance ionization efficiency. For example, formic acid (FA) is 
often used in concentrations of 0.1% to 1% (v/v) to enhance ESI+ efficiency. FA, like any 
other acid, salt or base, can result in two major interferences with the bioassay. Firstly, 
the pH of the bioassay which is crucial for the protein-ligand interaction can be affected. 
Secondly, interaction of any kind, for example ionic or hydrophobic, with the protein can 
denature its structure. This adds to the influence of the organic modifier and might lead 
to more unfolding. In Chapter 2.2, for example, even 0.1% (v/v) FA in the mobile phase in 
combination with methanol caused unacceptable protein unfolding. In this case, reducing 
the mobile phase content of FA to 0.01% (v/v) resulted in a sufficient compromise between 
bioassay compatibility and enhancement of ESI+ efficiency. 
The influences on the bioassay described above are less critical with isocratic elution LC, 
because they are at least constant. When gradient chromatography is used in HRS, this 
leads to changing assay conditions during the chromatographic run, due to the changing 
modifier content. Mainly, the assay window (the maximum signal) is reduced with increas-
ing protein unfolding. Furthermore, in assays based on signal reduction, the high signal 
baseline decreases as a consequence of protein unfolding which complicates peak detec-
tion and integration. On the one hand, this can be prevented by increasing DM to the point 
where the change in influence is negligible compared to the noise and in return accepting 
the accompanying decrease in sensitivity. On the other hand, the changing assay window, 
as long as it sufficiently large over the whole gradient, does not prevent effect detection 
nor does it significantly change measured IC50 values. Additionally, the increased modifier 
concentration reduces tailing and precipitation of excessively hydrophobic compounds in 
the bioassay. The tradeoff here is the increased protein concentration which ensures a suf-
ficient assay window at higher modifier concentrations. Issues with (manual and automatic) 
peak detection and integration can be minimized by subtracting a blank gradient run from 
every bioassay chromatogram [Chapter 2.2]. Another possible interference of the gradient, 
which has to be taken into account during assay development, is a change in detection 
properties of the analyte or tracer (in the bioassay detection), such as fluorescence wave-
length, quantum yield or ionization efficiency.
Two solutions have been offered to combine gradient chromatography with bioassays 
aiming to eliminate the drawbacks, i.e., a counter gradient system and high-temperature 
LC. The counter gradient system is an intricate setup which splits off half of the LC flow 
pre-column to a storage unit and releases it post-column in reverse order during the next 
run [6]. Alternatively, a second gradient LC system can be coupled post-column with which 
the mirror image of the LC gradient is pumped [9]. As a result, the solvent entering the bio-
assay is always approximately a 50:50 mix of both LC solvents. The baseline shift during 
gradient elution is reduced with only a 2-fold dilution. However, the system adds quite 
some complexity to the HRS platform. Additionally, it is limited to symmetrical gradients 
and switching between two gradient programs requires at least once the gradient run time. 
Alternatively, high-temperature liquid chromatography (HTLC) employs isocratic solvent 
elution in combination with a temperature gradient. As solvents change their polarity with 
temperature, for example water reaches the polarity of methanol at around 200°C, HTLC 
can very effectively replace organic modifier gradients in RP-LC. Because the effluent is 
cooled post column, there is no influence of the gradient on the bioassay. Though tempera-
ture stability of the analytes can be an issue, HTLC offers great advantages in combination 
with bioassays [10]. In some cases, the solvent can be simplified down to pure water with-
out compromising the separation allowing minimization of DM [11]. However, adsorption of 
hydrophobic analytes in the bioassay and MS sensitivity can become issues at these very 
low modifier concentrations.
In conclusion, the composition of the mobile phase is a compromise between separa-
tion efficiency, ionization efficiency and compatibility with the bioassay. The choice of the 
stationary phase is thus often limited by these restrictions. The flow rate and column di-
mensions are discussed in the following paragraph as this is, via DM, closely linked to the 
concept of flow splitting.
2.1.1.b)	Flow	splitting
Flow splitting has two main functions: 1) to allow the parallel use of several detectors, and 
2) to control the flow rate at which the eluent is provided to either detector. We first discuss 
principles behind flow splitting and the attributes of a good flow split. Later, we go into detail 
on how to optimize the split ratio.
Flow splitting is achieved by providing more than one exit for the eluent after the separation 
step. The total flow rate applied during the separation (uLC) then divides itself according to 
the resistance encountered. That means that the flow rate towards each exit (e.g. uBio and 
uMS) is such that the resistance or, in LC terms, the backpressure experienced as a conse-
quence of this flow rate is the same in all lines. One way to make a simple split is to take 
a connector with 1+N connections where one is connected to the LC column and N is the 
number of desired exits. The exits are then fitted with tubing of various dimensions. When 
calculating these dimensions, the first decision to be made is the operating pressure of 
the split. On the one hand, it should be high enough to compensate for post-split pressure 
differences and variations. For example, at an operating pressure of 50 bar, a difference 
of 1 bar in two lines already causes 2% change in split ratio while at an operating pressure 
of 5 bar the same interference renders the split effectively useless because of a 20% er-
ror. On the other hand, the pressure from the split adds to the demand on the LC system 
and should therefore not be excessive. While especially with analytical and microbore LC 
columns the optimal flow rate for separation is often only reached at backpressures over 
100 bar, standard LC equipment has an upper limit between 200 and 400 bar. Pressures of 
40 to 60 bar in the flow split have proven to be a sensible compromise. 
Of course, the pressure is not only dependent on split dimensions but also on solvent 
viscosity and total flow rate. Solvent viscosity is especially tricky to handle as it changes 
during a chromatographic gradient. However, this change does not influence the split ratio. 
For ease and safety of calculating and testing a split, it is useful to employ water as solvent. 
However, it is always necessary to check that the pressure is still sufficiently high for a sta-
ble split ratio at the lowest viscosity encountered in the gradient and that at the highest vis-
cosity the combined backpressure of column and split does not exceed the system limits. 
The uLC is determined mainly by the separation and by MS compatibility, the latter because 
the majority of the flow is usually directed towards this detector. Though it would be pos-
sible to add a waste line to the split in order to divert excess flow, the split is the part of 
the HRS system most liable to failure, the possibility of which increases with the number 
of exits. Additionally, splits with a larger number of exits are also increasingly complicated 
to prepare. Therefore, it is often preferred to match the column dimensions to the MS ion 
source to achieve compatibility without additional splitting. The influence of the split ratio on 
the decision for uLC is limited. The bioassay is usually carried out with a concentration-de-
pendent detector, for example a fluorescence detector. However, the split ratio has no 
direct influence on the concentration of the analyte in the fraction of eluent that enters the 
bioassay. The fraction of total injected analyte mass entering the bioassay, which is equiv-
alent to the split ratio, is of interest merely in samples considered mass limited with respect 
to the high absolute sensitivity of both HRS detectors [12]. 
There are also commercial solutions available for flow splitting, which operate by the same 
principles. In some variants, the split ratio is adjustable within a limited range. However, 
when using a costly commercial flow splitter, the integration of a sufficiently fine particle 
filter between column and split is advised as clogging of the split is a frequent problem es-
pecially in matrix intensive samples.
2.1.1.c) Bioassay
The flow rate directed towards the bioassay (uE) is a result of the desired DM and the flow 
rates at which the bioassay reagents are mixed in (uR1+uR2) (see Equation 1). This is ex-
emplified with values taken from the sEH HRS platform in Equation 1 [Chapter 2.3]. uBio 
is preferred to be as low as possible to minimize reagent consumption, while the ratio of 
uR1 to uE should be large enough to prevent protein unfolding (see Chapter 2.1.1.a). Both 
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are important as the purified protein often makes up for the bulk of the running cost of the 
HRS platform. There are two factors which limit minimization of the reagent flow. The flow 
rate needs to be exceptionally stable which becomes an increasing technical challenge the 
lower the flow rate is, which also sets a limit to the ratio of uR1 to uR2. Additionally, uBio has 
to match the dimensions of the optical detector used in the bioassay part to avoid extensive 
peak broadening in the detector cell. Thus, miniaturization of the bioassay by employing 
micro- or even nano-fluidic instrumentation promises significant cost reduction [13].
 Equation 1
One strategy frequently employed to stabilize the reagent flow is the use of pulse dampen-
ers. A main contribution to flow instability is the sinus-shaped fluctuation resulting from the 
work cycle of the pump pistons. This is true provided the appropriate measures (solvent 
degassing and regular seal maintenance) have been taken to prevent the formation of air 
bubbles in the solvent delivery system. The pulses are smoothened by passing the solvent 
over an oil-supported, impermeable membrane in the pulse dampener. For its function, it is 
necessary to apply high pressure to the solvent which is achieved by a restriction capillary 
providing 100+ bar backpressure. 
We can gain distinct advantages by delivering the reagents indirectly instead of pumping 
them through an LC pump. This can be achieved by running the pump on deionized water 
which is passed through a pulse dampener and restriction capillary to generate a stable 
solvent flow which in turn operates a superloop. A superloop is a plastic covered glass cyl-
inder. Both ends are sealed watertight but provide a standard LC connection. The cylinder 
also hosts a moveable, water tight piston. On the inlet side, the water enters the superloop 
and pushes the piston. On the outlet side, the reagents are stored. By the movement of 
the piston, the reagents are pushed out at the same flow rate as the water enters. The 
reagents are then mixed with the LC eluent. By using this setup, we save reagent solution 
as we need only fill the transfer tubing from superloop to mixer and not the significant void 
volume of an LC pump with reagent. By keeping the void volume of the transfer tubing low, 
the equilibration time, needed to achieve a stable assay baseline, is also shortened. In ad-
dition to saving expensive reagents, the setup reduces maintenance and increases lifetime 
of the pump as contact with chemical and/or biological reagents is avoided. The superloop 
is also easily cooled by placing it in an ice bucket. This allows to run an HRS system for 
days, depending on the stability of protein or reagents, without interruption.
There are a number of measures we should consider to achieve an optimal performance 
of the superloop. The piston should move as freely as possible within the superloop. Thus, 
regular greasing is essential. While filling the superloop with reagent solution and water, air 
bubbles should be avoided. These increase fluctuations in the outlet flow as they compress 
and decompress every time the piston movement is slightly hindered. Because prevention 
of air bubbles is not always possible, the superloop should be stored with the inlet slightly 
elevated. This at least prevents artifacts from release of the bubbles into the reactors during 
the analysis. The specific described superloop type has a pressure limit of around 10 bar.
Mixing of the eluent with the reagents is achieved with a T-piece. The mixing in an on-line 
post-column bioassay is highly efficient, especially when coiled reactors are used which 
is discussed later. This is one of the major advantages over well plate or test tube based 
assays and the reason why shorter incubation times can be achieved at similar reagent 
concentrations [Chapter 2.3]. 
Although, being essentially only a simple piece of PEEK, PTFE or fused silica tubing, 
much attention has to be devoted to the reactors in post-column bioassays. One reason 
is the fact that we purposefully introduce additional void volume between separation and 
detection. This necessarily leads to reduced separation efficiency by peak broadening. 
The efforts described in the following are only justified if other prominent sources of void 
volume are also meticulously managed. Minimal void volume connectors and T-pieces 
should be utilized and special attention has to be directed to avoiding ill-fitted connections. 
In addition, excessively large spectrophotometric detection flow cells compared to uBio are 
a main cause of peak broadening [14]. From post-column derivatization, the coiled open 
tubular reactor (coiled reactor) was adopted to reduce peak broadening. It is simply a spe-
cially ‘knitted’ PTFE tubing which induces secondary flow patterns thus increasing radial 
mass transfer and reducing peak broadening [15]. By increasing the radial mass transfer, 
the coiled reactor also contributes to the mixing of eluent and reagents. Other contribu-
tors to the deterioration of the separation are interaction between the reactor material and 
the analytes. In PEEK and PTFE reactors, these are mainly hydrophobic interactions. We 
therefore recently proposed to use chemically modified fused silica tubing for highly lipo-
philic analytes [Chapter 2.2]. Chemical modification is necessary, as the use of untreated 
fused silica results in strong dipole-dipole or ionic interactions of the free silanol groups 
with nitrogen containing moieties often found in drug-like molecules. Instead, by chemical-
ly modifying the fused silica, its surface properties can be tuned to minimize interactions 
with the respective analyte. For example, polyethylene glycol (PEG) modified fused silica 
tubing has been successfully used for highly lipophilic drug-like molecules [Chapter 2.2]. 
A disadvantage of the fused silica tubing is that its low flexibility does not allow knitting it 
in the same way as the PTFE tubing. Therefore, depending on whether void volume or 
adsorption is the main cause of peak broadening, a choice must be made between coiled 
PTFE or straight fused-silica reactors until such time when fused-silica reactors with the 
knitted-coil geometry become available. A third option, which however has been applied 
only in miniaturized assay formats so far, is the use of glass microfluidic chips [13,16]. Like 
fused silica tubing, they can be deactivated by chemical modification [13]. On top of that, 
microfabrication of chips offers a lot of freedom in designing the flow paths. The introduc-
tion of hair-pin curves prevents a laminar flow profile [17], and thus enables efficient mixing 
and avoids excessive peak broadening (see above).
For optimal performance, the inner diameter (I.D.) of the tubing should match the flow rate 
applied. Additionally, this results in a large surface-to-volume ratio which is favorable for 
the heat transfer [15]. This tight and rapid temperature control is another advantage of the 
HRS over a classical HTS system and a second reason why shorter reaction times can be 
achieved [Chapter 2.3]. Furthermore, incubation, especially for longer times at elevated 
temperatures, in HTS results in evaporation, which is a major source of errors in HTS. Due 
to the (virtually) closed system, this is no issue in HRS. Of course, minimizing the I.D. is 
limited practically by the pressure limits of the superloop and economically because the 
length increases with the square of the diameter reduction. An I.D. around 250 µm pres-
ents the most common compromise, but longer incubation times might require 500 µm or 
750 µm I.D. tubing.
We have now discussed the delivery and mixing of a reagent with the column effluent. 
However, usually, there are at least two different reagents needed. On one hand, the en-
zyme or receptor whose interaction with or manipulation by the analytes is studied, and 
on the other hand, the substrate or tracer indicating inhibition of or affinity with the target 
protein. These two reagents might be delivered in one [13] or two separate steps [Chap-
ter 2.2 and 2.3]. Delivering protein and tracer with the same superloop reduces the com-
plexity and cost of the system. Whether the reagents can be pre-mixed, depends on the 
bioassay principle. For example, it is obviously not possible for bioactivity assays. Due to 
the short incubation times typical in HRS (usually ≤5 min), affinity assays can be negatively 
influenced as well. While binding to the protein is usually quite fast, competition reaches 
equilibrium significantly slower [18]. Therefore, it is often favorable for the sensitivity of the 
affinity/activity detection to make a first mixing and incubation step of the protein with the 
eluent, thus allowing fast association with the analytes, and then to introduce the substrate 
or tracer. Nonetheless, for binders with slow association kinetics (small kon), which do not 
reach equilibrium in the first incubation step, concentration sensitivity of the affinity mea-
surement is lowered and IC50 values are underestimated. This issue may also be observed 
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in bioactivity assays.
Of course, as in any biological assay, the post-column bioassay should be buffered and 
contain the appropriate co-factors, for example NADPH or Mg2+. Sometimes, reagents like 
BSA are added to improve protein stability. On top of that, chemicals may be added which 
help to prevent adsorption of analytes, proteins and substrate/tracer to the coiled reactors. 
This presents a major challenge, especially due to the large surface-to-volume ratio in HRS 
(see above). Often, reagents which are classically employed to counter unspecific binding 
are used to this end. A few examples are ELISA blocking reagent, PEG or lactic acid. These 
have the additional advantage of preventing unspecific binding to the target protein, but 
their influence on protein stability has to be carefully monitored. 
Detection of substrate conversion or tracer competition is most often achieved with a chro-
matographic fluorescence detector. When using a spectrophotometric LC detector, a main 
source of interference are air bubbles in the detector cell. These can be effectively prevent-
ed by creating backpressure at the detector outlet, either by sufficiently narrow I.D. waste 
tubing or by using commercially available backpressure regulators. Herein, the pressure 
limits of the detector cell as well as of the superloops have to be carefully observed to 
prevent damage to the system. However, usually a pressure excess of only 1–4 bar is 
sufficient.
In most cases, fluorescence detection (usually of a tracer) is preferred because it is superi-
or to other detectors in combining sensitivity, selectivity and linearity, while still being appli-
cable to a large number of molecules. Sensitivity is very important as it is directly related to 
reducing reagent consumption and therefore the assay cost. Selectivity is a prerequisite for 
any homogeneous assay, as the detection should not be disturbed by other bioassay con-
stituents present [19]. For example, in an activity assay with fluorescence product detec-
tion, the substrate should not show similar fluorescence properties [Chapter 2.3]. Linearity 
is also important, but rarely a hurdle. Two orders of magnitude linearity allow the detection 
of 2–200% binding or activity which is more than sufficient to obtain good IC50 curves for 
both inhibitors as well as agonists/ligands.
2.1.1.d) MS detection
As elaborated in Chapter 1.1.4.a), structure elucidation by MS has become an integral 
part of HRS. HR-MS instruments are preferred as accurate analyte masses and superior 
full-spectrum sensitivity can be obtained. The strength of HRS lies in the analysis of mix-
tures of unknown compounds, and this application requires full-spectrum acquisition in-
stead of SRM or neutral loss methods. In addition, firstly, the limit of detection with respect 
to the injected concentration is usually lower for drug-like molecules in the MS response 
than in the bioassay, partly due to DM. Secondly, the data acquisition speed of the MS 
instrument is not a limiting factor. Therefore, the full-spectrum speed and sensitivity of 
HR-MS instruments is sufficient, and the advantages of (triple) quadrupole MS in speed 
and sensitivity of targeted analysis are irrelevant to HRS. As for related compounds, much 
structure information is obtained from fragmentation analysis. HR tandem MS instruments, 
like quadrupole–time-of-flight (Q-TOF) or ion-trap–time-of-flight (IT-TOF) combinations, are 
ideally used in HRS setups. The differences in the spectral data obtained from unit-reso-
lution MS instruments as compared to HR-MS instruments have been discussed in Chap-
ter 1.1.4.a). The resulting differences in the depth of structure elucidation are plainly visible 
when comparing earlier HRS systems featuring unit-resolution MS [20] with the data re-
ported in Chapter 4.1.
In case the bioassay is also based on MS detection, an interesting synergy is the combina-
tion of structure and affinity measurements within one MS instrument [2].
2.1.2 Data analysis
2.1.2.a)	Differences	between	HRS	and	HTS
Influence of shorter incubation times
As the incubation time is generally limited to max. ~5 min by peak broadening, incubation 
times are often much shorter in on-line bioassays than in HTS assays. Note that this is 
not applicable to HRS assays based on high-resolution fractionation, as in such cases the 
bioassay is essentially decoupled from the LC, and thus does not have to take place within 
the LC timescale. One of the consequences is that competition between the analytes and 
the tracer/substrate in on-line bioassays is more likely to be under kinetic rather than under 
thermodynamic control (compare Equation 2). This can have an influence on the detected 
IC50 values and the sensitivity of the assay. In the two superloop setup, this creates a bias 
towards binders/inhibitors with a slow dissociation kinetic (koff). However, as current opin-
ion sees slow koff as favorable due to a link with better PK/PD properties, this bias seems 
acceptable [21]. When looking to association kinetics (kon), most binders/inhibitors reach a 
significant amount of binding in 30 s of pre-incubation. The sensitivity of the assay is there-
fore only negatively influenced in binders/inhibitors with a very slow kon. 
       Equation 2
Slow assays might not be possible, but on-line assays usually allow quite a time reduction 
from HTS.
The assay signal
One difference in data analysis between HRS and HTS is the calculation of the signal which 
is directly linked to the origin of the reference. In HTS, the reference is represented by the 
control sample which gives the assay readout without any observable effect. Replicates 
produce a mean and standard deviation (SD) of the control, µC and σC, respectively. This is 
essentially an external reference. In another experiment, mean and SD of the sample are 
obtained, µS and σS, respectively. The signal is then calculated by subtracting the means 
|µS–µC|. In HRS, no control sample needs to be measured. The baseline of the on-line bio-
assay readout provides an easily accessible and highly relevant internal reference for each 
individual sample. Thus, the signal in HRS is identified as the peak height (|µH|). Therefore, 
contrary to HTS, changes in the background do not influence the signal which results in a 
lower SD of the peak height (σH) compared to σS. However, changes in the (theoretical) sig-
nal at full effect, the assay window, are equally uncorrected. The variation of the reference, 
also called the noise, is usually calculated differently in HRS than in HTS (see σC). Instead 
of calculating the standard deviation of the baseline, the maximum deviation of the baseline 
signal is calculated which is more easily accessible. This is halved to account for positive 
and negative deviation from the baseline. Though the noise is slightly overestimated in this 
way, this method is more robust in dealing with baseline changes due to gradient elution.
In bioassays, there is always a (spectrometric) signal which indirectly visualizes the under-
lying bioactivity/bioaffinity. For correct measurement of this signal, the chromatographic de-
tector has to be within its linear range. However, the resulting concentration-signal depen-
dence is not linear due to the underlying biochemical interaction. If the detector response 
is linear, the typical sigmoidal dose-response curves result when plotting |µH| against the 
logarithm of the concentration. However, the influence is not limited to the peak height. As 
in any chromatographic peak, the analyte molecules are distributed according to a Gauss-
ian distribution because of the longitudinal diffusion of the initially homogenous injection 
plug (Vi), each data point has its own analyte concentration. This results in a distortion of 
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the ideal Gaussian shape in the bioassay detection. Fortunately, the sigmoidal curve has 
a significant pseudo-linear part, usually between 10 and 90% of the assay window, thus 
allowing the calculation of important peak parameters like the full width at half maximum 
(FWHM) (see Figure 4). However, if |µH| is outside this pseudo-linear range, the conse-
quences are much the same as if a classical signal would be outside the linear range. For 
example, if µH is above 90% of the assay window, the FWHM increases as the flanks of the 
peak are still growing linear while the peak is not, the so-called overloading effect.
While the use of signal intensity (height) is natural to a pharmacologist, as HTS and other 
batch assays simply do not show peaks, separation scientists prefer working with peak ar-
eas, as these are less sensitive to fluctuations in the separation than the peak heights are. 
The most prominent assumption is the detection of an underlying (pseudo-) linear phenom-
enon. However, in order to obtain reliable IC50 values, we would like to acquire sufficient 
data points in the non-linear parts of the dose response curve (this increases the quality of 
the data fitting), automatically violating that assumption. As a consequence, employing the 
peak area of the bioassay response would create a relatively large, systematic y-error in 
the asymptotic region of the dose-response curve (see Figure 4). Due to the fact that the 
curve is asymptotic towards a y-value, the x-value error caused by distortion of the FWHM 
calculation is far less influential. More importantly, while the y-value error in the peak area 
increases continuously with increasing injected concentration, the x-value error in the cal-
culated concentration becomes increasingly meaningless with increasing x-values. In ad-
dition, the FWHM of the pseudo-linear range might be used for the non-linear range thus 
reducing the x-error for the most affected data points close to the pseudo-linear range. The 
determination of IC50 values from the dose-response curve is discussed in more detail in 
the next section.
Dilution calculations
As explained earlier, there are two types of dilution, DM and DC, whose product forms the 
total dilution D. While DM represents essentially the same step as the mixing of the ana-
lyte solution with the assay reagents necessary in HTS, DC is unique to HRS. DM is sim-
ply calculated by dividing the total flow rate through the bioassay detector (uBio) by the 
flow rate with which the analyte containing effluent enters the bioassay (uE). DC results 
from the transformation of the injection volume (Vi) into the near-Gaussian distribution (see 
Chapter 2.1.1a)) and can therefore be calculated by Equation 3. With DM and DC, we can 
calculate the final concentration (cF) at µH from the injected concentration (ci), using Equa-
tion 5. It has to be remembered, however, that Equation 5 is derived for an ideal Gaussian 
distribution which means that the results grow less accurate the more the shape of the 
bioassay peak deviates from the ideal (see discussion in the previous section). Therefore, 
this concept should be further developed in the future to include deviations from the ideal 
distribution, for example, by including the peak tailing factor in a revised equation.
        Equation 3
        Equation 4
        Equation 5
MS structure elucidation
Most often HRS is used for the analysis of mixtures of related molecules. These are mix-
tures of molecules that (often) have the same or similar core structures. They can be de-
rived, for example, from chemical or biochemical diversification approaches [Chapter 3] or 
they could be different molecules from one class or type of natural products [12,22]. The 
structure of individual compounds is identified by a combination of accurate-mass mea-
surements and CID-fragmentation experiments (see also Chapter 1.1.4.a)). As HRS often 
deals with unknown compounds, data-dependent acquisition (involving switching between 
MS and MSn mode) is of key importance. MS instrument settings should be optimized us-
ing an available model compound from within the compound class targeted at expected 
concentrations. If data-dependent precursor selection fails, the afflicted experiments have 
to be repeated with manual precursor selection after data processing of the MS1 data. Pep-
tides and small proteins might be elucidated (partly) by database comparison [12] or by top-
down proteomics approaches. For small molecules, the first step is deducing the elemental 
composition of the parent ion. To this end, a range of elemental compositions pre-selected 
from prior knowledge of the analyte class, modification pathways, etc. is matched to the ac-
curate mass. Based on the stringency in matching accurate and exact mass and the range 
of elemental compositions allowed, one or more elemental compositions are yielded. For 
the fragmentation analysis, the elemental compositions can be limited to that of the precur-
sor ion. Specific neutral losses can then be used to identify functional groups and elucidate 
their connectivity [Chapter 1.1.4.a)]. If several possibilities for the precursor ion exist, some 
wrong elemental compositions might be uncovered through proof by contradiction that is if 
no sensibly neutral losses connect the precursor ion with the product ions. 
Figure 4: Theoretical dose response curve. The dots represent the curve which would be 
expected when using peak height as readout. The triangles at high concentrations present 
the systematic y-value error which would occur when using peak area instead of peak 
height.
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Structure-affinity matching
Matching the structure and the affinity of a molecule by matching its MS and its bioaffinity 
response starts by aligning the extracted ion currents (EIC) of the MS detection with the 
bioaffinity chromatogram (e.g. from the fluorescence detector). As both chromatograms 
result from the same chromatographic run, one chromatogram is simply time-adjusted for 
the stable retention time delay (Δr) which is a consequence of differences in post-column 
void volume. Variations in flow rate could cause Δr to vary. Therefore, the SD of the total 
retention time could be used as a boundary [Chapter 3.1]. All MS peaks with retention times 
(tr,MS) within this SD around the bioaffinity peak with tr,BIO are accepted as peaks potentially 
having bioaffinity. This is evidently overcautious, especially considering all measures taken 
to ensure flow stability in the bioassay, because the analytes usually spend significantly 
more time in the separation part than post-column. Additionally, variations in temperature 
and solvent composition influence only the chromatographic retention time and not the 
additional time spend post-column. However, other factors are usually more crucial for an 
accurate peak matching (see below). In most HRS setups, the FWHM of the bioaffinity 
peaks is larger than the SD of tr let alone the deviation of Δr. Especially when dealing with 
overloading (see above) in either of the responses, peak maxima and consequently tr-val-
ues can be difficult to identify. Therefore, we often mark both MS and bioaffinity peaks at 
their onset rather than at their top, because this is better defined. Nonetheless, this may 
result in different marks for the same compound depending on its concentration and thus 
in unstable retention time differences for different compounds, because the onset is further 
away from tr in a broad peak than it is in a sharp peak. Consequently, the variation in peak 
width (Δw) is another criterion for the accuracy in the peak matching and overloaded peaks 
have to be even more carefully assigned. If peaks are assigned on the onset, it is more 
logical to use the width at 10% rather than FWHM. Δw can be deduced, for example, from 
IC50 measurement curves during the validation and then 0.5•Δw can be used in the same 
way as described for the SD of tr above. The alignment of the two chromatograms and the 
matching via Δr can also be tested and possibly adjusted if a known affinity compound is 
present. However, co-elution of other affinity compounds and overloading of either the MS 
or the bioaffinity response can influence this matching as well.
2.1.2.b) Validation
Validation is the final stage of every assay development, not excluding HRS systems. In 
HRS, we usually start by validation of the bioassay and add the MS later for further vali-
dation of the whole setup. A good first validation step is the measurement of a number of 
specific assay parameters which give a quick first quality assessment of the assay and if 
necessary show potential for improvement. Simple measurements reveal all contributions 
to the background signal as well as the assay window [Chapter 2.3]. An assay window 
(for calculation see below) with a signal-to-noise ratio (S/N) between 50 and 100 is an 
indication of a good-quality bioassay, because it allows detection (S/N≥3) of the flat part of 
the sigmoidal curve between 5 and 10% signal and quantitation (S/N≥9) of (most of) the 
pseudo-linear part of the sigmoidal curve between 10 and 90% signal [Chapter 2.2 and 
2.3]. The former greatly enhances sensitivity of the bioassay, the latter is essential to ob-
tain good-quality IC50 values. If sufficient S/N is not yet reached, the individual background 
contributions provide a clue to which part still has to be optimized. For example, if by far the 
largest contribution comes from the tracer, decreasing the tracer concentration or increas-
ing the enzyme concentration are obvious starting points. It should be mentioned here that 
sometimes lower S/N for the assay window are preferred due to cost considerations or 
other limitations, excepting the loss in assay quality [13,23]. 
We quickly explain how two important benchmarks of bioassay quality can be calculated 
in an HRS setup, the assay window and the Z’ factor [24]. For both of them, we need µH at 
full inhibition or binding (µHmax) as well as the baseline noise. For activity assays, µHmax can 
often be found by comparing the signal at the incubation temperature and at 0°C (where 
virtually no enzymatic reaction is observed). Injection of an analyte concentration which 
results in complete inhibition or binding is a way to find µHmax which works in both activity 
and affinity assays. To calculate the S/N of the assay window, we simply divide µHmax by 
the noise. The Z’-factor as defined for HTS is given in Equation 6 [24]. Like the S/N, it re-
flects the ratio between the noise and the assay window. However, in contrast to S/N, the 
Z’-factor accounts for the deviation in the signal as well as in the baseline, and thus for the 
likelihood of both false negatives and false positives. To measure the Z’-factor, the mean 
(µ) and SD of positive (subscript C+; maximum signal) and negative control (subscript C–; 
no signal) have to be determined.
        Equation 6
With the adjustments discussed in Chapter 2.1.2.a), we derived the Z’Chrom-factor for HRS in 
Equation 7 [Chapter 2.2]. μC+–μC- is identified with µHmax and consequentially, SDC+ changes 
to SDHmax. As discussed, the baseline represents the internal (negative) control and there-
fore SDC- becomes the noise.
        Equation 7
HRS platforms have been successfully used to quantify the affinity/activity of analytes by 
measuring their IC50 values. However, this is no core strength of HRS platforms as to 
this end they still rely on purified compounds as much as HTS platforms, due to the as 
yet missing capacity of HRS platforms to quantify unknown compounds (see Chapter 5). 
Nonetheless, it is valuable to discuss the measurement of IC50 values in HRS platforms. In 
the context of validation, good sigmoidal curves confirm that signal changes observed are 
indeed due to interaction of the analytes with the target and do not result from (non-spe-
cific) interferences or artifacts. If literature values measured with the same assay principle 
are available, the actual IC50 values provide a validation. However, great caution is advised 
when comparing IC50 values as there are many pitfalls. Even seemingly identical assay for-
mats can show major differences. A classic example is the use of different substrates in an 
activity assay, but sometimes changes in buffer constituents might impact the interaction of 
analyte and target as well. Additionally, kinetics might impact IC50 values when comparing 
assays with largely different incubation times (see Chapter 2.1.2.a), Influence of shorter 
incubation times) [Chapter 2.2] [18]. However, this is by no means an issue unique to HRS, 
although it appears more pronounced than in HTS. In terms of application, measuring IC50 
values with HRS sometimes offers an advantage as well. Due to the influences discussed 
in The assay signal [Chapter 2.1.2.a)], HRS assays are often either of higher quality at the 
same protein concentration or necessitate a lower protein concentration to achieve the 
same quality. While the influence of the former on IC50 value quality is evident, the latter 
allows a better distinction of high-affinity binder/inhibitors [Chapter 2.2]. The reason is that 
half of the protein concentration (cP) is the theoretical lower limit of measurable IC50 values, 
because below that limit the enzyme is simply titrated. For example, we have cp of 90 and 
450 nM in an HRS assay and in an HTS assay, respectively, and an analyte with an IC50 
of 45 nM. If we add the analyte at 45 nM, it interacts with 50% of the protein in the HRS 
assay thus correctly giving an IC50 value of 45 nM. Note that also all analytes with higher 
affinity yield this value. If we add the same analyte concentration to the HTS assay, it only 
occupies 10% of the protein binding sites. Only with 225 nM of the analyte, we reach 50% 
interaction thus the apparent IC50 in the HTS is 225 nM (0.5•cP). We should add that this 
advantage is more often observed in affinity assays as in activity assays the cp can be re-
duced by increasing the incubation time.
Similar to HTS, IC50 values are determined by measuring a series of concentrations and 
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fitting the resulting dose-response curve. To this end, the individual concentrations of the 
pure compound are injected into the HRS platform. This can be done either in flow injection 
analysis (FIA) mode accounting for the injection peak by subtraction of a blank injection 
or by isocratic elution with minimal retention thus separating the injection peak. Then, the 
critical step is the calculation of cF by dividing the injected concentration ci by the two dilu-
tion events (see Equation 5). The models and algorithms used for fitting the dose-response 
curve and calculating the IC50 are the same as in HTS. Theoretically, it is possible to de-
duce individual IC50 values by injecting a dilution series of a mixture. The repeatability of 
IC50 values in HRS systems seems to be quite good, as can be judged by almost identical 
values obtained for TAK-715 in different studies (81 nM (71 to 92 nM) [Chapter 2.2] and 
71 nM (36 to 140 nM) [Chapter 3.2]). 
A good approach to test the complete HRS platform, and especially the structure-affinity 
correlation, is the analysis of mixtures of pure compounds, preferably containing both effec-
tors (inhibitors, ligands, etc.) and non-binders [Chapter 2.2] [13]. The first indication is that 
the correct number of compounds is detected in the MS response and that only as many 
signals as effectors are detected in the bioassay response. Then, the MS and bioassay 
responses are matched blindly and the compounds are identified from the MS response. 
Only the effectors should show bioaffinity.
2.1.3 Conclusions
The strong link between molecular structure and individual biological effect, which is cre-
ated by the integration of separation, bioassay and structure elucidation, is undoubtedly 
the greatest potential of HRS. In addition, the (virtually) closed system, the efficient mixing 
and heat exchange, and the internal control offered by the baseline hold the possibility to 
achieve high-quality bioassays in the on-line post-column mode. Though throughput is 
not a primary attribute of HRS, the data density intrinsic to the approach is so high that it 
presents both a potential and a challenge. Similar to any hyphenated system, a challenge 
is presented by finding a useful compromise between the complex requirements of each 
individual analytical technique. However, such a compromise has been reached in various 
ways and sometimes even synergies become evident. Dilution is a key factor to compat-
ibility, but at the same time one of the biggest hurdles for HRS sensitivity (with regard to 
amount and concentration LOD). We have shown that a great number of the (data analysis) 
concepts, generally applied to bioassays, can be adapted to HRS, though some of these 
derived concepts would surely benefit from further refinement. Exploring the potentials of 
HRS can certainly lead to routine application in the future, especially if accompanied by 
continued technical development of the systems.
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Abstract
A high resolution screening method was developed for the p38α mitogen-activated protein 
kinase to detect and identify small molecule binders. Its central role in inflammatory 
diseases makes this enzyme a very important drug target. The setup integrates separation 
by high performance liquid chromatography with two parallel detection techniques. High 
resolution-mass spectrometry gives structural information to identify small molecules 
while an on-line enzyme binding detection method provides data on p38α binding. The 
separation step allows the individual assessment of compounds in a mixture and links 
affinity and structure information via the retention time. Enzyme binding detection was 
achieved with a competitive binding assay based on fluorescence enhancement which has 
a simple principle, is inexpensive and easy to interpret. The concentrations of p38α and the 
fluorescence tracer SK&F86002 were optimized as well as incubation temperature, formic 
acid content of the LC eluents and the material of the incubation tubing. The latter notably 
improved the screening of highly lipophilic compounds. For optimization and validation 
purposes, the known kinase inhibitors BIRB796, TAK715 and MAPKI1 were used among 
others. The result is a high quality assay with Z’-factors around 0.8, which is suitable 
for semi-quantitative affinity measurements and applicable to various binding modes. 
Furthermore, the integrated approach gives affinity data on individual compounds instead 
of averaged ones for mixtures.
Introduction
Kinases are certainly among the most important target classes in contemporary drug 
discovery [1]. The mitogen-activated protein kinase p38 (p38) is one prominent example 
of a drug-target kinase especially its most important isoform p38α [2, 3]. It is involved 
in signal transduction pathways, transmitting signals through successive activation 
by phosphorylation [4]. Being one of the important mediators for a cell’s response to 
extracellular stimuli, this pathway presents a promising opportunity for drug intervention [5]. 
Because p38α is heavily involved in inflammation processes, the envisaged diseases are 
mostly chronic inflammatory diseases like rheumatoid arthritis, psoriasis or Crohn’s disease 
[6]. Several p38α inhibitors, which target these diseases, are currently in different stages of 
preclinical and clinical development up to phase II [7, 3]. Nearly all known kinase inhibitors 
show interactions with the highly conserved ATP-binding pocket. Therefore, most early 
kinase inhibitors, possessing only these interactions, exhibited poor kinase selectivity [5]. 
Although different systems of categorization exist, these will be called type I inhibitors. Type 
I inhibitors used in this study are TAK715 [8], MAP kinase inhibitor 1 (MAPKI1) from Merck 
KGaA [9] and SK&F 86002 (SKF) [9]. The discovery of an allosteric binding pocket adjacent 
to the ATP-binding site led to the discovery of inhibitors using both sites (type II). BIRB796 
is a prominent example of this type of binding [10, 11]. Consequently, type III binders 
like 1-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-3-(4-chlorophenyl)urea (pyrazolourea) are 
targeting only this allosteric site [12]. The type IV inhibitors are not binding to either of the 
two pockets, as has been discovered e.g. for GNF-2 binding to the Brc-abl kinase [13]. 
The importance of p38α has led to a multitude of assay principles for the identification 
of small molecules targeting this kinase [14, 15]. Among the cell-free in vitro formats for 
p38α, those based on activity and those based on affinity can be distinguished. As readout 
for activity based methods, scintillation [11] and fluorescence polarization [16] have been 
used among others [14, 15]. These formats require expensive reagents (antibodies, etc.) 
and rely on labels which can impair the usefulness of results, or they involve handling 
radioactivity. In addition to these drawbacks, activity assays can, by definition, not employ 
the non-phosphorylated kinase as target. This is the advantage of affinity based assays. 
However, scintillation [17], chemiluminescence [16] and fluorescence polarization [18] 
suffer from similar reagent based drawbacks as mentioned above. Furthermore, some label 
free technologies, like surface plasmon resonance [16] or isothermal titration calorimetry 
[19], have been employed, which avoid additional reagents and the problems of molecular 
probes. Still, these techniques are complex and instrumental requirements and logistics 
may limit their throughput. A relatively simple approach was used by Pargellis et al during 
the discovery of BIRB796 [10, 11]. The method is based on fluorescence enhancement 
and requires solely native p38 and the small molecule kinase inhibitor SKF. SKF shows 
fluorescence, which is strongly enhanced upon binding to the target enzyme. Therefore, 
high fluorescence intensity indicates a high concentration of the enzyme-tracer complex. A 
compound showing affinity to the target enzyme will compete with the tracer thus reducing 
the concentration of enzyme-tracer complex and thereby reducing the fluorescence. This 
principle enables a competitive binding assay in a homogeneous setup, which is based on 
the strong difference in fluorescence intensity between the free tracer and the enzyme-tracer 
complex. Because of its convenience and the possibility to use non-phosphorylated p38α 
as target, this technique presented a good basis for the development of a high resolution 
screening (HRS) platform. HRS is defined by the combination of separation and screening 
in an integrated system. Therefore, it enables the affinity assessment and the simultaneous 
structural characterization of individual compounds in mixtures [20, 21]. This feature makes 
HRS platforms especially attractive when complex mixtures such as metabolic incubations 
[22], combinatorial mixtures [21] or natural extracts [23] are screened where dereplication, 
affinity and structural information are crucial. In contrast to conventional high throughput 
screening (HTS), isolation of individual compounds not showing affinity can be avoided. 
Thus, the laborious development of high yield synthesis and isolation methods can be 
limited to compounds showing the desired affinity. One common approach in HRS is the 
use of on-line post-column assays, which have been recently reviewed by Shi et al [24]. 
Colourimetry, fluorescence and mass spectrometry based readouts were developed in 
both homogeneous and inhomogeneous formats. Homogeneous setups are easier to 
apply, so their significance exceeds inhomogeneous setups in cases where background 
fluorescence is of minor importance. However, HRS formats described so far are either 
activity based [21, 23] or target a receptor [20, 22]. We report the implementation of the 
enzyme p38α as the first kinase to be targeted in an on-line post-column binding assay 
(HRS system). Furthermore, the screening of highly lipophilic molecules was greatly 
improved by the unprecedented use of covalently modified fused silica tubing as material 
for post-column incubation, resulting in improved affinity signals.
Materials and Methods
Materials
Human recombinant p38α, ORGX, BIRB796 and TAK715 were a kind gift of MSD research 
laboratories (Oss, The Netherlands). SKF and MAPKI1 were purchased from Merck KGaA 
(Darmstadt, Germany). ELISA blocking reagent was delivered by Roche Diagnostics 
(Mannheim, Germany). Pyrazolourea was obtained from Ambinter (Paris, France). All other 
chemicals were from Sigma-Aldrich (Schnelldorf, Germany). Fused silica tubing (250 μm 
inner and 375 μm outer diameter) untreated or covalently coated with PEG, methyl or 
methyl/phenyl groups was also purchased from Sigma-Aldrich (Schnelldorf, Germany). 
96 ‘flat’ bottom chimney well, black polypropylene microtiter plates from Greiner bio-one 
(Alphen a/d Rijn, The Netherlands) were used. Methanol (LC-MS Grade) and formic acid 
(ULC-MS Grade) were obtained from Biosolve (Valkenswaard, The Netherlands). Purified 
water was generated with a Milli-Q academic from Millipore (Amsterdam, The Netherlands).
Instrumentation
96 well plate experiments were performed on a Victor3 plate reader from Perkin-Elmer 
(Groningen, The Netherlands). The setup used for the on-line assay included two LC-20AD 
and two LC-10AD isocratic pumps, a SIL-20AC autosampler, one CTO-20AC and one 
CTO-10AC column oven, an RF-10AXL fluorescence detector, a CBM-20A controller and 
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an Ion Trap-Time-of-flight (IT-TOF) mass spectrometer equipped with an ESI source all 
products of Shimadzu (’s Hertogenbosch, The Netherlands). HR-MS spectra were obtained 
from m/z 200 to 650 switching positive- and negative-ion mode with 10 ms accumulation 
time each. The curved desolvation line and the heating block were equilibrated at 200°C 
and the voltages applied were 5 kV to the interface and 1.7 kV to the detector. Nitrogen 
(99.9990%) was used at flows of 1.5 L/min and 10 L/min as nebulising gas and drying gas, 
respectively. To allow accurate mass measurements, external calibration of the IT-TOF was 
performed using TFA clusters.
Furthermore, two superloops and two pulse dampeners made in house were used.
Plate Reader Assay
A 20 mM TRIS-HCl buffer (pH 7.5), containing 10 mM MgCl2, 2 g/L PEG 6000 and 0.2 g/L 
ELISA blocking reagent (TRIS buffer), was used in all experiments. All solutions of p38α 
were prepared in TRIS buffer. Enzyme stock solutions were stored at –80°C until use. 
During on-line experiments, the enzyme solutions were kept at 0°C. A stock solution of 
SKF (2 mM) was made in DMSO and further diluted with TRIS buffer. Solutions of inhibitors 
were prepared in water:methanol 1:1 containing 0.01% formic acid from 2 mM or 5 mM 
stock solutions in methanol (DMSO in case of MAPKI1). Small molecules stock solutions 
were stored at -20°C.
For plate reader measurements, the wells were filled with 50 μL enzyme solution, 12.5 μL 
inhibitor solution and 50 μL SKF solution in the given order. Fluorescence was measured 
at 25°C with the wavelength of absorption and emission being 355±4 nm and 405±5 nm, 
respectively. The sum of ten flashes was used as readout to improve performance. 
Saturation of a 90 nM solution of p38α with SKF was determined by using a concentration 
range from 40 nM to 2500 nM of SKF. The Z’-factor is a measure for assay quality. If not 
otherwise stated, it was calculated according to the original publication of Zhang et al [25]. 
A more detailed explanation is given in the results and discussion section. Measurements 
of the Z’-factor dependence on enzyme concentration were performed on three days with 
five repeats per day and a final concentration of 3 μM SKF. For full inhibition, TAK715 
was added to a final concentration of 1 μM, while the control values contained only the 
corresponding amount (see above) of HPLC solvents.
On-line Assay
HPLC solvents were water:methanol 100:1 (solvent A) and methanol:water 100:1 (solvent 
B) both containing 0.01% formic acid. The instrumental setup described by de Vlieger et 
al [20] was used for the analysis with one enzyme binding detection line and the following 
modifications (cf Figure 1). HPLC was done either in flow injection analysis mode (FIA – 
where no separation column is present) or with a SunFire C18 column 30 x 2.1 mm, 3.5 μm 
particles (Waters, Milford, MA, USA) (Figure 1 - 2). 10 μL of the sample were injected 
(Figure 1 - 1) into a flow of 113 μL/min. Elution was performed at 40°C either isocratic at 
different methanol concentrations or using a binary gradient. Post-column, the flow was 
split 1:9 (Figure 1 - 3), sending 100 μL/min to high resolution/mass spectrometry (HR-MS) 
detection and 13 μL/min to the enzyme binding detection. To the 13 μL/min HPLC eluent, 
first 50 μL/min of a 200 nM p38α solution were added (Figure 1 - 4) and thereafter 50 μL/
min of a 1400 nM solution of SKF (Figure 1 - 6). These solutions were constantly released 
by a linear setup of an LC-10AD pump, a pulse dampener with restriction capillary and a 
superloop each. Following each addition, the mixture was incubated in PEG deactivated 
fused silica loops of 25 μL (Figure 1 - 5) and 20 μL (Figure 1 - 7), respectively. The incubation 
loops were kept at 25°C in a second column oven. The resulting incubation times were 
24 s for the target-ligand interaction (Figure 1 - 5) and 11 s for the target-tracer interaction 
(Figure 1 - 7). Finally, at concentrations of 90 nM p38α and 630 nM of SKF the fluorescence 
was measured with excitation at 355±7.5 nm and emission at 425±7.5 nm (Figure 1 - 8). 
The used detector settings were gain 4, recorder range 1 and sensitivity medium.
The influence of the methanol concentration on the maximum signal was assessed in two 
consecutive measurements. To this end, a stepwise gradient was used starting at 100% 
A and increasing the fraction of B by 15% approximately every 10 min. In the first run, 
the baseline without inhibition was recorded. In the second run, MAPKI1 was added to 
the SKF solution for full inhibition, reaching a final assay concentration of around 0.9 μM. 
By comparing these measurements, the assay window in relation to the different organic 
modifier concentrations can be estimated.
In order to assess the influence of the incubation tubing material, two measurements were 
carried out, in which the volume and therefore the incubation time was kept constant: In 
the first experiment, polyether ether ketone (PEEK) of 250 μm and 170 μm inner diameter 
(ID), polytetrafluoroethylene (PTFE) of 250 μm ID and untreated fused silica of 250 μm ID 
were compared by injecting a 2 μM solution of ORGX in FIA mode at 60% B. In a second 
experiment, 250 μm ID fused silica tubing with covalent coatings of different polarity 
were compared. In these experiments, a 20 μM solution of ORGX was injected in FIA 
mode at 60% B. The coatings were PEG (polar), a mixture of phenyl and methyl groups 
(intermediate) or methyl groups only (non-polar). 
The on-line Z’-factor was calculated from triplicate injections each of a control (blank) 
experiment and a full inhibition sample on five different days. The full inhibition sample 
was a mixture of 50 μM BIRB796, 20 μM ORGX and 20 μM TAK715 while the control 
sample was a 1:1 mixture of the solvents. The separation was carried out with the following 
gradient: 0 to 1.0 min isocratic at 50% B, 1.0 to 12.5 min linear to 90% B, 12.5 to 14.5 min 
isocratic at 90% B, 14.5 to 15.0 min linear to 50% B and 15.0 to 21.0 min isocratic at 50% B.
MAPKI1 and TAK715 were tested in a mixture with six drug molecules to simulate a 
screening situation. Carbamazepine, norethisterone, warfarin, phenylbutazone, celecoxib 
and diclofenac were used as test compounds without p38α affinity. TAK 715 was injected 
at 20 μM concentration, the others at 50 μM. The mixture was separated with the following 
gradient: 0 to 2.0 min isocratic at 50% B, 2.0 to 32.0 min linear to 70% B, 32.0 to 38.0 min 
isocratic at 70% B, 38.0 to 38.5 min linear to 50% B and 38.5 to 50.0 min isocratic at 50% B.
For the measurements of IC50 values, isocratic elution was applied, taking care that the 
substance peak showed separation from the injection peak. TAK715 was eluted at 85% B, 
BIRB796 at 50% and MAPKI1 at 70%. Solutions of nine different concentrations for each 
inhibitor were prepared in 50% methanol, 50% water and 0.01% formic acid from 5 mM 
stock solutions of TAK715 and BIRB796 in methanol or a 2 mM stock solution of MAPKI1 
in DMSO. The following concentrations for each inhibitor were prepared: 50 nM, 100 nM, 
Figure 1: Scheme of the on-line setup. The system enables the separation of mixtures and 
subsequent parallel detection of enzyme binding and accurate mass. The samples are injected (1) 
into and separated (2) by an HPLC system. The eluent is split (3) between HR-MS and enzyme 
binding detection. The fraction which enters the enzyme binding detection is mixed with the target (4) 
and the tracer (6), and incubated after each mixing step (5 & 7). Finally, the fluorescence is measured 
(8) as readout of affinity towards p38α. In parallel, the second part of the eluent is analyzed by HR-
MS (9), delivering structural information to identify the small molecules tested.
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200 nM, 500 nM, 1 μM, 2 μM, 5 μM, 10 μM and 20 μM for TAK715; 500 nM, 1 μM, 2 μM, 
5 μM, 10 μM, 20 μM 50 μM, 100 μM and 200 μM for BIRB796 and 200 nM, 500 nM, 1 μM, 
2 μM, 5 μM, 10 μM, 20 μM 50 μM and 100 μM for MAPKI1. These nine concentrations and 
a blank were injected in triplicate for every inhibitor. 
To finalise the binding mode studies, the pyrazolourea compound was used as an example 
of a type III inhibitor. It was injected at a concentration of 100 μM and tested under isocratic 
conditions at 70% B. 
Results and Discussion
Assay conditions optimization
Optimization was carried out in a 96 well format. The protocol of Regan et al [10] was 
used with some modifications. Since Mg2+ ions are known to be involved in ATP binding 
and can potentially influence binding of inhibitors to the ATP binding site, MgCl2 was 
added. Furthermore, ELISA blocking reagent and PEG 6000 were added in order to avoid 
non-specific binding and unwanted interactions with the material of the enzyme binding 
detection [26]. Enzyme and tracer concentrations were optimized under these conditions. 
The fluorescence signal showed a linear dependence on the enzyme concentration (cf 
Online Resource 1 Figure S1). The most suitable p38α concentration was therefore 
chosen considering the Z’-factor measurements. The signal dependence on the tracer 
concentration, depicted in Figure 2A, displays the asymptotic form of saturation behaviour. 
The final concentration of 630 nM SKF is selected to be slightly above the saturation 
value. This choice presents a compromise between avoiding deviations of the signal 
due to variability in the tracer concentration and maximising the sensitivity with regard to 
detection limits for binders. Namely, competition reduces this sensitivity with increasing 
tracer concentration.
There are several factors mainly related to the HPLC separation system, which can have 
a negative influence on the assay performance. Methanol, formic acid and the incubation 
temperature are the most prominent of these variables. Using typical HPLC conditions 
such as 50% methanol and 0.1% formic acid at 37°C completely inhibited the fluorescence 
enhancement. As a result, these factors were carefully optimized and need to be controlled 
cautiously. The influence of organic modifier at no and full inhibition is shown in Figure 2B. 
The assay window decreased with increasing organic modifier (methanol) content. However, 
the Z’chrom-factors for the different compounds measured at different MeOH concentrations, 
due to gradient elution, showed only minor differences thereby proving the robustness 
of the on-line setup even at high methanol concentrations. Increasing temperature also 
yielded a similar decrease in maximum signal as seen with methanol. In order to guarantee 
robustness and enable the use of up to 90% methanol in the HPLC separation, the formic 
acid concentration in the eluent and the incubation temperature were restricted to 0.01% 
and 25°C, respectively. Hence, the temperatures of the HPLC separation step and the 
enzyme binding detection were controlled separately.
The screening of highly lipophilic compounds is not only challenging in off-line screening 
due to adhesion and solubility issues [27] but also presents challenges in on-line screening 
approaches [26]. In on-line screening systems, the amount of organic modifier is usually 
kept low to prevent protein degradation. On the other hand, the tubing used for incubation 
loops is mostly PEEK or PTFE. The favoured interaction of non-polar compounds with 
these surfaces results in peak broadening and tailing, thus decreasing resolution and 
sensitivity. By using polar material for the incubation loops, this effect was significantly 
decreased. Figure 3A shows a two to threefold increase in signal height and reduced tailing 
when untreated fused silica tubing is used instead of PEEK. Although, PTFE compared to 
PEEK already yields decreased peak width, the width is additionally approximately halved 
with untreated fused silica. The polarity of the incubation coil material plays a crucial role 
explaining these findings. This can clearly be seen in Figure 3B where the influence of fused 
silica tubing with covalent coatings of different polarities on the peak shape was compared. 
The polar (PEG coated) tubing gave the best results while peak height and shape degraded 
towards intermediate (methyl/phenyl coated) and non-polar (methyl coated) surfaces. This 
indicates the influence of tubing polarity on post-column band broadening and justifies a 
preference of polar coated fused silica tubing over PEEK and PTFE in the presented study, 
taking the structural features of the studied compounds into account. 
Validation of the p38α binding assay
The quality of the p38α binding assay was assessed using the method of Zhang et al [25]. 
The Z’-factor is introduced as a single value to judge assay quality, because it incorporates 
the SD of signal and background as well as the assay window. Therefore, it indicates the 
ability to distinguish between signals and false positives or false negatives. According to 
this method, the Z’-factor was calculated with equation 1 for several enzyme concentrations 
in the plate reader based setup. μs and μc are defined as the average signal of the sample 
and the control, respectively. Consequently, σs and σc are the standard deviations (SD) of 
these values.
      Equation 1
Figure 2: Optimization of the p38α affinity assay. A) Saturation curve of the tracer for 90 nM p38α 
(n=3). Full saturation was reached at 630 nM SKF, which was consequently the selected tracer 
concentration.
B) Influence of the organic modifier concentration on the enzyme binding detection. I) is the baseline 
at different percentages of organic modifier in HPLC mobile phase, which shows the maximum signal 
reached at these different MeOH concentrations. In opposition, line II) shows the fluorescence signal 
at maximum inhibition hence the difference between both lines describes the maximum assay window. 
II) was measured by premixing SKF with MAPKI1 (900 nM final concentration) in the superloop.
A
B
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For the sake of comparability, the number of experiments (n=15) was kept the same in plate 
reader and on-line based measurements. However, this is recognized as a relatively low 
number for plate reader experiments. Therefore, an additional plate reader experiment with 
n=50 was performed, yielding a Z’-factor of -0.02. The conclusion from both experiments 
was as follows: The plate reader based assay at 90 nM p38α gave insufficient results 
with Z’-factors lower than 0. In the plate reader assay, a Z’-factor above 0.5, indicating 
an excellent assay, could only be achieved by raising the p38α concentration to 450 nM. 
Table 1 compares this data with the results of the on-line setup, in which 90 nM p38α was 
sufficient for an excellent assay. As a confirmation, the signal to noise ratios (S/N) were 
also calculated (Table 1), resulting in the same conclusions.
Regardless of the findings of the last paragraph, the on-line setup has two disadvantages. 
Reagent consumption is usually higher in an on-line setup than in a plate reader based assay. 
Furthermore, the separation step introduces an additional dilution due to chromatographic 
peak broadening, which requires higher analyte concentrations. There are additional 
differences between the two setups, which should be adequately reflected in the Z’-factor. 
Kool et al. already applied the Z’-factor to chromatography based on-line assays, adapting 
the variables of equation 1 in order to take into account these discrepancies [28]. A main 
advantage is the internal control value (μc) represented by the baseline, which is more 
relevant than an external control, because it is available for each individual experiment. 
For a complete consideration of the differences between the on-line and the plate reader 
setup, all classical variables are systematically substituted with parameters more suitable 
to the on-line approach. Doing this without compromising the comparability of this Z’-factor 
is not trivial but possible. The assay window (μc-μs), as determined by the difference of the 
mean of control (no inhibition) and signal (full inhibition), could more suitably be expressed 
as the mean of the peak height of full inhibition (μH), thereby still describing the desired 
parameter. Thus, the assay window is automatically corrected for changes in the baseline, 
representing the internal control. The SD of the sample (σs) would then consequentially 
be identified with the SD of the peak heights at full inhibition. For the control, usually no 
signals are obtained and changes of the baseline between samples are irrelevant as they 
have already been taken into account. The SD of the control (σc) can therefore logically be 
identified with the baseline deviation within one sample. This value is in chromatography 
better known as the noise. The measure of three times the noise is often used as limit 
of detection. This is consistent with the ideas behind the Z’-factor as both interpretations 
of 3σc are aimed at avoiding false positives. In summary, the transition from an external 
control to an internal one strengthens the reproducibility and accuracy of the assay and 
should therefore be appropriately reflected in the determination of Z’-factors. Therefore, an 
adjusted Z’-factor for the use in on-line systems is proposed in equation 2 on basis of the 
previous argumentation.
         Equation 2
Figure 3: Influence of the reaction coil material on the peak shape. A) PEEK and PTFE were 
compared with untreated fused silica tubing. A 2 μM solution of ORGX was injected in FIA mode 
at 60% methanol. B) At the same conditions, a 20 μM solution of the same inhibitor was injected. 
Fused silica tubing with covalent coatings of either PEG (polar), a mixture of methyl and phenyl 
groups (intermediate) or only methyl groups (non-polar) was compared for their influence. In both 
experiments, peak width and asymmetry increased with decreasing polarity while the peak height 
decreased as a consequence. Fused silica tubing, coated with PEG (polar), exhibited drastically 
improved performance over the compared materials.
Figure 4: Comparison of MS and enzyme binding detection chromatogram. The matching of the 
fluorescence trace of the enzyme binding detection (above) and the total ion current (TIC) of the MS 
(below) for BIRB796 (1), ORGX (2) and TAK715 (3) are shown. Depicted is a triplicate from the Z’chrom-
factor determination. The excellent reproducibility in response, peak shape and retention time are 
clearly visible for both the enzyme binding detection and the MS signal. The low variability enables 
an easy and accurate matching of the two traces.
Table 1: Z’-factors and signal to noise rations (S/N) for plate reader 
and/or on-line based enzyme binding detection
Inhibitor a c (p38α) [nM] Z’ or Z’chrom 
b (n=15) S/N
Plate reader TAK715 90 -0.41 4
180 0.49 12
270 0.36 23
360 0.49 55
450 0.75 48
On-line BIRB796 90 0.77 70
ORGX 90 0.82 106
TAK715 90 0.80 97
a Concentration of the inhibitor was 1 μM TAK715 (final concentration) in the plate reader experiments. 
In the on-line setup ORGX and TAK715 were injected at 20 μM concentration and BIRB796 at 50 μM 
concentration for this purpose.
b In the plate reader experiments the Z’-factor was calculated according to equation 1. For the on-line 
experiments, equation 2 was used, yielding the Z’chrom-factor.
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The new interpretation of the Z’-factor could also be used to omit the measurements of a 
control, significantly shortening the time of Z’chrom-factor determination. Because the noise 
is calculated from the baseline of the chromatogram, a prerequisite is to have an empty 
time frame to observe both required values. Therefore, the first 4 min of the enzyme binding 
detection chromatogram were used to determine the noise. The mean noises calculated 
from signal and control runs were identical, thus proving the redundancy of the control 
measurements for Z’chrom-factor determinations.
The repeatability of triplicates is excellent, which is clearly visible in Figure 4, 5 and 6. This 
is true for the enzyme binding detection responses as well as for the chromatographic 
parameters like peak width, measured as full width at half maximum (FWHM), and retention 
time (tr). For the enzyme binding detection, the relative SDs are ≤10% for FWHM and <3% 
for tr. Low variability and noise compared to the total signal results in the high Z’-factor and 
signal-to-noise ratio (S/N) shown in Table 1. The high Z’-factors indicate the excellent intra- 
and interday reproducibility, However, the on-line setup showed comparable Z’-factors 
at five times lower enzyme concentration than needed in the plate based assay. This is 
directly related to the minimal measurable IC50. While IC50 values down to 45 nM can be 
distinguished in the on-line method, the plate reader method only allows differentiation 
of IC50 values of 230 nM and higher. Furthermore, the higher enzyme concentration 
needed diminishes the advantage of the plate setup with regard to reagent consumption. 
Therefore, the on-line setup has advantages beside the additional possibilities associated 
with separation.
High resolution screening of mixtures
In order to assess whether the presented HRS method was suitable for the identification of 
small molecule binders of p38α in mixtures, a solution of eight compounds was screened. 
Two of these were the kinase inhibitors MAPKI1 and TAK715 while the other six were 
drug molecules from different classes. As illustrated in Figure 5, all eight compounds could 
be separated for individual identification and affinity assessment. Based on HR-MS data, 
the structure was linked to a retention time. Accurate mass measurements enabled the 
unambiguous distinction of all compounds as two of them differed by less than 0.05 u. 
In case of more scarce knowledge of the sample, structure elucidation can be facilitated 
by HR-MSn experiments [21]. In parallel to the structure confirmation, the retention time 
is also linked with affinity information through the enzyme binding detection. However, 
the readout of the enzyme binding detection is delayed compared to the HR-MS readout, 
because of a higher void volume and a lower average flow rate after splitting. This delay 
was measured to be 0.5 min by comparing both detection times in several experiments. It 
remains constant as long as void volume and flow rates are unchanged. The retention time 
corrected for this delay is used to couple affinity to identity information. Two affinity peaks 
were detected, which were linked to the elution of the kinase inhibitors. In conclusion, 
the approach presents a fast method to match the structure and activity of compounds in 
mixtures.
Semi-Quantitative affinity measurements
Several known p38α inhibitors were tested for their dose related responses in the enzyme 
binding detection. Therefore, their injected concentrations had to be converted to final 
assay concentrations by taking into account the dilution factors. On one hand, splitting of 
the HPLC eluent and subsequent mixing with the reagents leads to dilution. This can be 
easily calculated from the ratios of the flow in the beginning and the end of the enzyme 
binding detection (113/13 = 9). On the other hand, the chromatographic dilution, meaning 
the transition from an injected plug to a series of peaks of (assumed) Gaussian shape, has 
to be taken into account. The corresponding calculations have been described elsewhere 
[29]. The necessary peak parameters were taken from the enzyme binding detection. 
By dividing the injected concentration by the product of both dilution factors, the final 
concentration at maximum peak height can be calculated and used in the IC50 calculations 
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Figure 5: HRS of a mixture of kinase inhibitors and drug molecules. MAPKI1 (4) and TAK715 (8) were 
mixed with carbamazepine (1), norethisterone (2), warfarin (3), phenylbutazone (5), celecoxib (6) and 
diclofenac (7). The mixture was separated by HPLC and measured with HR-MS and enzyme binding 
detection in parallel. Accurate mass measurements with low deviation (<8ppm) and well matching 
isotope patterns allowed unambiguous identification. Structure and affinity were easily matched via 
the corrected retention times. Consequently, the two affinity compounds were detected in the mixture.
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Figure 6: Quantitative data of the tested p38α inhibitors. Binding curves are depicted for several 
known p38α inhibitors. The inhibitors TAK715 (circles), BIRB796 (squares) and MAPKI1 (triangles) 
are shown. Standard deviations of triplicate measurements were smaller than data point size.
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(for a brief description see Online Resource 1).
Dose-response curves depicted in Figure 6 were measured in triplicate with excellent R2-
values of >0.998 and minimal standard deviation (SD) of the triplicates (<2% SD relative to 
assay window). This shows again the excellent reproducibility and accuracy of the assay. 
The IC50 values and, given in brackets, their 95% confidence intervals, calculated after 
correcting the concentrations for the dilution factors are 81 nM (71 to 92 nM) for TAK715, 
400 nM (360 to 440 nM) for BIRB796 and 760 nM (530 to 1100 nM) for MAPKI1. If the 
inhibitors are ranked for their affinity, the obtained results are in agreement with other 
methods, stating values of 7.1 nM for TAK715 [8], 18 nM for BIRB796 [10] and 35 nM for 
MAPKI1 [9]. However, the absolute values of measurements are 10 to 20 times higher 
than in literature. This can be explained by the profound differences in the assay formats. 
While the reported method gives affinities, the reference values were obtained by either 
activity assays (TAK715) or cell based functional assays (BIRB796, MAPKI1). Another 
specific reason responsible for this deviation is the slow binding kinetics of BIRB796. This 
compound is known to show an up to 12-fold deviation of its IC50 value, depending on the 
incubation time [11]. Despite the aforementioned issues, the method was proven to be 
suitable for the semi-quantitative assessment of small molecule relative affinities towards 
p38α serving as a selection tool in the drug discovery process.
Applicability and binding modes
The type of binding to p38α as discussed in the introduction can have a significant influence 
on the ability of a screening technology to detect this binding. SKF is a type I binder and 
should therefore enable the detection of type I and type II binders as they compete for the 
ATP-binding pocket. This has been proven by the detection of TAK715 and MAPKI1 (type 
I) as well as BIRB796 (type II). Furthermore, structural changes in p38α upon binding of 
type III inhibitors may allow the detection of such compounds. The rearrangement of p38α 
from the DFG-in to the DFG-out conformation results in a reorientation of Phe405 thereby 
affecting the ATP-binding pocket. Hence, we tested the pyrazolourea structure, which 
was discussed by Simard et al as an example of a type III inhibitor [12]. Figure 7 shows 
the enzyme binding detection of this compound to p38α, thereby proving the suitability of 
the method for the detection of type III inhibitors. Consequently, the assay is capable of 
detecting a wide range of p38α binders including type I, II and III binders.
Conclusion
An on-line binding assay for the separation and parallel assessment of identity and 
affinity of small molecules in complex mixtures towards non-phosphorylated p38α was 
developed. In terms of applicability, the scope of the presented HRS platform is different 
from conventional HTS assays. HTS is more suited for the screening of huge libraries 
where speed and low sample consumption are essential. The value of HRS lies in the 
parallel determination of structural and biochemical data of potential binders. While an 
HTS assay will only give a sum of compound affinities, HRS gives individual information 
on all (separated) molecules. The aim was to make available the advantages of the on-line 
approach, mainly the measurement of mixtures and a comparison of structure and affinity, 
for the important drug target p38α. An on-line post-column enzyme binding detection 
based on fluorescence enhancement was developed and its compatibility with modern 
HPLC separation techniques, such as gradient elution and increased temperature, was 
demonstrated. HR-MS as parallel readout is an integral part of the developed screening 
platform, allowing the identification of the tested molecules. Additionally, the prospects of 
measuring compounds individually in mixtures were demonstrated by matching identity 
and affinity. Regarding the presented assay validation data, it can be stated that a high 
quality assay was achieved. Finally, the assay provided ranking of various p38α inhibitors 
(types I, II and III) allowing the use within a drug discovery process.
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Figure S1: Baseline signal dependence on enzyme concentration in the plate reader setup. The 
maximum fluorescence, equivalent to the maximum enzyme-tracer complex concentration, was 
measured at different enzyme concentrations. 1250 nM of SKF were used. The data justifies the 
homogeneous setup as it proves the insignificance of the background fluorescence at the tested 
concentration. Furthermore, it suggests that the assay is tuneable to a desired compromise between 
quality and enzyme consumption.
Calculation of final inhibitor concentration
There are two factors of dilution which diminish the concentration of the tested compound 
in the enzyme binding detection. The first arises from the mixing of the HPLC eluent with 
the reagents of the enzyme binding detection. It can therefore be called mixing dilution 
(DM). DM is easily calculated by dividing the final flow rate in the fluorescence detector (uF) 
with the flow rate of the HPLC eluent entering the enzyme binding detection (uE), because 
this represents the ratio of volumes in any given time frame.
         Equation S1
The second factor is the chromatographic dilution (DC). It can be calculated assuming 
a symmetrical peak of Gaussian shape. Based on this assumption, the ratio between 
the height of a plug of the injection volume and the resulting Gaussian peak equals the 
dilution factor. Influences are the full width at half maximum (FWHM), the flowrate in the 
HPLC (uC) and the injection volume (Vi). It is imperative that the FWHM is taken from the 
fluorescence and not from the MS chromatogram. The bigger void volume in the enzyme 
binding detection leads to a broader peak because of diffusion and surface interactions.
         Equation S2 [1]
By combining these two factors the final concentration (cF) of the binders can be determined 
from the injected concentration (ci).
         Equation S3
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Abstract
In this study, an end-point based fluorescence assay for soluble epoxide hydrolase 
(sEH) was transformed into an on-line continuous-flow format. The on-line biochemical 
detection system (BCD) was coupled on-line to liquid chromatography (LC) to allow 
mixture analysis. The on-line BCD was based on a flow system wherein sEH activity was 
detected by competition of analytes with the substrate hydrolysis. The reaction product was 
measured by fluorescence detection. In parallel to the BCD data, UV and MS data were 
obtained through post-column splitting of the LC effluent. The buffer system and reagent 
concentrations were optimized resulting in a stable on-line BCD with a good assay window 
and good sensitivity (S/N > 60). The potency of known sEH inhibitors (sEHis) obtained by 
LC–BCD correlates well with published values. The LC–BCD system was applied to test 
how oxidative microsomal metabolism affects the potency of three sEHis. After incubation 
with pig liver microsomes, several metabolites of sEHis were characterized by MS, while 
their individual potencies were measured by BCD. For all compounds tested, active 
metabolites were observed. The developed method allows for the first time the detection 
of sEHis in mixtures providing new opportunities in the development of drug candidates.
Introduction
Soluble epoxide hydrolase (sEH) plays an important role in regulation of blood pressure, 
pain and inflammation [1]. In mammals, sEH is expressed in various tissues. The 
endogenous substrates of sEH are among others epoxyeicosatrienoic acids (EETs), which 
are hydrolyzed to dihydroxyeicosatrienoic acids (DHETs), thus leading to decreased blood 
levels of EETs. Various studies show, that EETs and epoxides of other unsaturated fatty 
acids are anti-inflammatory, analgesic agents and lower blood pressure [2; 3; 4]. The 
biological levels of epoxy fatty acids can be increased by sEH inhibitors (sEHis), leading to 
reduction in inflammation, pain, and cardiovascular diseases in various animal models [5; 
6]. Thus, sEHis are a promising new class of pharmaceutical drug candidates.
During the lead development process, metabolism studies play an important role. Not 
only the pharmacokinetic profile, but also the biological effects of metabolites are relevant 
for the action of drugs. Metabolites can be inactive, reactive, but also pharmacologically 
active towards the same pharmacological target or against off-targets. Screening metabolic 
mixtures for individual bioactive metabolites is not possible with standard end-point plate-
reader based screening methodologies. For sEH, several end-point assays have been 
developed, based on fluorescent detection, radiometry, and mass spectrometry [7; 8; 9]. 
However, these assays are only suited to screen pure compounds. The analysis of mixtures 
would only yield the sum of the total bioactivity of the mixture [10]. In order to assess the 
bioactivity of individual metabolites, fractionation has to precede the screening. As this is 
time-consuming, costly, and has to be performed at low resolution to prevent too much 
dilution, such approaches are inefficient for bioactivity profiling of metabolic mixtures [11]. 
One way of tackling this problem is the application of an on-line post-column screening 
approach, known as high-resolution screening (HRS) [12]. This technology continuously 
mixes bioassay reagents with the eluent after an LC separation of a mixture of compounds 
[13; 14; 15], such as metabolic mixtures [16]. For HRS screening with enzyme targets, 
like in this LC–BCD system, inhibition can be measured by detecting a decrease in the 
enzymatic formation of a fluorescent product. Splitting part of the LC eluent between the 
BCD and mass spectrometry (MS) enables correlation of bioactivity with identity for all 
individual metabolites [14; 17; 18].
This paper describes the development of an LC–BCD system for sEHis and its application 
in the efficient profiling of active oxidative metabolites. For this purpose, a fluorescence 
end-point plate-reader assay [7] was converted into an on-line BCD format. The on-
line BCD uses the non-fluorescent substrate (3-phenyl-oxiranyl)-acetic acid cyano-(6-
methoxy-naphthalen-2-yl)-methyl ester (PHOME), which is converted to the fluorescent 
product 6-methoxy-2-naphthaldehyde by sEH. The new analytical method was thoroughly 
optimized and validated. The obtained inhibition efficacy of known inhibitors compared well 
to literature values. Finally, microsomal incubations of three sEHis were screened for active 
metabolites.
Materials and Methods
Materials
Human recombinant sEH was expressed and purified as described [19]. The sEH inhibitors 
and the substrate (3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-
methyl ester (PHOME) as well as its fluorescent product are shown in Figure 1. Their 
synthesis was reported earlier: PHOME [8]; sEHi 1 [8]; sEHi 2 [20]; sEHi 3 [21]; sEHi 4 [22]; 
sEHi 5 [23]; sEHi 6 and sEHi 7 [24]. ELISA blocking reagent (EBR) was purchased from 
Roche Diagnostics (Mannheim, Germany). All other chemicals were from Sigma-Aldrich 
(Schnelldorf, Germany). Methanol (LC–MS Grade) and formic acid (ULC–MS Grade) were 
obtained from Biosolve (Valkenswaard, The Netherlands). The water used in this study was 
generated with a Milli-Q academic from Millipore (Amsterdam, The Netherlands).
Liquid chromatography – biochemical detection (LC–BCD) system
The LC–BCD system shown in Figure 2 includes separation, on-line BCD and additional 
parallel spectrometric detection. Separation and on-line BCD were done on an Agilent 
Technologies (Amstelveen, The Netherlands) 1100 LC system including a binary and two 
isocratic pumps, an autosampler, a column oven and a fluorescence detector. Separation 
Figure 1: Structures of A) the sEHis used in this study, and B) the reaction scheme of the substrate 
PHOME to its fluorescent product. 
A
B
70 71
2.32.3
was performed on a Waters (Milford, MA, USA) Atlantis dC18 column (100 x 2.1 mm, 3 μm 
particles) at 40°C. The mobile phase consisted of water:methanol 100:1 (v:v) as solvent A 
and methanol:water 100:1 (v:v) as solvent B, both containing 0.01% formic acid. A mixture 
of known sEHis (125 µM each) was separated using the following gradient: 0 to 2 min 
isocratic at 50% B, then a linear gradient to 90% B in 43 min and isocratic at 90% B for 
4 min; afterwards a linear decrease to 50% B in 2 min followed by 15 min re-equilibration. 
The LC gradient applied for the analysis of the metabolic incubations was as follows: 0 to 
2 min isocratic at 5% B, followed by a linear gradient to 95% B in 43 min, isocratic at 95% 
B until 49 min then a linear decrease to 5% B in 6 min followed by 10 min re-equilibration. 
For analysis in flow injection analysis mode (FIA), the same set-up was used, but without 
the column. The LC flow-rate was 150 μL/min and the injection volume 10 μL in all cases. 
The flow was post-column split (see Figure 2), directing 135 μL/min to the MS detection 
and 15 μL/min to the on-line BCD. In the BCD, the eluent was first mixed with 155 μL/min 
of a 5 nM sEH solution and incubated for 30 s. This allowed an initial interaction between 
analytes and enzyme. In a second step, a 30 μM solution of PHOME was added at 30 μL/
min and incubated for 5 min. Here, the substrate conversion to the fluorescent product took 
place which allowed detection of the enzyme activity. The incubations were done in 1.73 m 
straight 250 µm i.d. and 1.59 mm o.d. PTFE tubing (Sigma-Aldrich, Schnelldorf, Germany) 
and 2.26 m of 750 µm i.d. and 1.59 mm o.d. coiled PTFE tubing, forming 85 μL and 1 mL 
reactors, respectively. Both reactors were kept at 37°C by a Grant Instruments (Shepreth, 
UK) water bath. The enzyme and substrate solutions were delivered by in-house built 
superloops which were kept on ice [25]. The fluorescence was measured at excitation 
of 320±10 nm and emission of 460±10 nm. In parallel to the on-line BCD, detection was 
performed by UV at 210 nm and/or by mass spectrometry.
Both techniques are able to visualize both the binders and the non-binders. Additionally, 
MS provides structural information. The on-line BCD and the parallel UV or MS detection 
have different void volumes after the splitting and thus the elution times differ. The UV or 
MS and BCD chromatograms were aligned using a known compound, e.g., the residual 
parent compound in case of the metabolic incubations.
Determination of inhibitor potency
The potency of five known sEHis (Figure 1) was determined based on their apparent 
IC50 values to characterize the performance of the LC-BCD system. These sEHis have 
been selected in such a way that their IC50 values ranged from low to high nanomolar, 
thus covered approximately three order of magnitude of inhibitory activity. For measuring 
the IC50 values, dose-response curves were obtained by injecting the inhibitors into the 
LC–BCD system under isocratic conditions at 50% methanol in FIA mode. The following 
concentrations and one blank were injected in duplicate per inhibitor: 0.5, 1, 2, 5, 10, 20 
and 50 μM for sEHi 1; 1, 2, 5, 10, 20, 50, 100 and 200 μM for sEHi 2; 0.5, 1, 2, 5, 10 and 
20 μM for sEHi 3; 1, 2, 5, 10, 20, 100, 500 and 1000 μM for sEHi 4; 0.05, 0.1, 0.2, 0.5, 1, 
2 and 10 μM for sEHi 5.
Metabolite identification using mass spectrometry
LC–MS for metabolite identification was done either on a Bruker Daltonik (Bremen, 
Germany) micrOTOF-Q quadrupole time-of-flight hybrid MS, using the above described 
conditions, or using an ion-trap time-of-flight mass spectrometer (IT-TOF, Shimadzu, ‘s 
Hertogenbosch, The Netherlands). In the latter case, a 30-min gradient and a 100 × 2.1 
mm Waters XBridge C18 column (3.5 μm particles) was used. Positive-ion electrospray 
ionization (ESI) was applied in both instrument. Other relevant instrument settings are 
summarized in the Supporting Information. The mass accuracy was better than 5 ppm on 
both instruments. The accurate-mass data obtained were used to determine the elemental 
composition of the metabolites and accordingly of the fragments. 
Buffer and compound solutions
A 25 mM 2-bis(2-hydroxyethyl)amino-2-(hydroxymethyl)-1,3-propanediol (BIS-TRIS) buffer 
containing 1 g/L EBR, 1 g/L bovine serum albumin (BSA) and 0.1 g/L Tween 80 was used 
at pH 7.0. Stock solutions of the sEH inhibitors and PHOME were prepared at 20 mM 
concentrations in DMSO. sEH stocks of 100 μM (6 mg/mL) concentration were kept at 
-80°C until use and dilutions were handled on ice at all times. All PHOME and sEH dilutions 
were prepared in this BIS-TRIS buffer. 
Plate reader measurements
Plate reader based measurements were performed to evaluate the reagent concentrations 
on a Victor3 plate reader from Perkin-Elmer (Groningen, The Netherlands). Black 96 ‘flat’ 
Figure 2: Setup of the LC–BCD system. The system combines separation, on-line BCD and additional 
UV or MS detection in parallel. It includes (1) autoinjector, (2) reversed-phase LC column, (3) flow-
splitting between parallel (9) UV or ESI-MS detection and (4–8) the on-line BCD. The BCD comprises 
of (4) mixing of LC effluent and an sEH solution, (5) incubation with the enzyme, followed by (6) 
mixing of PHOME solution, (7) incubation with PHOME, and finally (8) fluorescence detection. 
Figure 3: Analysis of BCD 
parameters. Several sections of the 
graph are highlighted by horizontal 
double-headed arrows in contrast 
to important time points which 
are highlighted by vertical arrows. 
Sections 1, 3 and 8 show the buffer, 
the substrate related and the complete 
background levels of fluorescence, 
respectively. Furthermore, section 
5 depicts the baseline due to the 
enzymatic reaction. The points 2 
and 4 mark the introduction of the 
PHOME substrate solution and of the 
sEH enzyme solution, respectively. 
Point 7 indicates the start of the 
cooling of the incubation tubing, 
which stops the enzymatic conversion in section 8. The difference between the fluorescence at full 
steady state reaction (section 5) and the combined fluorescence background at completely stopped 
reaction (section 8), as indicated by a vertical double-headed arrow (number 6), indicates the assay 
window. The eight numbers are explained in more detail in the text.
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bottom chimney well, polypropylene microtiter plates from Greiner bio-one (Alphen a/d 
Rijn, The Netherlands) were used. The total sample volume was 200 μL and the plates 
were incubated at 37°C. Product formation was followed by measuring the fluorescence at 
355 ± 4 nm excitation and 460 ± 12.5 nm emission. The PHOME concentration was 50 μM 
and the sEH concentration 40 nM. Product formation was measured in 30 s intervals for 
20 min under the influence of two different BSA concentrations, 0.1 g/L and 1.0 g/L. End-
point measurements at 6 min were used to compare the activity of sEH under the influence 
of several solubilising agents. In additional experiments, the solubility of PHOME under the 
influence of these solubilising agents was tested in transparent plates. This was done by 
measuring precipitation of a 45 μM PHOME solution by visible absorption at 595±10 nm. 
Microsomal incubations
The LC–BCD/MS system was applied to investigate the metabolism of the three known 
sEH inhibitors sEHi 6, sEHi 1 and sEHi 7 and the bioactivity profile of their metabolites. 
Oxidative metabolites were generated by pig liver microsomal incubations in the presence 
of NADPH according to a modified version of a protocol described elsewhere [26]. In 
brief, reaction mixtures were prepared in 50 mM potassium phosphate buffer (pH 7.4) 
including 5 mM magnesium chloride. The mixtures containing 6 mM NADPH, 2.6 mg/mL 
pig liver microsomes and 100 mM sEHi were incubated for 2 h at 37°C. To ensure continued 
availability of NADPH, 5 mM glucose-6-phosphate and 5 U/mL glucose-6-phosphate 
dehydrogenase were used as regenerating system. Additionally, 10% (v/v) of a 10 mM 
NADPH solution in the above mentioned phosphate buffer was added after 30, 60 and 
90 min, respectively. The reactions were stopped by adding ice-cold acetonitrile 2:1 (v:v). 
The samples were then centrifuged at 16,000 g for 5 min. The supernatants were taken, 
freeze-dried and stored at –20°C. For the LC–BCD/MS analysis, the samples were re-
dissolved in a 30% aqueous methanol solution, providing 20-fold higher concentrations.
Results and Discussion
Development of an LC–BCD system for the detection of sEH inhibitors
The aim of this study was to develop a system for the bioactivity assessment towards 
sEH of individual compounds in complex mixtures. For this purpose, a homogeneous, 
continuous-flow detection format was applied based on the enzymatic conversion of the 
substrate PHOME and fluorescence readout of the reaction product (Figure 1) [7]. 
Initial plate-reader experiments were used as starting conditions for the optimization of 
the enzyme and substrate concentrations in the on-line setup. This was achieved by 
determining the signal-to-noise ratios (S/N) at full inhibition in the LC–BCD by injecting 
sEHi 2 at a concentration of 100 µM while the on-line BCD was performed at several 
enzyme/substrate concentration combinations. PHOME was applied at concentrations of 
4.5, 2.3 and 1.2 μM in combination with a sEH concentration of 4 nM. Concentrations of 
40, 8 and 4 nM sEH were tested at a PHOME concentration of 4.5 μM. Finally, a mixture of 
4 nM sEH and 4.5 μM PHOME was incubated off-line for 30, 45, 60 or 90 min and directly 
infused into the fluorescence detector in order to assess the fluorescence intensity at full 
substrate conversion.
In contrast to the earlier developed end-point plate-reader assay, an on-line format 
requires a shorter incubation time. The BCD system was set up with a 5 min reaction 
time in order to minimize band broadening in the LC–BCD system. In order to increase 
the solubility of PHOME at room temperature, 0.1 g/L Tween 80 were added to the buffer 
without measurable influence on the enzymatic conversion (data not shown). The substrate 
was used close to its limit of solubility (30 μM) in the superloop, thus with a substrate 
concentration of 4.5 µM in the reaction coil (Figure 2). This concentration is lower than the 
Michaelis-Menten-constant (KM) of PHOME for sEH, which is above its limit of solubility [8]. 
Thus, at a concentration of 4.5 µM of PHOME, the enzyme is not in saturating condition 
allowing the sensitive detection of inhibitors. Additional actions to shorten the reaction time 
comprise a BSA concentration of 1.0 g/l rather than 0.1 g/l.
The enzyme concentration was adjusted to yield about 20% substrate conversion in a 
5-min reaction time. This low percentage of conversion ensures that the reaction is still 
in the initial conversion stage where no significant rate and concentration limiting effects 
are observed. It was found that only 4 nM sEH in the reaction coil were sufficient, which is 
almost identical to the concentration of 3 nM in the end-point method [7]. 
Figure 3 shows the most important BCD parameters and demonstrates that the reaction 
causing the BCD baseline is of enzymatic nature. Section 1 of Figure 3 shows the background 
level of fluorescence generated with buffer-filled superloops. When the PHOME substrate 
solution was introduced (point 2 in Figure 3), the fluorescence signal somewhat increased 
due to fluorescence of the substrate and/or autohydrolysis and/or presence of trace amount 
of the fluorescent product in the substrate (section 3 in Figure 3). After the enzyme is added 
to the other superloop (point 4 in Figure 3), a rapid increase in the signal is observed 
resulting in a stable baseline due to the steady state of the enzymatic reaction (section 5 in 
Figure 3). When cooling of the reaction coil on ice (point 7 in Figure 3), the signal returns to 
the baseline of substrate solution (section 8 in Figure 3). The absence of conversion under 
these conditions clearly demonstrates that the increased fluorescence signal is caused by 
the enzymatic conversion of PHOME to its fluorescent product.
The most important parameter of the BCD system is the difference between the steady 
state of the reaction serving as baseline of BCD and the background signal (number 6 in 
Figure 3, indicating the difference in fluorescence signal between section 5 and section 8 in 
Figure 3), also known as assay window. In this case, the assay window is nine times higher 
than the substrate fluorescence. Together with the stability of the signal, a signal-to-noise 
ratio of 70 results between full inhibition of sEH and the steady state, allowing a detection 
of as little as 5% inhibition of the added sEH. In conclusion, the data quality of the on-line 
BCD is more than adequate to detect the significant part of the sigmoidal dose-response 
behaviour of inhibitors between 10% and 90% inhibition.
As the sEHis are introduced into the on-line BCD from an LC setup, their activity is 
visualized as a negative chromatographic peak which is a result of the indirect enzymatic 
activity measurement: higher inhibitor activity means less fluorescent product formation. 
Furthermore, the dose-response behaviour in the on-line BCD changes to a sigmoidal one 
due to the underlying competitive biophysical interactions between enzyme, substrate and 
inhibitor. All this is apparent from Figure 4A where the overlaid BCD chromatograms of a 
dilution series of several sEHi 1 concentrations are shown.
Characterization of the LC–BCD system 
The performance of the LC–BCD system to quantitatively measure the potency of sEHis 
was tested by analysis of five known inhibitors at different concentrations in FIA mode, 
which is a fast way to measure IC50 values if pure compounds are available. As shown in 
Figure 4A, the injection of sEHi 1 resulted in negative peaks in the BCD chromatogram with 
increasing negative peak heights upon injecting increasing concentrations. The variance 
in peak height between duplicate injections was generally lower than 10% (in 90% of 36 
samples). As previously shown for various enzymes the negative peak height in LC–BCD 
systems can be used to calculate the percentage of inhibition [18; 27]. Based on the 
resulting dose response curves (Figure 4B), it is possible to quantitatively rank the sEHis 
by their potency. Among the compounds tested, sEHi 5 was the most active and sEHi 4 the 
least active inhibitor. In order to deduce IC50 values for each compound, the dilution of the 
injected amount of inhibitor in the LC–BCD system has to be taken into account [18; 28]. 
The dilution results from the mixing of LC eluent and BCD reagents (Dm) which depends 
on the flow rates of eluent entering the on-line BCD (uE) and the total flow at detection (uF).
      Equation 1
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In addition, inhibitors injected are also diluted due to their residence time in the flow system 
(DC). In a test tube or well plate experiment, the inhibitor can be assumed to be evenly 
distributed after mixing. The same is only true for the diagonal distribution in the on-line 
BCDs. In the longitudinal dimension, which is reflected on the time axis, the inhibitor is 
distributed according to a near-Gaussian distribution which is typical to chromatography. 
This phenomenon is a result of longitudinal diffusion of the initially homogeneous injection 
plug (Vi). It further dilutes the injected concentration (ci). The full width at half maximum 
(FWHM) and the flow rate (uC) have to be derived from the same chromatogram, preferably 
from the BCD chromatogram which results in uC = uF.
     Equation 2
Therefore, the final concentration at the maximum negative peak height (cF), which can be 
calculated from equation 3, was used for the dose-response curves. 
      Equation 3
Thus, the dilution factors are calculated individually for every measurement, and they 
range from 71 to 210, The final concentrations were plotted against the corresponding 
percentages of inhibition and the data fitted with GraphPadPrism (GraphPad Software, 
La Jolla, US). This results in the sigmoidal dose-response curves shown in Figure 4B. 
The reproducibility of the data points measured (see above) and the quality of the all fits, 
expressed by resulting R2-values of >0.975, are further indications of the high data quality.
The calculated IC50 values for the five compounds tested are given in Table 1. They covered 
a range of about three orders-of-magnitude. This demonstrates that the developed LC–
BCD method allows the measurement/detection of highly potent as well as weak sEHis. 
The potency of sEHi 5 was remarkably high, with an apparent IC50 value of 2 nM. Given an 
enzyme concentration of 4 nM in the reaction coil, this is the highest potency which can be 
observed with the setup [9]. Most importantly, the newly developed LC–BCD method ranked 
the potency of the tested inhibitors in the same order as commonly employed end-point 
assays, except for sEHi 2 (Table 1). However, for few sEHis, the determined IC50 differed 
significantly from literature values: For sEHi 2, the observed potency by LC–BCD was 
about 20-fold higher compared to the value from an end-point assay, while the measured 
IC50 value for sEHi 4 was about 4-fold higher than previously reported (Table 1). Similar 
to our observations, up to 20-fold differences have been described between different sEH 
assays, because the measured potency for individual sEHis is substrate-dependent [9]. 
This observation is substantiated with the results for sEHi 1. For this compound, using the 
same substrate, a very good agreement was found between our data and the literature [7]. 
The potencies for sEHi 3 and sEHi 5 are also consistent with literature values, despite use 
of different substrates (Table 1). Overall, the results from the analysis of individual sEHis in 
the LC–BCD system show, that the negative peak height is a suitable quantitative measure 
for the potency of inhibitors, and that the data obtained are in good agreement with other 
methods to characterize the potency of sEHis. 
In contrast to end-point assays, the LC–BCD system combines identity and activity detection 
after chromatographic separation. It thus allows assessment of individual compounds in 
mixtures. This is demonstrated by analysing a mixture of sEHi 6, sEHi 1, sEHi 7, and two 
compounds without sEH activity, diclofenac and phenylbutazone. In this case, the BCD 
signal shows only three major peaks, which corresponded well with the elution times to 
the three sEHis, whereas in the corresponding LC–UV or LC–MS all five compounds are 
observed (data not shown). These experiments show that the developed LC–BCD system 
allows assessing the bioactivity of individual compounds in mixtures. In only one analysis 
step, it can distinguish between active and non-active compounds in mixtures.
Application of LC-BCD on the analysis of metabolic mixtures of sEHis
In order to demonstrate the applicability of the LC–BCD system to the analysis of unknown 
mixtures, in vitro microsomal incubations of three sEHis were analysed. The LC–MS 
data showed that each compound was metabolized to several metabolites (Figure 5). 
By combining BCD traces and MS extracted ion chromatograms, the peaks of active 
compounds can be directly identified and structurally characterized.
For sEHi 6, three bioactivity peaks were observed (Figure 5A). The main peak eluting 
around 43.2 min in LC–MS, peak A4MS, corresponding to peak AIIIBCD in LC–BCD, is 
Figure 4: Analysis of sEHi in FIA 
mode. A BCD signals of injections (10 
µL) of eight different concentrations 
of sEHi 1 [blank (black), 0.5 μM 
(blue), 1 μM (green), 2 μM (red), 
5 μM (violet), 10 μM (light blue), 
20 μM (brown) and 50 μM (grey)]. 
The percentage of sEH inhibition, 
calculated from the negative peak 
height, is plotted against the inhibitor 
concentration for five different 
sEHis in panel B [sEHi 1 (●), sEHi 2 
(■), sEHi 3 (▲), sEHi 4 (▼) and 
sEHi 5 (♦)]. Mean and range of 
a determination in duplicate are 
shown. The concentration is given 
as final concentration of the inhibitor 
in the reaction coil, taking a dilution 
factor into account. 
Table 1: IC50 values determined for sEHi 1-5 and comparison to literature values
Compound LC–BCD system nMa Literature values Substrate
sEHi 1 19 (1) 29 ± 13 nM [7] PHOME
sEHi 2 25 (1) 684 nM [22] CMNPCb
sEHi 3 12 (2) 15 nM [23] CMNPCb
sEHi 4 880 (90) 171 nM [22] CMNPCb
sEHi 5 2.6 (0.6) 2 nM [23] CMNPCb
a Mean and difference (in brackets) from individual fitting of the duplicate curves.
b cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyloxyran-2-yl)methylcarbonate
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the parent compound (protonated molecule [M+H]+ with m/z 277.228). The three peaks 
A1MS, A2MS and A3MS, eluting at 35.0 min, 35.8 min and 38.0 min, respectively, in LC–MS, 
were not observed in the control incubations (data not shown). These compounds could 
be tentatively identified as hydroxylated metabolites because all contained an additional 
oxygen compared to the parent compound ([M+H]+ with m/z 293.223). While peak A1MS is 
not bioactive, peaks A2MS and A3MS correspond to the peaks AIBCD and AIIBCD, respectively. 
Note that peak A3MS consists of three non-separated compounds thus three different mono-
hydroxylated metabolites with m/z 293.209, which were not well separated. The peaks 
A5MS and A6MS are present as contaminants; they shows the same nominal mass as the 
oxygenated metabolites and the parent sEHi 6, but different accurate mass (m/z 293.209 
and 277.217, respectively).
The LC–BCD chromatogram of the metabolic incubation trace of sEHi 1 showed four 
peaks (Figure 5B). The main peak BIVBCD corresponds to peak B9MS, the parent compound 
([M+H]+ with m/z 227.214). In this case, six mono-hydroxylated metabolites (B2MS through 
B7MS, [M+H]+ with m/z 243.208) were observed (Figure 5B). These metabolites gave rise 
to peaks BIBCD and BIIBCD. By careful evaluation of the peak shapes and retention times, it 
may be concluded that B2MS and at least two of the metabolites B4MS to B7
MS are bioactive. 
The oxidated dehydrogenated metabolite B1MS ([M+H]+ with m/z 241.192) is clearly not 
bioactive, whereas the peak shape of the dehydrogenated metabolite B8MS ([M+H]+ with m/z 
225.197) matched the retention time of BIIIBCD. This is an excellent example of the added 
value of the LC–BCD approach: whereas the minor peak B8MS would be easily ignored in 
an MS-only approach, its strong corresponding peak BIIIBCD cannot be overlooked. 
Compared to sEHi 6 and sEHi 1, sEHi 7 showed less metabolic conversion: only two mono-
hydroxylated metabolites were detected ([M+H]+ with m/z 409.306) (Figure 5C). The main 
peaks CIIBCD and C3MS correspond to the parent compound ([M+H]+ with m/z 393.312). 
The two metabolites C1MS and C2MS are not well separated and result in only one peak in 
the LC–BCD chromatogram. The retention time of C1MS corresponds to the peak CIBCD, 
indicating the compound is bioactive, but the increased tailing of CIBIO suggests that C2 is 
bioactive as well.
All three sEHis were metabolized in the aliphatic chains and rings at either side of the urea 
function. A more detailed structural analysis was not possible as MS fragmentation only 
occurred in or next to the urea function. For all three sEHis tested, LC–BCD/MS analysis 
allowed the tentative identification of at least two inhibitory active metabolites. In only a 
single step analysis of 60 minutes, active metabolites can be detected. Moreover, it is 
possible to distinguish between active and non-active metabolites and to characterize 
bioactive compounds by their inhibitory potency and MS spectra. 
Conclusion
A new LC–BCD system for the detection of sEHis in complex mixtures has been developed. 
The detection principle is a continuous-flow enzyme activity assay coupled on-line to LC 
with parallel MS detection. The substrate PHOME allowed sensitive and robust monitoring 
of bioactivity by fluorescence. After thorough optimization of the assay conditions, the 
incubation time in the BCD was reduced from 60 to 5.5 min. With a sEH concentration 
of only 4 nM in the reaction coil, the signal-to-noise ratio for complete sEH inhibition was 
still higher than 60. Analysis of several known sEHis demonstrated that the peak height, 
observed in LC–BCD can be used as quantitative measure for sEH inhibition. Moreover, 
the obtained potencies, measured as IC50 values, for sEHis are in good agreement with 
previously reported values. The LC–BCD system is able to perform bioactivity analysis of 
individual compounds in mixtures. This was successfully demonstrated by the analysis 
of a standard mixture as well as of in vitro metabolic conversions of three known sEHi 
containing both active and non-active metabolites towards sEH. Here, LC–BCD revealed 
the formation of new active metabolites, which could be simultaneously characterized by 
LC–MS. 
With the developed LC–BCD system, inhibitors can be detected and characterized in a 
single analysis. Given the increasing interest in sEH as drug-target for various diseases, 
this new technique may pave the route for the detection of new classes of sEHis in natural 
products or crude mixtures arising from organic synthesis. Moreover, metabolism studies 
with LC–BCD as read out will allow the identification of active metabolites in early stages 
of lead development and thus assist the identification of the best compounds as drug 
candidates. 
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Supplementary Material
LC–MS for metabolite identification was done either on a Bruker Daltonik (Bremen, 
Germany) micrOTOF-Q quadrupole time-of-flight hybrid MS, using the above described 
conditions, or using  an ion-trap time-of-flight mass spectrometer (IT-TOF, Shimadzu, ‘s 
Hertogenbosch, the Netherlands). In the latter case, a 35-min  gradient and a 100 × 2.1 mm 
Waters XBridge C18 column (3.5 μm particles) was used. In the Bruker quadrupole time-
of-flight hybrid MS, an electrospray ionization (ESI) source operated in positive-ion mode 
at the following settings: capillary voltage 4500V; end plate offset -500V; nebulizer gas 1.8 
bar; drying gas 8.0 L/min at 200°C. For accurate mass measurements, the TOF settings 
were automatically calibrated prior to the measurements by infusing a 5 mM sodium formate 
solution. Mass spectra were collected between m/z 50 and 1000. 
In the Shimadzu ion-trap time-of-flight mass spectrometer, the ESI source was operated 
in positive-ion mode at a needle voltage of 4.5 kV, a temperature of 200°C on the source 
heating block and the curved desolvation line, a drying gas pressure of 62 kPa and a 
nebulising gas flow-rate of 1.5 L/min. For accurate mass measurements, the IT-TOF 
was externally calibrated on a weekly basis using sodium TFA clusters. MS spectra were 
collected between m/z 150 and 650 and MS/MS spectra between m/z 100 and 650, both 
with 10 milliseconds ion accumulation. The precursors were selected data-dependent with 
a width of 3 Da and fragmented at 50% CID energy.
The mass accuracy was better than 5 ppm on both instruments. The accurate-mass 
data obtained were used to determine the elemental composition of the metabolites and 
accordingly of the fragments. This was done with the software provided by the respective 
instrument manufacturers, ESI Compass 1.3 from Bruker Daltonik and LCMSsolution 
3.50 from Shimadzu. The relevant elemental composition in each case was extracted by 
applying additional restrictions next to the mass accuracy. It should not contain more atoms 
of any kind than the original compound except for oxygens which are known to be added by 
phase I metabolism. For the fragments, the restriction followed the elemental composition 
of the parent ion. Both assumptions are reasonable because the metabolites are linked 
to the original inhibitor by well-known metabolic pathways while the fragments can only 
arise from the parent ion selected for fragmentation. This proved sufficient to arrive at one 
possible elemental composition.
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Abstract
In this study, an integrated approach is developed for the formation, identification and 
biological characterization of electrochemical conversion products of p38α mitogen-activated 
protein kinase inhibitors. This work demonstrates the hyphenation of an electrochemical 
reaction cell with a continuous-flow bioaffinity assay and parallel LC-HR-MS. Competition 
of the formed products with a tracer (SKF-86002) that shows fluorescence enhancement in 
the orthosteric binding site of the p38α kinase is the readout for bioaffinity. Parallel HR-MSn 
experiments provided information on the identity of binders and non-binders. Finally, the 
data produced with this on-line system were compared to off-line generated electrochemical 
conversion products. The electrochemical conversion of 1-(6-chloro-5-((2R,5S)-4-(4-
fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-3aH-indol-3-yl)-2-morpholinoethane-
1,2-dione (DMPIP) resulted in eight products, three of which showed bioaffinity in the 
used continuous-flow p38α bioaffinity assay. Electrochemical conversion of BIRB796 
resulted, amongst others, in the formation of the reactive quinoneimine structure and its 
corresponding hydroquinone. Both products were detected in the p38α bioaffinity assay, 
which indicates binding to the p38α kinase.
Introduction
Electrochemistry (EC) is increasingly described as a tool to support the formation and 
identification of drug oxidation products [1]. Efforts are reported to mimic a human 
metabolite profile [2] or to produce specific reactive metabolite species [3]. The application 
of electrochemical techniques specifically focused at drug development is reviewed by 
Hillard et al [4]. These applications are mainly directed at the study of reactive oxygen 
species, oxidation and reduction of prodrugs, and the alkylation of DNA. Bauman and Karst 
[5] recently described the principles and use of on-line electrochemistry-mass spectrometry 
(EC-MS) in drug metabolism studies. Jurva et al. systematically compared the oxidation 
of drugs by EC-MS and by cytochrome P450s [6]. This approach provides chemical 
information on the products formed by electrochemistry and facilitates the comparison with 
in-vitro incubation models [7, 8]. The chemical information obtained can eventually be used 
to correlate biological action of already characterized metabolites to the products analyzed. 
However, this is not feasible for newly formed products for which no biological data are 
yet available. Still, few examples in EC related drug metabolism studies employ detection 
of biological activity [9, 10] and, to the best of our knowledge, none tested for a specific 
target enzyme or receptor. More importantly, in studies employing EC-MS or EC-LC-MS, 
biological testing seems to be a completely new development. This is surprising because 
the biological activity of the metabolites towards the drug target is of utmost importance for 
the efficacy of a drug. For many years, we have been developing hyphenated screening 
assays to obtain chemical and biological information in a combined manner [11]. This 
resulted in several approaches to assess bioaffinity, e.g., on-line receptor binding [12], 
enzyme activity assessment [13], bacterial growth inhibition [14], as well as several other 
strategies which allowed us to identify and characterize bioactive compounds [15-17] in 
(complex) mixtures. These mixtures included natural extracts, crude synthesis products, 
medicinal chemistry compound libraries, degradation products by light or harsh chemical 
conditions as well as in vitro metabolic incubations.
The implementation of a device for electrochemical oxidation in our on-line screening 
platform would lead to a fully automated process of formation of drug-related chemical 
entities followed by their simultaneous chemical and biological characterization. This leads 
to a quick feedback between the modifications of a lead compound and their consequences 
for binding to the drug target. Furthermore, instable and/or reactive products could be 
analyzed directly after their formation and as such have less chance of degradation.
In this paper, we describe the hyphenation of EC with our recently developed liquid 
chromatography (LC) - on-line p38α mitogen-activated protein kinase binding assay 
(p38α bioaffinity assay) with parallel high resolution MS [18]. EC provides relatively clean 
samples and has shown to facilitate the formation of interesting molecules for drug research 
[19]. The p38α mitogen-activated protein kinase (p38α kinase) is a prominent example 
of a drug target kinase [20] and is heavily involved in inflammation processes [21]. The 
hyphenation of these techniques to develop a fully integrated platform can facilitate the 
hit-to-lead selection process in drug discovery. This complete hyphenation of EC with LC 
and ultimately with parallel detection by p38α bioaffinity assay and high resolution MS 
combines modification with separation, bioaffinity determination and structure elucidation 
on a new level of integration.
Materials and methods
Chemicals
Acetonitrile, methanol (LC–MS grade) and formic acid (ULC–MS grade) were obtained 
from Biosolve (Valkenswaard, The Netherlands). Water was produced by a Milli-Q device 
of Millipore (Amsterdam, The Netherlands). Nitrogen 5.0 was purchased from Praxair 
(Vlaardingen, The Netherlands) and used in all MS experiments. SKF-86002 (SKF) was 
delivered by Merck KGaA (Darmstadt, Germany). Enzyme-linked immunosorbent assay 
(ELISA) blocking reagent was purchased from Roche Diagnostics (Mannheim, Germany). 
Ammonium acetate and ammonium hydrogen carbonate were obtained from Mallinckrodt 
Baker (Deventer, the Netherlands). Fused silica tubing (250-mm inner and 375-mm outer 
diameter) covalently coated with polyethylene glycol was obtained from Sigma-Aldrich 
(Schnelldorf, Germany). Human recombinant p38α kinase, BIRB796, TAK715, 1-(6-chloro-
5-((2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-3aH-indol-3-yl)-2-
morpholinoethane-1,2-dione (DMPIP) and SB203580 were a kind gift of MSD Research 
Laboratories (Oss, the Netherlands). 
Structures of the kinase inhibitor standards 
used can be found in Figure 1. All other 
chemicals were from Sigma-Aldrich 
(Schnelldorf, Germany).
Instrumentation
A schematic representation of the complete 
on-line setup is shown in Figure 2. The 
system consists of four modules: (A) an 
electrochemical reaction cell, (B) an LC 
system, (C) a continuous-flow bioaffinity 
assay unit, equipped with a fluorescence 
detector, and (D) a mass spectrometer.
A Roxy electrochemical reaction cell (Antec 
Leyden, Zoeterwoude, the Netherlands) 
equipped with a glassy carbon electrode 
was controlled by the Decade II Potentiostat 
either manually or under Dialogue software 
control (Antec Leyden). The 10 mM kinase 
inhibitor standards, dissolved in 25% ACN 
and 75% 1 mM aqueous buffer, were infused 
at a flow rate of 5 mL/min with a Harvard 
Apparatus (Hollister, USA) syringe pump. The 
conversion products were collected either in 
an autosampler vial (“off-line” mode) or in 
100 mL volume PEEK tubing (“on-line” mode) 
serving as an injection loop mounted in a 
Figure 1: Structures of the kinase inhibitors used 
for electrochemical conversion experiments
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remote controlled six port valve (VICI, Schenkon, Switzerland).
In the off-line mode, collected fractions were injected via the autosampler, whereas in the 
on-line mode the six port valve with the 100 mL PEEK tubing acted as the injection valve to 
a Shimadzu LC system (‘s Hertogenbosch, the Netherlands), consisting of two LC-10ADvp 
pumps, a DGU-14A solvent degasser, a SIL-10ADvp auto injector, two CTO-10ASvp column 
oven, an SPD-10Avp UV-detector and a SCL-10Avp system controller. The LC separation 
was performed on a Waters Xbridge C18 column (2.1 mm x 100 mm I.D., 3.5 µm particles). 
The mobile phases consisted of 99% water with 1% methanol (solvent A) and 1% water 
with 99% methanol (solvent B), both containing 0.01% formic acid. A generic gradient was 
applied for the separation: isocratic for 2 min at 20% B, gradient to 90% B until 18 min, 
isocratic at 90% B until 22 min, a gradient back to 20% B until 23 min and isocratic re-
equilibration at 20% B until the end of the run at 30 min. The flow-rate was 113 mL/min. The 
column temperature was kept at 40°C. All standards eluted with significant retention, which 
provided sufficient resolution for the separation of products with slightly differing polarities. 
Initial off-line experiments were performed with the EC unit and an LC-MS system, without 
the p38 bioaffinity assay attached, in order to optimize the EC conditions. For this, the LC 
system was coupled via an electrospray ionization (ESI) interface to a Thermo Finnigan 
LCQ Deca ion trap mass spectrometer (LRMS) (Breda, the Netherlands). Experimental 
conditions for the ion trap MS were as follows: Capillary temperature 200°C, sheath gas 
flow 45 arbitrary units, aux gas flow 5 arbitrary units, source voltage 5 kV and capillary 
voltage 6 V. The instrument was used in positive-ion ESI mode for full spectra acquisition 
between m/z 150 and 650. 
In on-line experiments with the complete setup, a post-column split was applied (see 
Figure 2), with 13 mL/min of the LC mobile phase being directed to the p38α bioaffinity 
assay and 100 mL/min to the MS system. The post-column fluorescence enhancement 
based bioaffinity assay towards the p38α kinase was identical to the system previously 
described by us [18]. Important features of the system are shown in Figure 2. Competition 
of the formed products with a tracer (SKF) that shows fluorescence enhancement in the 
orthosteric binding site of the p38α kinase is the readout for bioaffinity. Stability of the flow 
system is essential for the quality of the assay as small changes in the reaction parameters 
have relatively pronounced consequences in the signal. Therefore, a stable reagent flow 
is important in order to keep the noise to a minimum. This was achieved by a linear setup 
of an LC pump, a pulse dampener, a restriction capillary and a superloop. The state-of-
the-art LC pump delivered a constant flow of water. The pulse dampener was based on an 
impermeable membrane and had a comparably extensive water reservoir. The restriction 
capillary was chosen to produce ca 70 bar backpressure at the applied flow rate of 50 mL/
min. As a result, a constant and stable flow entered the superloop. The superloop served 
as a reagent reservoir of constant volume which released exactly the same flow rate as 
it received. Compared to a delivery by the pump alone, reagents were also more easily 
cooled and pump maintenance was reduced which further improved the stability of the 
system.
Parallel to the p38α bioaffinity assay, the electrochemical conversion products were 
analyzed using a Shimadzu ion-trap time-of-flight hybrid mass spectrometer (LC-IT-TOF-
MS), equipped with an ESI source and operated in positive-ion mode to obtain accurate 
m/z values for [M+H]+ and fragment ions. The ESI needle voltage was set to 4.5 kV, while 
the source heating block and curved desolvation line temperature were set to 200°C. 
Drying gas pressure was set at 62 kPa and nebulizing gas was applied at a flow-rate of 
1.5 L/min. MS2 and MS3 spectra were acquired in data-dependent mode with the following 
settings: full-spectrum MS with m/z 200 – 650, MS2 with m/z 150 – 650 and MS3 acquisition 
with m/z 100 – 650 with ion accumulation time of 10 ms, precursor isolation width of 
3 Da and collision energy set at 75% for TAK715 and 50% for all other compounds. The 
accurate-mass fragmentation data obtained were used for structure identification. External 
calibration of the instrument was based on sodium TFA clusters and allowed a mass 
accuracy lower than 5 ppm. From the measured accurate mass, the elemental composition 
of the products and their fragment ions were calculated. In order to extract the relevant 
elemental compositions, restrictions were applied to exclude those which have more atoms 
of any kind than the substrate plus possible modifications. This is reasonable because the 
products are linked to the substrate by electrochemical modification. For fragments, the 
elemental composition of the precursor ion was used as restriction. The few compositions 
left were analyzed for electrochemical modifications possibly leading to the formation of 
products with a specific composition. Where CID fragments were concerned, this analysis 
was based on reasonable neutral losses. The procedure was sufficient to restrict the 
discussion to only one elemental composition.
Optimization of electrochemical conversion
For flow-through electrochemical reaction cells, important parameters reported are pH, 
electrode voltage, organic modifier content and flow-rate [5, 6]. Several techniques can 
be used to find the optimal conditions. Those include cyclic voltammetry, direct EC-MS 
coupling, and off-line EC and LC-MS experiments [5, 22]. The latter method was applied 
in this study. We evaluated per substrate 4 different potentials (0; 0.4; 0.8; 1.2 and 1.5 V) 
and 4 different pH values (3.5; 5.0; 7.0; 10.0). The four different buffers used to vary the pH 
were: an ammonium formate / formic acid buffer with pH 3.5, an ammonium acetate / acetic 
acid buffer with pH 5.0, and two ammonium hydrogen carbonate buffers with pH 7.0 and 
10.0, adjusted with formic acid and sodium hydroxide, respectively. Each series resulted 
in 20 samples. The series was injected in duplicate, which due to the 30 min LC run time 
resulted in a well defined 10 hrs difference between the two duplicate analyses of the same 
sample. This provided an indication of the stability of the products formed. 
From the off-line optimization data, optimum conditions were selected to be applied in the 
on-line mode, using the complete setup. These conditions are summarized for the three 
model compounds in Table 1.
Results and discussion
In this study, an integrated approach is developed for the formation, identification and 
biological characterization of conversion products derived from p38α kinase inhibitors. This 
work demonstrates the hyphenation of an electrochemical reaction cell with a continuous-
flow bioaffinity assay and parallel LC-HR-MS. The recently developed p38α bioaffinity 
Figure 2: Scheme of the on-line setup. (1) On-line electrochemical conversion of inhibitor. (2) 
Gradient LC separation of products formed. (3) Split of 1:9 to MS and p38α bioaffinity assay. (4) 
Reaction coil for enzyme binding. (5) Addition of tracer molecule. (6) Detection of enzyme tracer 
complex by fluorescence and parallel HR–MSn for structural information of binders.
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assay, based on fluorescence enhancement, was used as a model assay to investigate the 
possibilities of this combination, but the approach is not limited to this specific continuous-
flow assay. Parallel HR-MSn experiments provide information on the identity of binders and 
non-binders. Finally, the data produced with this on-line system were compared to that of 
off-line generated electrochemical conversion products.
First of all, the electrochemical conversion of the kinase inhibitors had to be optimized 
for substrate conversion and product formation. Formation and identification of bioaffinity 
products is the ultimate goal of the method. High substrate conversion simplifies the bioaffinity 
assessment by reducing the interference of the unmodified inhibitor. The off-line and on-
line approaches employ the same flow-through EC instrument which is operated under 
the same experimental conditions in both cases. Therefore, the off-line data generated for 
validation of the on-line setup can be used to extract the optimal electrochemical reaction 
conditions for both setups. An excerpt of the off-line generated data can be found in the 
Online Resource figure S2. Although the EC and LC-MS approach can be considered 
laborious for reaction optimization only, it has advantages over other methods. Cyclic 
voltammetry will not give any information on product formation and direct EC-MS analysis 
can be strongly hampered by ion suppression effects as well as by unwanted up front 
fragmentation.
Figure 3 shows an overlay of the bioaffinity traces of on-line electrochemistry-LC-p38α 
bioaffinity assay experiments and the relevant extracted ion chromatograms (EIC) from 
the simultaneous LC-MS experiments for the compound DMPIP (C28H30ClFN4O4, [M+H]
+ 
with m/z 541.2012). Clearly, bioactive products were formed under all conditions applied, 
although in different relative concentrations. The four negative peaks in the affinity 
chromatogram indicate binding/affinity of three conversion products to the p38α kinase by 
displacing the tracer ligand upon elution from the LC column. The affinity is linked in the 
same figure to the EIC for identification of the binders. As the products showing affinity are 
the same under all conditions, the EICs are derived from one measurement. As reported 
previously, the retention times in the bioaffinity detection as well as in the MS detection are 
very stable (<3% relative standard deviation) [18]. This is expectable with state-of-the-art LC 
equipment, even more so with reagent delivery through pump, pulse dampener, restriction 
capillary and superloop which ensures stability of the bioaffinity trace. An increase in peak 
tailing is the only difference expected between bioaffinity and MS chromatograms in terms 
of chromatographic parameters. Even this only applies to highly nonpolar compounds as a 
result of the low organic modifier content of the bioaffinity assay. Therefore, the bioaffinity 
and MS chromatograms are matched by their stable retention time difference. The validity 
of this retention time difference can be double checked if a known binder is present in the 
mixture, in this case the substrate of the EC. The correlation of a bioaffinity peak with an 
EIC peak is achieved with high certainty because a margin of twice the maximum relative 
standard deviation of the retention time, in this case ca 30 s, is applied. If more than two 
EIC peaks would be matched within ±30 s to a bioaffinity peak, both compounds were 
possibly responsible for the bioaffinity signal. Fortunately, this case did not occur in the 
investigation. Please note that bioaffinity chromatograms were correlated with EIC at the 
front of the peak. In this way, peaks are more easily assessed when overloading of either 
readout leads to broad peaks with poorly defined maxima.
The major affinity peak is due to the unmodified kinase inhibitor, DMPIP. The seemingly 
large broadening of this affinity peak is due to the sigmoidal dose-response character of 
the bioassay. Based on the bioaffinity profile, the product with m/z 539.1902 (D –2.011 u) 
showed to be the main bioactive product in the oxidative mode. However, in the reductive 
mode, this product was less abundant and a product with m/z 472.1461 (D –69.0551 u) 
also showed significant binding to the p38α kinase. In both the reductive and the oxidative 
mode, a minor affinity peak was observed corresponding to hydroxylated DMPIP, with m/z 
557.1962 (D +15.9950 u).
Identification of the (bioactive) products was done using the HR-MSn data obtained in parallel 
with the bioaffinity measurements. Based on the fragmentation of the unmodified kinase 
inhibitor, the sites of modification were identified as far as possible. The fragmentation of 
DMPIP allowed the annotation of characteristic fragments to be used for the determination 
of the modification sites. Figure 4 shows the structure of DMPIP with the characteristic 
parts of the molecule involved in the fragmentation reactions.
Important fragments observed in the MS/MS spectra of DMPIP are C+D with m/z 319.0480 
and C with m/z 206.0003. Table 2 summarizes the identification study.
Below, the MS structure elucidation of two ions is discussed in detail. A full description of 
Figure 3: Correlation of bioaffinity profiles (top) and HR-MS traces (bottom) of electrochemical 
conversion products related to DMPIP.
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Table 1: Optimized electrochemical conversion conditions for DMPIP, BIRB796 and SB203580. 
Inhibitor EC conditions
 pH potential 
DMPIP
3.5 + 1.2 V  
10.0 + 1.2 V – 1.5 V
BIRB796
3.5 + 0.8 V  
10.0 + 0.8 V  
SB203580
5.0 + 1.5 V  
10.0 + 1.5 V  
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the structure elucidation for all ions observed is avoided in order to focus the discussion 
on the innovative combination of techniques. As an example, the MS and MS/MS spectra 
for the bioactive product with m/z 472.1461 are given in figure 5. The m/z difference 
compared to the parent compound is D –69.0551 u, consistent with a net loss of C4H7N. 
The data indicate that the molecule is modified in the D part, see figure 4. Parts A+B 
and C are detected unmodified, whilst the fragment of C+D shows the net loss of C4H7N. 
Fragmentation of the [M+H]+ additionally results in de neutral loss of CO2, leading to an 
unmodified B+C fragment. The characteristic losses of C4H7N and CO2 prove the hydrolysis 
of the amide in part D to a carboxylic acid, which is further supported by the MS3 fragments 
(data not shown). Therefore, full structure elucidation could be achieved by MSn analysis 
for this product. For the product with m/z 539.1902, attributed to a dehydrogenation of 
part B, absolute identification is not possible. The attribution is made by exclusion. As 
fragment CD is observed unchanged, modification in parts C and D is excluded. Since 
the dehydrogenation is observed in a BC fragment and C has already been excluded, the 
modification has to be in part B. A modification ‘across’ parts B and C can also be excluded, 
as the connecting amide has no hydrogen atoms to lose and as any other possibility would 
have to involve the formation of a new bond. This would require proximity which is hindered 
by the rigid structure of the C part and the connecting amide. The only likely crosslink 
between B and C would produce the loss of HCl instead of H2. All other B-C crosslinks would 
lead to new carbon-carbon bonds which would block the formation of the CD fragment.
Other products were identified in a similar way. The products of oxidation in part D (m/z 
472.1461 and m/z 557.1962) as well as dehydrogenation in part B (m/z 539.1902) of DMPIP 
all retained the affinity for the p38α kinase, see table 2. Products not showing bioaffinity 
include methoxylation of part A (m/z 571.2110, C29H33ClFN4O5
+; see also below), cleavage 
of methane from part B (m/z 525.1720, C27H27ClFN4O4
+) and the loss of C3H4 from part B 
(m/z 501.1715, C25H27ClFN4O4
+). The electrochemically induced cleavage of part A resulted 
in a product with m/z 431.1476 (C21H24ClN4O4
+).
The bioaffinity assessment of the products based on the inhibitor BIRB796 (C31H37N5O3, 
[M+H]+ with m/z 528.2975) showed that next to BIRB796 itself, two bioactive electrochemical 
conversion products were formed. Figure 6 shows the extracted ion chromatograms of the 
three bioactive compounds aligned with the bioaffinity trace. The two additional bioactive 
compounds were the main conversion products, being identified as the quinoneimine (m/z 
413.1985, C25H25N4O2
+, D 115.0990 u) and the hydroquinone (m/z 415.2134, C25H27N4O2
+, 
D 113.0841 u), both being present in all conversion samples.
Interestingly, Regan et al. described the structure-activity relationships of BIRB796 and 
some of its fragments [23]. The hydroquinone was found to bind to the kinase, while the 
reactive quinoneimine was addressed neither in this publication nor elsewhere in literature. 
The fact that we can detect bioaffinity of the reactive quinoneimine underlines the importance 
of a quick and clean sample handling technology between formation and analysis of the 
conversion products. In this respect, our on-line approach can be of added value with respect 
to the assessment of the affinity of reactive species. Other electrochemical conversion 
products of BIRB796 were not bioactive. These included a product with m/z 230.1652 
Figure 4: Structure of DMPIP and characteristic parts for MS/MS identification of electrochemical 
conversion products.
Table 2: Identification of electrochemical conversion products related to DMPIP based on high 
resolution MSn experiments (for explanation: see text). MS fragmentation is not to be confused with 
EC modifications (e.g., hydrolysis). For conclusions on nature and site of the EC modifications drawn 
from the MSn data, please refer to the text. Binding to p38α kinase is defined as an S/N ratio of > 3 in 
the p38α bioaffinity assay (see also figure 3). 
Tr in min. [M+H]+ Change 
in 
formula
Molecular 
formula
MSn
AB C CD other
fragments
16.1 541.2012 - C28H31 ClFN4O4
+ √ √ √ -
9.3 431.1481 -C7H6F C21H24ClN4O4
+ - √ - D
11.9 501.1699 -C3H4 C25H27ClFN4O4
+ - - √ BC-C3H4
12.8 525.1699 -CH4 C27H27ClFN4O4
+ -CH4 - √ -
14.0 472.1461 -C4H7N C24H24ClFN3O4
+ √ √ -C4H7N -CO2
15.6 557.1962 +O C28H31ClFN4O5
+ √ √ +O -
15.6 529.1649 -C2H4 +O C26H27ClFN4O5
+ - √ A,
-CO, -H2O
17.5 571.2118 +CH2O C29H33ClFN4O5
+ - - √ D, -H2CO
19.6 539.1902 -2H C28H29ClFN4O4
+ - - √ BC-2H
MS fragmentation is not to be confused with EC modifications (e.g., hydrolysis). For conclusions on 
nature and site of the EC modifications drawn from the MSn data, please refer to the text. Binding to 
p38α kinase is defined as an S/N ratio of >3 in the p38α bioaffinity assay (see also Figure 3).
The products showing bioaffinity are underlined in gray. 
Figure 5: MS and MS/MS spectra of the electrochemical conversion product of DMPIP, with 
m/z 472.1461. Annotations related to the parent structure (figure 4) are included in the spectra.
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corresponding to C14H20N3
+ and a low abundant product with m/z 273.1710 corresponding 
to C15H21N4O
+
, co-eluting with the unmodified BIRB796. Structure proposals can be found 
in the Online Resource figure S1. Oxidation at pH 7.0 and 10.0 resulted in two additional 
products with m/z 386.1863 (C24H24N3O2
+) and 411.1821 (C25H23N4O2
+). 
For SB203580 and its conversion products, affinity determination was hampered by the 
auto-fluorescence of SB203580 and its products at the wavelengths used for the detection 
of the enzyme-tracer complex in the p38α bioaffinity assay. Electrochemical conversion of 
SB203580 (C21H17FN3OS
+, [M+H]+ with m/z 378.1071) resulted in the formation of single 
(m/z 394.1026) and double oxygenated analogues (m/z 410.0969). The main product 
could be identified as the sulfone product based on its fragmentation pattern described 
previously by Henklova et al [24]. The rather scarce fragmentation of SB203580 did not 
allow proposing structures of the other products generated by electrochemical conversion.
In order to compare the on-line formation with the conventional off-line generated 
products, a set of off-line electrochemical conversion experiments was conducted. This 
included variation of pH and electrochemical potential for the conversion of the inhibitors. 
The samples were measured twice, once immediately after generation and once with an 
additional storage time of 10 hours. In this way, a focus was set on the effects of storage as 
a major difference between the off-line and on-line approach. For DMPIP and SB203580, 
no differences were observed in the conversion profiles between off-line and on-line 
conversion and analysis. This means that product formation is comparable between the 
two modes. The results of the off-line experiments also help to explain the origin of the 
methoxylation product for DMPIP. It may be suggested that the methoxylation does not 
take place in the EC cell, but rather via a reaction of a reactive intermediate with methanol 
in the LC mobile phase. However, the off-line experiments provide evidence against this. 
The off-line data, shown in figure S3, are not consistent with an intermediate reaction 
with the LC eluent, because, if it would be reacting, the amount of methoxylated product 
should be the same or less after storage (depending on the stability of the intermediate). 
However, the data actually show a higher abundance of methoxylated product after storage 
which indicates a reaction of an intermediate within the EC reaction mixture. Furthermore, 
if a reaction would take place during the chromatographic step, the peak shape of the 
methoxylated product would be seriously deteriorated. This is not observed. For BIRB796, 
differences were observed between off-line and on-line conversion products. The peak 
area of the reactive quinoneimine significantly decreased in the duplicate measurement 
after 10 hrs (see Online Resource figure S2), whilst in the pH 7 samples the hydroquinone 
was only present after 10 hrs. The products with m/z 230 and m/z 273 had an increased 
peak area in all duplicate samples and can therefore be either considered as secondary 
conversion products or degradation products. This is a direct consequence of the storage 
and handling steps and can be avoided in the on-line approach presented in this paper.
Conclusion
Electrochemical conversion of drug molecules has already been demonstrated to be a 
valuable tool to assist in drug metabolite identification studies. As an additional valuable 
feature, we showed that electrochemistry coupled on-line with LC-MS/bioassay can be 
used for the generation of small focused libraries of bioactive structures closely resembling 
the parent structures and assessment of their bioaffinity profile. The hit rate in these 
focused libraries can be significant. With the integration of direct affinity assessment of 
the electrochemical conversion products, one can quickly determine critical positions 
of a molecule influencing its affinity towards the target protein. Moreover, the on-line 
hyphenation of formation with identification and affinity determination strategies allows 
the affinity assessment of reactive species since sample handling steps and times are 
significantly reduced. The latter was clearly demonstrated by the affinity determination of 
the reactive quinoneimine of the BIRB796 inhibitor. All of these results stress the importance 
of employing biological characterization as an integral part of EC studies concerned with 
drug metabolism or lead discovery/optimization.
In principle, the on-line integrated setup could be expanded to an automated system 
applicable in routine analysis. Instead of by infusion, the parent compounds could be flow-
injected into the electrochemical reaction cell. Solvent select valves could be used for 
convenient and automated changing of the solvent composition and pH. Evidently, the 
subsequent electrochemical conversion can also be fully automated and controlled via the 
appropriate controlling software during the analytical runs. The complete setup should be 
capable of implementation in fully automated and integrated analytical workflows in drug 
discovery laboratories.
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Figure S2: Product profiles of BIRB796 for the off-line 
conversion. The x-axis gives the varying EC reaction 
conditions being different pH and voltage. For every 
pH/voltage pair and every ion, there are two rows in 
the x-dimension, the left one representing the first 
measurement and the right one the measurement with 
an additional storage time of 10h. The y-axis gives the 
area of MS response in arbitrary units calculated from 
the total ion current (A) or the extracted ion currents 
(B and C).
A) The area of BIRB796 is calculated from the total ion 
current because of the coexistence of the single- and 
double-charge protonated molecule. This indicated 
stability of the MS response over time as well as the 
chemical stability of BIRB796.
B) The highest signals at low pH are obtained from 
m/z 413.1 (black and dark blue) and 415.2 (grey 
and light blue) later identified 
as the quinoneimine and the 
hydroquinone, respectively. 
Their signals are lower at 
every pH in the x+10h sample 
(dark and light blue) than in the 
immediate measurements (black 
and grey). This hints to instability 
or reactivity which is in line with 
the structures proposed.
C) The opposite effect is 
observed for the analytes with 
m/z 273.2 (black and dark 
blue) and 230.2 (grey and 
light blue). Their response is 
always higher after additional 
storage (dark and light blue) 
which implies their formation 
by a secondary reaction 
or degradation step. The 
apparent changes in the 
profile under off-line conditions 
emphasize the need to avoid 
liquid handling and storage 
steps.
Figure S3: Product profiles of DMPIP 
for the off-line conversion. The 
x-axis gives the varying EC reaction 
conditions being different pH and 
voltage. For every pH/voltage pair and 
every ion, there are two rows in the 
x-dimension, the left one representing 
the first measurement (black) and the 
right one the measurement with an 
additional storage time of 10h (blue). 
The y-axis gives the area of MS 
response in arbitrary units calculated 
from the extracted ion currents.
A) The area calculated from the MS 
response of DMPIP is stable over time. 
Only the samples at pH 3.5 at 0 and 
800 mV show a large deviation. As 
figure B and C show no response at 
these conditions, this is not relevant for 
the analysis.
B) The product with m/z 539.1 which 
showed the highest affinity in the 
later on-line analysis is presented 
here. It was identified as the 
product of a dehydrogenation in the 
dimethylpiperazine ring of DMPIP. It 
seems to be stable at high pH, but 
instable at low pH.
C) The product of methoxylation 
(m/z 571.0) has a higher response 
after storage. As explained in 
the Discussion, this indicates the 
reaction of an intermediate with 
the EC mixture and excludes 
interference of the eluent. It also 
seems to be pH dependent as the 
response is more similar at higher 
pH.
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Abstract
Mutants of bacterial Cytochrome P450 BM3 from Bacillus megaterium have gained increasing 
interest to support drug metabolism studies by producing human relevant biotransformation 
products and/or to support drug discovery by producing libraries of new chemical entities 
based on initial lead compounds. In this study, a library of 33 P450 BM3 mutants was used 
to diversify TAK-715, a representative (highly lipophilic) inhibitor of p38α mitogen-activated 
protein kinase (p38α). To simultaneously determine the individual bioaffinity and identity of 
the different products, an analytical high-resolution screening approach was used, based 
on post-column on-line bioaffinity profiling with parallel mass spectrometric identification. 
The screening of the product mixtures produced demonstrated that introducing mutations 
in the active site of the P450 BM3 resulted in different product profiles. Several P450 BM3 
mutants were mimicking the metabolic profile obtained by human liver microsomes. The 
major biotransformation products of TAK-715 could be produced with the most active P450 
BM3 mutant in sufficient amounts to enable further structure elucidation by 1H-NMR and 
quantification of their p38α affinity.
Introduction
A relatively new development in drug discovery is the application of biocatalysts for the 
generation of new chemical entities or even unique compound libraries [1,2]. When 
using monooxygenase systems, such as the cytochrome P450 enzymes (CYPs), the 
biotransformation products are particularly interesting in lead optimization as they can 
show improved physicochemical properties, such as solubility, and target selectivity 
without significant loss of their pharmacological activity compared to the parent itself. 
CYPs are also involved in the majority of drug metabolism reactions: in particular CYP1A2, 
CYP2D6, CYP2C9, CYP2C19 and CYP3A4 are responsible for the bulk of metabolism 
of known drugs in humans [3]. Because of the potential pharmacological activity of drug 
metabolites, safety studies on circulating metabolites are required [4]. As a consequence, 
organic synthesis is needed to obtain sufficient amounts of pure compound. Biosynthetical 
approaches are upcoming alternatives to organic synthesis. Biocatalysts, i.e., enzymes, 
can perform reactions with a high degree of regio- and stereo- selectivity that often cannot 
be achieved by organic synthesis [5,6]. Obviously, CYPs are emerging as biocatalysts due 
to their catalytic versatility and extremely wide substrate diversity [7,8]. Here, bacterial 
CYPs are preferred to mammalian CYPs because they are soluble, show much higher 
turnover rates and can be expressed at high levels in E. coli. A very promising candidate as 
biocatalyst for the generation of large quantities of biotransformation products of drugs is 
P450 BM3 (CYP102A1) from Bacillus megaterium. This enzyme shows the highest catalytic 
activity ever recorded for a CYP [9]. Recently, many research groups have succeeded in 
expanding the substrate selectivity of P450 BM3 and improving its catalytic properties by 
site-directed and/or random mutagenesis, as recently reviewed [10].
Although several P450 BM3 mutants can perform oxygenation reaction with a high degree 
of regio- and stereoselectivity [11,12], biosynthesis of drug metabolites using engineered 
P450 BM3s can lead to the formation of multiple metabolites [1,13-15]. Structural 
identification and characterization of pharmacological and toxicological properties of the 
individual components in such mixtures requires elaborate semi-preparative fractionation. 
Alternatively, characterization of compounds in complex mixtures can be performed using 
the high-resolution screening (HRS) approach, that combines analytical separation with 
post-column on-line bioaffinity profiling, based on enzyme inhibition or displacement 
of tracer compounds, and parallel identity assessment with mass spectrometry (MS). 
This approach has been successfully used for the identification of ligands/inhibitors of 
several drug targets, such as human estrogen receptors α and β, acetylcholinesterase, 
acetylcholine binding protein, proteases and peptidases, and drug metabolizing enzymes 
such as CYPs and glutathione S-transferases [16]. The combination of P450 BM3-mutants 
as biocatalyst and a HRS platform has been previously used to study activity of metabolites 
of norethisterone and the mycotoxin zearalenone to the ligand binding domains of (human) 
estrogen receptors (hER) as drug targets [17,18].
Recently, a HRS methodology has been developed for the on-line screening of inhibitors 
of p38α mitogen-activated protein kinase (p38α) with simultaneous structure elucidation by 
high-resolution MS (HR-MS) [19]. The p38α is an important drug target in contemporary 
drug discovery because it plays a central role in inflammatory cellular signalling processes 
[20]. Several companies have reported preliminary human clinical results for p38α inhibitors, 
but until now no drug has reached the market [21]. 
In the present study, a library of P450 BM3 mutants was used to prepare mixtures of 
biotransformation products of the p38α inhibitor TAK-715 (N-[4-[2-ethyl-4-(3-methylphenyl)-
1,3-thiazol-5-yl]-2-pyridyl]benzamide, see Figure 3) and to characterize these using the 
p38α HRS platform. The high turnover rates of P450 BM3s and the convenient large-scale 
production and purification protocols for these enzymes allow semi-preparative production 
of human relevant metabolites or new chemical entities for further pharmacological 
profiling [1]. TAK-715 was one of the most potent p38α inhibitors from a series of synthetic 
4-phenyl-5-pyridyl-1,3-thiazoles [22,23]. TAK-715 was advanced to clinical Phase II trials 
for rheumatoid arthritis, but was discontinued [24]. Recently Verkaar et al. showed that 
TAK-715 is able to inhibit the Wnt-3α-stimulated β-catenin signalling pathway [25] whose 
aberrations are associated with several malignancies, most notably cancer [26]. Therefore, 
lead diversification of TAK-715 is still relevant. Previously reported lead optimization 
of typical p38α inhibitors was performed using a library encompassing rather lipophilic 
compounds. Application of the P450 BM3 mutant mono-oxygenases is anticipated to 
improve the physicochemical properties of the lead compounds, while maintaining their 
bioaffinity. 
Materials and methods
Chemicals
Human recombinant p38α and TAK-715 were a kind gift of MSD Research Laboratories (Oss, 
the Netherlands). SKF86002 was delivered by Merck KGaA (Darmstadt, Germany). Fused 
silica tubing (250-μm inner and 375-μm outer diameter) covalently coated with polyethylene 
glycol (PEG) was purchased from Sigma-Aldrich (Schnelldorf, Germany). Methanol 
(LC–MS grade) and formic acid (LC–MS grade) were from Biosolve (Valkenswaard, the 
Netherlands). All other chemicals were of analytical grade and were obtained from Sigma-
Aldrich (Schnelldorf, Germany). Human liver microsomes (HLM) pooled from different 
individual donors were obtained from BD Gentest TM (San Jose, USA) and contained 20 
mg/mL protein (Cat. No. 452161).
Expression and isolation of P450 BM3 mutants 
Expression of the CYP 102A1 mutants was performed by transforming competent E.Coli 
BL21 cells with the corresponding pET28+-vectors, as described previously [27]. For 
expression, 600 mL Terrific Broth (TB) medium (24 g/L yeast extract, 12 g/L tryptone, 4 mL/L 
glycerol) with 30 mg/mL kanamicin was inoculated with 15 mL of an overnight culture. The 
cells were grown at 175 rpm and 37°C until the OD600 reached 0.6. Then, protein expression 
was induced by the addition of 0.6 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The 
temperature was lowered to 20°C and 0.5 mM of the heme precursor δ-aminolevulinic acid 
was added. Expression was allowed to proceed overnight. Afterwards, cells were harvested 
by centrifugation (4600 × g, 4°C, 25 min), and the pellet was resuspended in 20 mL Kpi-
glycerol buffer (100 mM potassium phosphate (KPi) pH=7.4, 10% glycerol, 0.5 mM EDTA, 
and 0.25 mM dithiothreitol). Cells were disrupted by French press (1000 psi, 3 repeats) and 
the cytosolic fraction was separated from the membrane fraction by ultracentrifugation of 
the lysate (120.000 × g, 4°C, 60 min). CYP concentrations were determined using a carbon 
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monoxide (CO) difference spectrum assay.
Selection of the P450 BM3 mutant library
In the present study, 33 mutants of P450 BM3 were selected which could be expressed at 
good levels and which showed catalytic diversity towards a variety of drugs and steroids. 
Mutants M01 (R47L, F87V, L188Q, E267V, G415S), M02 (R47L, L86I, F87V, L188Q, 
N319T), M05 (R47L, F81I, F87V, L188Q, E267V, G415S) and M11 (R47L, E64G, F81I, 
F87V, E143G, L188Q, E267V, G415S) were previously constructed by a combination 
of three site-directed mutations and subsequent random-mutagenesis by error-prone 
PCR [13]. Mutants M01 and M11 where used as templates for additional site-directed 
mutagenesis of active site residues, guided by available crystal structures of P450 BM3 
and by computational modeling of the active site of P450 BM3 [28]. Positions which were 
selected for mutagenesis were residues 72, 74, 82, 87 and 437 which appear to be key 
active site residues which have profound influence on regio- and stereoselectivity of P450 
BM3 mutants.
Position S72 and A74 are both located in the substrate binding channel [7,29] and have 
been shown to influence regioselectivity and activity [15,30]. The effect of a negatively 
charged residue (Asp or Glu) in both M01 and M11 in position 72 and 74 is evaluated in 
this work. 
Mutation A82W was selected because it strongly influenced regioselectivity of steroid 
hydroxylation when applied to M01 and M11 [11]. 
Mutations at position 87 have been extensively studied as the amino acid lies very close to 
the heme, according to available crystal structures of P450 BM3. In our previous studies, we 
mutated this position in M11 to all possible amino acids, showing that mutation at position 
87 has strong influence in the metabolism of alkoxyresorufins, and the regioselectivity of 
testosterone and clozapine metabolism [27,31].
Mutation of L437 was shown to have strong influence of regio- and stereoselectivity of 
α-ionone hydroxylation [12]. This position was mutated in M11 to the negatively charged 
residue Glu (L437E) and to three polar residues Asn (L437N), Ser (L437S), and Thr 
(L437T), which differ in size and hydrogen bonding capabilities.
Biotransformation of TAK-715 by P450 BM3 mutants and human liver microsomes
Incubations of TAK-715 were performed in 100 mM Kpi buffer pH 7.4 with 250 nM P450 
BM3 mutants. The final volume of the incubation was 200 μL, with 100 µM substrate 
concentration. The reactions were initiated by addition of a NADPH regenerating system 
with final concentrations of 0.2 mM NADPH, 20 mM glucose-6-phosphate and 0.4 U/mL 
glucose-6-phosphate dehydrogenase. The reaction was allowed to proceed for 60 min 
at 25°C and was terminated by the addition of 200 µL of cold methanol. For human liver 
microsomes (HLM), a final microsomal protein concentration of 5 mg/mL was used and 
these incubations were performed as described above, at 37°C instead of 25°C. Precipitated 
protein was removed by centrifugation (15 min, 14000 × g), and the supernatant was 
analyzed by UPLC using an Agilent Technologies 2000 system and a Zorbax Eclipse 
XDB-C18 column (1.8 mm, 50 mm × 4.6 mm; Agilent Technologies, USA). The gradient 
used was constructed by mixing the following mobile phases: eluent A (0.8 % methanol, 
99 % water, and 0.2 % formic acid); eluent B (99 % methanol, 0.8 % water, and 0.2 % 
formic acid) with a flow rate of 1 mL/min. The gradient was programmed as follows: from 0 
to 8 minutes linear increase of eluent B from 40% to 100%; from 8 to 9 minutes, isocratic 
100% B; from 9 to 9.5 minutes linear decrease from 100% to 40% of eluent B; from 9 to 
12 minutes isocratic 40% eluent B. The products and substrate were detected at 254 nm. 
HRS analysis of biotransformation products of TAK-715 using the LC-p38α kinase 
affinity/MS platform
The HRS analysis of the biotransformation products is conducted with an LC–enzyme 
binding detection/MS platform which has been described previously [19]. The platform 
comprised a LC–MS system from Shimadzu (‘s Hertogenbosch, the Netherlands), including 
two LC-20AD and two LC-10AD isocratic pumps, an SIL-20AC, a CTO-20AC and a CTO-
10AC column oven, an RF-10AXL fluorescence detector, an SPD-AD UV/VIS detector, and 
a CBM-20A controller coupled to an ion-trap time-of-flight hybrid mass spectrometer for HR-
MS equipped with an electrospray ionization (ESI) source. In short, the biotransformation 
product mixtures were separated on an Xbridge C18 column 100×2.1 mm with 3.5 µm 
particles (Waters, Milford, MA, USA) at 40°C and a flow rate of 113 µL/min. 
The gradient used was constructed by mixing the following mobile phases: eluent C (1 % 
methanol, 99 % water, and 0.01 % formic acid); eluent D (99 % methanol, 1 % water, and 
0.01 % formic acid). The gradient was programmed as follows: from 0 to 2 minutes isocratic 
at 20% D; from 2 to 18 minutes, linear increase of eluent D from 20% to 90%; from 18 to 
22 minutes, isocratic 90% D; from 22 to 23 minutes linear decrease from 90% to 20% of 
eluent D; from 23 to 30 minutes re-equilibration isocratic at 20% eluent D. Post-column, the 
flow was split in a ratio of 1:9 directing 13 µL/min to the bioaffinity detection and 100 µL/
min to UV/VIS and ESI-HR-MS analysis. The bioaffinity detection is based on competition 
of analytes with a tracer showing fluorescence enhancement. Affinity towards p38α is 
assessed by mixing the analytes with 45 nM of enzyme and 630 nM of tracer, SKF86002. 
The readout occurred at excitation 355 nm and emission 425 nm, 15 nm bandwidth each, 
in the flow-through fluorescence detector. The UV/VIS detector was operated in dual 
wavelength mode at 210 nm and 254 nm. For ESI, the needle voltage was set to 4.5 kV 
and the source heating block and the curved desolvation line were kept at 200°C. A drying 
gas pressure of 62 kPa and a nebulizing gas flow-rate of 1.5 L/min assisted the ionization. 
Full spectra were obtained in the positive-ion mode between m/z 200 and 650. MS2 and 
MS3 spectra were obtained in data-dependent mode between m/z 100 and 650 with an ion 
accumulation time of 10 ms, a precursor isolation width of 3 Da and a collision energy of 
75%. For the analytes in the large-scale incubation mixture, MS2 and MS3 spectra were 
generated with manual precursor selection and data-dependent analysis, respectively. The 
IC50 determinations were done in flow-injection analysis (FIA) mode, which means the 
separation column was replaced by a low dead volume union (VICI, Schenkon, Switzerland). 
The lower dead volume reduces analysis time and minimizes peak broadening compared 
to a column elution without retention. In these experiments, an injection volume of 50 µL 
was used to achieve adequate final concentrations for full inhibition. Negative peak heights 
were plotted against the corresponding final concentrations. The latter were calculated as 
described earlier [19].
Large-scale production and isolation of biotransformation products by preparative 
HPLC
The biotransformation products of TAK-715 were produced on a semi-preparative scale 
by incubation with the most active P450 BM3 mutant as biocatalyst. A 100 mL reaction 
volume containing 1 µM P450 BM3, 100 µM TAK-715 and NADPH regenerating system (as 
described above) was prepared in 100 mM KPi buffer at pH 7.4. The reaction was allowed 
to continue for 5 h at 25°C. To achieve maximal conversion of TAK-715, the incubation 
was supplemented every hour with 3 mL of 30 µM P450 BM3 M11 and 5 mL NADPH 
regenerating system (20× concentrated). The reaction mixture was extracted three times by 
100 mL ethyl acetate. The combined organic layers were collected in a round-bottom flask 
and evaporated to dryness using a rotary evaporator. The residue was redissolved in 10 
mL of 50% MeOH/H2O and applied by manual injection on a preparative chromatography 
column Luna 5 µm C18 (250 × 100 mm i.d.) (Phenomenex, Torrance, CA, USA), which was 
previously equilibrated with 40% eluent B. A flow rate of 2 mL/min and a gradient using the 
eluent A and B was applied for separation of formed TAK-715 biotransformation products. 
The gradient was programmed as follows: from 0 to 40 min linear increase of eluent B from 
40 to 100%; from 40 to 50 min isocratic 100% B, from 50 to 55 min linear decrease to 40% 
B, and then re-equilibration was maintained until 65 min. Biotransformation products were 
detected using UV detection at 254 nm and collected manually. Collected fractions were 
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first analyzed for purity and identity by the analytical UPLC. Fractions containing individual 
metabolites were evaporated to dryness under nitrogen stream and dissolved in 1 mL 
deuterium oxide to exchange acidic hydrogen atoms by deuterium atoms. Finally, after 
drying by a SpeedVac evaporator, the residues were redissolved in 500 µL of methanol-d4 
and 1H-NMR spectra were recorded at room temperature. 1H-NMR-analysis was performed 
on Bruker Avance 500 (Fallanden, Switzerland) at 500.23 MHz. Afterwards, the samples 
were dried and redissolved in 30% MeOH and subjected to LC–enzyme binding detection/
MS analysis. LogP values were calculated with ChemBioDraw Ultra version 12 from the 
structures obtained.
Results and discussion
Biocatalysed synthesis of lead compounds from TAK-715 by P450 BM3 mutants; 
comparison to human liver metabolism
TAK-715 was incubated for 60 min with a library of 33 mutants of bacterial P450 BM3 
and pooled human liver microsomes (HLM), and subsequently analysed by UPLC. The 
results of these incubations, including the percentage of conversion of substrate and 
profile of metabolites, are tabulated in Table S1 of the ESI. As shown in Figure 1, in total 
eight metabolites were found after incubation of TAK-715 with HLM, encoded TAK-P1 to 
TAK-P8 based on their order of elution, whereas six products were observed with P450 
BM3 (TAK-P3 and TAK-P4 were not observed). The P450 BM3 only produced human 
relevant metabolites of TAK-715. The most active P450 BM3 were M11 and its mutants at 
position 74 and 437. M11 produced TAK-P7 as major product, representing 42 ± 3% of the 
total biotransformation. TAK-P5 was produced as 22 ± 2% of the total biotransformation, 
whereas TAK-P1, TAK-P2, TAK-P6 and TAK-P8 were formed at 13% or less. Mutation to 
a negatively charged amino acid (Asp or Glu) or hydrogen bond donor (Thr) in positions 
74 or 437 of M11 has little to no effect on activity but changed the profile significantly by 
producing threefold higher amounts of TAK-P1, making this the major product (Table S1). 
In contrast, mutant M11 V87I did not produce any TAK-P1, making it more selective to 
produce TAK-P7 (60% of total biotransformation).
TAK-P5 turned out to be the major product for 22 out of the 33 P450 BM3-mutants studied 
Figure 1: Ultra-performance liquid chromatography chromatograms obtained after incubations of 
TAK-715 (100 µM) incubated for 60 minutes with 200 nM P450 BM3 M11 (upper line) and 5 mg/mL 
human liver microsomes (lower line). UV-Detection of metabolites was at 254 nm.
(Table S1). In particular, the mutants showing relatively low activity appeared to be highly 
selective in the production of TAK-P5. The only mutant which showed a significantly 
different profile was M11 L437N which was the only mutant to produce TAK-P6 as the 
major product (38%). 
Based on its high activity and its ability to produce most of the products at significant amounts, 
M11 was selected to further evaluate the affinity of the TAK-715 biotransformation products 
towards p38α in the on-line HRS-affinity assay and to perform a large-scale incubation to 
obtain sufficient amounts of the products for 1H-NMR and further affinity assessments with 
individual compounds.
From Table S1, it can also be concluded that the P450 BM3 mutants were able to form 
almost all human-relevant metabolites although with different activities and with strongly 
different product ratios. After 60 minutes of incubation, 33 ± 2 % of the substrate was 
converted by HLM, corresponding to 25.2 nmol product/min/CYP. The main metabolite 
was TAK-P7, which represented 29 ± 3% of the total metabolism, respectively. Metabolites 
TAK-P1, TAK-P2, TAK-P5 and TAK-P6 were formed at comparable amounts by HLM, 
ranging from 14 to 20% of the metabolites, whereas the minor metabolites TAK-P3, TAK-P4 
and TAK-P8 were formed at 3 to 5% of total metabolism. 
Parallel on-line bioaffinity assay and mass spectrometry of TAK-715 biotransforma-
tion products produced by P450 BM3 M11 and HLM
Although HLM incubations are not in the focus of this investigation, they produce the same 
products as BM3 M11 as well as a few other minor products. Affinity analysis was per-
formed for both HLM and P450 BM3 M11 incubations. Figure 2A shows the extracted-ion 
and bioaffinity chromatograms for the TAK-715 metabolites produced by HLM, whereas 
Figure 2B shows the same for the products generated by BM3 M11. Retention times differ 
from the chromatograms shown in Figure 1, because another HPLC system was used. 
However, the order of elution was unchanged. Next to TAK-715, four of its biotransforma-
tion products and eight of its metabolites showed affinity towards p38α (Figure 2). Data on 
these compounds are summarized in Table S1. 
As expected, TAK-715 (eluting at 39.5 min, [M+H]+ with m/z 400.151) showed a strong 
bioaffinity. The second strongest decrease in fluorescence was found at 33 min, closely 
corresponding to TAK-P6 (32.7 min) and TAK-P7 (33.0 min). The lower resolution of the 
HRS-system did not allow to attribute the bioaffinity signal to any of these metabolites. 
MS analysis showed that TAK-P6 and TAK-P7 with m/z 416.146 and 430.123 correspond 
to a mono-oxygenated TAK-715 and double oxygenated/dehydrogenated TAK-715, 
respectively. The mono-oxygenated product TAK-P5 (31.4 min, m/z 416.146) and the 
double oxygenated products TAK-P1 (23.0 min, m/z 432.138) and TAK-P4 (27.8 min) also 
showed bioaffinity. TAK-P3 (24.3 min, m/z 430.123) only showed a very weak bioaffinity 
signal. The products TAK-P2 (24.3 min, m/z 446.121) and TAK-P8 (34.5 min, m/z 416.146) 
did not show significant bioaffinity. 
Next to the eight metabolites previously found by UPLC, two additional metabolites were 
identified based on small bioaffinity peaks in the HRS system. TAK-P9 (8.4 min, m/z 
312.119) can be rationalized by hydrolysis of the amide-bond of one of the mono-
oxygenated TAK-715 products. TAK-P10 (17.4 min, m/z 448.138) apparently results from 
triple oxygenation of TAK-715. The bioaffinity signal at 4.5 min appeared to be unrelated 
to TAK-715.
Preparative scale biosynthesis of TAK-715 biotransformation products
To obtain sufficient amounts of TAK-715 biotransformation products for NMR structural 
identification and affinity testing of isolated products to p38α, a large-scale (100 mL) 
incubation was performed of TAK-715 with mutant P450 M11. Figure S1 of the ESI shows 
the preparative HPLC chromatogram of the product mixture obtained. After 5 hours of 
incubation, with hourly additions of enzyme and cofactors, almost 90% conversion of 100 
μM of TAK-715 was obtained. LC–MS/MS measurements were performed to confirm the 
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Figure 2: Correlation between biochemical detection (p38α kinase affinity trace, upper 
trace) and extracted ion chromatograms from the MS detection (lower traces) of oxidative 
metabolites of TAK-715 produced in incubations with (A) human liver microsomes (HLM), 
and (B) p450 BM3 mutant M11.
identity of isolated products. The main product TAK-P1 (35.7 min) represents 39% of the 
total biotransformation and corresponds to 1.5 mg of product formed. Two mono-oxygenated 
products (TAK-P5 and TAK-P6, 42.6 min and 43.5 min) represent 27% (1.0 mg) and 12% 
(0.4 mg) of the total biotransformation, respectively. TAK-P7 (43.8 min) represents 15% 
of the total biotransformation (0.6 mg), whereas TAK-P2 (37 min) was formed at less than 
5%. Interestingly, also a small amount of TAK-P4 was found in the large-scale incubation. 
The relative product amounts obtained by large-scale incubation are slightly different from 
that obtained in the screening experiment because of the longer incubation time (5h vs. 1h) 
and higher enzyme/cofactor concentration. Also, the less efficient aeration of large-volume 
incubations might contribute to the different profile.
Structure elucidation of TAK-715 biotransformation products
For five of the products of TAK-715 (m/z 400.148), sufficient material was obtained to 
acquire a 1H-NMR spectrum, which together with the LC–MS/MS data allowed structure 
elucidation. By comparison with the spectra and fragmentation patterns of TAK-715, it 
was possible to assign the structural modifications for most of the products (Table 1). The 
details of the 1H-NMR spectra can be found in Table S2 of the ESI. Data on interpretation of 
the LC–MSn spectra are discussed in more detail elsewhere  [32]. The proposed structures 
of the products are summarized in Figure 3.
TAK-P5 and TAK-P6, both with m/z 416.146, indicate mono-oxygenation at different 
positions. The integrals and coupling pattern of the 1H-NMR spectrum of TAK-P5 showed 
that all 12 aromatic hydrogen atoms and the hydrogen atoms of the ethyl moiety were still 
present (Table S2). The fact that the singlet of the benzylic methyl group was no longer 
observed, whereas the chemical shifts of the aromatic protons were shifted upfield, indicates 
that TAK-P5 results from hydroxylation of the benzylic methyl group. For TAK-P6, the 
1H-NMR-spectrum indicates hydroxylation at the methylene carbon of the ethyl side chain: 
the triplet of the terminal methyl group in TAK-715 was changed to a doublet, whereas the 
quartet of the original methylene group was shifted upfield and showed half the integral. 
The secondary loss of acetaldehyde in the LC–MS/MS data of TAK-P6 was consistent with 
hydroxylation at this position.
TAK-P7 (m/z 430.123) was the major metabolite formed by HLM. Its 1H-NMR spectrum 
showed all aromatic hydrogen atoms and an unchanged ethyl side chain. Similar to TAK-P5, 
the signal of the benzylic methyl group was not observed, whereas the signals of the 
Table 1: Identification and characterization of TAK-715 biotransformation products
p38α kinase affinity (nM)
tr (min)
a code m/z of 
[M+H]+
Structural
modification
IC50 95% Conf.
interval
23 TAK-P1 432.138 + 2O 460 ± 165 240 to 890
24.3 TAK-P2 446.121 + 3O – 2H No affinity
25.2 TAK-P3 430.125 + 2O – 2H + (n.q.)b
27.8 TAK-P4 432.141 + 2O + (n.q.)
31.4 TAK-P5 416.146 + O 310 ± 33 250 to 380
32.7 TAK-P6 416.146 + O 38 ± 4 31 to 47
33 TAK-P7 430.123 + 2O – 2H 1500 ± 203 1100 to 1900
34.5 TAK-P8 416.146 + O No affinity
8.4 TAK-P9 312.119 – C7H4O + O + (n.q.)
17.4 TAK-P10 448.138 + 3O + (n.q.)
39.4 TAK-715 400.151 71 ± 26 36 to 140
a tret = retention time in the HRS analysis (Fig. 2A and 2B); 
b n.q., not quantified.
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aromatic ring of the benzylic ring were strongly shifted upfield. This, in combination with the 
LC–MS/MS data, indicates that the benzylic methyl group is metabolized to a carboxylate 
group, e.g., by further oxidation of TAK-P5 by two successive oxidation reactions (Figure 
3).
TAK-P1 (m/z 432.138, consistent with two sequential oxygenation reactions) showed a 
1H-NMR spectrum in which both the signals of the benzylic methyl group and the ethyl 
side chain of TAK-715 were strongly affected, suggesting that this product results from 
hydroxylation of both alkyl side chains. The coupling pattern and integrals of the signals of 
the ethyl side chain show that hydroxylation occurred at the methylene group, similar to the 
changes observed in the spectrum of TAK-P6.
Similarly, the 1H-NMR spectrum of TAK-P2 (m/z 446.138) showed strong changes in the 
signals of the benzylic methyl group and the ethyl side chain. The signals of the ethyl 
side chain point to hydroxylation at the methylene position, similar to TAK-P1 and TAK-P6, 
whereas the signals of the benzylic group showed the same changes as observed in 
TAK-P7, indicative for formation of a carboxylic acid by sequential oxidations (Figure 3).
For products TAK-P3, TAK-P4 and TAK-P9, no 1H-NMR data could be obtained; no P450 
BM3-mutant produced these in sufficient amounts. Thus, no purification was attempted. 
Structure elucidation for these products, based on the LC–MS/MS fragmentation [32], is 
summarized in Table 1 and Figure 3. For metabolites TAK-P8 and TAK-P10, which result 
from single and triple oxygenation reactions, respectively, no useful fragment ions were 
found in LC–MS/MS. 
Biotransformation of TAK-715 appeared to occur almost exclusively at its alkyl side chains. 
TAK-P5 and TAK-P7 result from sequential oxygenation on the benzylic methyl group. 
The intermediate aldehyde was not detected, suggesting that it extensively undergoes 
further oxygenation to TAK-P7 and, to lesser extent, TAK-P3. Although conversion of the 
alcohols to carboxylates is often catalysed by sequential alcohol dehydrogenase, aldehyde 
dehydrogenase and oxidase reactions, conversion of TAK-P5 to TAK-P7 appears to be 
fully catalysed by P450 BM3. So far, only few examples have been described on the 
multistep oxidation of a methyl group to a carboxylic acid by CYPs. Oxidation of a methyl 
of the t-butyl moiety of terfenatine and ebastine to their corresponding carboxylic acids 
fexofenadine and carebastine in HLM was previously shown to be catalysed by CYP3A4 
and CYP2J2 [33,34]. More recently, yet unidentified microbial P450s from Streptomyces 
platensis were also shown to be capable to produce fenofexadine from terfenatine [35]. 
Similar to our P450 BM3 incubations, no intermediate aldehyde was found, indicating 
that the conversion of aldehydes to acids by P450s is highly efficient. The availability of 
biocatalysts for conversion of methyl groups to carboxylic acids is considered of high value 
because chemical synthesis is laborious, and because incorporation of carboxylic acids in 
drug molecules might be beneficial for water solubility, might decrease the risk of hERG 
inhibition [35], and might restrict passage of the blood-brain-barrier.
Combining the product profiles of the different P450 BM3 mutants (Table S1) with structural 
modifications observed in the products (Figure 3), it can be concluded that oxygenation 
of the benzylic methyl group is by far the major pathway for all mutants studied. The sum 
of TAK-P5 and TAK-P7, both only involving modification of the benzylic methyl group, 
represents from 50 to 100% of the products, dependent on the mutant. Because TAK-P1, 
TAK-P2 and TAK-P3 might be secondary oxidation products of TAK-P5 and TAK-P7, 
the total contribution of this pathway might even be underestimated. The most selective 
mutants, which almost specifically produce the primary product TAK-P5, showed only very 
low enzyme activity, explaining why no secondary product was observed. Only for mutants 
M11 V87I and M11 V87F, the change in the product profile might be attributed to changes in 
substrate orientation, because this is the only mutant which did not show any oxygenation 
of the ethyl side chain: the benzylic methyl oxygenation appeared to represent 90% of the 
biotransformation. Mutant M11 L437N showed the highest amount of product TAK-P6, and 
relatively low levels of TAK-P5 and TAK-P7, which suggests that mutation L437N causes a 
shift from benzylic methyl hydroxylation to hydroxylation of the ethyl side chain.
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3.23.2 Estimation of product affinity (IC50)The products TAK-P1, TAK-P2, TAK-P5, TAK-P6 and TAK-P7 were isolated by preparative 
HPLC. After checking their purity by 1H-NMR and analytical HPLC, the concentration of each 
stock solution was determined by using a standard curve of TAK-715, assuming that the 
extinction coefficients of each product was equivalent to that of TAK-715. This inaccuracy 
can be resolved by correcting for the extinction coefficient once product standards are 
available. Subsequently, different concentrations of TAK-715 and TAK-715 metabolites 
were analysed using the p38α HRS system in flow-injection mode in order to assess the 
affinity of each compound. Figure 4 shows the concentration dependence of binding of the 
individual products and TAK-715 to p38α, after correction for the dilutions intrinsic to the 
HRS-system. Calculated IC50-values of TAK-715 and its products are presented in Table 1.
For both TAK-715 and TAK-P1, not all data points of the full binding curve were considered 
in the IC50 determination, but those, which had been compromised by interferences, were 
excluded. This is neither due to a shortcoming in the assay nor due to experimental error. 
On the contrary, these are two excellent examples of the power of the HRS platform 
to resolve interferences. In case of the highly lipophilic TAK-715, peak tailing due to 
nonspecific binding to materials of the HRS system deformed the Gaussian shape so 
severely at concentrations higher than 60 nM (5µM injected) that it was not possible to 
calculate the local concentration in the assay. Also, the baseline for the following injection 
could not be recovered in a reasonable time. In the case of TAK-P1, (auto)fluorescence 
at the assay wavelengths appeared to interfere with the p38α affinity measurement at 
high concentrations. Due to the different concentration-dependent behaviour of both 
contributions, e.g., increase of TAK-P1 (auto)fluorescence and decrease of fluorescence 
enhancement of the tracer by displacement at increasing TAK-P1 concentration, a 
W-shaped peak was obtained whose area no longer reflects the fraction of binding. It is 
important to note that these phenomena would also affect plate reader based assays, 
albeit with different manifestations. Adsorption to the well plate surface and a mean signal 
for positive and negative fluorescence contributions would result from high lipophilicity 
and auto-fluorescence, respectively. The first diminishes the actual concentration of the 
binder while the latter results in an underestimation of the negative signal height. Both 
effects will alter the dose-response curves and are difficult to detect in a plate reader setup. 
However, in a HRS setup, these interferences are easily detected and the analysis can 
thus be restricted to the uncompromised concentrations. Despite the incomplete binding 
curves, the IC50-values and 95% confidence intervals can still be estimated for TAK-715 
and TAK-P1 by fitting the data points by the same fitting procedure as was used for the 
other compounds with complete binding curves. The IC50 obtained for TAK-715, 71 nM is 
consistent with the value observed previously with this platform [19].
As shown in Figure 4, for three of the products, TAK-P1, TAK-P5, and TAK-P7, the binding 
curves obtained were shifted to higher concentrations, compared to TAK-715. The largest 
shift was observed with TAK-P7. This product showed an IC50-value of 1500 ± 203 nM 
which is a 20-fold lower affinity than TAK-715. With IC50-values of 460 ± 165 nM and 
310 ± 33 nM, respectively, TAK-P1 and TAK-P5 showed 5- and 7-fold decreased affinity. 
Interestingly, TAK-P6 showed high affinity (IC50-value of 38 ± 4 nM). However, due to the 
large standard error of the IC50-value of TAK-715, the difference in affinity of TAK-P6 is 
not statistically significant. For TAK-P2, no binding curve was obtained, indicating that this 
product completely lacked affinity to p38α.
These measurements indicate that oxygenation of the benzylic methyl group appears to 
be detrimental for affinity to p38α. The fact that TAK-P7 shows a very low affinity, whereas 
TAK-P2 shows no affinity at all, indicate that the carboxylic acid strongly disturbs binding to 
p38α. These results are consistent with these results of Miwatashi et al. which showed that 
modifying the benzylic methyl group of TAK-715 by other substituents, or by positioning 
the methyl group to the ortho- or para-position, in all cases led to a strong loss in affinity 
towards p38α [23]. Apparently, the benzylic methyl group at the meta-position of TAK-715 is 
essential for its affinity. This is further confirmed by the high affinity of TAK-P6 in which only 
the ethyl side chain is hydroxylated. Again, this seems consistent with the study of Miwatashi 
et al. [23] which showed that modification of the thiazole-2-ethyl moiety of TAK-715 to other 
alkyl substituents (methyl, propyl) or a large substituent such as 4-methylsulfonylphenyl 
only showed little effect on p38α affinity.
Conclusion
The results of the present study show that the combination of a catalytically diverse set of 
P450 BM3 mutants, as a toolbox to diversify a drug, and a HRS-systems capable of rapid 
screening for affinity to p38α kinase is a promising platform to generate potential novel lead 
compounds which might have improved physicochemical properties (by improved water 
solubility) and desired pharmacological properties. As exemplified by TAK-715 as model 
compound, the P450 BM3 mutants were able to produce almost all metabolites produced by 
human liver microsomes at significant levels. Furthermore, profiling the effect of structural 
modifications introduced by P450 on p38α kinase affinity gives valuable information on 
which structural elements are critical and which are non-critical for affinity. This is an 
essential tool in the construction of pharmacophore models and the lead optimization 
process. In addition, it would reduce the necessity of synthesizing large lead libraries by 
the medicinal chemist.
Finally, our results confirm that biocatalysis with CYPs can provide compounds with improved 
pharmacological and/or physicochemical properties compared to the lead itself which are 
not easily accessible by classic organic synthesis. This approach can be considered as an 
extra tool, next to the chemical synthesis in the typical medicinal chemistry approach.
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Figure 4: Concentration-dependent binding of TAK-715 and purified products TAK-P1, 
TAK-P5, TAK-P6 and TAK-P7 to p38α kinase as determined by HRS in flow-injection analysis. 
Percentage of binding was calculated by the concentration-dependent displacement of the 
tracer SKF86002 from p38α kinase. Error bars represent standard deviation.
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Supplementary Material Table S1: Percentage of conversion and ratio between the biotransformation products of TAK-715 
incubations with human liver microsomes (HLM) and 33 mutants of P450 BM3α.
Enzyme % Conv TAK-P1 TAK-P2 TAK-P3 TAK-P4 TAK-P5 TAK-P6 TAK-P7 TAK-P8
m/z of [M+H]+  )b )a 432.138 446.121 430.123 432.138 416.146 416.146 430.123 416.146
HLM 33 19 14 5 3 17 10 28 4
M11 38 11 6 0 0 22 3 42 13
M11 L437E 36 35 9 0 0 23 15 16 2
M11 A74E 36 35 8 0 0 18 13 24 2
M11 A74D 33 34 7 0 0 20 14 24 3
M11 L437S 31 20 7 0 0 25 15 27 6
M11 L437T 30 33 5 0 0 23 15 20 3
M11 V87I 25 0 0 0 0 32 0 60 8
M01 L437E 20 18 0 0 0 42 26 9 5
M11 V87F L437S 20 21 0 0 0 44 20 9 6
M11 A82W 19 3 2 0 0 23 4 57 11
M05 19 6 0 0 0 34 6 40 14
M01 S72D 18 11 2 0 0 38 8 28 13
M11 V87F L437N 18 23 0 0 0 31 23 13 10
M01 A82W 18 5 0 0 0 38 5 48 4
M01 S72E 17 14 0 0 0 48 26 7 5
M01 A74D 17 13 0 0 0 48 26 7 6
M11 V87I L437N 16 4 0 0 0 47 6 28 15
M11 A82W V87F 15 0 0 0 0 78 0 0 14
M11 V87F 15 0 0 0 0 82 5 6 7
M11 L437N 15 9 0 0 0 29 38 18 6
M11 S72D 12 12 6 0 0 52 17 6 7
M11 V87A 10 10 0 0 0 53 8 25 4
M11 V87I L437S 9 0 0 0 0 70 1 6 23
M01 7 0 0 0 0 60 14 6 20
M11 V87Y 7 0 0 0 0 76 6 6 12
M02 7 0 0 0 0 75 10 6 9
M11 V87L 6 0 0 0 0 79 5 3 13
M11 A82Y L437S 4 0 0 0 0 100 0 0 0
M11 A82Y V87I 4 0 0 0 0 85 15 0 0
M11 A82Y V87F 4 0 0 0 0 100 0 0 0
M11 V87Q 3 0 0 0 0 85 15 0 0
M01 A82C 3 0 0 0 0 100 0 0 0
M11 A82W L437S 2 0 0 0 0 100 0 0 0
a. All values represent averages of three individual experiments; RSDs were always less than 10% 
b. [M+H]+-values as determined by accurate-mass measurements by HR-MS.
Figure S1: Preparative HPLC-UV (254 nm) chromatogram of mixture of biotransformation products 
obtained by large-scale incubation of TAK-715 with P450 BM3 mutant M11. 
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Table S2: 1H-NMR-spectra of TAK-715 and major biotransformation products formed by P450 BM3 
M11.
TAK-715 TAK-P 1 TAK-P 2 TAK-P 5 TAK-P 6 TAK-P 7
Ha 1.45-1.48 
(3H,t)
1.61-1.63 
(3H,d)
1.64-1.65 
(3H,d)
1.45-1.48 
(3H,t)
1.62-1.64 
(3H,d)
1.44-1.49 
(3H,t)
Hb 3.09-3.13 
(2H,q)
5.08-5.12 
(1H,q)
5.08-5.12 
(1H,q)
3.09-3.14 
(2H,q)
5.08-5.12 
(1H,q)
3.08-3.14 
(2H,q)
Hc 2.33 (3H s) ~ 4.9* (s) - ~ 4.9* (s) 2.32 (3H,s) -
Hd 7.19-7.26 
(3H,m)
7.19-7.26 
(3H,m)
7.64-7.66 
(1H,d)
7.35-7.39 
(3H,m)
7.18-7.25 
(3H,m)
7.58-7.62 
(1H,d)
He “ “ 7.43-7.46 
(1H,t)
“ “ 7.40-7.43 
(1H,t)
Hf “ “ 7.99-8.01 
(1H,d)
“ “ 7.98-8.00 
(1H,d)
Hg 7.34 (1H,s) 7.51-7.54 
(3H,m)
8.18 (1H,s) 7.51-7.54 
(3H,m)
7.34 (1H,s) 8.14 (1H,s)
Hh 6.95-6.96 
(1H,d of d)
7.00-7.01 
(1H,d of d)
7.00 (1H,s) 6.98-6.99 
(1H,d of d)
6.97-6.98 
(1H,d of d)
6.95-6.96 
(1H,d of d)
Hi 8.21-8.22 
(1H,d)
8.23-8.24 
(1H,d)
8.25-8.26 
(1H,d)
8.22-8.23 
(1H,d)
8.22-8.23 
(1H,d)
8.21-8.22 
(1H,d)
Hj 8.31 (1H,d) 8.30 (1H,d) 8.33 (1H,d) 8.29 (1H,d) 8.31 (1H,d) 8.31 (1H,d)
Hk - - - - - -
Hl 7.94-7.96 
(2H,d)
7.94-7.95 
(2H,d)
7.94-7.95 
(2H,d)
7.94-7.95 
(2H,d)
7.94-7.96 
(2H,d)
7.94-7.95 
(2H,d)
Hm 7.51-7.54 
(2H,d of d)
7.51-7.55 
(3H,m)
7.51-7.54 
(2H,d of d)
7.51-7.54 
(3H,m)
7.51-7.54 
(2H,d of d)
7.51-7.54 
(2H,d of d)
Hn 7.59-7.62 
(1H,t)
7.59-7.62 
(1H,t)
7.58-7.60 
(1H,t)
7.59-7.62 
(1H,t)
7.59-7.62 
(1H,t)
7.58-7.62 
(1H,t)
* Chemical shift and integral of benzylic protons could not be determined accurately due to interfer-
ence with solvent signal.
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Abstract
Four hydrophobic p38α mitogen-activated protein kinase inhibitors were refluxed with 
7.5% hydrogen peroxide at 80°C and irradiated with visible light in order to generate 
more hydrophilic conversion products. The resulting mixtures were analysed in a high-
resolution screening (HRS) platform, featuring liquid chromatographic separation coupled 
in parallel with a fluorescence enhancement based continuous-flow affinity bioassay 
towards the p38α mitogen-activated protein kinase and with high-resolution (tandem) mass 
spectrometry on an ion-trap–time-of-flight hybrid instrument. The results were compared 
with similar data where chemical diversity was achieved by means of electrochemical 
conversion or incubation with either human liver microsomes or cytochrome P450s from 
Bacillus megaterium (BM3s). In total, more than 50 conversion products were identified. 
The metabolite-like compound libraries studied are discussed in terms of the reactions 
enabled, the retention of affinity, and the change in hydrophilicity by modification, in 
summary the ability to generate bioactive, more hydrophilic potential lead compounds. In 
this context, HRS is demonstrated to be an effective tool as it reduces the effort directed 
towards laborious synthesis and purification schemes.
1. Introduction
Despite the efforts in, for example, combinatorial chemistry, drug discovery still relies mainly 
on the utilization of purified compounds for biological affinity or activity testing, due to the 
limitations of classical high-throughput assays [1]. However, almost every synthetic or 
biosynthetic endeavour initially produces a mixture of compounds mainly because of side 
reactions. As a consequence, significant effort is directed towards optimization of synthesis 
[2] and purification [3] schemes for discovery compounds. An approach to overcome this 
bottleneck is the use of high-resolution screening (HRS), which is based on the bioaffinity 
assessment of individual compounds in a mixture [4] instead of requiring pure compounds 
or yielding a summed response like in high-throughput assays. By assessing all reaction 
products of a (parallel) synthesis, optimization and purification efforts can be directed 
towards active products without having to make a pre-selection.
HRS relies on a combination of separation, mostly liquid chromatography (LC), and 
hyphenated bioassays. The technology has matured in recent years by gradual improvements 
in stability and reproducibility as well as by the integration of mass spectrometry (MS) for 
structure elucidation [4]. We recently developed an HRS platform for the contemporary 
drug target p38α mitogen-activated protein kinase (p38α) which was thoroughly validated, 
for example by comparison of obtained IC50 values with other formats [5]. It enabled us to 
simultaneously assess the structure and affinity towards p38α of individual small molecules 
in a mixture. p38α is a key node in the cellular response to inflammatory stimuli and has 
thus been proposed as a drug target for therapy of chronic inflammatory diseases like 
psoriasis, rheumatoid arthritis or Crohn’s disease [6]. Many high-affinity p38α inhibitors 
have been created and some of them have advanced as far as clinical phase III in the 
drug development pipeline [7, 8]. Current p38α inhibitors are often very lipophilic, which 
negatively influences their solubility and bioavailability [9]. 
We investigated modifications of know p38α inhibitors by various means aiming to improve 
their physicochemical properties, which are pivotal aspects in steering bio-availability, 
while retaining high affinities. Oxidative metabolism can decrease the lipophilicity of the 
inhibitors and may retain their target affinity [10]. Therefore, techniques used for producing 
metabolites or metabolite-like compounds may present a promising route to lead libraries 
with improved physicochemical properties. Next to the increase in hydrophilicity, for example 
by hydroxylation, these bioactive metabolites may have more selectivity as well [11, 12]. 
Therefore, we studied several methods that have been used to produce more hydrophilic 
metabolites, in order to generate metabolite-like lead libraries of conversion products (CPs) 
from different known p38α inhibitors. Chemical oxidation with hydrogen peroxide (H2O2), 
which is generally used to simulate the influence of molecular oxygen on drugs during long 
term storage [13, 14], may yield similar products as metabolic reactions, though not by the 
same mechanisms [15]. Irradiation of drugs with intense visible light (Light), also applied in 
stability testing, was investigated as well [13]. This approach might not be as promising for 
the generation of metabolite-like compounds, but Light can initiate photochemical reactions, 
which possibly modify the scaffold of the molecule, resulting in new active core structures 
[14, 16]. Electrochemical conversion (EC) has been shown to be able to reproduce certain 
metabolic reactions, especially N- and O-dealkylation or P- and S-oxidation [17]. HRS data 
on EC generated libraries of CPs of p38α inhibitors have been reported earlier [18]. An 
interesting biosynthetic approach is the use of genetically engineered bacterial variants 
of metabolic enzymes, e.g., cytochrome P450s from Bacillus megaterium, especially one 
called BM3 [19]. These BM3s can be engineered to be highly regio- and stereo-selective 
[20] as well as for specific product profiles [21]. The library generation of CPs for the p38α 
inhibitor TAK-715 by means of BM3 mutants has been reported elsewhere [21]. In vitro 
metabolism simulation by human liver microsomal incubations (HLM) was investigated and 
compared with the other methods in order to additionally explore the usefulness of HRS in 
selecting suitable methods for metabolite synthesis in safety testing [22].
This manuscript is part of and actually concludes a larger study. Here, we present the 
structure and affinity profiles of the lead libraries of CPs of the p38α inhibitors produced 
with H2O2 and Light. In addition, these new results are critically compared to previously 
reported data, obtained with the other modification methods, with respect to the reactions 
enabled, the retention of affinity, and the change in hydrophilicity by modification, based on 
the results of our HRS platform. This enabled us to establish an initial qualitative Structure-
Activity Relationship (SAR), which in turn allows us to assess the usefulness of employing 
these methods as toolbox in the generation of metabolite-like lead libraries and judge the 
potential of their products as lead molecules. Thereby, we show that the implementation 
of the HRS platform together with a variety of modification methods is likely to create an 
effective lead optimization process as it reduces the effort directed towards laborious 
synthesis, purification and testing schemes.
2. Materials and Methods
2.1 Materials
The human recombinant p38α mitogen-activated protein kinase as well as its inhibitors 
DMPIP (1-{6-chloro-5-[(2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl]-
3aHindol-3-yl}-2-morpholinoethane-1,2-dione), SB203580 (4-[4-(4-fluorophenyl)-2-(4-
methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine) [23], BIRB796 (N-[3-(tert-butyl)-1-(4-
methylphenyl)-1H-pyrazol-5-yl]-N’-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-urea) 
[24], and TAK-715 (N-[4-[2-Ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide) 
[25] come from various sources. Human liver microsomes (HLM) pooled from different 
individual donors were obtained from BD Gentest TM (San Jose, CA, USA; Cat. No. 
452161) and contained 20 mg/mL protein. Methanol (LC-MS grade) and a 30% hydrogen 
peroxide solution were purchased from Biosolve (Valkenswaard, the Netherlands) and J.T. 
Baker (Deventer, Holland), respectively. Formic acid was obtained from Merck (Darmstadt, 
Germany). All other chemicals were obtained from Sigma-Aldrich (Steinheim, Germany) 
at the highest purity available. Water was generated with a Milli-Q purification system 
(Millipore, Amsterdam, Netherlands). 
2.2 Chemical oxidation
The p38α inhibitors were oxidized by refluxing (ca. 80°C) with hydrogen peroxide. Incubation 
times were 105 min for DMPIP, 180 min for SB203580, and 300 min for TAK-715 (refer to 
Section 1 of the electronic supplementary material (ESM)). Sampling was done by means 
of a syringe from a three-neck flask via a septum. The reaction solutions were diluted 
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from 1 mM stock solutions in methanol to a solvent composition of 75% aq. hydrogen 
peroxide and 25% MeOH. They contained an optimized hydrogen peroxide concentration 
of 7.5% (w/w) and an inhibitor concentration of 100 µM. Control incubations under reflux 
conditions containing no hydrogen peroxide were included to assess the influence of 
thermal degradation.
2.3 Photochemical modification
Photochemical modification (Light) was induced by irradiating aliquots of an inhibitor with 
intense light of the visible range (>310 nm [16]) at room temperature. The exclusion of 
UV-wavelengths is expected to result in more specific reactions and prevent advanced 
decomposition. The light was generated by a 150W Xenon lamp model L21 equipped with 
an AEG transformer. The reaction solutions, diluted from 1 mM stock solutions in methanol 
to a solvent composition of 75% water and 25% MeOH, were placed at a distance of 15 cm 
from the lamp. The concentrations of the inhibitors were 100 µM for DMPIP and SB203580 
and 10 µM for TAK-715 (see ESM Section 1), respectively. Incubation times were 120 min 
for DMPIP, 300 min for SB203580, and 30 min for TAK-715 in Light (refer to ESM Section 1). 
The use of closed Duran glass vessels excluded light of the UV range (<310 nm [16]) and 
hindered evaporation. Samples were taken with a syringe. To protect the environment from 
UV radiation, the whole setup was shielded with aluminium foil. Control incubations, which 
assess the contribution of heat generated by the Xenon lamp, were prepared by wrapping 
the samples in aluminium foil to exclude irradiation. 
2.4 Microsomal incubations
In order to investigate how closely the products of the modification methods resemble 
human metabolites, human phase I metabolism was simulated in vitro by incubation with 
human liver microsomes (HLM). Phase I oxidative metabolites were generated by HLM 
and cofactor NADPH using a modified version of a protocol described elsewhere [26]. In 
brief, the reaction mixtures were prepared in 50 mM potassium phosphate buffer (pH 7.4) 
including 5 mM magnesium chloride. The incubation mixtures contained 100 mM p38α 
inhibitor, 2 mg/mL human liver microsomes and 6 mM NADPH, and were incubated for 2 h 
at 37°C. Constant availability of NADPH was ensured by a regenerating system of 5 mM 
glucose-6-phosphate and 5 U/mL glucose-6-phosphate dehydrogenase and by adding 
10% (v/v) of a 10 mM NADPH solution in the above mentioned phosphate buffer after 30, 
60 and 90 min. The reactions were stopped by addition of ice-cold acetonitrile 2:1 (v:v). The 
samples were subsequently centrifuged at 16,000 × g for 5 min at 4°C. The supernatants 
were taken, freeze-dried and stored at –20°C. For the HRS analysis, the samples were 
re-dissolved in a 30% aqueous methanol solution, providing 10-fold higher concentrations.
2.5 HRS analysis
Analysis of structure and affinity towards p38α was conducted with an HRS platform 
developed earlier [5]. The HRS platform consisted of two LC-20 AD pumps, two LC-10 
AD pumps, a SIL-20 AC autosampler, a CTO-20 AC and a CTO-10 AC column oven, an 
RF-10AXL fluorescence detector, an SPD-AD UV/VIS detector, a CBM-20A controller, and 
an ion-trap–time-of-flight mass spectrometer equipped with an ESI source, all products of 
Shimadzu (’s Hertogenbosch, the Netherlands). In short, 10 µL (100 µL for TAK-715 in Light) 
of the mixture of CPs were separated on a Symmetry C18 column (2.1 x 100 mm, 3.5 μm 
particles; Waters, Milford, MA, USA) at 40°C and a flow rate of 113 µL/min. LC solvents 
included water, methanol and formic acid in the ratios 99% / 1% / 0.01% for solvent A and 
1% / 99% / 0.01% for solvent B. Analytes were eluted with several gradients optimized per 
compound and per modification method (see ESM Section 2). The eluent was split, one 
part being analysed by electrospray ionization high-resolution (tandem) mass spectrometry 
(HR-MSn) on the Shimadzu ion-trap–time-of-flight mass spectrometer, another constantly 
mixed with the bioassay reagents and detected by the fluorescence detector. Details on the 
HR-MSn conditions can be found elsewhere [27]. 
Figure 1: HRS chromatograms of A) TAK-715 in H2O2 and B) DMPIP in Light. The top trace is the 
fluorescence chromatogram (bioaffinity trace); affinity towards p38α is observed as a negative peak. 
The bottom traces are the extracted ion chromatograms (EIC) for the different CPs. The colors of the 
EICs match their corresponding tags (CP numbers). For the m/z values of the EICs, refer to the CPs 
in A) Table 2 and B) Table 1. Top and bottom chromatograms are aligned to correct for void volume 
differences. In this way, structure and affinity data can be correlated [18].
3. Results
This paper integrates the new data on CPs generated by Light and H2O2 with data 
generated by other conversion methods. In this sense, it is part of and summarizes and 
concludes a larger study [5, 18, 21, 27]. Additionally, it provides a critical comparison of 
the different methods and summarizes the role of HRS in the study. The conversion of 
four p38α inhibitors (see Tables 1 to 4 for their structures) with five different modification 
strategies (EC, Light, H2O2, BM3, and HLM) results in a very large and complex data set. 
Therefore, interpretation of the HR-MSn spectra of the four parent drugs and the structure 
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the compound identity and the p38α affinity as well as with hydrophilicity information [28] 
as judged from relative retention time (RRT, [29]) (see Tables 1 to 4). As discussed before, 
this presents a strong basis for assembling a thorough SAR. This is nicely illustrated in the 
typical HRS chromatograms shown in Figure 1. The p38α affinity is observed as a negative 
peak in the fluorescence chromatogram (top traces in Figure 1). The affinity peaks are 
numbered according to the figure number, Roman numbers and a superscript BIO, e.g., 
1A-IBIO for the first affinity peak in Figure 1A. The CPs are indicated with the m/z of their 
protonated molecule, e.g., CP296 corresponds to a CP with m/z 296. Different extracted-
ion chromatograms (EIC) are shown for the various CPs. Additionally, UV detection at 
210 nm in line with the MS detection allows a (semi-)quantitative statement on abundance 
of CPs. Minor and major CPs/metabolites are defined as having less or more than 20% 
peak area, respectively, as compared to the largest peak at UV 210 nm [30].
3.1	Oxidation	with	hydrogen	peroxide
First, the hydrogen peroxide concentration was optimized by testing 3.0%, 7.5%, and 15% 
(w/w) at a reflux temperature of ca. 80°C to increase reaction speed [31]. With 3.0%, little 
conversion was achieved, whereas 15% resulted in undesired advanced decomposition 
of the molecule. As the controls showed that temperature increase alone did not result 
in significant side reactions, refluxing with 7.5% hydrogen peroxide was applied. The 
conversion efficiency, measured as the reduction in the parent compound peak area by 
LC–UV, is ca. 50% after 180 min for SB203580, 30% after 300 min for TAK-715 and 90% 
after 105 min for DMPIP (see ESM Section 1). BIRB796 was not included in this part of 
the study, because initial experiments indicated that urea hydrolysis, due to the prevailing 
acidic conditions, is the main reaction pathway.
3.1.1 DMPIP
The conversion of DMPIP ([M+H]+ with m/z 541; C28H31ClFN4O4
+) by hydrogen peroxide 
(see Table 1) produces two abundant products, both with increased hydrophilicity. The 
major product CP557A (C28H31ClFN4O5
+), containing a hydroxylation in the B part (cf. 
Table 1), is the only one showing affinity, although significantly lower than DMPIP. Whereas 
MS and UV responses are 2 to 10 times higher, respectively, the affinity response is at 
least 30 times lower. For the minor product CP501 (C25H27ClFN4O4
+), a double dealkylation 
product of the piperazine ring, no affinity signal is observed. 
3.1.2 TAK-715
In treatment of TAK-715 ([M+H]+ with m/z 400; C24H22N3OS
+) with hydrogen peroxide, a large 
number of minor products is yielded which almost exclusively have increased hydrophilicity 
(see Table 2 and Figure 1A). The strongest UV and MS signal comes from the amide 
hydrolysis product CP296 (C17H18N3S
+) which is probably responsible for the first and highest 
of the product affinity peaks (1A-IBIO) and is also among the most hydrophilic products 
(RRT 0.35). At least 9 different mono-oxygenated CPs (CP416D to L, C24H22N3O2S
+) can 
be distinguished by reWtention time varying largely in hydrophilicity (RRTs range from 0.56 
to 1.20). Additionally, two doubly-oxygenated compounds (CP432C and D, C24H22N3O3S
+) 
are observed at RRT 0.57 and RRT 0.61. These and other CPs (Table 2) are discussed in 
more detail in ESM Section 4. At RRTs between 0.5 and 0.8, overlapping affinity peaks are 
observed (1A-IIBIO, 1A-IIIBIO and 1A-IVBIO), indicating that some of the mono-hydroxylated 
and possibly some of the double-oxygenated products have affinity for p38α. Due to the 
high complexity of this sample (Table 2 and Figure 1A), separation is insufficient for exact 
affinity assignment. Only CP432D and CP416G can clearly be attributed to 1A-IIIBIO and 
1A-IVBIO, respectively, as the onset of both affinity peaks cannot be attributed to any other 
CP. However, the width of 1A-IIIBIO and 1A-IVBIO suggests that there are other co-eluting CPs 
with affinity. As this study is conducted under a screening paradigm, any further attempt 
to achieve sufficient separation, thus allowing additional structure identification by MS and 
more precise affinity assignment, was considered to be out of its scope. Finally, 1A-VBIO 
elucidation of the more than 50 CPs found (see Tables 1 to 4) was reported separately [27]. 
Here, we first report the results on the compound libraries of CPs generated using H2O2, 
Light, and HLM. Proposed structures of the CPs are given in Section 3 to 6 of the ESM. 
Next, we review and compare the results from the five compound modification strategies 
in terms of the reactions enabled, the retention of affinity, and the change in hydrophilicity 
by modification, and thus the ability to generate valuable lead compounds, with potentially 
improved efficacy, selectivity, and importantly bioavailability. 
The HRS platform assesses in parallel the bioaffinity of the CPs by an on-line post-column 
affinity assay and their structure by HR-MSn. This provides a direct correlation between 
Table 1: Summary of the conversion products of DMPIP generated with the five applied modifi-
cation methods. The profile groups (A to D) used in structure elucidation are circled in grey [24]. 
Isomeric modifications were attributed to the individual profile groups. For structure proposals for 
these CPs, see ESM Section 3.
Compound p38 
affinitya
RRT m/z Delta Modification Method
Parent X 1.00 541.204 x x x
CP431 O 0.57 431.148 -C7H5F 
-H2
Dealkylation of A and de-
hydrogenation in B
EC
CP433 O 0.34 433.165 -C7H5F Dealkylation of A BM3
CP472 X 0.86 472.146 -C4H7N Amide hydrolysis EC
CP501 O 0.74, 0.67 501.170 -C3H4 Double dealkylation in B EC, H2O2
CP505 ? 0.88 505.226 -HCl New 5-ring B and C Light
CP523A,C O 0.63 (A), 
0.69 (C),
523.235 +H2O 
-HCl
Light
CP523B, D O 0.67 (B), 
0.72 (D)
523.235 “ Exchange of Cl for H in C  
and OH in B
Light
CP525 O 0.80 525.170 -CH4 Methyl loss from B EC
CP529 O 0.96 529.165 -C2H4+O All modifications in B EC
CP537 ? 0.88 537.252 -HCl
+CH4O
Light
CP539 X 1.22, 1.39 539.187 -H2 Dehydrogenation in B EC, Light
CP541A ? 0.88 541.204 x Light
CP541B X 0.96 “ “ Light
CP541C X 1.34 “ “ Light
CP557A X 0.75 557.197 +O OH in B H2O2
CP557B X 0.95 “ “ Oxygenation in D EC
CP557C - 1.10 “ “ N-oxide in C HLM
CP559 X 0.80 559.213 +H2O Water addition to C or D Light
CP571 O 1.08 571.212 +CH2O Methoxylation in A or B EC
CP573 ? 0.88 573.226 +CH4O Light
a X: affinity; O: no affinity observed; ?: unclear, mostly due to co-elution; -: not measured
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in the bioaffinity trace indicated the presence of another CP, not initially recognized in the 
MS data, corresponding to CP384 (C24H22N3O2
+) in which sulphur has been exchanged for 
oxygen. CP384 only generates a very minor peak in the TIC, and as this sulphur-oxygen 
exchange reaction was not expected, an EIC trace was initially not generated either. This is 
a good example of the power of the on-line post-column affinity assay [4]: a low-abundance 
compound with relatively high affinity, missed in UV or MS detection, will be detected by 
the affinity detection. Thus, the HRS platform is in a positive way biased towards binders.
3.1.3 SB203580
The major CP of SB203580 ([M+H]+ with m/z 378; C21H17FN3OS
+) is the S-oxidation product 
CP394C (C21H17FN3O2S
+). No affinity peaks were observed because these are masked 
Table 2: Summary of the conversion products of TAK-
715 generated with the four applicable modification 
methods. Individual carbon atoms, at which modifica-
tions take place, are numbered. For structure propos-
als for these CPs, see ESM Section 4.
a X: affinity; O: no affinity observed;  
?: unclear, mostly due to co-elution;
Compound p38 affinitya RRT m/z Delta Modification Method
Parent X 1.00 400.149 x x x
CP279 ? 1.14 279.096 -C7H7NO Benzamide loss and  
dehydrogenation
Light
CP294A ? 0.37 294.107 -C7H4O 
-H2
Amide hydrolysis and  
dehydrogenation
H2O2
CP294B O 0.48 “ “ “ H2O2
CP296 O (Light 
HLM),
X (H2O2)
0.75, 
0.35, 
0.35
296.123 -C7H4O 
+O
Amide hydrolysis Light, HLM,  
H2O2
CP312 X 0.21 312.117 -C7H4O Amide hydrolysis and OH HLM
CP312B ? 0.33 “ “ H2O2
CP384 X 0.91 384.172 -S +O H2O2
CP398A ? 1.04 398.134 -H2 Light
CP398B O 1.35 “ “ Ring formation between  
carbon-9 and carbon-20
Light
CP398C ? 1.13 “ “ H2O2
CP400 O 1.18 400.149 x Isomer of TAK-715 Light
CP414 ? 1.04 414.128 -H2 +O H2O2
CP416A X 0.80 416.144 +O OH at carbon-14 BM3, HLM
CP416B X 0.83 “ “ OH at carbon-2 BM3, HLM
CP416C O 0.87 “ “ OH? BM3, HLM
CP416D ? 0.57 “ “ H2O2
CP416E+F ? 0.64 “ “ H2O2
CP416G X 0.70 “ “ H2O2
CP416H+I ? 0.74 “ “ H2O2
CP416J O 0.87 “ “ H2O2
CP416K ? 1.11 “ “ H2O2
CP416L ? 1.20 “ “ H2O2
CP430A X 0.64 430.123 -H2 +2O OH at carbon-2 or-3 and 
aldehyde at carbon-14 
HLM
CP430B X 0.84 “ “ Carboxylic acid at carbon-14 BM3, HLM
CP432A X 0.58 432.139 +2O OH at carbon-2 and  
carbon-14
BM3, HLM
CP432B X 0.70 “ “ Two OH in ethyl group (BM3), HLM
CP432C ? 0.57 “ “ H2O2
CP432D X 0.61 “ “ H2O2
CP446 O 0.62 446.121 -H2 +3O Carboxylic acid at carbon-14 
and OH at carbon-2 or-3
BM3, HLM
CP448 X 0.44 448.138 +3O HLM
Table 3: Summary of the conversion products of SB 203580 generated with the four applicable 
modification methods. Individual carbon atoms, at which modifications take place, are numbered. 
For structure proposals for these CPs, see ESM Section 5.
Compound RRT m/z Delta Modification Method
Parent 1.00 378.108 x x x
CP243 1.26 243.094 -C7H5NS Sulfoxide replacement in CP305 Light
CP289 1.58 289.081 -C6H3N Sulfoxide to thioether in CP305 Light
CP305 1.16 305.077 -C6H3N +O See ESM Section 5 Light
CP316 1.18 316.125 -CH2OS Sulfoxide replacement H2O2
CP321 1.53 321.072 -C6H3N +2O Methyl hydroxylation in CP305 Light
CP362 1.44 362.113 -O Sulfoxide to thioether Light
CP376 0.60 376.113 -F+H+O -HF + H2O H2O2
CP392 0.68 392.108 -F+H+2O -HF + H2O + O H2O2
CP394A 0.76 394.103 +O Aromatic OH H2O2
CP394B 0.80 “ “ Aromatic OH H2O2
CP394C 1.05, 1.10, 
1.12
“ “ S-oxidation HLM, H2O2, 
EC
CP394D 1.12, 1.24 “ “ N-oxidation HLM, H2O2
CP394E 1.36 “ “ OH in pyridine ortho to N H2O2
CP410A 0.83 410.098 +2O Aromatic OH (CP394A) and 
S-oxidation
H2O2
CP410B 0.88 “ “ Aromatic OH (CP394B) and 
S-oxidation
H2O2
CP410C 1.29 “ “ S- and N-oxidation H2O2
CP410D 1.43 “ “ S-oxidation and  
OH in pyridine ortho to N
H2O2
CP424A 1.37 424.115 +O +CH2O Both in fluorophenyl ring Light
CP424B 1.44 “ “ OH at carbon-14, 
OCH3 in pyridine ring
Light
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by strong auto-fluorescence as indicated by positive fluorescence peaks throughout the 
bioaffinity trace. Next to CP394C, four other mono-oxygenation isomers and four different 
double-oxygenated CPs are observed (Table 3). The latter CPs result from a combination 
of S-oxidation (CP394C) with each of the other mono-oxygenation reactions. Their 
hydrophilicity nicely follows the hydrophilicity trend of their respective mono-oxygenation 
CPs. These and other CPs (Table 3) are discussed in more detail in ESM Section 5. 
3.2	Photochemical	modification
The conversion efficiency for the photochemical modification (Light) is ca. 20% after 
300 min for SB203580, 90% after 300 min for TAK-715 and 70% after 120 min for DMPIP 
(determined by LC–UV; see ESM Section 1). BIRB796 was also not included in this part of 
the study, as initial experiments yielded only products of advanced decomposition.
3.2.1 DMPIP
DMPIP ([M+H]+ with m/z 541; C28H31ClFN4O4
+) in Light yields a number of minor products 
(Table 1). CP539 (C28H29ClFN4O4
+), the product of a dehydrogenation in the B part (cf. 
Table 1), shows the highest affinity and the strongest UV response. As expected, this 
modification increases the lipophilicity of the molecule (RRT 1.39). While the UV response 
of CP539 is only slightly more than 10% of the residual substrate, the height of the affinity 
peak is almost 75% of that of DMPIP. Furthermore, three minor affinity signals are observed 
(Figure 1B). The shoulder (1B-IIIBIO) at the beginning of the substrate affinity peak (1B-SBIO) 
is induced by CP541B (C28H31ClFN4O4
+), an isomer of DMPIP. Peak 1B-IIBIO might result from 
up to four co-eluting compounds, being another substrate isomer CP541A (C28H31ClFN4O4
+), 
a dechlorination and ring formation product (CP505, C28H30FN4O4
+), a product showing 
the addition of methanol (CP573, C29H35ClFN4O5
+), and CP537 (C29H34FN4O5
+) combining 
the modifications of CP505 and CP573. The structure elucidation of these four CPs was 
hindered by their low abundance and limited fragmentation in MSn [27]. Peak 1B-IBIO seems 
to correlate to a product of (at least apparent) water addition (CP559, C28H33ClFN4O5
+). For 
more information and additional CPs, see ESM Section 3. 
3.2.2 TAK-715
TAK-715 ([M+H]+ with m/z 400; C24H22N3OS
+) in Light produces three major (CP398A and B 
and CP400) and two minor (CP279 and CP296) CPs (Table 2), none of which show affinity, 
although affinity of CP398A and CP279 may be masked by that of TAK-715. The fact that 
the amide hydrolysis product (CP296, C17H18N3S
+) does not show affinity here, as opposed 
to H2O2, is most likely a concentration effect. Some other CPs (Table 2) are discussed in 
ESM Section 4. Except for CP296, all products were less hydrophilic than the substrate.
3.2.3 SB203580
SB203580 ([M+H]+ with m/z 378; C21H17FN3OS
+) in Light forms only minor products. Again, 
no affinity peaks were observed (see 3.1.3). Some CPs (Table 3) are discussed in ESM 
Section 5. CPs of Light show exclusively decreased hydrophilicity.
3.3 In vitro metabolism
HLM incubations of the four kinase inhibitors will be discussed except for TAK-715 which 
have been described elsewhere [21], but the results are included in Table 2. This addresses 
the question whether the other modification methods produce real metabolites in addition 
to interesting CPs, because HLM incubations are still the gold standard in cell-free in vitro 
metabolism [32].
3.3.1 DMPIP
The incubation of DMPIP with HLM results in only one minor mono-oxygenation metabolite 
CP557C (C28H31ClFN4O5
+), produced by N-oxidation of the C ring (cf. Table 1).
3.3.2 SB203580
The in vitro metabolism of SB203580 ([M+H]+ with m/z 378; C21H17FN3OS
+) has been 
investigated by Henklova et al. [33]. However, in addition to the reported S-oxidation 
metabolite (CP394C, C21H17FN3O2S
+), we observed a minor metabolite showing N-oxidation 
instead (CP394D, C21H17FN3O2S
+) (Table 3). This additional finding is probably due to the 
higher sensitivity of HR-MSn, which significantly increases the signal-to-noise ratio when 
analysing complex samples.
3.3.3 BIRB796
The transformation of BIRB796 ([M+H]+/[M+2H]2+ with m/z 528/265; C31H38N5O3
+/
C31H39N5O3
2+) resulted in a more complex mixture (Table 4). Two mono-oxygenation 
metabolites, CP544A and CP544B (C31H39N5O4
2+), were observed at RRTs of 0.84 and 
0.87, respectively. These result from hydroxylation of the A part (CP544A) or of the A or B 
part (CP544B) (cf. Table 4). Other low-abundant mono-oxygenation products were present 
at higher RRT. Furthermore, two co-eluting double-dealkylation metabolites were detected. 
CP502 (C29H37N5O3
2+) and CP458 (C27H33N5O2
2+) show the loss of ethyne and dihydrofuran, 
respectively, from part D. Additionally, three metabolites are partly co-eluting at RRTs of 
1.27 and 1.25. One of these less hydrophilic metabolites is the hydroquinone CP415 (RRT 
1.27, C25H27N4O2
+) resulting from loss of the ethyl-morpholino group by O-dealkylation. 
Additionally, CP1052 (C62H72N10O6
2+) is a dimerization product with two additional bonds 
in the C and/or D part. CP459 (C27H31N4O3
+) results from oxidative deamination of the 
Table 4: Summary of the conversion products of BIRB796 generated with the two applicable mod-
ification methods. The profile groups (A to D) used in structure elucidation are circled in grey [24]. 
Isomeric modifications were attributed to the individual profile groups. For structure proposals for 
these CPs, see ESM Section 6.
Compound p38 
affinitya
RRT m/zb Delta Modification Method
Parent X 1.00 264.653 (2) x x x
CP230 O 0.95 230.165 (1) -C17H18N2O3 AB EC
CP273 O 1.04 273.171 (1) -C16H17NO2 AB+CO+NH3 EC
CP413 X 1.22 413.199 (1) -C6H13NO quinoneimine EC
CP415 X 1.19, 1.27 415.215 (1) -C6H11NO ether hydrolysis EC,HLM
CP458 - 0.90 229.632 (2) -C4H6O 2x N-dealkylation in D HLM
CP459 - 1.25 459.242 (1) -C4H7N alcohol for morpholino HLM
CP502 - 0.90 251.645 (2) -C2H2 O-and N-dealkylation 
in D
HLM
CP544A - 0.84 272.650 (2) +O OH in A or B HLM
CP544B - 0.87 “ “ OH in A HLM
CP1052 - 1.25 526.285 (2) dimerization with two 
bonds in part C or D
HLM
a X: affinity; O: no affinity observed; -: not measured
b Charge state (n): [M+nH]n+
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morpholino group, exchanging the latter for a hydroxyl group. Most metabolites show 
relatively low UV peak areas, except for the peak that corresponds to the three co-eluting, 
less hydrophilic metabolites (CP415, CP459, and CP1052). This peak has about 20% of 
the UV area of the residual substrate peak.
4. Discussion
4.1	Comparison	of	compound	modification	methods
The results of the five modification methods (H2O2, Light, EC, HLM and BM3) are discussed 
and compared in different ways. First, we look at the structures of the CPs generated 
and correlate them to affinity. The parallel setup of on-line post-column affinity assay and 
MSn enables a straightforward structure-affinity comparison and significantly reduces the 
risk of errors in the correlation. Hydrophilicity, as a physicochemical parameter of major 
importance in modern drug discovery [9], is used in addition to affinity in order to assess 
the quality of the products as potential new leads. To this end, CPs are marked as more 
hydrophilic (RRT<0.90), unchanged (0.90≥RRT≤1.10) or less hydrophilic (RRT>1.10) 
compared to the substrate based on their RRTs. The clogP values of the substrates were 
calculated with ChemBioDraw version 12 to be 5.8 for BIRB796 (logP 5.2 [34]), 6.5 for 
TAK-715, 2.7 for SB203580 and 2.3 for DMPIP. Finally, the most interesting CPs as seen 
from various viewpoints are highlighted. The ability to generate human relevant metabolites 
using the modification methods is also briefly discussed.
4.1.1 DMPIP
An overview of the CPs yielded from DMPIP is given in Table 1 and ESM Section 3. In 
general, there is little overlap in the products of DMPIP between the different modification 
methods, except the double N-dealkylation product CP501, generated by H2O2 as well 
as EC, and the dehydrogenation product CP539, appearing in Light and EC. CP433 was 
almost exclusively produced by BM3, whereas a similar product CP431 with an additional 
double bond in the B ring was produced by the EC. Light is the only method inducing 
chlorine hydrogen exchange (CP523A to D), isomerisation (CP541A to D) and the addition 
of water (CP559). In contrast, methyl abstraction (CP525) and amide hydrolysis (CP472) 
are exclusively found in EC. H2O2, EC and HLM all produce an oxygenated compound 
(CP557A to C). However, all three modifications are found in different parts of the molecule 
and while EC produces hydroxylation, HLM results in N-oxidation. 
Seven of the 22 CPs showed bioaffinity, ten did not and for another five the analysis was 
inconclusive. From correlating structure and affinity, we can conclude that the fluorobenzyl 
ring is more important for affinity than the morpholino group, as removal of the former in 
CP433 and CP431 leads to complete affinity loss while upon loss or modification of the 
latter in CP472 and CP557B affinity is retained. Furthermore, the dimethyl substitution at 
the piperazine ring seems crucial as all dealkylations such as the loss of a methyl group 
in CP525, and the hydrocarbon losses in CP501 and CP529 delete affinity. Addition of 
a hydroxyl group (CP557A) on the other hand seems to be at least less detrimental to 
affinity. Dehydrogenation even produces the high-affinity compound CP539. Interestingly, 
the exchange of the chlorine for a hydrogen atom has a huge negative effect on affinity. 
Additionally, at least two of the three substrate isomers (CP541A to C) are binders. These 
could be promising modified scaffolds for further lead library diversification. 
Many CPs showed an improvement in physicochemical properties: fifteen of the 22 CPs 
were more hydrophilic, five had similar hydrophilicity and only two were less hydrophilic 
than the substrate. Interestingly, the only metabolite from HLM was less hydrophilic than 
the substrate. 
The most interesting compound of this series is probably CP539 as it showed by far the 
highest product affinity peak in all DMPIP derived mixtures. Whether this was due to higher 
abundance and/or higher affinity than other products cannot be determined. Unfortunately, 
CP539 shows decreased hydrophilicity, but the reduction of stereochemical complexity 
might be advantageous. Furthermore, CP472 and CP557A are of special interest because 
they show bioaffinity and increased hydrophilicity. Additionally, CP472 is simpler and the 
hydroxyl group of CP557A might result in more specific interactions with the target, for 
example through hydrogen bonding.
4.1.2 TAK-715
The CPs related to TAK-715 are listed in Table 2 and ESM Section 4. Electrochemical 
conversion was not achieved under the tested conditions [18]. In the other methods, 
generally, four types of modifications were observed. Dehydrogenation was found in all 
methods, whereas oxygenation occurred in HLM, BM3 and H2O2, and the hydrolysis of the 
amide bond in Light, H2O2 and HLM. A combination of oxygenation and dehydrogenation 
was also frequently observed. Additionally, in Light, a loss of the complete benzamide moiety 
as opposed to simple hydrolysis is observed. This is especially interesting as a similar 
reaction is observed in collision-induced dissociation (CID) of the protonated molecule [27]. 
HLM and BM3 show the most similar profile, HLM having slightly more products, including 
those with amide hydrolysis [21]. However, H2O2 also yields many products with similar 
modification to HLM and BM3, but with much more isomeric mono-oxygenated products. 
Additionally, only H2O2 and HLM show a combination of amide hydrolysis and oxygenation. 
Finally, Light shows three products not observed with the other methods. 
Twelve of the 32 CPs showed bioaffinity, six did not and for another fourteen the analysis 
was inconclusive. The higher number of CPs results in a higher uncertainty in the affinity 
determination, mainly owing to co-elution, especially of the mono-oxygenation isomers in 
H2O2. HLM and BM3 showed the most impressive results in generating CPs with affinity, 
but also H2O2 created quite a number of affinity compounds. Correlating structure and 
affinity indicates that many of the oxygenation products retain affinity, even after multiple 
reactions (up to three were observed). CP416B even has similar affinity as TAK-715 [21]. 
Loss of the phenyl ketone group by amide hydrolysis seems to have some effect on affinity, 
because the affinity of CP296 is only observed at high concentration in H2O2 but not at the 
lower concentration in Light. This discrepancy might also result from (possible) affinity of 
co-eluting CP294A and/or CP312B. Dehydrogenation by ring formation in CP398B exerts a 
strong negative influence on affinity, whereas formation of a carbonyl group at the aromatic 
methyl group in CP430A and CP430B only results in lower affinity, e.g., CP430B affinity is 
about 20 times lower than TAK-715 [21]. The TAK-715 isomer (CP400) also does not show 
affinity.
By generating many oxygenated CPs, HLM, BM3 and H2O2 also produced a compound 
library with many more hydrophilic CPs. In Light, this was only the case for CP296. In total, 
23 of the 32 CPs were more hydrophilic, whereas six had decreased hydrophilicity. The 
latter were equally contributed by Light and H2O2, but accounting for as much as 60% of 
products in Light and only 16% in H2O2. 
A rather unusual reaction for BM3 is the formation of a carboxylic acid from the aromatic 
methyl group in CP430B [21]. Though possessing the right elemental composition, the 
aldehyde CP414 from H2O2 is unlikely to be the missing link between the alcohol CP416A 
and the carboxylic acid CP430B, as under aqueous conditions an aldehyde would be 
transformed into the carboxylic acid by a strong oxidizing agent like hydrogen peroxide. The 
most interesting CP is CP416B, which not only shows significantly increased hydrophilicity 
but also similarly high affinity as TAK-715.
4.1.3 SB203580
The CPs of SB203580 which were produced are summarized in Table 3 and ESM Section 5. 
No affinity signals for CPs of SB203580 have been observed in any of the measurements, 
possibly due to the strong auto-fluorescence of SB203580 at the assay wavelength. 
Oxygenation was introduced by all modification methods. Next to the major metabolite, i.e., 
the S-oxidation product CP394C, also reported by Henklova et al [33], many other mono- 
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and double-oxygenated isomers have been generated. In Light, the oxygenation was often 
accompanied by additional reactions, and in H2O2 by dehalogenation. Interestingly, the CP 
profile generated by EC is most similar to HLM, whereas H2O2 produces all products of HLM 
but also many more, such as CPs involving loss of the sulfonyl group (CP316). The most 
uncommon reactions are again observed with Light, such as S-reduction to the thioether 
CP362, methoxylation in CP424A and CP424B, and the breakdown of the imidazole ring to 
CP305 and its related products.
Generating more hydrophilic CPs was less successful: Only six of the 19 CPs were more 
hydrophilic. Interestingly, all six more hydrophilic compounds were from H2O2, as were six 
of the less hydrophilic compounds. 
4.1.4 BIRB796
CPs of BIRB796 were only generated by EC and HLM. Initial tests indicated that BM3, 
H2O2 and Light were not suitable to produce interesting compound libraries. The ten CPs 
observed are listed in Table 4 and ESM Section 6. Only the two hydroxylation isomers in 
HLM are more hydrophilic.
There is little overlap between HLM and EC CPs. Where HLM mainly catalyses hydroxylation 
and N- and O-dealkylation, EC is mostly active around the urea function. However, two CPs 
generated by both methods are important in metabolism studies: the reactive quinoneimine 
CP413 and its corresponding unstable hydroquinone CP415. Both CPs showed affinity. 
They are the main products in EC whereas CP415 seems to be among the most abundant 
CPs in HLM. The fact, that CP413 is only detectable in HLM close to the limit of detection, 
does not mean that CP413 is not an important metabolite. On the contrary, quinoneimines 
may react with free cysteines in proteins to form covalent drug-protein adducts [35]. They 
can be detected as GSH adducts in specially designed experiments [36] which were outside 
the scope of this investigation.
4.2 Conversion products as metabolite standards
Another interesting aspect of this study is the possibility to generate metabolites formed 
using HLM by other conversion methods (H2O2, EC, Light, and/or BM3s), as this may yield 
an alternative to conventional organic synthesis. The synthesis of standards for metabolic 
analysis often is a bottleneck in the drug discovery phase. It might be assumed that BM3, 
as another biotransformation method, shows the closest resemblance of product profiles. 
As discussed in detail elsewhere [21], the HLM and BM3 profiles for TAK-715 were very 
closely related for some mutants. Herein, the flexibility of the BM3 approach is crucial. 
However, H2O2 was found to produce an HLM metabolite of TAK-715 which BM3 did not. 
For DMPIP, the HLM metabolite CP557C was not produced by BM3 or any other method, 
although H2O2 and EC did give other oxygenation products. For SB203580, H2O2 was 
the only method to produce both HLM metabolites, the S- and the N-oxidation product, 
although in addition to a large number of other compounds. EC worked very well here as 
its only major product was the main metabolite CP394C. For BIRB796, HLM can only be 
compared to EC. At first glance, the overlap seems quite limited. However, EC produces 
one (possibly two) very important metabolites as main product(s), CP413 and CP415, 
which, being reactive species might be very interesting for the toxicology of BIRB796 [37]. 
Another interesting observation in this study was that, contrary to general expectation, 
many HLM metabolites with decreased hydrophilicity were observed. Only for TAK-715, 
all metabolites were more hydrophilic, while for DMPIP and SB203580 exclusively less 
hydrophilic metabolites were observed. This underlines the importance of taking into 
account metabolites with decreased hydrophilicity when developing analytical methods for 
metabolite identification.
Though BM3 has the most possibilities to be tuned for the production of specific metabolites, 
the tendency of H2O2 to produce many metabolite-like isomers can also be exploited. 
With adequate fractionation technology, it might even be more advantageous to produce 
many standards simultaneously with H2O2, especially at a stage when the true metabolite 
identities are not yet confirmed. EC confirmed its value in the generation of reactive 
metabolites, exemplified by CP413 and CP415, but is also useful for the generation of 
stable metabolites, as is shown for SB203580. Thus, the combination of all four methods 
represents a valuable toolbox for the generation of metabolite standards. HRS contributes 
to the application of this toolbox by rapidly identifying the method(s) of choice for a specific 
substrate. The standards can then be produced by up-scaling and purification which can 
also be monitored with the HRS system.
5. Conclusion
Four modification methods were investigated for their potential to produce metabolite-
like compounds. The main goal was to find CPs with retained affinity and increased 
hydrophilicity, which may act as lead compounds in further drug discovery. Therefore, the 
data evaluation emphasized the reactions occurring, the affinity of the CPs towards p38α 
and the hydrophilicity of the CPs. 
First of all, it can be concluded that the HRS system is very useful for the described type 
of study. An efficient analysis of the modifications introduced via the different methods 
was enabled. Affinity and identity of the CPs could be assessed simultaneously. However, 
ambiguity remains in some cases. Limited chromatographic resolution may hinder 
identification of the CP with affinity, especially in very complex mixtures, such as with TAK-715 
in H2O2 and DMPIP in Light (Figure 1). Whereas many conversion reactions like oxygenation, 
dehydrogenation and amide hydrolysis are readily identified, limited fragmentation (and/or 
sensitivity) may hinder structure elucidation of CPs, for example in distinguishing between 
N-oxidation and aromatic hydroxylation, or between different oxygenated isomers. Direct 
quantitation of CPs from a mixture is still missing in the HRS technology, as is also true 
for early metabolic profiling, unless radioactivity detection is applied [38]. However, the 
qualitative affinity data in combination with the MS structure analysis were sufficient to 
achieve an initial structure-activity assessment. The combination of hydrophilicity, affinity 
and structure efficiently starts the characterization of CPs concerning their usefulness as 
potential new lead compounds. The strong link between the three properties, ensured by 
the HRS platform, increases the confidence in all results. All this is possible, and was in 
fact achieved, without fractionation, directed synthesis or extensive sample preparation. 
Mostly, mixtures of related compounds are analysed in a single chromatographic run. This 
leads to an extremely efficient collection of a multitude of relevant data on the prospective 
lead compounds. In earlier work, we demonstrated that this provides a very efficient basis 
to focus purification efforts on favourable compounds which can then be followed up by in-
depth structural characterization and further biological testing [21].
Although H2O2 and Light converted all tested substrates, the CPs produced did not always 
show affinity or increased hydrophilicity. EC failed to convert TAK-715. After pre-screening, 
BM3, was only applied to TAK-715 and DMPIP. In terms of the number of products, 
successful combinations of modification method and substrate were EC/DMPIP, Light/
DMPIP, Light/SB203580, H2O2/TAK715, H2O2/SB203580, BM3/TAK715, HLM/TAK715 and 
HLM/BIRB796. 
Retention of affinity is more or less evenly distributed among the tested conversion methods. 
There is no single one which exclusively or predominantly forms affinity compounds. With 
50-70% of the related CPs showing retention of affinity, the screening of DMPIP and 
TAK-715 was quite successful in this respect. All methods, except HLM, are reasonably 
well scalable. H2O2 only requires low cost reagents and Light and EC minor investment 
in apparatus. BM3, however, necessitates expensive purified enzymes and cofactors. Of 
course, this comparison applies to the analytical scale. It might be very different at larger-
scale production. High cost and limited availability, apart from ethical considerations, in 
combination with a low catalytic activity exclude HLM as an alternative for biosynthesis.
H2O2 yielded mostly more hydrophilic CPs, with the exception of some N-oxides and 
the general tendency for less hydrophilic CPs in SB203580. H2O2 also produced more 
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isomeric species than the other methods. Although this increases the chance of finding 
affinity compounds, it reduces the method’s value in the production of specific CPs. BM3 
incubation seems less generally applicable but, when applicable, is efficient in generating 
more hydrophilic CPs with high affinity. Furthermore, it is possible to tune these enzymes 
for the production of either complex mixtures with a variety of CPs or specific CPs [21]. 
EC is complementary to the other methods by producing unique products, as is most 
obvious in DMPIP and BIRB796. It shows its strength in the conversion of BIRB796 where 
it enables the analysis of the reactive quinoneimine [18]. While it is reasonable to assume 
that this metabolite is also produced by HLM, it is the low matrix content and direct analysis 
capabilities featured by the EC which readily allowed structure and affinity analysis of the 
reactive species. In this respect, the complexity and reactivity of the sample matrix increase 
in the order Light<EC<H2O2<BM3~HLM. A more complex matrix will not only hinder the 
analysis, especially of reactive products, but also increases the difficulty of purification, 
if desired at a later stage. Therefore, EC is the most promising method to study relevant 
reactive species. Unfortunately, the CPs from EC and Light show no general tendency 
towards more hydrophilicity, although such CPs are still frequently observed. However, 
Light opens up a wider range of reaction pathways which often results in at least some 
unique products. Structural changes induced in Light are not easily identified by HR-MSn as 
Light displays the unique possibility to induce strong structural isomerism even in the core of 
the molecule. Inducing structural changes to the molecules core, while maintaining affinity 
(see CP541B and CP541C of DMPIP), can lead to a new scaffold for optimization which 
could be desirable, for example when selectivity of the old scaffold has proven insufficient.
Therefore, the four modification methods are highly complementary with regard to the 
substrates converted, the reactions observed, the isomers formed from similar reactions, 
the retention of affinity in different substrates and the tendencies for more hydrophilic CPs. 
All of them created interesting CPs that have the potential to be further explored as lead 
compounds.
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Supplementary Material
Section 1 Experimental details
The optimization of temperature and hydrogen peroxide concentration for H2O2 and of the 
incubation time for H2O2 and Light was monitored on an LC–UV setup. This consisted 
of two LC-20AD pumps, an SIL-20AC autosampler, an SPD-20AD UV/VIS detector, a 
CBM-20A controller (all products of Shimadzu, ’s Hertogenbosch, The Netherlands) and a 
Mistral column oven (Spark Holland, Emmen, The Netherlands). With an injection volume 
of 10 μL, chromatographic separations were achieved on a Symmetry C18 column (2.1 x 
100 mm, 3.5 μm particles; Waters, Milford, MA, USA) at 40°C and a flow rate of 113 µL/min. 
LC solvents included water, methanol and formic acid in the ratios 99% / 1% / 0.01% for 
solvent A and 1% / 99% / 0.01% for solvent B. The following gradient was used: 2 min iso-
cratic at 20%B, then a linear gradient to 90% at 18 min, washing at 90% for 4 min (22 min) 
and afterwards re-equilibration at 20% from 23 min to 30 min. UV detection was achieved 
at 280 nm.
10 µl injections of samples with a 100 µM starting concentration were used in all H2O2 
and Light conversion experiments with the exception of TAK-715 in Light. TAK-715 was not 
soluble at 100 µM without the presence of hydrogen peroxide which decreased the pH and 
thereby most probably increased the polarity of TAK-715 by protonation in H2O2. Therefore, 
the starting concentration of TAK-715 in Light was decreased to 10 µM. Consequentially, 
the injection volume was increased to 100 µL to yield similar concentrations in the LC–UV 
and HRS analysis.
The substrate consumption was quantified by LC–UV using calibration curves of the inhibi-
tors at concentrations between 5 and 100 µM for DMPIP and SB203580. For TAK-715, the 
injected concentrations were between 50 and 100 µM or between 1 and 10 µM in the cali-
bration for H2O2 and for Light, respectively. All calibration solutions were freshly prepared in 
the same way as the respective sample solutions. This was important, because significant 
matrix effects were observed when comparing calibration curves with and without hydro-
gen peroxide. The injection volumes for the calibration solutions were the same as for the 
respective conversion experiments.
For optimization of the incubation time, aliquots were taken at different time points.
In Light at 0, 10, 20, 30, 45, 60, 75, 90, 105 and 120 min for DMPIP; 
every 30 min from 0 to 300 min for SB203580; and 
at 0, 3, 6, 9, 12, 15, 20, 25 and 30 min for TAK-715.
In H2O2 every 15 min from 0 to 105 min for DMPIP; 
every 30 min from 0 to 180 min for SB203580; and 
at 0, 75, 120, 165, 210, 255 and 300 min for TAK-715.
This yielded the optimized incubation times and the corresponding conversion rates de-
scribed in the manuscript. Both calibration solutions and samples were measured tripli-
cate. In H2O2, the standard deviation was generally higher than in Light, probably because 
photochemical reactions are started and stopped much more reliably by introducing and 
removing the light source than the oxidation reaction are by heating and cooling.
Section	2:	Overview	chromatographic	conditions
In the measurements of samples from EC, BM3 and HLM (TAK-715 only), an Xbridge 
C18 column (100×2.1 mm with 3.5 µm particles; Waters, Milford, MA, USA) was used. 
For samples from H2O2, Light and HLM (DMPIP, SB203580 and BIRB796) experiments, 
a Symmetry column (same dimensions and manufacturer) was applied. Because the 
results reported here originate from several independent studies, different gradient pro-
grams were used. A flow rate of 113 μL/min and a column temperature of 40°C were ap-
plied in all cases. 
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Table S1: Overview of the binary solvent gradients used in different parts of the study, depending on 
conversion method and starting compound investigated.
Time %B Time %B Time %B Time %B Time %B Time %B
0 20 0 40 0 20 0 20 0 20 0 20
2 20 2 40 2 20 2 20 2 20 2 20
18 90 45 90 10 90 8 50 20 50 20 50
22 90 52 90 13 90 10 50 21 50 21 50
23 20 53 40 14 20 26 90 26 90 26 90
30 20 60 40 20 20 28 90 33 90 33 90
29 20 34 20 34 20
35 20 40 20 40 20
Used 
for:
EC, BM3 
(DMPIP)  
and HLM 
(DMPIP, 
SB203580, 
BIRB796)
BM3  
(TAK-715) 
and HLM 
(TAK-715)
H2O2 
(DMPIP)
Light 
(DMPIP, 
SB203580)
H2O2 
(SB203580)
Light  
(TAK-715)
Section 3: Structure proposals of DMPIP related CPs
The structure elucidation by LC–MSn was described in detail elsewhere [1]. For the con-
venience of the reader, structure proposals are drawn here on the basis of that analysis. 
In this way, the structure-activity discussion can be followed more visually. Note that the 
structures of the corresponding molecules are depicted, not the ions detected by LC–MSn. 
Additionally, CP537 and CP573, which were not yet discussed, are examined.
DMPIP 
CP431 
CP433 
CP472 
CP501 
CP505 
CP523A and C 
Four isomers CP523A to D (C28H32FN4O5
+) are 
produced by dechlorination and hydroxylation in 
Light, none of which show affinity. In contrast to 
CP523B and D, for CP523A and C the spectral 
data was insufficient for a structure proposal.
CP523B and D 
CP525 
CP529 
CP537 
CP537 (C29H34FN4O5
+) is a combination of the 
dechlorination and ring formation observed in 
CP505 and the addition of methanol found in 
CP573. The structure elucidation of CP537 was 
hindered by low abundance and limited fragmen-
tation in MSn.
CP539 
CP541A, B and C 
These are isomers of the substrate DMPIP. Even 
where fragmentation is different among the iso-
mers, interpretation of the fragmentation trees 
is extremely challenging. Thus, as in this case, 
structural isomers of the substrate are often not 
identified by LC–MSn.
CP557A 
CP557B 
CP557C 
CP559 
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CP571 
CP573 
This product, showing the addition of methanol 
(CP573, C29H35ClFN4O5
+), did not provide suffi-
cient fragmentation in MSn to propose a structure.
Section 4: Structure proposals of 
TAK-715 related CPs
The structure elucidation by LC–MSn was de-
scribed in detail elsewhere [1]. For the conve-
nience of the reader, structure proposals are 
drawn here on the basis of that analysis. In this 
way, the structure-activity discussion can be fol-
lowed more visually. Note that the structures of 
the corresponding molecules are depicted, not the 
ions detected by LC–MSn. Additionally, some CPs, 
which were not yet discussed, are examined.
The low-abundance CPs partially derived from 
amide hydrolysis are relatively polar and show 
RRTs similar to CP296. These include CP294A 
and B, CP310, CP312B and CP328. It is reason-
able to assume that these are present as a num-
ber of isomers which are not chromatographically 
resolved.
TAK-715 
CP279 
CP279 (C17H15N2S
+) corresponds to a loss of the 
benzamide moiety including the amine and an 
additional dehydrogenation. Whether this is a 
direct reaction or occurs via the amide hydrolysis 
product CP296, which is also present in minor 
amounts in Light, is unclear.
CP294A and B 
CP296 
CP310 
This low-abundance CP of H2O2 combines three 
different modifications, being amide hydrolysis, 
oxygenation and dehydrogenation (m/z 310.102, 
C17H16N3OS
+).
CP312 and B 
CP328 
This low abundant product of amide hydrolysis 
and double-oxygenation (m/z 328.113, 
C17H18N3O2S
+) is made in H2O2.
CP384 
In this CP, the sulphur has been exchanged for 
oxygen (C24H22N3O2
+). Whether the oxygen oc-
cupies the same position in the new molecule is 
unclear.
CP398A 
CP398B 
CP398C 
A dehydrogenation product (C24H20N3OS
+). which 
cannot be further evaluated due to insufficient 
LC–MSn data.
CP400
This CP is one of the major products in Light and 
an isomer of TAK-715 (C24H22N3OS
+). 
CP414 
A product of combined oxygenation and dehydro-
genation (C24H20N3O2S
+). As it was produced by 
H2O2, CP414 is unlikely to be an aldehyde as this 
would most likely be converted to the carboxylic 
acid under these strong oxidizing conditions.
CP416A 
CP416B 
CP416C 
CP416D to J 
Unfortunately, due to extensive co-elution 
of these seven mono-oxygenation isomers 
(C24H22N3O2S
+), structure elucidation was not 
achieved by LC–MSn. As this study was focused 
on a screening paradigm, further separation was 
not attempted. However, their RRTs between 
0.57 and 0.87 indicate that most of them will be 
hydroxylated [2].
CP416K and L 
The RRTs of over 1.1 of these two mono-oxygen-
ation CPs indicate N-oxidation [2].
CP430A 
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CP430B 
CP432A 
CP432B 
CP432C and D 
These two double-oxygenation isomers 
(C24H22N3O2S
+) did not yield sufficient LC–MSn 
data for structure elucidation.
CP446 
CP448 
Section 5: Structure proposals of 
SB203580 related CPs
The structure elucidation by LC–MSn was de-
scribed in detail elsewhere [1]. For the conve-
nience of the reader, structure proposals are 
drawn here on the basis of that analysis. In this 
way, the structure-activity discussion can be fol-
lowed more visually. Note that the structures of 
the corresponding molecules are depicted, not the 
ions detected by LC–MSn. Additionally, some CPs, 
which were not yet discussed, are examined.
The CPs marked with an asterisk are related to 
CP305 for which two alternate structure propos-
als are given [1]. For the sake of brevity, only one 
possible form is given for the related CPs.
SB203580 
CP243* 
CP289* 
CP305 
One of the two most abundant CPs (by MS re-
sponse) in Light.
CP316 
Interestingly, CP316 (C20H15FN3
+) is similar 
to a gas phase CID fragment (m/z 315.117, 
C20H14FN3
+•). The methyl-sulfoxide group has 
been replaced by hydrogen decreasing polarity.
CP321* 
CP362 
One of the two most abundant CPs (by MS re-
sponse) in Light.
CP376 
Resulting from a combination of dehalogena-
tion and mono-oxygenation (C21H18N3O2S
+), this 
is one of the two most polar CPs derived from 
SB203580 in H2O2.
CP392 
Resulting from a combination of dehalogenation 
and double-oxygenation (C21H18N3O3S
+), this 
is one of the two most polar CPs derived from 
SB203580 in H2O2.
CP394A and B 
These CPs result from aromatic hydroxylation 
(RRT 0.76 and 0.80).
CP394C 
CP394D 
CP394D is an N-oxidation product (RRT=1.24).
CP394E 
CP394E shows strongly reduced polarity which 
matches cLogP calculation of an ortho-hydroxyl-
ated pyridine [1].
CP410A 
Combines the S-oxidation of CP394C and the 
aromatic hydroxylation of CP394A.
CP410B 
Combines the S-oxidation of CP394C and the 
aromatic hydroxylation of CP394B.
CP410C 
Combines the S-oxidation of CP394C and the 
N-oxidation of CP394D.
CP410D 
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CP424A 
CP424B 
Section 6: Structure proposals of 
BIRB796 related CPs
The structure elucidation by LC–MSn was de-
scribed in detail elsewhere [1]. For the conve-
nience of the reader. structure proposals are 
drawn here on the basis of that analysis. In this 
way, the structure-activity discussion can be fol-
lowed more visually. Note that the structures of 
the corresponding molecules are depicted, not the 
ions detected by LC–MSn. Additionally, some CPs, 
which were not yet discussed, are examined.
BIRB796 
CP230 
CP273 
CP413 
CP415 
CP458 
CP459 
CP502 
CP544A 
CP544B 
CP1052 
This CP is essentially a dimer of two BIRB796 
molecules. The two substrate molecules are 
probably linked by two new bonds resulting in 
the loss of two times H2 compared to two full 
BIRB796 molecules. Both links are found in part 
C and/or part D.
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Abstract
The p38 mitogen-activated protein kinase α (p38α) is an important drug target widely 
investigated for therapy of chronic inflammatory diseases. Its inhibitors are rather lipophilic, 
and as such not very favourable lead compounds in drug discovery. Therefore, we explored 
various approaches to access new chemical space, create diversity, and generate lead 
libraries with improved solubility and reduced lipophilicity, based on known p38α inhibitors, 
e.g., BIRB796 and TAK-715. Compound modification strategies include incubation with 
human liver microsomes and bacterial cytochrome P450 mutants from Bacillus megaterium 
(BM3) and treatment by electrochemical oxidation, H2O2, and intense light irradiation. 
The MS/MS fragmentation pathways of p38α inhibitors and their conversion products (CPs) 
have been studied in an ion-trap–time-of-flight MSn instrument. Interpretation of accurate-
mass MSn data for four sets of related compounds revealed unexpected and peculiar 
fragmentation pathways which are discussed in detail. Emphasis is put on the usefulness 
of HR-MSn based structure elucidation in a screening setting and on peculiarities of the 
fragmentation with regard to the analytes and the MS instrument. 
In one example, an intramolecular rearrangement reaction accompanied by the loss of a 
bulky group is observed. For BIRB796, the double-charge precursor ion is used in MS2, 
providing a wider range of fragment ions in our instrument. For TAK-715, a number of 
related compounds could be produced in a large-scale incubation with a BM3 mutant, 
thus enabling comparison of the structure elucidation by 1H-NMR and MSn. A surprisingly 
large number of homolytic cleavages is observed. Competition between two fragmentation 
pathways involving either the loss of CH3
• or OH• radicals was observed for SB203580 and 
its conversion products.
Introduction
The mitogen-activated protein kinase p38, especially its isoform p38α, is an important target 
in drug discovery and development directed at chronic inflammatory diseases like Crohn’s 
disease and rheumatoid arthritis [1-3]. It is involved in signal transduction pathways through 
successive activation by phosphorylation [4]. Several p38α inhibitors are in different stages 
of (pre)clinical drug development [2,5]. Typical examples are TAK-715 [6], BIRB796 [7,8]  
and SB203580 [9] (see structures in Figures 4-6).
In the past few years, we worked on the development of an integrated platform based 
on high-resolution screening (HRS) to assist in lead optimization and enhancing lead 
diversity in drug discovery processes, e.g., involving an on-line bioaffinity assay for steroid 
metabolites [10]. HRS is the parallel analysis of molecular structure and affinity/activity 
towards a target protein performed on a mixture of related compounds and assessing both 
qualities individually for each compound. Therefore, the platform consists of a combination 
of liquid chromatography and parallel on-line continuous-flow bioactivity/bioaffinity 
screening and high-resolution mass spectrometry (HRMS) [11]. In this way, simultaneous 
bioactivity/bioaffinity assessment and (tentative) molecular structure elucidation in mixtures 
of related compounds is possible. 
Recently, we reported an HRS platform to study p38α binding, which enables high-quality 
bioaffinity assessment (Z’=0.8; S/N up to 100) [12]. This enables us to investigate mixtures 
of p38α inhibitors and their related substances, generated by various means of metabolism-
like compound conversion. Such an approach can be especially useful for highly lipophilic 
compounds like kinase inhibitors, as the compound modification may result in more polar, 
but still bioactive analogues that are commonly more difficult to generate by conventional 
organic synthesis. 
For example, the use of electrochemistry in an on-line combination with the HRS platform 
resulted in a number of related substances for p38α kinase inhibitors, including unstable 
and reactive conversion products [13]. Mixtures of related substances can also be 
generated enzymatically, e.g., biosynthetically using (human) microsomal incubations or 
by incubation with specific bacterial mutants (BM3) of cytochrome P450s [14]. Alternatively, 
other (chemical) means such as photochemistry or oxidative reagents can be applied. 
These different means to create chemical diversity of p38α kinase inhibitors are compared 
in a separate study, involving assessment of bioaffinity and identity by the HRS platform 
[15].
This paper focuses on the structure elucidation aspect of the HRS platform with special 
attention on MS fragment interpretation. The study resulted in a wealth of MS/MS data, 
not only for the kinase inhibitors itself, but also for their related substances, that is: their 
conversion products (CPs). The interpretation of these data and the identification of most 
of the CPs of the typical small-molecule kinase inhibitors TAK-715, BIRB796, SB203580, 
and DMPIP are discussed in more detail in this paper. Emphasis is on specific pathways, 
fragments crucial in structure elucidation, noticeable observations of the gas-phase 
chemistry, and the potential of using an ion-trap–time-of-flight hybrid instrument in a 
screening setting, where fragmentation methods have to be comprehensive. Some of the 
applied conversion methods enabled the generation of sufficient material of the related 
substances in order to confirm the HRMS identification with 1H NMR spectroscopy data. 
Materials and methods
Chemicals 
The human recombinant mitogen-activated protein kinase p38α isoform and its inhibitors 
DMPIP (1-{6-chloro-5-[(2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl]-
3aHindol-3-yl}-2-morpholinoethane-1,2-dione), SB 203580 (4-[4-(4-fluorophenyl)-2-
(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine), BIRB796 (N-[3-(tert-butyl)-1-(4-
methylphenyl)-1H-pyrazol-5-yl]-N’-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-urea), 
TAK-715 (N-[4-[2-Ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide) were 
obtained from various sources. Methanol (LC–MS grade) and formic acid (LC–MS grade) 
were from Biosolve (Valkenswaard, the Netherlands). All other chemicals were of analytical 
grade and were obtained from Sigma-Aldrich (Schnelldorf, Germany).
Generation of related substances of p38α kinase inhibitors
Various methods of compound conversion were used. Each of these methods is discussed 
briefly but has been described in detail elsewhere. Electrochemistry adds (reduction) or 
removes (oxidation) electrons from the substrate on a surface electrode which results in 
further reaction for example with the solvent [13]. During incubation with (human) liver 
microsomes [14,15] or with mutants of cytochrome P450 BM3 [14] the enzymes present 
catalyse specific reactions like hydroxylation. Oxidation with hydrogen peroxide occurs 
mainly via reactive oxygen species [15] while photochemical conversion is the result of the 
excitation of electrons in the substrate by intense visible light irradiation [15].
HRS platform: LC with parallel bioaffinity screening and high-resolution MS
The HRS analysis of structure and bioaffinity of the CPs is conducted with the integrated 
LC–p38α binding assay/MS platform shown in Figure 1 which has been previously reported 
[12]. In short, the platform consists of a Shimadzu (‘s Hertogenbosch, the Netherlands) 
LC–MS system, including two LC-20AD and two LC-10AD isocratic pumps, an SIL-20AC 
autosampler, a CTO-20AC or a CTO-10AC column oven, an RF-10AXL fluorescence 
detector, an SPD-AD UV/VIS detector, a CBM-20A controller, and an ion-trap–time-of-flight 
hybrid mass spectrometer (IT–TOF) for HRMS, operated with an electrospray ionization 
(ESI) source. The mixtures of CPs were separated in the chromatographic part of the HRS 
platform on an Xbridge C18 column 100×2.1 mm with 3.5 mm particles (Waters, Milford, 
MA, USA) at 40°C using a flow rate of 113 mL/min. The following mobile phases were 
employed: eluent A (1 % methanol, 99 % water, and 0.01 % formic acid); eluent B (99 % 
methanol, 1 % water, and 0.01 % formic acid). With these, the gradient was constructed as 
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follows: from 0 to 2 min isocratic at 20% B; from 2 to 18 min, linear increase of eluent B from 
20% to 90%; from 18 to 22 min, isocratic at 90% B; from 22 to 23 min linear decrease from 
90% to 20% of eluent B; from 23 to 30 min re-equilibration to isocratic conditions at 20% 
eluent B. Because the different modification techniques were assessed in several studies, 
both gradient profile and stationary phase varied. For example, the reaction mixtures were 
most complex in the Light and H2O2 incubations, so specialized gradients were used per 
substrate. An overview about chromatographic conditions can be found in Section 1 of the 
Supporting Information and the associated text.
The eluent was split post-column in a ratio of 1:9 using 13 mL/min in the bioaffinity detection 
and 100 mL/min in ESI-HRMS analysis. The p38α binding assay is not described here as 
the bioaffinity data is irrelevant to the structure elucidation and the discussion of the MS 
fragmentation. Ionization by ESI was achieved with the following settings: needle voltage 
4.5 kV; source heating block and the curved desolvation line temperature 200°C; drying 
gas pressure 62 kPa; nebulizing gas flow-rate 1.5 L/min. The IT–TOF instrument provides a 
resolution of ~10,000 (FWHM) in both MS and MSn modes. External calibration on sodium 
trifluoroacetate clusters was applied. The mass accuracy achieved for precursor ions and 
fragments was generally within ±5 ppm; otherwise, the actual mass accuracy obtained for 
a particular ion is specified. Deviations larger than ±5 ppm can mostly be explained by low 
abundance or overlap with the isotope pattern of other species.
Full spectra were obtained in the positive-ion mode between m/z 200 and 650. MS2 and 
MS3 spectra were obtained in data-dependent mode between m/z 100 and 650 with an 
ion accumulation time of 10 ms and a precursor isolation width of 3 Da. MS, MS2 and MS3 
spectra as well as bioaffinity data are collected in a single run of the HRS platform. Where 
necessary, the collection of MS2 and MS3 spectra was repeated with manual precursor 
selection in MS2 using the HRS platform with inactive bioaffinity detection. The collision 
energy was set to 75% for TAK-715 and its products and to 50% for all other compounds. 
Structure elucidation was based on calculating the elemental composition of precursor and 
fragment ions from the accurate-mass measurements. Several restrictions were applied 
to limit the analysis to relevant elemental compositions. For the parent ions, the elemental 
composition of the substrate plus a reasonable number of atoms which can be added 
by the respective modification techniques was used as a cut off. Mostly, this is restricted 
to oxygen, but also carbon and hydrogen were used where for example methoxylation 
was possible. For the analysis of fragment ions, the restriction criterion applied was the 
elemental composition of the precursor ion. With these restrictions, most often only one 
elemental composition was yielded within 5 ppm error. In rare cases, where in spite of the 
restrictions several elemental compositions were obtained, the false compositions could 
be easily excluded on basis of carbon-hydrogen ratio, carbon-nitrogen ratio and/or the 
absence of a sensible modification route in the case of the parent ions and/or the absence 
of sensible neutral losses in the case of the fragments. The structures of the CPs should 
be viewed as carefully compiled proposals as confirmation by a second, independent 
analytical technique or through synthesis of standards was out of the scope of this study. 
An exception is presented by the five purified TAK-715 derived CPs analysed by NMR 
where such confirmation has been demonstrated.
Where applicable, 1H-NMR analysis was performed on a Bruker Avance 500 (Fallanden, 
Switzerland) at 500.23 MHz.
Results
The molecular structure of the major conversion products (CPs) originating from four 
structurally different p38α inhibitors was elucidated using accurate-mass measurement 
and MS2 and MS3 data from an IT–TOF MS instrument. These CPs were generated by Figure 1: Schematic setup of the HRS platform. The analysis of MS fragmentation and the resulting 
structure proposals of the CPs are the topic of this manuscript. Therefore, the HR-MS part is 
highlighted because it provides the accurate mass fragmentation data.
Figure 2: MS/MS spectra of the four substrates. The precursor ions are selected in the ion trap within 
a window of ±1.5 amu around the following m/z values A) m/z 541.2 for DMPIP, B) m/z 378.1 for 
SB203580, C) m/z 529.3 for BIRB796 and D) m/z 400.1 for TAK-715.
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different modification methods, being enzymatic incubation with human liver microsomes 
(HLM) and a bacterial cytochrome P450 BM3 mutant as well as by chemical treatment 
using electrochemical oxidation, H2O2, and intense light irradiation. The resulting mixtures 
of CPs were analysed by LC coupled to a continuous-flow p38α enzyme binding assay and 
parallel HRMS to obtain MS2 and MS3 data. The interpretation of MS3 data is discussed in 
this paper, whereas affinity data for the CPs as well as comparison between the various 
modification strategies is discussed elsewhere [15].
The structure elucidation of CPs generally proceeds in three steps. First, the MS2 and 
MS3 data of the parent compounds were interpreted in considerable detail, trying to 
recognize representative fragments to act as profile groups in the molecule [16,17]. In 
the second step, from a comparison of the elemental composition of the CPs with that of 
the parent compound, the nature of the modification was established. In the third step, 
the fragmentation of the CPs was compared to that of the parent to assess modification 
of the representative fragments in order to narrow down the site of modification and to 
propose structures of the CPs. Data on relative retention time (RRT) were used to assist 
in identifying the modification, e.g., to differentiate between hydroxylation and N-oxide 
formation [18]. In the case of five BM3-generated CPs of TAK-715, a fourth step involved 
purification of the CPs by preparative LC and subsequent acquisition and interpretation of 
the 1H-NMR spectra, guided by the knowledge obtained from the MSn data [14]. The data 
are summarized in the Tables 1 to 4. For most CPs, not all fragments are tabulated, but 
rather the fragments important for structure elucidation. MSn spectra of most of the CPs are 
included in the Supporting Information. The discussion is not comprehensive as it does not 
include structure elucidation of all CPs found.
Structure elucidation of DMPIP conversion products
The fragmentation of DMPIP (m/z 541.204, C28H31ClFN4O4
+) has partly been described 
elsewhere [13]. The fragmentation is more readily discussed, if the molecule is divided 
into four parts (A to D, see Figure 3) at the main fragmentation sites. The major fragment 
Figure 3: Structure and profile groups of DMPIP as well as proposed structures for the fragment ions. Ta
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consistent with the addition of H2O (Δ +18.001 Da) to the C or D part, and another showing 
the loss of HCl (CP505, m/z 505.226, C28H30FN4O4
+). The latter modification probably 
involves the generation of a five-membered ring between carbon formerly carrying the 
chlorine atom and the B part. At least four isomers are observed of CP523 (m/z 523.235, 
C28H32FN4O5
+), which are consistent with a combination of both modifications. The 
observation of several isomers already proves that the chlorine is not directly exchanged 
by a hydroxyl group. Despite significant co-elution, two of the major isomers, CP523B and 
CP523D, can be identified as loss of Cl from the C-ring and presence of OH in the B-ring. 
This is concluded from an accordingly modified CD-fragment and similarities to CP557A 
fragmentation, respectively. 
The example of the mono-oxygenated CPs nicely demonstrates the strength of the profile-
group approach [16,17]. The structural isomers CP557A, B and C can be shown to be 
distinctively modified in part B, D and C, respectively. On top of that, the RRT [18] is very 
helpful to identify CP557A as a hydroxylation and CP557C as an N-oxidation product. 
However, if the RRT of the product is close to 1.00, as for CP557B, the latter approach is 
less helpful. In CP539, the addition of a single double bond remarkably changes the pattern 
of proton/hydride rearrangement during CID and even leads to the onset of homolytic 
cleavage of the amide bond. Another interesting change in CID fragmentation, caused 
by modification, is observed in the CPs characterized by hydroxylation of the B part, 
namely CP557A and CP523B and D. This modification activates an internal fragmentation 
of the piperazine ring not observed in any of the other CPs, including DMPIP itself. The 
interpretation of structural isomers of the substrate remains a challenge as the fragmentation 
trees are either to similar or the changes are extremely difficult to interpret.
Structure elucidation of SB203580 conversion products
The fragmentation of SB203580 (m/z 378.108, C21H17FN3OS
+) in the IT–TOF is similar to 
that in the Q–TOF [21]. The only fragment ions observed (see also Figure 2B) are due to 
the loss of CH3
• (F363; m/z 363.084, C20H14FN3OS•+) and of SOCH3• (F315; m/z 315.117, 
C20H14FN3
•+). The SB203580 CPs found with all applicable conversion methods are 
summarized in detail in Table 2; MSn spectra of most of the CPs are included in Section 6 
of the Supporting Information.
In H2O2, EC and HLM conversion, the major product formed (CP394C; m/z 394.103, 
C21H17FN3O2S
+) is consistent with transformation of the sulfoxide to a sulfone group [21]. 
From the unmodified F315 fragment and the absence of F363 (or a corresponding F363+O; 
m/z 379.080, C20H14FN3O2S
+•) alone, S-oxidation cannot be distinguished from CH3-
hydroxylation. However, under Light, a compound with CH3-hydroxylation was observed 
for which H2C=O loss was strongly favored over SO2CH3
• loss (see CP321 below). Having 
the fragmentation patterns of both modifications allows to distinguish them. A minor product 
in HLM and H2O2 conversion is another mono-oxygenation product (CP394D). The major 
fragment (F363+O) excludes both CH3-hydroxylation and S-oxidation. In MS3, the odd-
electron ion F363+O is further fragmented by OH• loss (m/z 362.078, C20H13FN3OS+), 
suggesting N-oxidation [22,23]. This is consistent with the comparably high RRT [18]. The 
strong preference for the CH3
• loss over OH• loss from the N-oxide suggests that the OH• 
loss is significantly easier from the odd-electron ion than from the even-electron ion [24-26]. 
Minor products of H2O2 conversion include two mono-oxygenation isomers (CP394A and 
CP394B), which also show F363+O as major fragment. However, these two species involve 
hydroxylation at the aromatic system, as F315+O (m/z 331.112, C20H14FN3O•+) is observed. 
The latest eluting isomer (CP394E) shows the same fragmentation pattern, consistent 
with either a lipophilic aromatic hydroxyl product or an unusually stable N-oxide. cLogP 
calculations predict that hydroxylation in ortho-position to the nitrogen of the pyridine ring 
results in significantly increased lipophilicity. 
Four double-oxygenated isomers (m/z 410.098, C21H17FN3O3S
+) were observed in H2O2 
conversion. The two earliest eluting isomers (CP410A and CP 410B) show the loss of 
SO2CH3
• to generate F315+O. This indicates a combination of S-oxidation and aromatic 
observed in MS2 (see Figure 2A) is due to the CD-part (m/z 319.048, C15H12ClN2O4+); the 
complementary AB-part (m/z 223.161, C13H20FN2+) is also observed as well as the C-part 
(m/z 206.000, C10H5ClNO2
+). Two other fragments can be explained by an intramolecular 
rearrangement of the fluorobenzyl group, [19,20] which in effect results in the loss of 
dimethylpiperazine (the B-part, C6H14N2) and the formation of the fragment ion with m/z 
427.087 (ACD; C22H17ClFN2O4+). The fragment ion with m/z 286.043 (AC-CO; C16H10ClFNO+) 
is a secondary fragment of the ACD-ion, involving the loss of both the D-part and CO (see 
Figure 3). In MS3 of ACD, a fragment ion with m/z 312.024 (AC-H2; C17H8ClFNO2+, 6 ppm) 
is formed which is consistent with the loss of part D as morpholine-N-carbaldehyde and 
thus requires ring formation in the A and/or C part. The two other ions observed in MS3, m/z 
284.029 (C16H8ClFNO
+, 6 ppm) and m/z 257.041 (most likely C17H7NO2
+•, –24 ppm), are 
probably fragments of this AC-H2 fragment resulting from the loss of CO and a combination 
of HF and Cl•, respectively. MS3 of CD results in the C-ion (m/z 206.000, C10H5ClNO2+). The 
MS3 spectrum of AC-CO can be readily explained in terms of neutral losses, that is: m/z 
258.048 due to the loss of CO, m/z 222.072 due to the loss of CO and HCl, m/z 196.069 
due to the loss of CO, HCN, and Cl•, and m/z 109.044 due to C7H6F
+ (–7 ppm; A-part), but 
proposing fragmentation routes and fragment structures is more difficult.
The DMPIP CPs found with all conversion methods are summarized in detail in Table 1; 
MSn spectra of most of the CPs are included in the Section 5 of the Supporting Information. 
In general, only a few of the above identified fragments of DMPIP are actually observed 
for the CPs, especially the CD-ion. CPs generated by EC are discussed in more detail 
elsewhere [13].
In HLM incubations, DMPIP gave only one minor mono-oxygenated CP (CP557C; m/z 
557.197, C28H31ClFN4O5
+). Both the (CD+O)-ion in MS2 (m/z 335.045, C15H12ClN2O5+) and 
the (C+O)-ion (m/z 221.995, C10H5ClNO3+) in MS3 contain this modification. However, the 
C-ion is mainly observed with an additional water loss (m/z 203.986, C10H3ClNO2+). The 
water loss and RRT indicate N-oxidation rather than aromatic hydroxylation in the C-ring 
[18].
In BM3 incubations, DMPIP almost exclusively produced CP433 (m/z 433.165, 
C21H26ClN4O4
+), consistent with dealkylation of the fluorobenzyl group (loss of A), which 
could be identified based on accurate mass only.
In H2O2, DMPIP produces two abundant CPs. The major product is CP557A (m/z 557.196, 
C28H31ClFN4O5
+), which is a mono-oxygenated CP. The MS2 spectrum indicates the oxidation 
must have taken place in the B-part, as the m/z-values for the ACD-, CD-, and AC-CO-ions 
are not changed (see Figure 3). The fragment ion with m/z 376.108 (C18H19ClN3O4
+) results 
from the loss of both the A-part (C7H6F) and cleavage in the oxidated dimethylpiperazine 
ring, involving the loss of C3H6NO. This ring cleavage, which is not observed for the DMPIP 
itself, apparently is stimulated by the presence of the extra O at the dimethylpiperazine 
group. In MS3, this ion shows losses of either C3H7N (57.056 Da) to an ion with m/z 319.052 
(CD; C15H12ClN2O4+) or of the D-part to an ion with m/z 261.043 (C13H10ClN2O2+). This 
behavior in MS3, the RRT of 0.75, and the absence of losses of H2O, OH
• or O suggest 
hydroxylation rather than N-oxidation.
The minor product (CP501, m/z 501.170, C25H27ClFN4O4
+) was also observed in EC 
experiments and was identified as resulting from the loss of C3H4 from the dimethylpiperazine 
group [13].
Photochemical conversion of DMPIP yields a product CP539 (m/z 539.187, C28H29ClFN4O4
+), 
also observed in EC experiments, [13] which is due to dehydrogenation of the B part. 
This interpretation is supported by the increased lipophilicity, and the observation of an 
unmodified CD fragment in MS2 as well as a neutral loss of the unmodified A part as a 
radical leading to a BCD fragment (m/z 430.139, C21H23ClN4O4+•). Interestingly, the modified 
AB fragment (m/z 223.161, C13H20FN2+), is observed with m/z 219.129 (C13H16FN2+) 
and 220.135 (C13H17FN2
+•, –10 ppm), thus showing an additional H2 loss, maybe due to 
conjugation. 
Other photochemical CPs observed include a product (CP559, m/z 559.213, C28H33ClFN4O5
+), 
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hydroxylation; the RRT are in good agreement with assuming an S-oxidation of CP394A 
and CP394B. The third isomer (CP410C) shows the loss of either OH• (m/z 393.096, 
C21H16FN3O2S
+•) or SO2CH3
• to F315+O, indicating an N-oxide-S-oxide product, which is 
also consistent with the RRT, as both modifications increase lipophilicity. F315+O alone 
does not establish S-oxidation. The fragment might also result from an SOCH2 loss from 
m/z 393, in the case of an unmodified sulfoxide group. However, S-oxidation is proven 
by fragmentation of m/z 393, thus after OH• loss, resulting in the loss of the sulfonyl 
moiety either as SO2CH3
• (m/z 314.106, C20H13FN3
+, 11 ppm) or as SO2CH4 (m/z 313.101, 
C20H12FN3
+•), but not as SOCH2 leading to F315+O. It is interesting to observe that, 
because the S-oxidation completely suppresses the CH3
• loss, the OH• loss in this case 
occurs from an even-electron ion. Based on RRT, the last isomer (CP410D) seems to be a 
combination of the lipophilic aromatic hydroxylation product CP394E and the S-oxidation. 
Like for CP410A and CP410B, the only MS2 fragment is F315+O, thus the nature of the 
modifications must be the same.
Photochemical conversion of SB203580 results in two major and four minor products. 
One major product (CP362; m/z 362.113, C21H17FN3S
+) results from the conversion of the 
sulfoxide into the corresponding thioether. Fragment ions consistent with the loss of CH3
• 
and CH3S
• confirm this interpretation. 
Based on its elemental composition and the assumption that no major rearrangement 
takes place, the other major product (CP305; m/z 305.077, C15H14FN2O2S
+) involves a 
decomposition of the imidazole ring, that is: replacing pyridine and its linking carbon in 
the imidazole ring by an O-atom (see structure proposals & comments in Section 3 of the 
Supporting Information). The position of the O-atom is not easy to assess as MSn fragments 
show an arrangement of the N-atoms which is different from the original imidazole ring. Both 
phenyl rings are observed with a free amide, thus suggesting that carbon-3 and -5, each with 
an N-atom linked to it, are bridged by the O-atom. However, whether this rearrangement of 
the modified imidazole ring occurs in the liquid phase during light irradiation or in the gas 
phase during ionization and/or fragmentation is not clear. Three of the minor products can 
be considered to be secondary products of CP305. CP243 (m/z 243.094, C14H12FN2O
+) 
is consistent with the replacement of the methylsulfoxide with H, CP289 (m/z 289.081, 
C15H14FN2OS
+) with conversion of the sulfoxide into the corresponding thioether, whereas 
CP321 (m/z 321.072, C15H14FN2O3S
+) involves hydroxylation of the methyl group, as 
indicated by the loss of H2C=O to yield the ion with m/z 291.059 (C14H12FN2O2S
+) rather 
than the loss of SO2CH3
• that would occur after S-oxidation (see CP394C). 
Two minor isomeric products (CP424A and CP424B; m/z 424.115, C22H19FN3O3S
+) result 
from combined hydroxylation and methoxylation. In MS2, both CPs generate an ion with 
m/z 259.088, due to the loss of C8H7NOS (H3C–S(=O)–C6H4–CºN), indicating that the 
modifications are either in the pyridine or in the fluorophenyl ring. In the MS2 spectrum of the 
earlier eluting CP424A, the ion with m/z 155.052 (C8H8FO2
+) indicates both modifications 
have occurred in the fluorophenyl ring. A similar fluorophenyl fragment was not observed 
for other CPs of SB203580. For CP424B, the fluorophenyl fragment is observed with m/z 
Figure 4: Structure of SB203580. Ta
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123.025 (C7H4FO
+) in MS3. This correlates to a quinone like structure of this carbocation 
including carbon-3 and an added oxygen. As the para-position is blocked by fluorine, the 
aromatic hydroxylation must be ortho to carbon-3, otherwise, there would be no quinone. 
Since the methoxylation is present in the ion with m/z 259 but not in the ion with m/z 123, 
it must have occurred in the pyridine ring. 
Interestingly, the loss of SO2CH3
• indicates S-oxidation (CP394C) while methyl hydroxylation 
leads to different fragmentation (CP321), but only because the methyl hydroxylation is more 
unambiguously interpretable. This means that both structures can be determined without 
standards when both fragmentation trees are available. CP424B is one of the rare cases 
were an aromatic hydroxylation can be linked to a single carbon atom (14a and 14b are 
chemically identical). The reason is that a very small fragment containing the hydroxylation 
can be generated whose quinone-like structure can only be explained by ortho-, but not 
by meta-substitution. Most importantly, the ability of the IT–TOF instrument, as opposed to 
a Q–TOF type instrument, to provide a parent daughter relationship among the fragments 
is crucial in elucidating the structure of some CPs, especially CP410C.
Structure elucidation of BIRB796 conversion products
For a discussion on its fragmentation, BIRB796 (m/z 529.300; C31H38N5O3
+) can be divided 
into four parts (see Figure 5). Major fragments (see Figure 2C) result from cleavages in 
the urea moiety, leading to two sets of complementary fragments: the AB-part and the 
CD-part with cleavage on either 
side of the carbonyl. This results in 
the fragments AB with m/z 230.164 
(C14H20N3
+), AB+CO with m/z 256.143 
(C15H18N3O
+), CD with m/z 273.158 
(C16H21N2O2
+, –7 ppm), and CD+CO 
with m/z 299.138 (C17H19N2O3
+). Both 
AB fragments show the loss of the 
B-part (C4H8) to the A-part, that is: m/z 
200.082, (A+CO; C11H10N3O+) and m/z 
174.103 (A; C10H12N3+) (see Figure 5). 
In our instrument, BIRB796 also 
generated a double-charge ion 
([M+2H]2+; m/z 264.652, C31H39N5O3
2+). 
The MS2 spectrum with the double-
charge ion as precursor ion partly 
yields all the fragments observed in 
the MS2 of the single-charge ion, but 
in addition fragment ions with m/z 
414.206 (ABC+•; C25H26N4O2+•), m/z 
413.197 (ABC-2H; C25H25N4O2+), 
both due to the loss of the D-part, 
as well as fragment ions with m/z 
229.156 (AB+•; C14H19N3+•, –6 ppm), 
m/z 114.092 (D; C6H12NO+, 6 ppm), 
and m/z 100.076 (D–CH2; C5H10NO+) 
(see Figure 5). It is quite intriguing to 
observe the formation of pairs of odd-
electron and even-electron ions for 
m/z 414/413 and for m/z 229/230 from 
the double-charge ion. No double-
charge fragment ions were observed. 
In this particular case, the MS2 on 
the double-charge precursor ion also 
enables to get around the low-m/z 
cut-off typical of the ion trap: for the 
double-charge precursor ion with m/z 
264.7, fragment ions with m/z 100 and 
114 are observed, whereas they were 
not for the single-charge precursor 
ion with m/z 528.3. Further MS3 
fragmentation of the various fragment 
ions is summarized in Section 2 of the 
Supporting Information. In the MS data 
of the CPs, not all these fragments 
are actually observed; AB+CO, A+CO 
and D were observed most frequently. 
As the fragmentation of the double-
charge ion provides better abundance 
and information of the four profile 
groups recognized in BIRB796, it 
was chosen as precursor ion in the 
structure elucidation of most CPs. The 
BIRB796 CPs found with all conversion 
Figure 5: Structure and profile groups of BIRB796 as well as proposed structures for the fragment 
ions in MS2 with [M+H]+ or [M+2H]2+ as precursor ions. Ta
bl
e 
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methods are summarized in detail in Table 3; MSn spectra of most of the CPs are included 
in Section 7 of the Supporting Information.
In HLM incubations, BIRB796 generates a complicated mixture of CPs. Two major mono-
oxygenated CPs (m/z 272.650, C31H39N5O4
2+; [M+H]+ with m/z 544.293) were observed, 
CP544A and CP544B, for which RRTs suggest hydroxylation. For CP544A, in-source 
fragmentation yields an ion with m/z 263.646, consistent with an easy H2O loss. In MS
2, 
three fragments are observed, m/z 114.093, indicating no change took place in the D-part, 
as well as m/z 254.129 (C15H16N3O
+) and m/z 227.141 (C14H17N3
+•), consistent with AB+CO–
H2 and AB+•–H2, respectively, most likely due to a H2O loss, indicating hydroxylation in 
the AB-part. For CP544B, the modification can be attributed to the A-part, because an 
A+CO+O fragment (m/z 216.077, C11H10N3O2+) is observed. 
Another major conversion product is CP502 (m/z 251.645, C29H37N5O3
2+; [M+H]+ with m/z 
502.283), consistent with a combined O- and N-dealkylation (effective loss of C2H2) from 
the morpholine ring. The observation of AB+CO, AB, AB+•, and A+CO fragments in the 
MS2 spectrum confirms this interpretation. 
CP458 (m/z 229.632, C27H33N5O2
2+; [M+H]+ with m/z 458.255) is a minor CP, resulting from 
a double N-dealkylation in the morpholine ring, thus involving the effective loss of C4H6O 
(dihydrofuran). This modification is supported by the observation of an unmodified AB+CO 
fragment. 
A major product CP415, observed as single-charge ion (m/z 415.215, C25H27N4O2
+; effective 
loss of C6H11NO), results from O-dealkylation of the ethyl-morpholino group (loss of D). This 
and the related CP413 (m/z 413.199, C25H25N4O2
+; effective loss of C6H13NO), which is 
consistent with subsequent hydroquinone formation, have been observed by EC conversion 
[13]. Although the modification into CP415 can be quite unambiguously identified from the 
accurate mass, further confirmation is obtained from MS2 data, showing fragments due 
to AB+CO and A+CO, indicating the changes are not in the AB-part, and an ion with m/z 
160.078 (C10H10NO
+, 11 ppm) consistent with the C-part. 
Another CP (m/z 526.285, C62H72N10O6
2+ and m/z 351.192, C62H73N10O6
3+; [M+H]+ with m/z 
1051.555) is a dimeric product involving two new (C–C) bonds, as four hydrogen atoms 
are missing. In MS2, fragments AB+CO and A+CO are observed, indicating the linkages 
must be in part C or D. 
This compound shows a strong preference for the double-charge ion, both in the parent 
and some CPs. This is especially striking considering the relatively small differences in 
relevant parameters such as size, polarity or number of nitrogen atoms as compared to, for 
example, DMPIP. In fact, the exact position of one of the protonation sites can be deduced 
by following the change from double-charge to single-charge preference in the CPs (see 
Table 3). All CPs retaining the morpholine-N prefer the double-charge state, but as soon as 
the morpholine-N is replaced by a hydroxyl group (CP459) the single-charge ion becomes 
more abundant. Thus, the morpholine group is protonated at the N-atom.
Structure elucidation of TAK-715 conversion products
Fragmentation analysis of TAK-715 and its conversion products is not trivial. TAK-715 
shows a very complicated fragmentation tree with a large number of fragments. On top of 
that, the fragmentation pattern changes drastically in some CPs. This can give additional 
information, but restricts the usefulness of characteristic parent fragments in the profile-
group approach [16,17]. In MS2, TAK-715 (m/z 400.148, C24H22N3OS
+) shows two major 
fragments (see Figure 6 and Figure 2D). A loss of water (m/z 382.137) is probably favoured 
by an equilibrium between the amide moiety and its hydroxylimine resonance structure, 
stabilized by coupling of the aromatic systems of the phenyl and the pyridine ring and an 
intramolecular hydrogen bond to the pyridine nitrogen (see Figure 6). The other major 
fragment F279 (m/z 279.095, C17H15N2S+) corresponds to the loss of the benzamide (C6H5–
C(=O)NH2, 121.053 Da). Although fragmentation of the amide bond would be expected 
with complementary fragment ions with m/z 105.034 due to C6H5–CºO
+ and m/z 296.122 
[27], the fragment ion F279 is observed instead. This unexpected fragmentation is probably 
also a consequence of the stabilization of the amide bond. This cleavage is also frequently 
found in the MS2 spectra of the CPs, and can thus be used to exclude modification in 
this phenyl ring. Additionally, several minor fragments are observed. One is the ion F297 
(m/z 297.106, C17H17N2OS
+) which can only be explained by an unusual rearrangement 
of the amide oxygen from the hydroxylimine form, first leading to the structure proposed 
in Section 4 of the Supporting Information and then to the loss of benzonitrile (C6H5–CºN, 
103.042 Da). Secondary fragmentation is considered uncommon in a single fragmentation 
experiment in ion-trap MS instruments. However, several fragments of TAK-715, which 
require two bond cleavages for formation, were observed both in MS2 and MS3. The 
fragment F264 (m/z 264.072, C16H12N2S+•) originates from a loss of CH3• from F279. 
This is supported by observing the fragmentation pathway m/z 400.148 → m/z 279.095 
→ m/z 264.072 in the MS3 experiments. Based solely on this fragmentation, it is unclear 
whether the methyl radical is lost from the methyl or the ethyl group. However, the fragment 
F224 (m/z 224.053, C14H10NS+), which is observed in MS2 and in MS3 via the pathway 
m/z 400.148 → m/z 279.095 → m/z 224.053, is helpful in this respect. The difference in 
elemental composition between F279 and F224 is C3H5N which is consistent with the loss 
of propionitrile from the ethylthiazole part (carbon-1, carbon-2, carbon-3 and nitrogen-7; 
see Figure 6). The ethyl group is thus no longer present in the F224 fragment. By observing 
an additional pathway m/z 400.148 (→ m/z 279.095) → m/z 224.053 → m/z 209.029, 
where CH3
• is lost from the F224 fragment, the ethyl group is excluded as source of this 
radical. The remaining two minor fragments in MS2, F252 (m/z 252.084, C16H14NS+) and 
F197 (m/z 197.042, C13H19S+), result from the loss of HCN from the pyridine ring of the 
ions F279 and F224, respectively. Next to the analysis of the parent fragmentation, the 
1H-NMR signals of TAK-715 were assigned [14]. Large-scale incubation of TAK-715 with 
BM3 mutant M11 and subsequent preparative LC resulted in sufficient material of five CPs 
to allow 1H-NMR spectroscopy. These data are shown in Table 5 and discussed here only 
in context of the identification by MSn; MSn spectra of most of the CPs are included in 
Section 8 of the Supporting Information. 
Three fragments were picked as profile groups, representative of different parts of TAK-715: 
(1) F279 or its corresponding fragments, which is due to the loss of benzylamide, was used 
to observe or exclude modification in the cleaved phenyl ring, (2) F264 was employed as 
representative of the CH3 group (carbon-14), and (3) F224 or its corresponding fragments 
which is representative of the ethyl group (carbon-2 and -3). The TAK-715 CPs found with 
all conversion methods are summarized in detail in Table 4.
CP416A (m/z 416.143, C24H22N3O2S
+) is one of the mono-oxygenated products. In MS2, 
it shows a fragment with m/z 277.080 (C17H13N2S
+) which corresponds to F279+O–
H2O. Although both an OH group and an N-oxide can show the loss of H2O, the RRT 
points to hydroxylation [18]. The H2O loss suggests the presence of an α-H, enabling 
a 1,2-elimination, thus an OH group in an aliphatic rather than in an aromatic system. 
Furthermore, an MS3 fragment (m/z 262.056, C16H10N2S
•+), corresponding to F264+O–H2O, 
seems to exclude the modification of the CH3 group at carbon-14 (Figure 6). This would 
lead to the conclusion that one of the ethyl carbons has been hydroxylated. However, NMR 
analysis [14]. suggests otherwise: All aromatic protons are still present, only the m-methyl-
phenyl ring protons are shifted to a lower field. The triplet and the quartet of the ethyl 
group are unchanged, whereas the singlet of the methyl group has shifted to a higher 
field. Unfortunately, as the signal is masked by a solvent signal, it cannot be integrated. 
Nevertheless, it still proves hydroxylation of the CH3 group at carbon-14. This apparent 
mismatch between the MSn and the NMR data can be explained by assuming that the H2O 
loss is accompanied by the rearrangement of a remote hydride to carbon-14. This would 
explain the H2O loss as well as the loss of the apparently unmodified CH3 group as CH3
•. In 
conclusion, the hydroxylation in CP416A was assigned to carbon-14. 
CP416B (m/z 416.143, C24H22N3O2S
+) is another mono-oxygenated product. In the MS2 
spectrum of CP416B, an ion with m/z 295.092 (C17H15N2OS
+, 6 ppm), corresponding to 
P297+O–H2O, is more dominant than the ion with m/z 277.080, corresponding to P279+O–
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H2O. A strong indication for hydroxylation of the ethyl moiety is found in a fragment 
with m/z 372.118 (C22H18N3OS
+), consistent with a loss of acetaldehyde (C2H4O); no 
corresponding fragment is observed for the parent. Ethyl hydroxylation is supported by 
NMR data: [14]. The triplet of the three protons on carbon-3 has changed to a doublet at 
slightly lower field and the proton at carbon-2 is still split into a quartet but the signal has 
shifted to a lower field by almost 2 ppm. Unfortunately, integration of this signal was not 
successful because of a very strong overlapping water signal at ca. 4.9 ppm. All other 
protons were accounted for by integration: the methyl singlet and all aromatic signals are 
unchanged. In conclusion, hydroxylation in CP416B has taken place at carbon-2 in the 
ethyl group.
CP432A (m/z 432.138, C24H22N3O3S
+) is a double-oxygenated product. The fragment 
ion in MS2 with m/z 293.074 (C17H13N2OS
+) corresponds to F279+2xO–H2O. In MS3 of 
this fragment, a fragment ion with m/z 250.056 (C15H10N2S
+•), consistent with a homolytic 
cleavage of a C2H3O
•, reveals a modification in the ethyl group. At first, this could suggest 
that both modifications took place in the ethyl group as otherwise the loss of an ethoxy 
radical (C2H5O
•) would have been expected. However, as already discussed for CP416A, 
H2O loss from a hydroxylation at carbon-14 can result in hydride rearrangement from 
remote positions. In the fragment with m/z 293.074, the water loss from the methyl group 
has already occurred, probably forming a carbonyl group from the hydroxyl group in 
the ethyl moiety, which could explain the elimination of the C2H3O
•. The NMR data [14]. 
Figure 6: Structure of TAK-715 and proposed structures for its fragment ions in MS2 and MS3. The 
fragmentation pathway is based on ion-trap MSn data, as outlined in the text. Ta
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show that the second hydroxylation has indeed taken place at carbon-14 as the aromatic 
signals are equivalent to CP416A, whereas the other hydroxylation is in the ethyl group 
as this modification did not influence the aromatic signals in CP416B either. Furthermore, 
in CP432A the doublet (3H) and the quartet (1H) for the hydroxylated ethyl group are 
observed at exactly the same shifts as those in CP416B. In the NMR spectrum of CP432A, 
integration is possible because the water signal at 4.9 ppm is far less pronounced. In 
conclusion, CP432A most likely contains a combination of the two hydroxylations from 
CP416A and CP416B although absolute stereochemistry at carbon-2 was not elucidated. 
The MS data for CP430B (m/z 430.123, C24H20N3O3S
+) are consistent with double-
oxygenation and a dehydrogenation. The major fragment (m/z 308.085, C17H14N3OS
+), 
which is observed next to a H2O loss, probably results from a H2O loss from a fragment with 
m/z 326.097 (C17H16N3O2S
+), consistent with a common amide bond cleavage. This results 
in a fragment ion with an amine group at the pyridine ring and the loss of a neutral (C7H4O). 
In MS3, the fragment with m/z 308.085 shows the loss of CO (m/z 280.091, C16H14N3S
+). 
This serial loss of water and CO points to the presence of a carboxylic acid function. In the 
NMR spectrum, [14]. again, no changes are observed in the number of aromatic protons or 
in the shifts for the protons in the phenyl and the pyridine ring. Furthermore, the ethyl group 
signals are unchanged. This indicates a carboxylic acid group in CP430B on carbon-14. 
Indeed, this also explains the shift to an even lower field than in CP416A of the m-methyl-
phenyl ring protons.
CP446 (m/z 446.118, C24H20N3O4S
+), the fifth compound of which NMR data were obtained, 
contains a triple-oxygenation and a dehydrogenation. Its fragmentation pathway m/z 446.118 
→ m/z 324.080 → m/z 296.083 is equivalent to the pathway 430.123 → m/z 308.085 → 
m/z 280.091 observed in CP430B, keeping in mind the difference of one oxygen atom 
between the CPs. Therefore, the carboxylic acid group at carbon-14 is expected to be 
present in CP446 as well. Further analogies between CP446 and CP430B are observed 
in the aromatic region of the NMR spectra where shifts, integrals and coupling are almost 
identical. This suggests not only a carboxylic acid on carbon-14 but also the localization of 
the third additional oxygen atom in the ethyl group. Indeed, the proton signals for the protons 
at carbon-2 and carbon-3 are identical to those in CP416B and CP432A. To summarize, 
CP446 is modified to a carboxylic acid on carbon-14 and a hydroxyl moiety at carbon-2. A 
combination of the modifications found in CP416B and CP430B possibly leads to CP446, 
keeping in mind the undefined stereochemistry at carbon-2.
These five CPs were observed with both BM3 mutant M11 and HLM incubations. In 
HLM incubations, five other CPs were observed, two of which were also produced by 
BM3, however, not abundant enough in the large-scale incubation to justify purification. 
Therefore, their possible structures have to be derived from MS3 data only. 
CP432B (m/z 432.138, C24H22N3O3S
+) is another double-oxygenated product. The MSn 
data suggests that both hydroxylations have taken place in the ethyl group, probably one 
at each carbon. The main clue is a fragment with m/z 372.119 (C22H18N3OS
+), consistent 
with a loss of 60.021 Da, due to either C2H4O2 or two consecutive losses of H2C=O. An 
additional fragment with m/z 313.136 (C21H17N2O
+), consistent with a loss of HS=C=N from 
the ion with m/z 372.119, links the 60.021 Da loss to the ethyl group as the HS=C=N loss 
from the thiazole ring is only possible after the loss of the ethyl moiety as C2H4O2. 
CP430A (m/z 430.125, C24H20N3O3S
+, 6 ppm) is another double-oxygenated and 
dehydrogenated product. In MS2, a fragment ion with m/z 308.086 (C17H14N3OS
+) is 
observed, corresponding to the loss of water and 104 Da (C7H4O), similar to CP430B. 
The ion with m/z 308.086 yields informative MS3 data. A neutral loss of CO to m/z 280.092 
(C16H14N3S
+), also observed in CP430B, indicates a carbonyl group. The subsequent loss 
of CH2=CHCºN (acrylonitrile) to an ion with m/z 227.063 (C13H11N2S
+) indicates that the 
earlier water loss involves two protons from the ethyl group. Otherwise, a propionitrile loss 
(C2H5CºN), as observed for the parent (F279 > F224; m/z 279.095 → m/z 224.053), would 
be expected. Thus, with an OH group at the ethyl, an aldehyde at carbon-14 is the only 
option to explain both the mass shift and the CO loss. 
The photolytic conversion of TAK-715 produces four major and one minor CPs. One of the 
major products is CP400 (m/z 400.149, C24H22N3OS
+), an isomer of TAK-715. Remarkably, 
in MS2 of CP400, the H2O loss, which is dominant in TAK-715 and most of its CPs reported 
here, is no longer favoured. As a result, F297 is now the most abundant fragment, rather than 
F279. Instead of F224 and F197, a fragment ion with m/z 254.100 (C16H16NS+) is observed, 
which is due to the HCNO loss from F297. A structure proposal for the isomer is given in 
Section 4 of the Supporting Information. In fact, in MS2 of this TAK-715 isomer, generated 
by intense light irradiation in solution, was predicted as a gas-phase rearrangement product 
(see above). Two other major products are isomers from a dehydrogenation reaction 
(CP398A and CP398B; m/z 398.134, C24H20N3OS
+). The modification did not occur in the 
benzamide part, because in MS2 both CPs yield the fragment ions F297-H2 (m/z 295.089, 
TAK-715 CP432A CP446 CP416A CP416B CP430B
Ha 1.45-1.48 
(3H,t)
1.61-1.63 
(3H,d)
1.64-1.65 
(3H,d)
1.45-1.48 
(3H,t)
1.62-1.64 
(3H,d)
1.44-1.49 
(3H,t)
Hb 3.09-3.13 
(2H,q)
5.08-5.12 
(1H,q)
5.08-5.12 
(1H,q)
3.09-3.14 
(2H,q)
5.08-5.12 
(1H,q)
3.08-3.14 
(2H,q)
Hc 2.33 (3H s) ~ 4.9* (s) - ~ 4.9* (s) 2.32 (3H,s) -
Hd 7.19-7.26 
(3H,m)
7.19-7.26 
(3H,m)
7.64-7.66 
(1H,d)
7.35-7.39 
(3H,m)
7.18-7.25 
(3H,m)
7.58-7.62 
(1H,d)
He “ “ 7.43-7.46 
(1H,t)
“ “ 7.40-7.43 
(1H,t)
Hf “ “ 7.99-8.01 
(1H,d)
“ “ 7.98-8.00 
(1H,d)
Hg 7.34 (1H,s) 7.51-7.54 
(3H,m)
8.18 (1H,s) 7.51-7.54 
(3H,m)
7.34 (1H,s) 8.14 (1H,s)
Hh 6.95-6.96 
(1H,dd)
7.00-7.01 
(1H,dd)
7.00 (1H,s) 6.98-6.99 
(1H,dd)
6.97-6.98 
(1H,dd)
6.95-6.96 
(1H,dd)
Hi 8.21-8.22 
(1H,d)
8.23-8.24 
(1H,d)
8.25-8.26 
(1H,d)
8.22-8.23 
(1H,d)
8.22-8.23 
(1H,d)
8.21-8.22 
(1H,d)
Hj 8.31 (1H,d) 8.30 (1H,d) 8.33 (1H,d) 8.29 (1H,d) 8.31 (1H,d) 8.31 (1H,d)
Hk - - - - - -
Hl 7.94-7.96 
(2H,d)
7.94-7.95 
(2H,d)
7.94-7.95 
(2H,d)
7.94-7.95 
(2H,d)
7.94-7.96 
(2H,d)
7.94-7.95 
(2H,d)
Hm 7.51-7.54 
(2H,d of d)
7.51-7.55 
(3H,m)
7.51-7.54 
(2H,d of d)
7.51-7.54 
(3H,m)
7.51-7.54 
(2H,d of d)
7.51-7.54 
(2H,d of d)
Hn 7.59-7.62 
(1H,t)
7.59-7.62 
(1H,t)
7.58-7.60 
(1H,t)
7.59-7.62 
(1H,t)
7.59-7.62 
(1H,t)
7.58-7.62 
(1H,t)
* Chemical shift and integral of benzylic protons could not be determined accurately due to interfer-
ence with solvent signal.
Table 5: 1H-NMR-spectra of TAK-715 and major CPs formed by BM3.
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C17H15N2OS
+) and F279-H2 (m/z 277.079, C17H13N2S+). From the low-abundance fragments 
F264-H2 (m/z 262.055, C16H10N2S+, –6 ppm) and F224-H2 (m/z 222.036, C14H8NS+, –8 ppm) 
in the MS2 spectrum of CP398B, it may be concluded that CP398B most likely results 
from the formation of six-member aromatic ring by bond formation between carbon-9 and 
carbon-20.
Although the profile-group approach is less useful for the structure elucidation of TAK-
715 CPs than for the other substrates, it still solved cases like CP398B. The possibility 
to be able to propose a structure for the substrate isomer CP400 is a rare case of luck. 
Intriguingly, the same rearrangement as observed in solution during Light incubations is, 
in the gas phase, key to explaining the fragment F297 of TAK-715. The interpretation of 
the fragmentation of the TAK-715 CPs included a warning that gas phase chemistry can 
be very different from solution phase chemistry. Though water loss in solution proceeds 
via proton rearrangement and therefore requires an α–proton, this does not seem to be 
necessary in the gas phase. In the water loss from the hydroxylated aromatic methyl group 
(carbon-14), a hydride rearrangement seems to be equally capable of restoring the charge 
neutrality. The need for an E1 mechanism due to the absence of a base in the gas phase 
and the extraordinary stability of water might level the playing field between proton and 
hydride rearrangement. The extended conjugated system might additionally enable the 
hydride rearrangement in the case of TAK-715 CPs.
Occurrence of homolytic cleavages
To a large extent, the data comply to the general finding that fragmentation of even-electron 
ions predominantly leads to even-electron fragment ions, which is described as the parity 
or even-electron rule [18,29]. However, (unusual) homolytic cleavages of even-electron 
ions are observed for SB203580, BIRB796 and TAK-715 as well as for several of their 
CPs. For SB203580, homolytic cleavage occurs exclusively in C-S bonds, as is common 
in methylsulfinyl or methylsulfonyl analogues  [29,30]. The fragment ABC+• of BIRB796 is 
stabilized by the formation of a semi-quinone structure, but notably is only observed with 
the double-charge precursor ion. The second homolytic cleavage from ABC+• to AB+• is 
then probably catalyzed by the existing radical. The methyl radical loss in TAK-715 from 
F279 to F264 and from F224 to F209 is more surprising. It might be speculated that this is 
again related to the sulfur in the aromatic system. The only expected homolytic cleavage 
in the CPs is the hydroxyl radical loss from the N-oxide CP394D. Although, it is clear 
that in DMPIP dehydrogenation induces homolytic cleavage, the uncertainty in locating the 
modification prevents an explanation. Amongst the TAK-715 CPs, we observe a homolytic 
cleavage of the hydroxylated ethyl group in CP432A. Interestingly, the hydroxylation of 
the methyl group does not promote its homolytic cleavage. On the contrary, CP416A still 
losses a methyl radical only after eliminating the additional hydroxyl group via dehydration 
and hydride rearrangement. Surprisingly, CP416B shows the loss of the hydroxylated ethyl 
group by heterolytic cleavage indicating that the methyl hydroxylation is also involved in 
mediating the homolytic cleavage of CP432A. 
Conclusion
This paper reports the structure elucidation of a wide variety of related substances of 
four kinase inhibitors, generated in different ways. Comparison between these compound 
conversion tools and the effect of conversion on bioactivity is reported elsewhere [15]. This 
discussion may serve as an example to demonstrate the power of MSn in combination with 
HRMS in structure elucidation of related substances, but can evenly well be used, if one 
wants, to highlight the limitations of such strategy. Although the profile-group approach [16, 
17] was applied as much as possible, each substrate required some adaptations in the 
elucidation strategy. Especially, the frequently observed deviations in the fragmentation 
behavior of the CPs compared to the parent compound lead to challenges in interpretation. 
In this respect, we may highlight the competition between H2C=O and SO2CH3 losses in 
CPs of SB203580, the competition between CH3
• and OH• loss from an N-oxide CP394D 
of SB203580, the hydride rearrangement in the water loss from a hydroxylated aromatic 
methyl group (carbon-14) in TAK-715, the influence of the presence of the morpholino 
group on double-charge ion generation in BIRB796, and the intermolecular rearrangement 
of the fluorobenzyl group in DMPIP. It sometimes turned out to be essential to know the 
parent daughter relationship between the fragments which was achieved by using an ion 
trap instead of a quadrupole for fragmentation. The best example is found in CP410C 
where SO2CH3
• (S-oxidation) was observed as neutral loss instead of OH• and SOCH2 
(unmodified sulfoxide). While known for a methylsulfinyl moiety in SB203580, the 
occurrence of (unusual) homolytic cleavages and radical losses in the fragmentation 
of the other compound classes is of interest. As such, this study does not only lead to 
structure elucidation of the related substances found, but also extend our understanding of 
fragmentation of protonated molecules in MSn.
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Supporting Information
Section	1:	Overview	chromatographic	conditions
Next to the Xbridge C18 column 100×2.1 mm with 3.5 µm particles (Waters, Milford, MA, 
USA), a Symmetry column (same dimensions and manufacturer) was used. The former 
was employed in the measurements of samples from EC, BM3 and HLM (TAK-715 only) 
experiments, while the latter was used for samples from H2O2, Light and HLM (DMPIP, 
SB203580 and BIRB796) experiments. Additionally, the gradients differ, mainly because 
they originate from several independent studies, and because separation on the generic 
gradient was generally not sufficient for the analysis of most samples. Flow rate and tem-
perature were the same in all cases. 
Table S1: Binary gradients.
Time %B Time %B Time %B Time %B Time %B Time %B
0 20 0 40 0 20 0 20 0 20 0 20
2 20 2 40 2 20 2 20 2 20 2 20
18 90 45 90 10 90 8 50 20 50 20 50
22 90 52 90 13 90 10 50 21 50 21 50
23 20 53 40 14 20 26 90 26 90 26 90
30 20 60 40 20 20 28 90 33 90 33 90
29 20 34 20 34 20
35 20 40 20 40 20
Used 
for:
EC, BM3 
(DMPIP)  
and HLM 
(DMPIP, 
SB203580, 
BIRB796)
BM3  
(TAK-715) and 
HLM (TAK-
715)
H2O2 (DMPIP) Light (DMPIP, 
SB203580)
H2O2 
(SB203580)
Light  
(TAK-715)
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(b)
The fragmentation of CP305 (m/z 305.077, C15H14FN2O2S
+) is explained starting from 
structure proposal B. MS2 results in major fragments with m/z 290.052 (C14H11FN2O2S+•), 
consistent with CH3
• loss, and m/z 184.044 (C8H10NO2S
+), consistent with an amide group 
at the (methylsulfinyl)benzene. MS3 on the ion with m/z 184.044 results in losses of NH3 
and HN=C=O, that is ions with m/z 167 and 141, respectively, and in loss of CH3
• to an 
ion with m/z 169.021 (C7H7NO2S
+•). MS3 on the ion with m/z 290.052 surprisingly results 
in fragments with m/z 140 and 123, consistent with protonated fluorobenzamide and the 
acylium ion due to the consecutive loss of NH3, as well as the ion with m/z 169.021 (loss 
of CH3•). The observation of two (protonated) amides, m/z 184 and m/z 140, favors the 
structure proposal B as there is no other way to link an oxygen to both carbon-3 and -5. 
However, this might also be created from A in the gas phase via an intramolecular nucle-
ophilic attack of an oxygen lone pair on the imine carbon.
Section 4: Structure proposal for TAK-715 isomer and fragmentation 
intermediate
Figure S2: Isomer of TAK-715 observed with Light and proposed as intermediate for TAK-715 CID 
fragmentation
Section 2: Additional information on BIRB796 MS3 fragmentation
Table S2: Further MS3 fragmentation of the various fragment ions of BIRB796.
Precursor in MS3 Fragment ions in MS3 Identification/Comments
m/z 414 (ABC+•) m/z 256.144 
m/z 230.165 & 229.157 
m/z 174.102
AB+CO
AB & AB+•
A
m/z 299 (CD+CO) m/z 212.069 
m/z 114.093
Loss of C4H9NO 
D
m/z 273 (CD) m/z 186.091 
m/z 100.077
Loss of C4H9NO 
C5H10NO
+ (part of D)
m/z 256 (AB+CO) m/z 200.081 
m/z 173.072
m/z 157.076 
m/z 133.076
A+CO (Loss of B)
A+CO – HCN
A+CO – HNCO
C8H9N2
+
m/z 230 (AB) m/z 174.103
m/z 147.093
m/z 133.076
A (Loss of B)
A – HCN
C8H9N2
+
m/z 229 (AB+•) m/z 214.132 
m/z 172.087 
m/z 145.076
Loss of CH3
•
Loss of B•
m/z 172 – HCN
m/z 200 (A+CO) m/z 173.071
m/z 157.076
m/z 147.092
m/z 133.076
Loss of HCN
Loss of HNCO
C9H11N2
+
C8H9N2
+
m/z 174 (A) m/z 157.076
m/z 147.091
m/z 133.076
m/z 120.082
Loss of NH3
C9H11N2
+
C8H9N2
+
C8H10N
+
Section 3: Details on the structure assignment of CP305
Figure S1: (a) Structure proposals for CP305 and (b) interpretation of its fragmentation.
(a)
Depicted are two structure proposals for CP305. A involves oxygenation of carbon-3, 
opening of the imidazole ring, and loss of methylpyridine. B has the same modifications 
but the atoms of the modified imidazole ring are rearranged. While A can be explained 
without any heavy atom rearrangements, B is more consistent with the fragmentation 
without gas-phase rearrangements in CID. Of both structures, a 5-ring analogue can be 
proposed in which the O-atom and the imine N-atom (A) or the two N-atoms are linked 
(B). However, the easy fragmentation makes the open variants more plausible.
H3C
S
N
H3C
N
O
NH2
+
For Sections 5 to 8 please refer to the supplementary material which is available on-line 
with the journal version and can be downloaded free-of-charge. 
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Abstract
Flow-through electrochemical conversion (EC) of drug-like molecules was hyphenated 
to miniaturized nuclear magnetic resonance spectroscopy (NMR) via on-line solid phase 
extraction (SPE). After EC of the prominent p38α mitogen-activated protein kinase inhib-
itor BIRB796 into its reactive products, the SPE step provided preconcentration of the 
EC products and solvent exchange for NMR analysis. The acquisition of NMR spectra 
of the mass limited samples was achieved in a stripline probe with a detection volume of 
150 nL offering superior mass sensitivity. This hyphenated EC–SPE–stripline-NMR setup 
enabled the detection of the reactive products using only minute amounts of substrate. 
Furthermore, the integration of conversion and detection into one flow setup counteracts 
incorrect assessments caused by the degradation of reactive products. However, apparent 
interferences of the NMR magnetic field with the EC, leading to a low product yield, so far 
demanded relatively long signal averaging. A critical assessment of what is and what is not 
(yet) possible with this approach is presented, for example in terms of structure elucidation 
and the estimation of concentrations. Additionally, promising routes for further improvement 
of EC–SPE–stripline-NMR are discussed. 
Introduction
Whereas hyphenation of electrochemical conversion (EC) and mass spectrometry (MS) 
has become an established technology, e.g., for studying drug metabolism to simulate 
cytochrome P450 biotransformation [1],  this is not true for hyphenation of EC and nuclear 
magnetic resonance spectroscopy (NMR). Although EC–NMR is not an entirely new idea 
[2,3], it has not been extensively studied. To some extent, this may be due to the mutual in-
fluence EC and NMR conditions may have, that is disturbance of the magnetic-field homo-
geneity in NMR and/or of the EC processes by induction of additional currents [4]. Despite 
this, EC–NMR has been applied frequently and successfully to the study of processes at 
electrode surfaces by solid-state NMR techniques [5]. However, in the context of pharma-
ceutical applications, such as studying of redox pairs in vitamins [6] or structure elucidation 
of electrochemical products of drug-like compounds, the liquid state and bulk view is more 
desirable. Since the 1970s, a few groups have designed in situ EC–NMR probes where EC 
is carried out directly in the field region of the NMR, either in static [4] or continuous-flow 
approaches [2]. This allows a direct look at the EC reaction, its products and intermediates 
without delay. This approach has several disadvantages and limitations, such as the need 
for a dedicated NMR probe, the need to use the same (inert deuterated) solvent in NMR 
and EC, and the possible overlap of analyte peaks with signals from additives like buffers 
and electrolytes. Recently, EC–NMR was reported for the analysis of EC products of ac-
etaminophen, using a conventional 60 µL NMR flow cell under steady state conditions [7]. 
Though high-quality spectra were achieved with commercially available equipment, the 
other disadvantages remain in effect. As demonstrated in hyphenation of liquid chromatog-
raphy (LC) and NMR [8,9], some of these problems can be solved by the application of an 
on-line solid phase extraction (SPE) step to decouple EC and NMR.
With respect to the application of EC–NMR in the drug discovery process, where initially 
only a few mg of a compound is available, a number of different setups are available [10]. 
Given the small sample amounts, an amperometric setup with a thin-layer cell is to be 
preferred over a coulometric setup. In addition, a flow-through approach is advantageous 
for the detection of unstable/reactive products [10,11]. Obviously, limiting the amount of 
sample used results in high demands on the NMR sensitivity, which is a weak spot of NMR. 
To enhance NMR sensitivity, there is a strong trend towards capillary or chip-based NMR 
techniques. While higher sample concentrations are required in capillary NMR to achieve 
comparable performance in terms of spectrum quality, the total amount of sample neces-
sary can be reduced up to 100-fold [8]. In microfluidic NMR, the sensitivity is improved by 
decreasing the detection volume in order to achieve high concentrations for mass-limited 
samples, because the same number of molecules is more effectively measured in a smaller 
volume [12]. As EC–NMR is somewhat underdeveloped, the implementation of miniatur-
ization and cryo technology in EC–NMR probes has not yet been reported. A relatively new 
trend in chip-based NMR is the stripline geometry featuring a planar resonator, which is 
optimised on radio frequency (rf) homogeneity, sensitivity and spectral resolution [13]. Pre-
viously, the stripline-NMR chip has been successfully used to analyse low concentrations 
of metabolites in human cerebrospinal fluid [14]. Moreover, the microfluidic stripline chip 
is perfectly suited for in situ measurements, for instance in a flow of analyte directed from 
the SPE to the NMR. Therefore, we chose a stripline-NMR setup for the detection of the 
relatively low sample amount produced by our EC setup.
Though requiring low absolute amounts of sample, the stripline-NMR setup demands high 
analyte concentrations. To this end, the intermediate SPE step enables significant sample 
preconcentration next to providing a favourable solvent exchange. The complete integra-
tion into one flow system in the EC–SPE–stripline-NMR platform greatly contributes to 
limiting the time elapsing between generation and analysis, thus preventing degradation. 
In order to achieve a more realistic assessment of the current state of this EC–SPE–
stripline-NMR technology, we studied EC reactions of the p38α mitogen-activated protein 
kinase (p38α) inhibitors BIRB796 and SB203580, which are highly relevant in contempo-
rary drug discovery [15,16]. BIRB796 is currently studied in clinical phase III for the treat-
ment of rheumatoid arthritis and Crohn’s disease [15]. The EC production of reactive or 
unstable conversion products of BIRB796 has been reported [11]. 
Figure 1: BIRB796 and its initial EC products. Electrochemical O-dealkylation at oxygen 9 results in 
the three major products shown. If not measured directly (on-line), these products undergo degrada-
tion reactions [11].
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Materials and Methods
Chemicals
Acetonitrile (ACN, LC-MS grade) and formic acid (ULC-MS grade) were delivered by Bio-
solve (Valkenswaard, The Netherlands). Water was purified by a Milli-Q academic from Mil-
lipore (Amsterdam, The Netherlands). BIRB796 (N-[3-(tert-butyl)-1-(4-methylphenyl)-1H-
pyrazol-5-yl]-N’-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-urea) (structure in Figure 1) 
and SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine) 
were obtained from various sources. All other chemicals were obtained from Sigma-Aldrich 
(Schnelldorf, Germany).
Electrochemical conversion
EC was achieved in a ROXY EC system (Antec, Zoeterwoude, The Netherlands) consist-
ing of a µ-PrepCell and a ROXY potentiostat. The µ-PrepCell consists of a three electrode 
setup with a glassy carbon working electrode, a titanium counter electrode and a HyREF™ 
(Pd/H2) reference electrode. A spacer thickness of 150 µm was employed resulting in a 
volume of 12 µL in the cell. The EC reaction mixture was supplied by a syringe pump at 
a flow of 5 µL/min, converted at the working electrode at a direct current voltage of 0.7 V, 
and directed to the SPE. The mixture consisted of 10% aqueous ACN containing 370 µM 
ammonium formate / 630 µM formic acid (pH 3.5) and 200 µM BIRB796.
The EC of BIRB796 was monitored at 254 nm at four different flow rates of 5, 10, 20 and 
40 µL/min by LC–UV (LC-20 system, Shimadzu, ‘s Hertogenbosch, the Netherlands) and 
analysed using a calibration curve of the standard (0–400 µM). The gradient, solvents and 
stationary phase used were the same as published earlier [11].
On-line Solid Phase Extraction
A SecurityGuard 4 × 2.0 mm C18 cartridge (Phenomenex, Utrecht, The Netherlands) was 
used. All steps were executed at room temperature at a flow rate of 5 µL/min. The trapping 
of the standards from the EC reaction mixture was done for 30 min, but the product mixture 
of BIRB796 was trapped for 60 min in order to achieve comparable concentrations for the 
competing quinoneimine and hydroquinone (See Figure 1). After a wash step with 99% 
D2O and 1% ACN-d3 for 10 min, the analytes were eluted with DMSO-d6 for 11 min. Finally, 
the wash step was repeated for re-equilibration. Additionally, a 200 µM 10% aqueous ACN 
solution of SB203580 containing 2% DMSO (due to solubility issues with SB203580) and 
1 mM ammonium bicarbonate (titrated to pH 10 with sodium hydroxide) was trapped and 
eluted, but not converted, using the same protocol.
Stripline chip, probe and microfluidics
The stripline structured rf coil consists of a stack of glass or fused silica substrates with 
etched microfluidic channels (see Figure S1 of the electronic supplementary material, ESM) 
[14]. The copper structures, two ground planes and the rf coil resonator, are sputtered and 
electroplated. A constriction in the middle of the rf detector locally enhances the current 
density, which results in a high rf field at the position of detection. The rf field is concentrated 
and rf homogeneity is enhanced by the two copper ground planes above and below the 
stripline. The layers are assembled and merged together with a bounding process so that 
they are leakage-free and stable. In the fused silica substrates, two microfluidic channels 
are etched, with a volume of 150 nl each, which may contain the sample; only one channels 
is used here. Fused silica capillaries (75 µm ID, 150 µm OD, ~15 cm long, Polymicro 
Technologies, Phoenix, AZ, USA) are glued into the top and bottom of the chip into the 
microfluidic channels to function as inlet and outlet. Via nanotight PEEK unions (P-779, 
Upchurch Scientific, Oak Harbor, WA, USA), both fused silica capillaries were connected 
to larger capillaries (150 µm ID, 360 µm OD at the inlet side and 250 µm ID, 360 µm OD 
at the outlet side) at the base of the magnet in order to protect the μ-PrepCell by avoiding 
a pressure buildup in the system higher than 10 bar. The inlet capillary was connected to 
the six-port switching valve (made in house) following the SPE unit. At the end of the outlet 
capillary, a shut-off valve (P-732, Upchurch Scientific) was used to prevent the sample 
from leaking out of the measurement area during measurements lasting longer than one 
hour. The homebuilt probe consists of an aluminum cylinder, the top of which is divided into 
halves in which the chip and the electronics circuit are placed [14]. 
Acquisition and processing
The stripline-NMR measurements were performed at room temperature in a VNMRS 
600MHz Varian NMR spectrometer, operated with VNMRJ software (Agilent, St. Clara, CA, 
USA). The 90° pulse length was 1.95 µs at 10 W power. At the start of the experiments, the 
shiming of the stripline-NMR probe was once performed on a 70% ethanol solution. Then, 
the chip was thoroughly flushed with solvent. With the sample solution in the probe, the 
shims were only slightly adjusted. Tuning and matching was performed on the sample in 
the probe.
The elution monitoring experiments by SPE–stripline-NMR (see Figure 3) were carried 
out by averaging 4 scans for one data point every 15 s. All other NMR experiments were 
performed in stopped-flow mode. The 3 mM BIRB796 standard spectrum (Figure 4B) was 
measured in 256 scans with a relaxation delay of 1 s; the acquisition took 9 min. The SPE–
stripline-NMR spectrum (Figure 4C) was measured by accumulating 1024 scans, taking 51 
min. The EC–SPE–stripline-NMR sample (Figure 4D) was measured in an array of 25 times 
256 scans with a relaxation delay of 2 s. The scans were summed afterwards. The complete 
experiment took 12 hr and 25 min. A total correlated spectroscopy (TOCSY) spectrum 
(Figure 5) was measured acquiring 128 t1 increments of 16 scans with a relaxation time 
of 2 s. A mixing time of 50 ms with MLEV-17 spinlock was used [17]. The experiment took 
approximately 2 hr and 45 min. A correlation spectroscopy (COSY) spectrum (Figure S2 in 
the ESM) was measured using 256 t1 increments of 256 scans on the SPE trapped sample 
[18]. The experiment took 45 hr. 
The 1 mM standard of BIRB796 depicted in Figure 4A was measured accumulating 
Figure 2: EC–SPE–stripline-NMR setup. The void volume of all connecting capillaries is specified.
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618 scans with a relaxation delay of 1 s. The product mixture shown in Figure 6B and 6C, 
before and after storage at room temperature, was measured with a relaxation delay of 
2.3 s using 130 and 160 scans, respectively. The COSY of the product mixture (data not 
shown) is measured obtaining 256 t1 increments of 8 scans with a relaxation delay of 2 s. 
More details on the off-line EC experiments measured by conventional NMR can be found 
in Section 3 of the ESM.
Data processing was done with MatNMR [19]. A zero filling up to 32000 points and a line 
broadening of 1 Hz were used for noise reduction. An asymmetric least squares function 
was employed for baseline correction [20]. For peak-picking a Lorentzian to Gaussian 
resolution enhancement (exp -0.7, Gauss -1.5 Hz) was applied. The 2D spectra were 
plotted using MatNMR and ACD/NMR Processor (Advanced Chemistry Development Inc, 
Toronto, ON, Canada). 
EC–SPE–stripline-NMR setup
A schematic diagram of the setup is given in Figure 2. The three syringe pumps (Model 
11 Plus Advanced, Harvard Apparatus, Holliston, MA, US), which were placed at ca. 1 m 
distance to the magnet, were linked to a four-way connector (VICI, Schenkon, Switzerland) 
and delivered in turn the EC reaction mixture, the wash solution and DMSO-d6. The EC 
reaction mixture passed the µ-PrepCell before arriving at the connector. The liquid from the 
four-way connector was guided to the SPE cartridge, which was connected to a six-port 
switching valve. During the trapping and half of the wash step, the SPE effluent was direct-
ed to waste in order to prevent contamination of the NMR probe with buffer salts and pro-
tonated solvents. When the wash step was halfway finished, the valve was switched and 
the wash solvent cleared the probe of analyte from the previous measurement. Afterwards, 
the new sample was eluted from the SPE cartridge with DMSO-d6 into the stripline-NMR 
probe. When the elution was complete, the valve was switched again and both the re-equil-
ibration and the trapping step could be performed during sample measurement. Because 
the correct timing of the elution is essential and the void volume negatively correlates with 
repeatability, all connection volumes have been optimized (see Figure 2), within the limits 
of the above mentioned pressure restrictions. The comparably large void volumes V1 and 
V2 are necessary for bubble-free filling of the µ-PrepCell.
Results and Discussion
The initial step in the EC–SPE–stripline-NMR setup was the EC of the substrate at a 
thin-layer electrode in the flow-through setup. Simultaneously, the products and residual 
substrate were trapped on the on-line SPE cartridge. After conversion/trapping, buffer salts 
and protonated solvents were washed away. Finally, substrate and products were eluted 
with DMSO-d6 into the stripline-NMR probe. There, 
1H NMR as well as COSY and TOCSY 
spectra were recorded with excellent mass sensitivity.
Optimization of EC and SPE steps
The EC conditions were transferred from a method published earlier [11] which used the 
same EC setup but with a ReactorCell instead of the µ-PrepCell. It was expected that a 
higher concentration of substrate could be converted with the µ-PrepCell. Indeed, instead 
of the low to medium conversion at 10 µM with the ReactorCell [11], ~90% consumption 
of BIRB796 was observed at 200 µM and 5 µL/min with the µ-PrepCell as assessed by 
LC–UV. The manufacturer indicates the optimal flow rate of the μ-PrepCell to be between 
20 and 50 µL/min. As a decrease in product consumption to ca. 50, 30 and 5% was ob-
served for 10, 20 and 40 µL/min, respectively, the original flow rate of 5 µL/min used in the 
ReactorCell was considered optimal. 
Trapping of the 200 µM standard of BIRB796 was possible for ca. 60 min. If trapping was 
continued after this period, breakthrough was observed. That indeed breakthrough was the 
cause of the detected analyte signal and not overloading of the stationary phase can be 
rationalized by comparing the trapped analyte weight of 32 µg with the estimated cartridge 
loading capacity of ~1 mg.
SPE–stripline-NMR
This paragraph deals with the optimization of the flow system and especially the hyphen-
ation of the SPE and the stripline-NMR step. Although the experiments were carried out in 
the complete EC–SPE–stripline-NMR setup, EC was not yet applied. Contrary to off-line 
SPE, where the sample is obtained as a homogeneous solution in a predefined volume, the 
elution of the analytes in on-line SPE is comparable to an LC experiment without retention. 
Therefore, the determination of the void time equivalent to the elution time of the analytes 
is critical to the success of the stopped-flow stripline-NMR measurements. With the void 
time known, the flow can be stopped when the top of the elution peak is in the stripline-
NMR channel. Obviously, an accurate and repeatable elution is one major determinant of 
the sensitivity of the system. The 1H signals of the tert-butyl group of BIRB796 and of the 
methyl group of SB203580 allowed us to follow the elution of both compounds by stripline-
NMR in the final EC–SPE–stripline-NMR setup, albeit with the voltage switched off. The 
reconstructed SPE–stripline-NMR chromatograms and their Gaussian fits are shown in 
Figure 3. The effective elution time, including the time to reach the stripline chip, was 
around 11 min for both compounds, its difference of 0.7 min being lower than the accuracy 
of the Gaussian fits (≤0.9 min). The elution time is expected to be the same for all com-
pounds not showing significant retention under these strong eluting conditions. This makes 
the SPE step widely applicable to compounds with medium to low polarity. The full width 
at half maximum (FWHM) for BIRB796 and SB203580 is 2.2 min or 11 µL and 1.4 min or 
7 µL, respectively. The resulting concentration factor at half height should therefore be 
around 15 to 20 fold. On the one hand, this results in a rather inefficient use of the sample, 
considering that the detection volume is only 150 nL. To some extent, this is due to the low 
flow rate applied, in combination with the large void volume which results from the use of a 
2 mm I.D. SPE cartridge, a conventional six-way switching valve, and the long transfer tub-
ing allowing the necessary distance between the SPE setup and the stripline-NMR probe. 
On the other hand, it reduces the strain on the repeatability of the elution, because even a 
Figure 3: Reconstructed SPE–stripline-NMR chromatograms. Elution of BIRB796 (dots) and 
SB203580 (boxes) from the SPE was monitored in real time by stripline-NMR using 1H signals from a 
tert-butyl and a methyl group, respectively. The calculated elution time served as basis for the align-
ment of analyte peak and measurement area.
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deviation of ~1 min leads to only 50% signal reduction, and on the sensitivity of the NMR 
experiment used to follow it, because multiple NMR spectra can be added to create one 
data point while following the elution. Both advantages are not to be underestimated when 
using such a highly experimental setup. However, the experimental data suggests that the 
signal would be strong enough to follow the elution using single scans instead of the four 
scans used per data point in these experiments. This would allow increasing the data point 
frequency from 0.07 to 0.33 Hz, thus enabling the detection of peaks with FWHM ≥12 s (7 
data points above 10% signal). Thus, the elution volume at half height could in principle be 
reduced to 1 mL which would result in a ca. 10-fold gain in analyte concentration or equal 
reduction in substrate consumption through improvement of the SPE dimensions. At the 
moment, the substrate consumption of the EC–SPE–stripline-NMR is six times less than 
in the conventional NMR. When considering that only one or two percent of the sample 
was actually measured in the EC–SPE–stripline-NMR, this difference theoretically rises to 
approximately 300-fold.
In order to assess whether the SPE step has an influence on the stripline-NMR, we first 
measured a 3 mM standard of BIRB796 by direct infusion into the stripline-NMR probe. The 
results were compared to a 30 min trapping and elution of a 200 mM standard. The aromatic 
region of the BIRB796 spectra obtained under different experimental conditions is present-
ed in Figure 4 whereas the corresponding chemical shifts and J-couplings are summarized 
in Table S1 of the ESM. All C-H signals are found at the same chemical shifts in both mea-
surements; the maximum deviation is about 0.05 ppm for proton 35. Similar differences are 
observed between conventional spectra in either DMSO-d6 or ACN-d3 which indicate that 
most likely small differences in residual ACN concentration cause these effects. Additional-
ly, the chemical shifts of BIRB796 measured by conventional NMR in DMSO-d6 do not devi-
ate by more than 0.05 ppm from the stripline-NMR measurements in the same solvent (see 
Figure 4 and Table S1 of the ESM), except for protons 12, 16 and 17 whose peaks change 
positions in the spectra between Figure 4A and Figure 4D. This allows comparison to off-
line EC samples measured with conventional NMR. The exchangeable protons attached to 
the urea nitrogen atoms (N20 and N23) are no longer observed in the sample measured by 
SPE–stripline-NMR which indicates a very efficient exchange with deuterons. By compar-
ing the average signal-to-noise ratios (S/N) of several peaks in the stripline-NMR and in the 
Figure 4: NMR spectra of the aromatic region of BIRB796. For the numbering, please refer to Fig-
ure 1. Spectra measured A) in conventional NMR (1mM, 618 scans), B) in the stripline-NMR setup 
(3 mM, 256 scans), C) in the SPE–stripline-NMR setup (200 µM, 1024 scans), and D) in the full 
EC–SPE–stripline-NMR setup (product mixture generated from 200 µM, 25x256 scans). The spectra 
displayed are limited to the aromatic region for better visibility. The chemical shifts and J-couplings 
are described in Table S1 of the ESM. The product mixture (D) is further described in the next section 
and Table S2 of the ESM. Figure 5: TOCSY spectrum of BIRB796 standard in the stripline-NMR
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SPE–stripline-NMR spectrum, a concentration of 2.4 mM (12-fold) could be estimated for 
the SPE–stripline-NMR experiment which fits well to the previously calculated 15–20-fold 
concentration at half-height. 
Furthermore, we recorded a COSY spectrum of BIRB796 by SPE–stripline-NMR. All ex-
pected coupling peaks were observed (see Figure S2 in the ESM) in effectively measuring 
as little as 360 pmol of sample. Unfortunately, an extensive measurement time (45 hr) 
proved necessary, as an attempt at recording a shorter COSY spectrum on the 3 mM 
standard was not successful. In the stripline-NMR experiment, relatively broad lines are 
found to which the long measurement time without lock might contribute. For a COSY, the 
diagonal peaks are in-phase whereas the cross-peaks have an anti-phase character, which 
may lead to vanishing signals in the case of broad peaks. This is in contrast to a TOCSY 
experiment, in which all peaks show in-phase absorptive lineshapes. It makes the TOCSY 
a more suitable experiment in our case. Therefore, we tried a TOCSY experiment on the 
standard, which took only 2 hr and 45 min and provided a much clearer correlation. As can 
be seen in Figure 5 and Figure S2 (see ESM), the same 3J-couplings between protons 11 
and 12, 15 and 16, and 17 and 18 are observed in the COSY and in the TOCSY spectrum.
EC–SPE–stripline-NMR
After an initial validation of the SPE–stripline-NMR part of the integrated platform, the next 
step was the measurement and structural analysis of the EC products of BIRB796. For 
assessment of the possibilities and limitations of the platform as well as for validation of the 
structural analysis, the on-line spectra are compared to reference spectra obtained off-line 
by collection, evaporation and reconstitution with a conventional NMR probe. There is a 
significant difference in the overall time consumption of the experiments which stresses the 
advantage of the EC–SPE–stripline-NMR over the conventional approach for the detection 
of reactive products and is shared by the larger scale flow approach [7]. The preparation 
for the conventional NMR measurements often took more than a regular working day (see 
ESM Section 3), meaning that for between 8 and 24 hr the sample was subjected to deg-
radation and for at least 7 hr at room temperature. In the EC–SPE–stripline-NMR, the time 
delay between generation and analysis was ca. 80 min. Though the NMR measurement it-
self was significantly longer, the products are far less likely to degrade in the elution solvent 
than in the reaction solvent, for example by acid-catalysis hydrolysis or dehydration [11]. 
Figure 6A shows that degradation is not observed in the EC–SPE–stripline-NMR setup.
For BIRB796, three main products are expected from EC–MS experiments [11]. The EC 
reaction is an oxidative O-dealkylation at the ether function. It produces 2-morpholinoetha-
nol, a quinoneimine and a hydroquinone structure (Figure 1). 2-morpholinoethanol was not 
observed in the EC–SPE–stripline-NMR spectrum, probably because it is too polar to be 
trapped by reversed-phase SPE. In the EC–SPE–stripline-NMR measurement, mainly the 
substrate and weak signals of the two other products are found, indicating low conversion 
efficiency in the EC–SPE–stripline-NMR, which conflicts with the high conversion rate mea-
sured by LC–UV. This might be due to interference of the magnetic field with the electrical 
currents of the EC. Unfortunately, the low conversion significantly hinders the routine appli-
cation of the current setup for the structure elucidation of the products. Some improvement 
in the product S/N, either by increased EC conversion, by an improved SPE method or by 
improved stripline-NMR sensitivity, is still needed before the EC–SPE–stripline-NMR can 
be used for product structure elucidation independently.
However, if the structure of the products is elucidated with the off-line EC experiments mea-
sured by conventional NMR, the fingerprint can be used to identify the products present 
in the EC–SPE–stripline-NMR spectrum (see Table S2 in the ESM). Figure 6B shows the 
peak assignments in the aromatic region after off-line EC. These assignments were sup-
ported by a COSY spectrum (data not shown) and analysis of the J-couplings of these sam-
ples. Some peaks overlap with peaks from solvent constituents in the EC reaction mixture 
which complicates a clear assignment. Next to the substrate, BIRB796, the hydroquinone 
and quinoneimine conversion products are observed. The peaks for 2-morpholinoethanol 
cannot be assigned with confidence, because the aliphatic region shows a lot of interfer-
ences and only minor differences with the parent chemical shifts are expected. Having the 
fingerprint of the hydroquinone and the quinoneimine from the off-line experiment enables 
us to identify some of their peaks in the EC–SPE–stripline-NMR spectrum and thereby con-
firm their presence. This is shown in Figure 6A which is a zoom of Figure 4D. Comparison 
of the data in Figure 6B and 6C shows that the peaks of the reactive/instable quinoneimine 
disappear after storage as is expected from earlier studies [11]. 
Conclusions and Perspectives
This study revealed the potential of the hyphenation of EC and miniaturized NMR in the 
proposed way. The EC–SPE–stripline-NMR platform allowed the acquisition of 1H NMR 
and COSY as well as TOCSY proton-proton correlation spectra at substrate concentrations 
compatible with a high conversion rate in EC. The spectral resolution and S/N is not as 
high as in the off-line experiments, but the differences are subtle considering that for the 
EC–SPE–stripline-NMR experiments six times less substrate was consumed. Employing a 
test compound which shows simpler NMR spectra, more pronounced spectral differences 
Figure 6: Aromatic region of the product mixture. A) The sample measured by EC–SPE–stripline-
NMR is magnified to reveal small product peaks. B) The sample is measure off-line by conventional 
NMR directly after re-dissolving and C) again the next day after storage at room temperature to show 
the stability of the different products. The substrate peaks are marked with ‘s’, the hydroquinone 
marked with ‘h’ and the quinoneimine with ‘q’. The quinoneimine is less stable than the hydroquinone 
[11]. After storage, the quinoneimine is not detected any more. This can be used additionally to dis-
tinguish the two products. An overview of the NMR signals of the two products in a numerical format 
can be found in Table S2 in the ESM.
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between substrate and product, and a higher conversion rate in EC might have lead to 
even higher quality NMR data, but consequently might have overestimated the usefulness 
of this technology at its current state of development in a drug discovery/development 
setting. The fact that every step of this hyphenated technology as well as the hyphenation 
itself can be improved significantly, either with existing technology or with easily imaginable 
technological improvements, promises this technology a future place in the analytical tool-
box. Even despite these possibilities, the integration and miniaturization already allows the 
use of 10-fold lower substrate concentrations at comparable sample volumes than recently 
published combinations of EC with conventional flow probe NMR [7]. Additionally, both 
flow-based approaches limit the time delay between product generation and analysis, thus 
counteracting interferences by degradation.
Possible improvements of the EC–SPE–stripline-NMR platform can be readily indicated. 
The relatively new stripline-NMR technology still awaits integration of recent improvements 
in NMR systems. For example, the addition of a deuterium lock channel would allow lon-
ger measurement times without compromising the resolution, thus improving sensitivity. 
However, interestingly, the maximum measurement time of 12.5 hr (12800 scans) for a 1H 
NMR spectrum, applied in this study, did not result in increased line width for the 9H peak 
compared with the 512 scan or even the single scan spectrum of the same EC–SPE–
stripline-NMR sample. Measurements of a 3 mM BIRB796 standard gave a line broadening 
of 0.2 Hz from single scan up to 256 scans. At longer measurement times, double lines are 
observed in some rare cases which may be prevented by use of a lock channel. A further 
advancement could be achieved by integration of cryotechnology, which has led to an up 
to 6-fold increase in sensitivity in other miniaturized probes [21]. This might fill an existing 
gap in quantitative integration which requires an S/N of 150 in order to achieve less than 
1% error [22]. In the EC–SPE–stripline-NMR (12800 scans), the conversion mixture gave 
an S/N of 75 for the doublet of proton 18 of the substrate and of only 5 for the hydroqui-
none. Thus, the SPE–stripline-NMR combination is only a factor of two short of achieving 
sufficient quality 1D spectra from 300 µL sample material at 200 µM concentration. An ad-
ditional way to improve sensitivity is found in the stripline-NMR chip. The limit of detection 
(LOD), which is given by the number of spins in 1 Hz bandwidth that need to resonate to 
achieve an S/N of 1 in a single scan [13], is with 4•1013 [spins/sqrt(Hz)] a factor of three 
higher than the theoretical value. This discrepancy is mainly attributed to losses due to the 
use of glass as a chip substrate. Therefore, other chip substrates might improve the sen-
sitivity significantly. A fused silica chip is currently under development, and the first tests 
indicate that lower LOD, thus higher sensitivity, can be expected. Another contribution to 
higher sensitivity may come from an improved resolution of the chip, since the line width 
negatively correlates with S/N. We found an FWHM of around 3 Hz, although in a previous 
stripline-NMR chip we have found an FWHM of less than 1 Hz [23]. Thus, improvements 
in line width are also anticipated for the newly designed chip. Together with the change 
in chip substrate, this is expected to improve S/N by at least a factor of five. The main 
challenge in this study was the unexpectedly low conversion rate. If the conversion rate of 
60% (long collection, estimated) to 90% (short conversion, measured) of the off-line exper-
iments would have been achieved in the EC–SPE–stripline-NMR setup, the resulting 4 to 
6-fold sensitivity increase would be sufficient for acceptable product spectra. 
Furthermore, improved tuning of the elution volume of the on-line SPE step to the stripline-
NMR probe, bridging the 50-fold gap between measurement and elution volume, would al-
low increased sensitivity or decreased substrate consumption and trapping time as well. Al-
though a second alternative would be the use of commercially available 5 µL NMR probes, 
these do not promise additional mass sensitivity as reported concentrations and measure-
ment times are comparable to those reported for the stripline-NMR herein [24]. Therefore, 
it is likely more beneficial to bridge this gap by miniaturization of the on-line SPE step.
In conclusion, the proposed improvements provide ample opportunity to close the small 
sensitivity gap to achieve a productive hyphenation of EC to miniaturized NMR, provided 
the conversion rate in EC can be brought to the off-line level. 
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Supplementary Material
Figure S1: 400 µm stripline, showing the stripline structure (with cap and ground planes removed) 
on top of the probe.
Section 3: Off-line EC and conventional NMR experiments
BIRB796 was converted to the product mixture in 6 hr under the conditions described in 
‘Electrochemical conversion‘. After 2 and 4 hr, the EC cell was cleaned and refilled as ope-
ration for longer than two hours resulted in significant decrease of conversion efficiency. 
The product mixture was dried at 30°C under a nitrogen stream. The dried sample was then 
stored at –20°C overnight and reconstituted in DMSO-d6 directly prior to the NMR mea-
surements. These measurements were executed on an Advance 500 NMR spectrometer 
using a 5 mm CryoProbeTM (Bruker, Fallanden, Switzerland) at 500.23 MHz. 
Figure S2: COSY Spectrum of BIRB796 measured in the SPE–stripline-NMR setup
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Abstract
In this paper we describe the hyphenation of high temperature liquid chromatography with 
ICP-MS and ESI-MS for the characterization of halogen containing drug metabolites. The 
use of temperature gradients up to 200°C enabled the separation of metabolites with low 
organic modifier content. This specific property allowed the use of detection methods that 
suffer from (significant) changes in analyte response factors as a function of the organic 
modifier content such as ICP-MS. Metabolites of two kinase inhibitors (SB-203580-Iodo 
and MAPK inhibitor VIII) produced by bacterial cytochrome P450 BM3 mutants and hu-
man liver microsomes were identified based on high resolution MSn data. Quantification 
was done using their normalized and elemental specific response in the ICP-MS. The im-
portance of these kinds of quantification strategies is stressed by the observation that the 
difference of the position of one oxygen atom in a structure can greatly affect its response 
in ESI-MS and UV detection.
Introduction
In early drug discovery programs, so-called metabolic stability assessment of drug candi-
dates, it is important to predict the clearance of a drug by cytochrome P450 (and other) 
enzymes in the human liver. Early in vitro metabolic stability screening provides the me-
dicinal chemists with information on the sites in the lead structures where metabolism is 
likely to occur (the so-called metabolic soft spots) [1]. The identification and quantification 
of metabolites requires advanced analytical technologies and the development in this area 
is an ongoing process [2]. Recently, we introduced a platform for the simultaneous bio-
activity testing and identification of drug metabolites [3]. Depending on the properties of 
the drugs investigated and the bioassay applied, the platform may be adapted to include 
alternative separation and/or detection technologies. One of the limitations of an on-line 
bioassay is the compatibility with LC mobile-phase composition [4], especially with respect 
to the organic modifier content. High-temperature liquid chromatography (HTLC) has been 
demonstrated to enable compound separation at constant (low) organic modifier content. 
Teutenberg et al. described the fundamentals and practical issues of HTLC in detail [5,6], 
including the use of low organic modifier concentrations. The benefits of HTLC combined 
with on-line bioassays were readily demonstrated [7]. However, a constant organic modi-
fier content is beneficial in other instances as well. Several analyte detection strategies 
suffer from (significant) changes in analyte response factors as a function of the organic 
modifier content. This may lead to under- or over-estimated concentrations of drug metabo-
lites present in the sample. This is certainly true for attractive tools like evaporative light 
scattering detection (ELSD) [8,9], electrospray ionization mass spectrometry (ESI-MS) [10] 
and inductively coupled plasma-mass spectrometry (ICP-MS). In the latter case, a solvent 
gradient does not only influence the response factor but also the stability of the ICP plasma. 
HTLC–ICP-AES was recently reported for the analysis of food ingredients [11]. Smith et 
al. pioneered the integration of HTLC with ICP-MS [12] for the quantification of a glycine 
conjugate of bromobenzoic acid.
Since its development, ICP-MS is mainly used for quantitative trace element determina-
tion. The main application area of elemental speciation is found in environmental studies. 
In pharmaceutical applications, the use of ICP-MS started with the profiling of inorganic 
impurities and nowadays is expanding to bioanalysis as well, especially involving phar-
macokinetic studies of platinum based cytostatics [13,14]. More recently, ICP-MS has to 
a limited extent been applied in drug metabolism studies of drugs readily detectable by 
ICP-MS, especially drugs containing Cl and Br, as reviewed by Gammelgaard et al. [15]. 
Although fluorine is an even more occurring halogen in drug molecules, low-level detection 
of fluorine by ICP-MS is hampered by its relatively high ionization energy. The elemental 
specificity, the large linear range, and its ability to quantify with an species-unspecific el-
emental standard are features of ICP-MS that can be used complementary to e.g., ESI-
MS. Cuykens et al. reported the use of ICP-MS with isotope dilution for profiling a drug in 
development [16] as well as the use of ICP-MS for the detection of glutathione adducts of 
clozapine based on S and Cl [17]. Wilson et al. reported interesting work on metabolite de-
tection in biological fluids with ICP-MS [18–20]. In this paper, we describe the application of 
HTLC in the identification and quantification of drug metabolites based on ESI-HR-MS and 
ICP-MS. Oxidation products of two kinase inhibitors, SB-203580-Iodo and MAPK inhibitor 
VIII, were generated with human liver microsomes, bacterial cytochrome P450 BM3 mu-
tants and electrochemical oxidation.
Experimental
2.1. Materials
Human liver microsomes (HLM), pooled from 50 donors were obtained from Xenotech (Lot 
no. 0710619) and contained 20 mg mL−1 protein. Drug metabolising bacterial cytochrome 
P450 BM3 mutants M02 [21] and M11 V87A [22] were provided by Dr. J.N.M. Comman-
deur (section Molecular Toxicology, VU University Amsterdam). Acetonitrile (ACN), metha-
nol (MeOH) both LC-MS grade and formic acid (F) ULC-MS grade were obtained from 
Biosolve (Valkenswaard, the Netherlands). Purified water was produced by a Milli-Q device 
of Millipore (Amsterdam, The Netherlands). Applichem (Lokeren, Belgium) supplied be-
ta-nicotinamide adenine dinucleotide phosphate (NADPH) tetrasodium salt. Isoclozapine 
was obtained from Axon Medchem (Groningen, The Netherlands), Clothiapine from Enzo 
Life Sciences (Raamsdonkveer, the Netherlands) and loxapine from Sigma–Aldrich (Zwi-
jndrecht, the Netherlands). SB-203580-Iodo (SB-I) and p38 MAP kinase inhibitor VIII were 
obtained from Calbiochem (Amsterdam, the Netherlands). Monosodium dihydrogen phos-
phate, disodium monohydrogen phosphate, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, magnesium chloride, ammonium acetate and dimethylsulfoxide (DMSO) 
were purchased at Sigma-Aldrich (Schnelldorf, Germany). The structures of all analytes 
are provided in Supplementary Figure S1.
2.2. Methods
Metabolic incubations with the P450 BM3 mutants had a final volume of 500 µL and con-
sisted of 500 nM enzyme and 100 µM substrate in 100 mM potassium phosphate buffer pH 
7.4 and were performed at 24°C. Of the substrates, stock solutions were made of 10 mM 
in DMSO. The DMSO concentration in the metabolic incubations was always below 2%. 
An NADPH regenerating system was used to initiate the reactions, resulting in final con-
centrations of 0.2 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units mL−1 glucose-
6-phosphate dehydrogenase.
Metabolite generation with HLM was performed at 37 ◦C. The incubations had a final vol-
ume of 500 µLand consisted of 1 mg mL−1 protein and 100 µM substrate in 100 mM potas-
sium phosphate buffer pH 7.4 containing 5 mM MgCl2. At time points 0 min and 90 min, 250 
µLsamples were taken from the incubation and added to 250 µL of ice-cold ACN, vortexed 
for 30 s and centrifuged for 15 min at 6000 rpm. The supernatants were filtered through a 
Phenex RC syringe filter 0.2 µm from Phenomenex (Utrecht, the Netherlands).
Electrochemical oxidation of SB-I was done by infusing a 10 µM standard in 25% ACN, and 
1 mM ammonium acetate buffer with pH 5.0 through a Roxy reactor cell equipped with a 
glassy carbon electrode controlled by a Decade II module and Dialogue software (Antec 
Leyden, Zoeterwoude, the Netherlands). Products were formed at +1.5 V with a flow-rate 
of 10 µL min−1 and collected in an autosampler vial insert.
2.2.1. HTLC–ESI-MS
A Shimadzu LC Ion Trap–Time of Flight (IT-TOF) MS system (Shimadzu, ‘s Hertogenbosch, 
the Netherlands) was equipped with an HT-HPLC 200 oven from SIM GmbH (Oberhausen, 
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Germany). A Waters Acquity UPLC BEH C18 1.7 µm, 2.1×50 mm column was used for 
separation. The column was mounted inside the oven with an in house made aluminium 
holder for optimal heat transfer (see Figure 1 for schematic representation of the setup). A 
stainless steel frit (1 µm) fixed into a Valco union (DaVinci Europe, Rotterdam,The Nether-
lands) was used as an inline filter. The integrated solvent preheating area and post-column 
cooling unit consisted of 25 cm and 30 cm stainless steel tubing (internal diameter of 0.3 
mm). In all HTLC experiments, the solvent preheating area was set 5°C above the starting 
temperature of the gradient while the post column cooling unit was set at a fixed value of 
25°C.
The IT-TOF-MS was equipped with an electrospray source and operated in positive ion 
mode. The interface voltage was set at 4.5 kV while the source heating block and curved 
desolvation line (CDL) temperature were at 200°C. Drying gas pressure was set at 62 kPa 
and nebulising gas was applied. MS3 spectra were acquired in data dependent mode with 
the following settings: fullspectrum MS from m/z 200–650, MS2 and MS3 acquisition from
m/z 80–650 with ion accumulation of 10 ms and collision energy set at 50%. The first min-
ute of the chromatogram was diverted to waste.
A standard mixture of 100 µM isoclozapine, clothiapine and loxapine in 3% DMSO, 97% 
H2O was analysed in isocratic mode, with eluent composition of 95% H2O, 0.2% FA and 
5% ACN or 5% MeOH (solvent Aa and Am, respectively). If not stated otherwise, a flow-
rate of 300 µL min−1 was applied. With 5% ACN as eluent, the temperature gradient started 
with 0.5 min at 110°C followed by a linear increase up to 175°C in 6 min where it was kept 
constant for 2.5 min. With 5% MeOH as eluent, the temperature gradient
started with 0.5 min at 130 ◦C followed by a linear increase up to 175°C in 4 min where it 
was kept constant for 2.5 min. The system was ready for the next injection after 12.5 min. 
For reference chromatograms, the following solvent gradient was applied: 1 min isocratic 
at 5% B linear increase in 11.5 min to 75% B, back to 5% B in 0.5 min where kept constant 
for 3 min. Solvent Ba and Bm were ACN, 0.2% FA and MeOH, 0.2% FA, respectively. The 
column was thermostated at 50°C.
The analysis of the SB-I samples was achieved using the following temperature gradient: 
5 min at 110°C, then a linear increase to 180°C in 8 min where kept constant for another 5 
min. The system was cooled down and after a total runtime of 20 min, it was ready for the 
next injection. An isocratic solvent Aa was used with a flow-rate of 600 µL min−1.
MAPK inhibitor VIII samples were analysed with a temperature gradient starting from 
120°C for 5 min, followed by a linear increase in 5 min to 200°C where kept constant for 5 
min. An isocratic solvent composition of 15% MeOH 0.2% FA was used with a flow-rate of 
600 µL min−1.
Thermostability of the standards was assessed by determining the peak areas of the stand-
ards in a set of experiments where isocratic and isothermal elution was performed. With 
increasing the temperature up to 200°C, this experiment can indicate possible on-column 
degradation.
2.2.2. ICP-MS
An Agilent 7500c ICP-MS equipped with a collision/reaction cell (Agilent Technologies, Am-
stelveen, the Netherlands) was used for the ICP-MS analysis. Tuning of the instrument was 
done using direct infusion and pneumatic nebulisation of the analyte solution in the mobile 
phase corresponding to its isocratic elution parameters. The plasma parameters for Br and 
I detection were as follows: RF power 1600 W, RF Matching 1.72 V, Sample depth 6.0 mm, 
Torch horizontal positioning 0.2 mm and vertical 0.6 mm. The carrier gas was 0.82 L min−1 
and the makeup gas was set to 0.10 L min−1, both gases were argon with 5.0 purity. For the 
detection of SO+, the RF power was 1600 W, the RF matching 1.70 V, sample depth 12.0 
mm, torch horizontal and vertical position were set at −0.4 mm. The carrier gas was 0.90 
L min−1 and the makeup gas 0.20 L min−1. The optional gas (O2) was set at 5% and was 
added to the plasma. The transfer line between the HTLC oven and the inlet of the ICP-MS 
was 50 cm of PEEK tubing with an internal diameter of 0.005 in.
Results and discussion
Thermal degradation of the standards was not observed under the conditions used. In the 
supporting information (Supplementary Figure S2) the extracted ion chromatograms of 
SB-I (as an example) are shown under increasing temperatures while isocratic elution was 
performed. The calculated peak areas had a standard deviation of less than 5%, indicating 
that the compound was stable throughout the analysis.
3.1. Solvent effect on electrospray ionization
For the three standards, isoclozapine (C18H19ClN4, [M + H]
+ with m/z 327.1371), loxapine 
Figure 1: Schematic representation of the HTLC-MS setup with, (1) injector and gradient pumps, 
(2) solvent preheating compartment, (3) column heating block, (4) post column cooling unit and (5) 
ICP-MS or ESI-MS.
Fig. 2. Comparison of ESI-MS peak areas (arbitrary units) of standards with temperature
and organic solvent gradients.
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(C18H18ClN3O, [M + H]
+ with m/z 328.1211) and clothiapine (C18H18ClN3S, [M + H]
+ with m/z 
344.0983), a comparison was made between the peak area in ESI-MS using either a tem-
perature or a solvent gradient. When using a temperature gradient at 5% of organic modi-
fier, the peak areas for the standards were affected by the type of organic modifier (MeOH 
or ACN) to a very small extend, as can be seen in Figure 2. In the solvent gradient, the peak 
areas in MeOH were higher than those in ACN (24% for isoclozapine, 17% for loxapine and 
16% for clothiapine), which is somewhat to be expected because ACN is the stronger sol-
vent, making the analytes elute at a lower ACN than MeOH concentration in the gradient. 
The solvent effect on the ESI-MS response obviously is a bit of a disadvantage in HTLC, 
where only 5% of organic modifier is used. Especially loxapine and clothiapine, eluting at 
higher concentrations of organic modifier in the solvent gradient, show a factor of 1.9 and 
2.3, decreased ESI-MS peak areas in the temperature gradient (Figure 2), respectively. 
The chromatograms of using a temperature gradient and a solvent gradient with ACN can 
be found in the supporting information, Supplementary Figure S3. In practical applications, 
not only the peak area but also the signal-to-noise ratio (S/N) is important. In the total-ion 
chromatogram (TIC), there is not much difference in S/N for the three compounds, when 
comparing the solvent and the temperature gradient. In the extracted-ion chromatograms 
(EIC), the S/N in HTLC mode is slightly lower than the S/N of the solvent gradient. This is 
consistent with the difference in ESI-MS response between the two modes as described 
above.
3.2. Hyphenation of HTLC to ICP-MS
The detection limits of the ICP-MS for Cl+ (m/z 35), Br+ (m/z 79), S+ (m/z 32) and I+ (m/z 
127) were determined by flow injection in a 5% MeOH or ACN, 0.2% FA solution. Using 
optional gas flow, the detection of SO+ (m/z 48, LOD 18 µM) was found to be more sensi-
tive than that of S+ (227 µM). This is due to the occurrence of a polyatomic interference 
of O2
+ (m/z 31.9898) with S+ (m/z 31.9721), both having m/z 32 in the ICP-MS due to its 
limited resolution. Isoclozapine, loxapine and clothiapine were readily separated and de-
tected with the HTLC–ICP-MS method. The chlorine specific detection demonstrated the 
hyphenation of HTLC to ICP-MS, with an LOD of 128 µM. As can be seen in Figure 3, the 
chromatogram of m/z 35 of the HTLC–ICP-MS analysis of a 250 µM mixture of clothiapine 
(5), iso-clozapine (3) and loxapine (4) resulted in five peaks with an S/N ratio above 3.
Peak number 1 is due to polyatomic interference of 34S + H+ (m/z 35) resulting from the 
high percentage of DMSO in the sample, or to the breakthrough of 35Cl+. (The unit-mass 
resolution ICP-MS used in this study does not allow discrimination of these two.) Peak 2 is 
due to an impurity in the isoclozapine standard. HR-MS data indicate an [M + H]+ with m/z 
355.1325 and a monochlorine isotope pattern for this impurity. The molecular formula is 
C19H19ClN4O, corresponding to additional CO in the molecule. Unfortunately, in MS/MS of 
the impurity, only the loss of H2O is observed. Therefore, it is difficult to make a structure 
proposal. Peaks 3, 4, and 5 were identified based on the HR-MS data as isoclozapine, 
loxapine and clothiapine, respectively.
For bromine with m/z of 79, the detection limit in ICP-MS was 0.5 µM and iodine could be 
detected down to 80 nM. For iodine, a linear calibration plot was achieved in the range of 
80 nM–80 µM (y = 3.96e4 x + 2.17e3 with R2 0.9976), the experimental conditions of the 
HTLC part of this are described above in Section 2.2.1. The detection limits were not as 
low as reported by others [15], but are sufficiently low for the detection of metabolites and 
impurities present in the in vitro incubation samples. Moreover, the separation method dif-
fers significantly and our injection volumes are a factor of 2–10 smaller.
3.3. Profiling bromine containing MAPK inhibitor VIII products
The ESI-MSn fragmentation pattern of MAPK inhibitor VIII ([M + H]+ with m/z 415.0207, 
C20H17BrClN2O
+) in the IT-TOF was elucidated to facilitate the identification of its metabo-
lites. Figure 4a shows the ESI-MSn spectra and Figure 4b the proposed fragmentation 
pathway. MAPK inhibitor VIII contains both a chlorine and a bromine atom; the characteris-
tic isotopic pattern is observed in ESI-MS. This feature is useful for the search of structur-
ally related metabolites in the incubation mixture by e.g., software assisted isotope pattern 
recognition and isotope filtering strategies [23]. In this case, we used HTLC–ICP-MS to 
search for all bromine containing compounds in the metabolic incubations. Subsequently, 
these bromine containing metabolites were identified based on their MSn spectra in the 
ESI-MS measurements.
Two metabolites of MAPK inhibitor VIII were found in the P450 BM3 mutant incubation 
samples when analysed with HTLC–ICP-MS (Figure 5) and LC–ESI-MS. The accurate 
masses of these metabolites are in accordance with a hydroxylated substrate ([M + H]+ 
with m/z 431.0156, peak 2 in Figure 5) and a quinone-type structure ([M + H]+ with m/z 
444.9949, peak 1 in Figure 5). The fragmentation patterns of these metabolites indicate 
that the oxidations took place in the toluene substructure, present in MAPK inhibitor VIII. 
The singly oxygenated metabolite (peak 2) could be tentatively identified from a different 
fragmentation behaviour in MSn compared to the parent drug. It showed a loss of H2O in 
MS2 and subsequent loss of a bromine radical in MS3, and not the toluene loss observed 
for the parent drug. Therefore, we propose that hydroxylation occurred at the methyl group 
and the water loss involves a six-member ring formation between the bromo-phenyl group 
and the chlorine substituted benzene ring. The loss of a halogen radical from an aromatic 
systems is often observed in ESI-MS/MS experiments [24]. The other metabolite (peak 
1) shows a mass difference of 29.9731 u, which is consistent with the loss of H2 and the 
gain of O2 (29,9742 u), thus C20H15BrClN2O3
+. In MS2, this metabolite shows the fragment 
ion with m/z 296.9789, indicating the loss of the (modified) toluene ring. The most likely 
way to explain the observed changes in the toluene ring is by quinone formation [25]. This 
apparently results in an easier loss of the complete side chain (C8H4O3) with hydrogen re-
arrangement rather than the stepwise loss of toluene and CO, as observed for the parent 
compound. The HTLC–ICP-MS chromatogram showed an additional bromine containing 
compound in the sample (peak 3, Figure 5), and was found to be an impurity in the ana-
lytical standard (m/z 439.0192, proposed formula C22H17N2OClBr
+, 4.8 ppm error). The ac-
quired MS2 data allowed us to propose a structure for this impurity (Figure 5). The formation 
of a six membered ring by adding C=C to connect the secondary substituted amine with the 
primary amine fits the accurate mass and matches the fragmentation spectra. Peak 4 is the 
substrate, MAPK inhibitor VIII with m/z 415.0207. In the HTLC–ESI-MS chromatograms, 
we did not observe additional metabolites or impurities missing the characteristic bromine 
and/or chlorine isotope pattern of MAPK inhibitor VIII.
3.4. Analysis of iodine containing SB-I and conversion products
The major fragment in MS2 of SB-I (C21H17IN3OS
+, [M + H]+ with m/z 486.0132) in the IT-
Figure 3: HTLC-ICP-MS chromatogram for chlorine (m/z 35) in a 250 µM standard mix of iso-clozap-
ine, loxapine and clothiapine using 5% ACN 0.2% FA as mobile phase. (1) Polyatomic inference of 34S 
+ H; (2) chlorine containing impurity with m/z 355.1325; (3) isoclozapine; (4) loxapine; (5) clothiapine.
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TOF instrument is the loss of a methyl radical, resulting in the fragment with m/z 470.9894. 
Performing MS3 experiments on this radical cation produces a major fragment with m/z 
423.0227 corresponding to the loss of SO. In addition, a minor fragment with m/z 344.0843 
is observed due to the loss of an iodine radical. The limited fragmentation under these 
conditions indicates that unambiguous metabolite identification by MSn will not be readily 
possible. Incubation of SB-I with the P450 BM3 mutants M02, M11 V87A and with HLM 
resulted in the formation of several metabolites (see Figure 6). This figure may be used 
to assess the ease at which HTLC is implemented: ESI-MSn and ICP-MS were performed 
on different days and in two different laboratories (Amsterdam and Groningen). In order 
to achieve this, the HTLC part of the system was dismantled in the first and reinstalled 
in the second laboratory. Nevertheless, highly comparable chromatographic results were 
achieved (Figure 6).
MSn spectra obtained by HTLC–ESI-MSn analysis of the metabolites of SB-I, indicate oxi-
dation at the sulphur, oxidation of the dehalogenated SB-I (m/z 376.1144) and two more 
oxidation products (m/z 502.0088). S-oxidation has also been reported for the fluorine 
substituted analogue SB-203580 [26]. Dehalogenation of the standard (m/z 360.1181) was 
observed in all samples, including the controls and dilutions from a freshly prepared stock 
solution.
Peak 1 in the ICP-MS chromatogram (Figure 6) is observed in the enzyme blank and in 
the t = 0 control as well, indicating a background signal of the human liver microsomal 
matrix and is therefore not included in Table 1. Peak 2 in the ESI-MS chromatogram with 
m/z 360.1181 can be identified as the dehalogenated SB-I and is present as an impurity in 
all samples containing SB-I. Increased ESI-MS peak areas in the active incubations com-
pared to control experiments indicate that dehalogenation is catalysed by the P450s. Since 
iodine is no longer present in the structure, this compound is not detected in the ICP-MS 
analysis. The presence of sulphur provides an additional feature to quantify these metabo-
lites, although we were able to detect S+ and SO+, these detection limits were not sufficient-
ly low enough to be used for quantification of these low abundant metabolites. Peak 3 is a 
Figure 4: a) Full HR-ESI-MS, MS/MS and MS3 spectra on MAPK inhibitor VIII. b) Proposed fragmen-
tation pattern and fragment structures of MAPK inhibitor VIII.
Figure 5: HTLC-ICP-MS chromatogram (m/z 79, Br+) of the incubation sample having MAPK inhib-
itor VIII as substrate.
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metabolite present in all active enzymatic incubations but the P450 BM3 mutants produce 
significantly more of this oxidized dehalogenated metabolite (m/z 376.1136, see Table 1). 
The loss of a CH3SO2 radical indicates oxidation of the sulphur. There are two possible 
explanations for the formation of this metabolite, either oxidation of the dehalogenated 
impurity or the reductive dehalogenation of the main metabolite, the sulphonated SB-I. 
More interesting is peak 4, present in both ICP-MS and ESI-MS traces of the HLM incuba-
tion. This indicates the presence of iodine in the structure. The m/z value is in accordance 
with hydroxylation of the parent compound (m/z 502.0088). This metabolite is only found 
in the HLM incubations and not in the mutant ones. Peak 5 is the parent compound with 
m/z 486.0132. Based on the ESI-MS data, the main metabolite was found to be oxidized 
at the sulphur into a sulphone, peak number 6, as is indicated by the subsequent losses of 
a CH3 radical and SO2 in two stages of MS
n. This metabolite was found in all incubations, 
but at different concentrations (Table 1). In incubations with HLM and with the mutant M11 
V87A only, an additional oxidated product with m/z 502.0088 was found (peak 7). Given the 
fact that the retention time for this product is higher than that of the parent, the compound 
might be an N-oxide [27]. With the formation of this specific compound, the M11 V87A BM3 
mutant mimics the in vitro human metabolism the most.
3.5. Response comparison of ICP-MS and ESI-MS
Table 1 not only provides information on the concentrations of metabolites, based on the 
response in ICP-MS, but also enables a comparison of the response factor in ESI-MS and 
ICP-MS. For example, the metabolite peaks 6 and 7 have the same chemical formula and 
the oxygen incorporated by metabolism results in only a relatively small difference in the 
chemical structure. However, whereas the concentrations of these metabolites are very 
similar (0.75 µM peak 6 and 0.72 µM for peak 7), the response in ESI-MS differs by a fac-
tor of ~25. (25.5×106 for peak 6 and only 1.0×106 for peak 7). The ICP-MS is a normalized 
detector for specific elements and therefore not sensitive to the difference in structure of 
these two metabolites. Additionally, the results of comparing the same calibration samples 
measured on both instruments show the difference in linearity, especially with the higher 
concentrations of SB-I measured. Calibration curves were measured from 0 to 80 µM of 
SB-I. The LOD for SB-I with HTLC–ICP-MS was 80 nM while with ESI-MS the LOD was as 
low as 10 nM. The linear range of the ICP-MS was found to be from 80 nM up to 80 µM, 
while in HTLC–ESI-MS linearity was observed from 20 nM to 10 µM. This demonstrates 
the potential of over- and/or underestimating the concentration of a metabolite based on 
its response in a regular LC–ESI-MS run. In this case, the small structural changes in the 
molecule and the limited linear response in ESI-MS require complementary normalized 
detection methods to provide an accurate assessment of the concentrations present in the 
sample.
Next to incubations with enzymes, we apply electrochemical oxidation to generate oxida-
tion products of drugs. In some cases, several human relevant metabolites can be pro-
duced in this way [28]. This is a relatively clean method to produce oxidation products and 
therefore may support metabolite identification studies. We applied electrochemical oxida-
tion to the iodine containing SB-I and use this additional sample to illustrate the strength of 
hyphenating HTLC to ICP-MS. The electrochemical oxidation products were analysed in 
both ICP-MS and ESI-MS configuration. The total compound concentration in this sample 
was 5–10 times lower than in the enzymatic incubations since the optimum electrochemical 
conversion conditions were found to include a substrate concentration of only 10 µM (data 
will be published elsewhere). Figure 7 shows the ICP-MS trace of iodine and the UV chro-
matogram at 254 nm. Unfortunately, in ESI-MS only the substrate was found, indicating 
that the concentrations of the formed products were below their ESI-MS detection limits. 
The latter was verified using a conventional solvent gradient analysis. Nevertheless, the 
concentrations of the products could be determined by the HTLC–ICP-MS analysis (Table 
2). The electrochemical oxidation process converted more than 60% of the initial SB-I into 
six iodine containing products. The major product was formed at a concentration of 4 µM, 
Figure 6: Comparison of HTLC-ICP-MS chromatogram with m/z 127 (lower trace) and HTLC–ESI-
MS chromatogram with extracted ions of SB-I and HLM related products. (m/z 502.0088 5×
magnified). See Table 1 for peak areas and peak identification.
Table 1: Formation of SB-203580-Iodo related products by different enzymatic systems including 
ICP-MS and ESI-MS data. For chromatograms of the HLM incubation see Figure 6.
Peak 
nr
Rt 
(min)
Enzyme ICP-MS ESI-MS
Area Conc. in µM Area [M+H]+ Molecular 
formula
2 1.4 M02
M11 V87A
HLM
–
–
–
–
–
–
15693726
14731403
11823036
360.1181 C21H17N3OS
3 1.8 M02
M11 V87A
HLM
–
–
–
–
–
–
4046358
3843774
582953
376.1136 C21H17N3O2S
4 3.2 M02
M11 V87A
HLM
–
–
3999
–
–
<0.08 (0.05)
–
–
437422
502.0088 C21H16IN3O2S
5 7.7 M02
M11 V87A
HLM
917471
876649
746022
23.1
22.1
18.8
113167098
104141596
82157923
486.0132 C21H16IN3OS
6 8.4 M02
M11 V87A
HLM
31814
20698
17126
0.75
0.47
0.38
25544346
15789179
8225095
502.0086 C21H16IN3O2S
7 11.0 M02
M11 V87A
HLM
–
27128
30589
–
0.63
0.72
–
998657
1044683
502.0086 C21H16IN3O2S
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while other products were formed in concentrations of 1 µM or lower. 
In this particular case, the total concentration of all products and the parent drug was found 
to be the same as the total concentration of the parent drug before oxidation. This means 
that no dehalogenation occurred in the electrochemical oxidation and that all products 
detected contained iodine. If this would be the case with in vitro metabolism studies, mass 
balancing can be done which significantly contributes to the elucidation of the drug metabo-
lism and to the metabolic and pharmacokinetic profiling. Moreover, the data in Table 2 and 
Figure 7 also indicate that not only the ESI-MS response but also the molar extinction coef-
ficient may significantly change upon oxidation. For instance, peaks 4 and 5 show similar 
response in ICP-MS, whereas their response in UV is significantly different. Therefore, in 
this specific case, the assumption that conversion products have the same UV extinction 
coefficient cannot be made since it would significantly underestimate the concentrations of 
products formed by oxidation.
Conclusions
The combined use of temperature gradients and isocratic solvent compositions enabled 
the profiling and quantification of several oxidation products of SB-I and MAPK inhibitor 
VIII by means of ICP-MS. Information on structures of the metabolites was obtained by 
ESI-HR-MSn experiments. The detection of drug metabolites by normalized and selective 
detection of a halogen using ICP-MS provides valuable and complementary information 
on the analytes. Whenever the halogen remains incorporated within the metabolites, they 
are detected, can be quantified, and even mass balancing is possible. However, if oxida-
tive dehalogenation occurs, mass balancing approaches become more difficult, especially 
when more than one metabolite looses the halogen from its structure. Nevertheless, the 
hyphenation of HTLC to structure independent detection methods such as ICP-MS and 
ELSD can contribute to the toolbox of researchers for the quantification of drug metabolites 
and other drug related molecules, e.g., process impurities, degradation products. The im-
portance of these kinds of quantification strategies is stressed by the observation that the 
difference of the position of one oxygen atom in a structure can greatly affect its response 
in ESI-MS and UV detection. Whether the incorporation of this atom is by P450 metabo-
lism, electrochemical oxidation, photodegradation or any other process is irrelevant for the 
strategy presented in this paper.
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This thesis aims at exploring new applications of high-resolution screening (HRS). Therefore, 
our goal was to improve the corresponding platforms and extend their possibilities, mainly 
by further integration of chromatography, mass spectrometry, bioassays and especially 
innovative synthetic methods. We developed HRS platforms for two targets, p38α mitogen-
activated protein kinase (p38α) and soluble epoxide hydrolase (sEH), which were previously 
not accessible by HRS [Chapter 2]. Furthermore, by integrating four complementary 
modification methods with the p38α HRS platform, we achieved an efficient and integrated 
approach to generate and screen metabolite-like lead libraries, yielding structure-affinity 
relationships [Chapter 3]. We thoroughly analyzed the possibilities and limitations of 
structure elucidation of related substances by liquid chromatography–(ion trap–time-of-
flight) high-resolution mass spectrometry (LC–HR-MSn) within the framework of HRS on 
basis of the kinase inhibitor derived metabolite-like lead libraries [Chapter 4.1]. Finally, we 
peaked into the future of HRS which may feature miniaturized NMR for additional structure 
elucidation [Chapter 4.2] and/or inductively coupled plasma MS (ICP-MS) for absolute 
quantitation [Chapter 5] integrated directly into the HRS platform.
As far as the development of HRS bioassays is concerned, on the example of p38α, we 
demonstrated the first on-line post-column bioaffinity assay reported for any enzyme target 
and integrated it into an HRS platform [Chapter 2.2]. For the sEH HRS platform, we were 
mainly interested in making the possibilities of HRS for metabolism studies available to this 
novel target and therefore took a very classic approach [Chapter 2.3].
For the p38α HRS platform, we additionally introduced new solutions for the screening of 
highly lipophilic compounds. The use of fused silica capillaries demonstrates that there 
are still possibilities to improve upon current HRS bioassays technology, even in aspects 
that have been as extensively studied as post-column reactors. In this example, the 
enhanced peak shapes improve chromatographic resolution and dilution calculation. We 
achieved excellent performance of the p38α and the sEH HRS platforms. For the p38α 
HRS platform, this is indicated by excellent figures-of-merit, such as a Z’-factor of ca. 
0.8 and an S/N of up to 100, and an affinity ranking in accordance with literature values. 
Unfortunately, the only tested compound of which affinity data on non-phosphorylated 
p38α was available (BIRB796), showed unconventionally slow binding kinetics, rendering 
a quantitative comparison of the IC50 values for validation purposes impossible, due to the 
limited incubation times achievable in HRS. Nonetheless, its affinity was detected as were 
those of representative compounds of all three types of ATP-competitive binding. 
The sEH HRS platform featured an S/N>60, though quality would have certainly profited 
from using state-of-the-art chromatographic equipment. We could very reliably match affinity 
and small-molecule structure and even tackle isobaric and many isomeric compounds. 
This holds for both HRS platforms, but was more extensively demonstrated for p38α 
[Chapter 2.2, Chapter 3] than for sEH [Chapter 2.3]. The clear advantages of HRS over 
HTS with respect to the bioassay level are exemplified by a decreased p38α concentration 
and a similar sEH concentration at significantly reduced incubation time. Obviously, the 
ability to analyze mixtures is an important advantage of HRS over HTS as well.
For both HRS platforms, we successfully tackled issues with enzyme stability. In addition, 
for the sEH HRS platform, we overcame issues with low substrate solubility. Furthermore, 
during the development and the HRS campaigns [Chapter 2, Chapter 3], we observed a 
number of interferences which are clearly visualized by the HRS bioassays. Examples are 
the auto-fluorescence and peak tailing in the p38α HRS platform, which interfere with the 
IC50 measurements [Chapter 2.2, Chapter 3.2], and to some extend the precipitation issues 
during the development of the sEH HRS bioassay [Chapter 2.3]. While the visualization 
of interferences might be seen as a disadvantage, we believe that it in fact is infinitely 
preferable to spot and address these issues than to put confidence in faulty data. Therefore, 
we regard the ability of the HRS platform to resolve interferences as one of the major 
strength of this approach.
There are several interesting directions in which both the p38α and the sEH HRS platform 
may be further developed. Parallel bioassays (two or even multiple), similar to the one 
developed for the estrogen receptors α and β [1], for binding selectivity analysis should 
be mentioned in this context. These could be applied to investigate selectivity over close 
family members or generally problematic off-targets. For example, in the case of p38α, 
the closely related kinases JNK-1, JNK-2 and JNK-3 could be simultaneously monitored 
for selectivity during lead optimization [2]. Additionally, detection of selectivity for the 
different p38 isoforms might lead to molecular probes which could be used to investigate 
the biological role of p38β, γ and δ in more detail [3]. Concerning off-targets, the increasing 
interest in the novel concept of translational research may lead to the exploitation of the 
large body of knowledge on p38 inhibitors in future drug discovery campaigns. For example, 
the suspected off-target interactions, related to certain side effects observed in the clinic, 
might be included in selectivity studies. 
In any case, next to selectivity detection, future developments of HRS bioassays lie in 
miniaturization, because the reduction in both reagent consumption and sample volume 
has important advantages [4]. Using less target protein helps to control the cost of HRS and 
thus improves its competitive position versus HTS. Enhanced mass sensitivity, possibly in 
combination with pre-concentration through the integration of on-line SPE, might finally 
allow HRS analysis of clinical samples in the future.
We further advanced integration in HRS platforms, synthesizing metabolite-like lead libraries 
and analyzing them for structure and affinity in one platform or even in one hyphenated 
system. Combining synthesis and analysis in one workflow resulted in an efficient exploration 
of neglected chemical space around a substrate scaffold, consequently yielding structure-
activity relationships with the input of no more than the substrates. These substrates 
were important p38α inhibitors, including a lead (DMPIP), a widely used molecular probe 
(SB203580) and clinical candidates (BIRB796and TAK-715). As we focused on metabolite-
like lead libraries, it seemed prudent to additionally investigate, whether the platforms would 
be useful in selecting production strategies for actual metabolites. To this end, we included 
in vitro metabolism by human liver microsomes (HLM) into the method comparison.
The electrochemical conversion (EC) HRS platform was certainly the most interesting 
integrated synthesis approach from an analytical point of view [Chapter 3.1]. The EC setup 
employed had already been successfully used in EC–MS and EC–LC–MS setups and 
required no intermediate sample pre-treatment step. Therefore, a completely integrated 
EC–LC–p38α binding/MS platform was achieved. This proved to be especially useful for 
the detection of reactive EC products [Chapter 3.1] which were also (partly) observed later 
in human liver microsomal incubations [Chapter 3.3].
The electrophilic reactivity of the observed quinoneimine also offers the possibility for a 
new synthetic approach. A pre-column incubation step with a mixture of nucleophiles could 
be integrated into the EC–HRS platform, allowing the production of extensive lead libraries 
with a broad chemical diversity in a rapid and automated fashion as well as the direct 
analysis of the reaction mixtures in the same system. Especially interesting might be the 
integration of a second electrochemical (detection) step between column and MS which 
would serve to probe the redox stability of the new compounds. Through this approach, it 
might be possible to find leads with a reduced tendency to form reactive products [5]. This 
is especially interesting, if adverse effects caused by reactive metabolites are known or 
anticipated. The general approach of EC–HRS might also be interesting in stages of drug 
discovery other than lead optimization. When fitting an EC–HRS platform with a bioassay 
for a notorious off-target, such as hERG [6], it could be very useful as a rapid metabolic 
alert screening. Though EC is not a complete mimic of human metabolism, redox weak 
spots and the toxicological consequences of the associated modifications may be identified 
early on in drug discovery.
The use of biocatalysts to generate metabolite-like lead libraries proved very successful 
as well. The library of Cytochrome P450 BM3 (BM3) mutants applied produced a number 
of conversion products. The products showed increased hydrophilicity and one of them 
even retained full p38α affinity [Chapter 3.2]. Because large parts of the BM3 mutant library 
were “humanized”, a significant overlap with products from HLM incubation was found. The 
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fact that, through up-scaling and purification, IC50 determination and NMR measurements 
were enabled, greatly enhanced the detail of information obtained. In addition, we thereby 
demonstrated how the initial results of the HRS platform can be used to guide further 
structural and pharmacological investigation of promising conversion products.
Subsequently, we compared the EC and the biocatalytic approach to chemically (H2O2) and 
photochemically (visible light) induced transformations [Chapter 3.3]. H2O2 was very good 
in making many different, more hydrophilic products, e.g., numerous oxygenated isomers. 
Photochemical conversion showed some unique products and can induce isomerism in 
the core structure, which may result in novel pharmacophores. One consequence of that 
isomerism is a more limited success in structure elucidation by MS [Chapter 4.1].
In comparison, all methods have their specific profile of strength and weaknesses. For 
example, biocatalysis and H2O2 are most successful in increasing hydrophilicity. While 
biocatalysis is the most laborious method, but can also be the most selective, H2O2 is 
very straightforward but often produces the most (isomeric) products. Photochemistry and 
EC do not favor increased hydrophilicity in the products, but photochemistry yields the 
most unique products. However, the EC–HRS platform is very favorable for the analysis of 
reactive products, due to its direct analysis capabilities.
In conclusion, all conversion methods are highly complementary and thus together present 
an interesting toolbox for the generation of metabolite-like lead libraries. We could show the 
impressive value of integrating synthesis of mixtures into the HRS strategy. The p38α HRS 
platform rapidly delivered an initial structure-activity relationship for the lead libraries and 
can be considered as a solid starting point for further pharmacological and toxicological 
investigation.
Next to producing lead libraries with favorable properties, perhaps unsurprisingly, 
especially the biocatalytic and the chemical approach showed potential for the synthesis 
of metabolite standards. The novelty is that the implementation of the HRS platform allows 
a focus on active metabolites for further evaluation while at the same time still providing a 
comprehensive overview. Again, this might also be an interesting application for off-target 
HRS bioassays. 
However, the biocatalytic and the chemical approach will require different strategies 
for metabolite standard production. By mutation, a biocatalyst can be generated which 
exclusively or predominantly produces one metabolite that is then easily purified. The 
strategy for H2O2 will rely on simultaneous purification of all (major) products, as conversion 
is undirected (high number of isomers) and there is little opportunity to tune the product 
profile. However, this will also provide standards which would be ignored in a focused 
approach, but might still be useful, for example when metabolites are detected in human 
that have not been predicted in in vitro or animal models.
Being an integral part of the HRS platforms, we closely investigated the possibilities and 
challenges of structure elucidation by LC–HR-MSn under the special circumstances of 
a (HRS) screening paradigm [Chapter 4.1]. The resulting restrictions include the use of 
“generic” settings for the ionization and fragmentation experiments as well as prohibiting 
the use of elaborate MS experiments like stable isotope labeling and H/D-exchange 
experiments. Nonetheless, the attribution of modifications to specific parts of the molecule 
is often successful and in special cases allows absolute structure elucidation, for example 
for CP472, a conversion product of DMPIP in the EC experiments [Chapter 3.1]. 
The sometimes drastic changes in fragmentation initiated by comparatively minor 
modifications and unexpected intra-molecular rearrangements presented challenges in the 
LC–HR-MSn structure elucidation. These rearrangements were also interesting examples 
of gas-phase chemistry, such as the electrocyclic rearrangement in the fragmentation of 
TAK-715, the rearrangement underlying the formation of CP305 (or its fragmentation) 
from SB203580, the hydride rearrangement leading to water elimination from the aromatic 
hydroxymethyl group in CP416A (derived from TAK-715), and the rearrangement of the 
whole para-fluoro-benzyl group in DMPIP. Additionally, we detected an unexpectedly high 
number of homolytic cleavages in violation of the even-electron rule. In the process, we 
showed, using ion-trap fragmentation in combination with HR-MS readout by time-of-flight, 
the value of clearly assigning precursor-product ion relationships for structure elucidation 
[Chapter 4.1].
Next to the HR-MSn structure elucidation, we pursued an intriguing possibility to incorporate 
NMR structure elucidation into an HRS platform in the future [Chapter 4.2]. As starting 
points, we took the reactive products of BIRB796 discovered in the EC–HRS platform 
[Chapter 3.1]. We set out to elucidate their structure by NMR. The logical choice for an 
approach that can be integrated with HRS was a miniaturized flow probe NMR in order to 
match the small sample volume and the flow-through EC system. 
In the end, we combined an up-scaled electrode, an SPE step for pre-concentration 
and solvent exchange, and a stripline-NMR chip probe equipped to a 600 MHz NMR 
instrument. The system was well suited for the detection of the BIRB796 standard, and the 
solvent exchange was efficient enough to be able to compare the EC–SPE–stripline-NMR 
results to conventional (2D-)1H-NMR. Unfortunately, the conversion rate of BIRB796 to its 
two reactive products was significantly lower than in the off-line experiments. Therefore, 
identification of the products could only be achieved by comparison with the conventional 
1H-NMR spectra, instead of by the desired independent structure elucidation. However, 
the platform showed promising results and there are numerous possibilities to close the 
existing sensitivity gap in order to allow direct integration into the HRS platform. 
Integrated LC–MS/NMR platforms are already used in pharmaceutical and other applications 
[7,8]. As combined MS and NMR structure elucidation is crucial in HRS applications as 
well [1], HRS platforms featuring this combined structure elucidation power are certainly a 
worthwhile aim.
A major enhancement of the possibilities and a major step towards a wider applicability 
of HRS is the integration of absolute quantitation into HRS platforms. For example, this 
may enable a quantitative structure-activity relationship (QSAR) directly from mixtures 
generated by the described modification methods. A simple injection of a dilution series of 
the mixture might suffice in order to obtain IC50 curves. Mainly due to the lack of standards, 
detection techniques focused on atoms rather than on molecules will be the methods of 
choice when dealing with unknown compounds. Detection techniques like MS or UV/VIS, 
which focus on molecular properties, show a large variation in response, depending on 
the molecular structure. While the response also shows large variation between different 
atoms when atomic properties are detected, it is relatively easy to find a common atom in 
many different organic molecules.
One atom property based method, which was already discussed, is NMR. However, NMR 
is influenced by the chemical environment of the detected atom which has consequences 
for the response. Fortunately, these are much less pronounced than in molecular property 
based detection techniques and can be minimized by careful consideration of experimental 
parameters such as relaxation time. The real issue with NMR is its currently inadequate 
sensitivity. Yet, if this hurdle can be overcome, NMR promises quantitation and additional 
structure information at the same time.
ICP-MS is much more sensitive and its response is virtually independent of the chemical 
environment, due to the constant atomic ionization efficiency and the huge difference 
between molecular bond energy and the atomic ionization energy [9]. Unfortunately, the 
main elements of organic molecules, hydrogen, carbon, oxygen, and nitrogen, cannot be 
targeted by LC–ICP-MS for various reasons. However, many pharmaceuticals contain a 
halogen and/or sulfur atom and there are even examples containing metal atoms. While we 
measured bromine and iodine very sensitively by ICP-MS, this was not the case for sulfur 
and chlorine [Chapter 5]. The observed isobaric polyatomic interferences may be resolved 
using reaction/collision cells or an ICP-HR-MS instrument [9]. This might allow sensitive 
quantification of sulfur or chlorine containing molecules, where detection limits with unit 
mass resolution ICP-MS were a factor of 30 or 200, respectively, short of HRS compatible 
quantitation [Chapter 5]. ICP-MS relies on stable solvent conditions and is therefore not 
compatible with classic solvent gradients [10]. High-temperature LC (HTLC) presents an 
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elegant way to achieve efficient separation at isocratic solvent conditions [Chapter 5]. HTLC 
is not only interesting for ICP-MS compatibility, but may also present a solution to reduce 
the organic modifier influence on post-column bioassays. Though the ESI-MS response is 
decreased at low organic modifier concentrations, the high sensitivity of ESI-MS usually 
allows a favorable compromise.
In its application to drug discovery and related fields, we have demonstrated many 
strengths and possibilities of HRS and encountered some of its limitations. However, the 
role HRS platforms will play in the future depends on many factors. At the moment, the 
development status of HRS platforms limits their application to niches where separation 
of complex mixtures is a key element, for example screening of natural product libraries 
[11,12]. The specific niche will determine the HRS platform’s outward appearance, e.g., 
whether pre-column affinity selection or post-column bioassays are employed, or whether 
on-line or at-line hyphenation is favored [Chapter 1.1.2]. Miniaturization may present a 
way to reduce HRS cost [4] and thus enhance its commercial competitive position versus 
HTS. However, knowledge presents a much greater hurdle towards the implementation of 
HRS platforms. Currently, a user has to be trained in all analytical and pharmacological 
disciplines related to the HRS platform. This will only change, if commercial solutions for 
robust and fully integrated systems as well as automated data analysis tools become 
available in the future. For HRS to be recognized as a real alternative in pharmaceutical 
screening and to create a demand for these solutions in the first place, next to maturity 
and user friendliness, one hurdle is potentially all-important. HRS does not smoothly fit the 
high-throughput batch approach dominating contemporary pharmaceutical industry and is 
thus very rarely seriously considered. However, this may very well change in the not so 
far future. The pharmaceutical industry is under great pressure to critically evaluate their 
R&D strategies and present more viable alternatives [13,14]. More flexible, quality-focused 
drug discovery campaigns and an increasing interest in flow chemistry as alternative to 
batch approaches may make HRS platforms an attractive tool. Flow chemistry might be 
integrated as demonstrated in the EC–HRS platform [Chapter 3.1] or with an intermediate 
on-line SPE step. With appropriate flow splitting and at substantially decreased cost, HRS 
might also be useful beyond discovery, for example for monitoring up-scaling or even for 
quality control of active pharmaceutical ingredient production based on the (side) effect 
rather than molecular composition. Thus, the “ideal” HRS platform of the future consists 
of a (multiple) modification method(s), state-of-the-art (multidimensional) separation, 
multiple bioassays for selectivity analysis, two independent structure analysis techniques 
like ESI-HR-MS (including MS/MS or MSn capabilities) and NMR, and two independent 
quantitation techniques such as ICP-MS and NMR, operates at micro- or even (partly) 
nano-scale, and can be used by scientists with diverse backgrounds. Applications might 
include fully automated quantitative structure-activity relationship studies and, without a 
modification method, the quantitative elucidation of the pharmacokinetic contributions of all 
pharmacologically or toxicologically relevant metabolites for metabolic profiling.
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Hoge-resolutie screening  
voor metaboliet-gerelateerde lead-bibliotheken
In dit proefschrift worden nieuwe applicaties van hoge-resolutie screening (HRS) onder-
zocht. Daarvoor streefden wij naar verbetering van bestaande systemen en verbreding van 
hun mogelijkheden. Hierbij hoorden geavanceerde integratie van chromatografie, mas-
saspectrometrie, bioassays en in het bijzonder innovatieve synthetische methodes. Wij 
ontwikkelden nieuwe HRS systemen voor twee doelproteïnen, p38α mitogen-geactiveerd 
proteïne kinase (p38α) en soluble epoxide hydrolase (sEH) [Hoofdstuk 2]. Verder bereikten 
wij een efficiënte en geïntegreerde aanpak voor het genereren en screenen van metabo-
liet-gerelateerde lead-bibliotheken, door integratie van vier complementaire modificatieme-
thodes met het p38α HRS systeem, welke uiteindelijk resulteerden in structuur-affiniteits-
relaties [Hoofdstuk 3]. Wij analyseerden grondig de mogelijkheden en beperkingen van 
structuuropheldering van gerelateerde stoffen met behulp van vloeistofchromatografie–
(ion-trap–time-of-flight) hoge-resolutie massaspectrometrie (LC–HR–MSn) in relatie met 
HRS gebaseerd op de metaboliet-gerelateerde lead-bibliotheken van de kinase remmers 
[Chapter 4.1]. Uiteindelijk waagden wij een poging om de (mogelijke) toekomst van HRS 
te exploreren. Deze zou mogelijk bestaan in integreren in het HRS systeem van gemini-
aturiseerde kernspinresonantie spectroscopie (NMR) voor verdere structuuropheldering 
[Hoofdstuk 4.2] en/of inductief-gekoppelde plasma MS (ICP-MS) voor absolute kwantifice-
ring [Hoofdstuk 5].
Het p38α systeem is het eerste on-line post-column bioaffiniteitsassay systeem voor een 
enzym, een belangrijke stap in de ontwikkeling van HRS bioassays [Hoofdstuk 2.2]. Bij 
het sEH HRS systeem waren wij voornamelijk geïnteresseerd in het toegankelijk maken 
van de mogelijkheden van HRS in metabolismestudies voor dit doelenzym en hebben we 
daarom voor een klassieke benadering gekozen [Hoofdstuk 2.3].
In het p38α HRS systeem hebben wij bovendien nieuwe oplossingen voor het screenen 
van zeer lipofiele stoffen geïntroduceerd. Het gebruik van fused-silica capillairen laat zien 
dat er nog steeds mogelijkheden zijn om de HRS bioassay technologie te verbeteren, 
zelfs in zo veelvuldig bestudeerde aspecten als post-kolom reactoren. In dit geval resul-
teerde de betere piekvorm in een betere chromatografische resolutie en nauwkeurigere 
verdunningsberekeningen. Wij bereikten uitstekende prestaties van zowel het p38α als het 
sEH HRS systeem. Voor het p38α HRS systeem blijkt dit uit uitstekende kengetallen zoals 
een Z‘-factor van rond 0.8 en een signaal/ruis verhouding (S/N) van 100. Verder kwam 
de gemeten affiniteitsranking overeen met de literatuurwaarden. Helaas toonde de enige 
teststof waarvoor affiniteitsdata op niet-phosphoryleerde p38α beschikbaar zijn (BIRB796) 
een buitengewoon langzaam kinetiek. Dat voorkwam een kwantitatieve vergelijking van 
de IC50 waarden voor validatiedoeleinden omdat vanwege de beperkte incubatietijden in 
HRS het evenwicht niet bereikt werd. Toch kon de affiniteit van BIRB796 en die van andere 
representatieve stoffen van alle drie types van ATP-competitieve binding gemeten worden.
Het sEH HRS systeem toonde een S/N van boven de 60 maar de kwaliteit zou veel beter 
zijn geweest als er modernere chromatografische apparaten waren gebruikt. Wij konden 
zeer betrouwbaar de affiniteit en de moleculestructuur combineren en daardoor zelfs iso-
bare en vele isomere componenten onderscheiden. Dit was in beide HRS systemen reali-
seerbaar maar kon in het p38α systeem [Hoofdstuk 2.2, Hoofdstuk 3] nog duidelijker wor-
den aangetoond dan in het sEH systeem [Hoofdstuk 2.3]. De duidelijke voordelen van HRS 
ten opzichte van hoge-doorvoer screening (HTS) met betrekking tot het bioassay gedeelte 
worden onder ander duidelijk in de lagere p38α concentratie en de vergelijkbare sEH con-
centratie ondanks de significant gereduceerde incubatietijd. De mogelijkheid om mengsels 
te analyseren is overduidelijk ook een belangrijke voordeel van HRS ten opzichte van HTS.
Verder hebben wij voor beide systemen enzymstabiliteitgerelateerde problemen opgelost 
en een oplossing gevonden voor de substraatoplosbaarheidsproblemen die bij het sEH 
systeem speelden. Ook hebben wij bij het opzetten van en tijdens de HRS experimenten 
[Hoofdstuk 2, Hoofdstuk 3] een aantal verstoringen gezien welke juist duidelijker zichtbaar 
waren in de HRS bioassays. Voorbeelden zijn de auto-fluorescentie en het peak tailing in 
het p38α HRS bioassay, welke de IC50 metingen verstoren [Hoofdstuk 2.2, Hoofdstuk 3.2], 
en gedeeltelijk de neerslagproblemen tijdens de ontwikkeling van het sEH HRS bioassay 
[Hoofdstuk 2.3]. De zichtbaarheid van de verstoringen zou als een nadeel aangemerkt kun-
nen worden, maar wij geven sterk de voorkeur aan het visualiseren en rekening houden 
met dit soort verstoringen boven het vertrouwen op onjuiste gegevens. Daarom zien wij het 
zichtbaar maken van verstoringen door het HRS systeem als een van zijn grote voordelen.
Een andere belangrijke ontwikkelingsstap is de integratie in HRS systemen van methoden 
voor de synthese van metaboliet-gerelateerde lead-bibliotheken, waarmee we zowel de 
synthese als de analyse van structuur en affiniteit in één aanpak of zelfs in een geheel 
geïntegreerd systeem realiseren. Dit resulteerde in een efficiëntere bestudering van de 
chemische ruimte rond een substraatkernstructuur, met als eindpunt een structuur-affini-
teitsrelatie met niet meer dan het substraat als inbreng. De substraten waren belangrijke 
p38α remmers, waaronder een lead-verbinding (DMPIP), een veelgebruikte moleculaire 
sonde (SB203580) en klinische kandidaat moleculen (BIRB796 en TAK-715). Omdat wij 
gefocusseerd waren op metaboliet-gerelateerde lead-bibliotheken, hebben wij ook uitge-
zocht of de synthesesystemen geschikt waren als productiestrategieën voor daadwerke-
lijke metabolieten. Daarom hebben wij ook in vitro metabolisme met behulp van humane 
lever mikrosomen (HLM) in de methodenvergelijking opgenomen.
Het elektrochemische omzetting (EC) HRS systeem was analytisch gezien zeker de mee-
st interessante geïntegreerde synthese-aanpak [Hoofdstuk 3.1]. Het EC apparaat was al 
succesvol ingezet bij EC–MS en EC–LC–MS systemen en vereiste geen intermediaire 
monsterbewerkingsstappen. Daardoor kon een volledig geïntegreerde EC–LC–p38α bin-
ding/MS systeem worden opgezet. Dit bleek bijzonder nuttig bij de detectie van reactieve 
EC producten [Hoofdstuk 3.1] welke (deels) ook later in de HLM incubaties teruggevonden 
worden [Hoofdstuk 3.3].
Het gebruik van biokatalyse voor het genereren van metaboliet-gerelateerde lead-biblio-
theken bleek ook heel succesvol te zijn. De gebruikte bibliotheek van Cytochrome P450 
BM3 (BM3) mutanten produceerde een aantal omzettingsproducten. Deze producten toon-
den verhoogde hydrofiliciteit en één ervan behield zelfs de volle p38α affiniteit [Hoofdstuk 
3.2]. Omdat grote delen van de BM3 bibliotheek ‘gehumaniseerd’ waren, was er een signi-
ficante overlap met producten van de HLM incubaties. Het feit dat wij door schaalvergroting 
en opzuivering ook IC50 waardes konden bepalen en NMR metingen konden uitvoeren 
heeft de informatiediepte duidelijk verhoogd. Verder hebben wij daardoor kunnen aantonen 
hoe de aanvankelijke resultaten van het HRS systeem kunnen worden gebruikt om verdere 
structuuropheldering en farmacologisch onderzoek van veelbelovende omzettingsproduc-
ten te sturen.
Vervolgens vergeleken wij de EC en de biokatalytische aanpak met chemisch (H2O2) of fo-
tochemisch (zichtbaar licht) induceerde omzettingen [Hoofdstuk 3.3]. H2O2 bleek zeer goed 
in staat om veel verschillende en meer hydrofiele producten te maken, bijvoorbeeld een 
grote aantal geoxydeerde isomeren. Fotochemische omzetting resulteerde in enige unieke 
producten en induceerde isomerie in de kernstructuur, wat mogelijk tot nieuwe farmacofo-
ren zou kunnen leiden. Een consequentie van isomerie is het wat beperktere succes in MS 
structuuropheldering [Hoofdstuk 4.1].
Iedere gebruikte synthesemethode heeft haar eigen profiel van sterke punten en beper-
kingen. Biokatalyse en H2O2 zijn bijvoorbeeld het meest succesvol in het verhogen van hy-
drofiliciteit. Terwijl biokatalyse de meest arbeidsintensieve methode is, maar ook de meest 
selectieve, is H2O2 zeer eenvoudig te gebruiken, maar produceert het vaak ook de meeste 
(isomere) producten. Fotochemie en EC hebben geen voorkeur voor hogere hydrofiliciteit 
in de producten, maar fotochemie levert de meeste unieke producten. Aan de andere kant 
is het EC–HRS systeem vanwege zijn directe analysemogelijkheden zeer krachtig voor de 
analyse van reactieve producten.
Wij concluderen dat alle omzettingsmethoden zeer complementair zijn en dus samen een 
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interessante verzameling vormen voor het genereren van metaboliet-gerelateerde lead-bi-
bliotheken. Zo waren wij in staat om de meerwaarde van de integratie van de synthese van 
mengsels met het HRS strategie te demonstreren. Het p38α systeem leverde in korte tijd 
een initiele structuur-affiniteitsrelatie voor de lead-bibliotheken op en kan als een solide 
startpunt voor verder farmacologisch en toxicologisch onderzoek gezien worden.
Naast het produceren van lead-bibliotheken met gunstige eigenschappen hebben, mis-
schien niet onverwacht, vooral de biokatalytische en de chemische aanpak potentieel voor 
de synthese van metabolietstandaarden getoond. De innovatie ligt hierbij vooral in de mo-
gelijkheid om zich voor gedetailleerd onderzoek op actieve metabolieten te focusseren en 
toch tegelijkertijd een breder overzicht te verwerven.
Omdat het een integraal bestanddeel van het HRS systeem is, hebben wij in meer detail 
naar mogelijkheden en beperkingen van structuuropheldering met behulp van LC–HR-MSn 
gekeken, zoals die in de bijzondere omstandigheden van een (HRS) screeningsomgeving 
optreden [Hoofdstuk 4.1]. De bijhorende beperkingen omvatten het gebruik van ‘generieke’ 
parameters voor ionisatie- en fragmentatie-experimenten en verhinderen van ingewikkelde 
MS experimenten zoals stabiele-isotooplabeling en H/D-uitwisseling. Niettemin was het 
relateren van modificatieposities naar specifieke delen van de moleculen vaak succesvol 
en kon in speciale gevallen zelfs de absolute structuur opgehelderd worden, bijvoorbeeld 
voor CP472, een omzettingsproduct van DMPIP in de EC experimenten [Hoofdstuk 3.1].
De soms drastische veranderingen in fragmentatie als gevolg van relatief kleine modifica-
ties en onverwachte intra-moleculaire omleggingen waren uitdagingen in de LC–HR-MSn 
structuuropheldering. Deze omleggingen waren tegelijkertijd interessante voorbeelden 
van gasfase-chemie, bijvoorbeeld de elektrocyclische omlegging in de fragmentatie van 
TAK-715, de omlegging voorgaande aan de vorming van CP305 (of zijn fragmentatie) uit 
SB203580, de hydride-omlegging met als gevolg watereliminatie vanuit de aromatische 
hydroxymethyl groep in CP416A (afkomstig van TAK-715), en de omlegging van de hele 
para-fluoro-benzyl groep in DMPIP. Bovendien detecteerden wij een onverwacht groot 
aantal homolytische breukreacties welke in strijd zijn met de even-elektron regel. Daarbij 
hebben wij, door gebruik te maken van de ion-trap fragmentatie in combinatie met time-of-
flight HR-MS detectie, het belang van een heldere relatie tussen precursor ion en product 
ionen voor structuuropheldering aangetoond [Hoofdstuk 4.1]. 
Naast de HR-MSn structuuropheldering verkenden wij een veelbelovende mogelijkheid om 
in de toekomst structuuropheldering met behulp van NMR te integreren met het HRS sys-
teem [Hoofdstuk 4.2]. Hierbij stonden de reactieve producten van BIRB796 centraal die 
in het EC–HRS systeem ontdekt werden [Hoofdstuk 3.1]. Hun structuur wilden wij met 
behulp van NMR ophelderen. De logische aanpak gericht op integratie met HRS zou een 
miniaturiseerde flow-sonde NMR kunnen zijn, waarmee de kleine monstervolumes en een 
doorstroom-EC-apparaat goed te combineren zijn. Uiteindelijk gebruikten wij een vergrote 
werkelektrode en een vaste-fase extractie (SPE) stap ten behoeve van voorconcentratie 
en oplosmiddeluitwisseling in combinatie met een stripline-NMR chip sonde en een 600 
MHz NMR instrument. Het systeem was goed geschikt om de BIRB796 standaard te detec-
teren. De oplosmiddeluitwisseling was efficiënt genoeg om een vergelijking van EC–SPE–
stripline-NMR resultaten en conventioneel (2D-)1H-NMR mogelijk te maken. Helaas was de 
omzettingsgraad van BIRB796 naar zijn twee reactieve producten in de on-line experimen-
ten duidelijk lager dan in de off-line experimenten. Daardoor was productidentificatie alleen 
mogelijk door het vergelijken met de conventionele 1H-NMR spectra in plaats van door de 
bedoelde onafhankelijke structuuropheldering. Toch liet het systeem veelbelovende resul-
taten zien en zijn er ook vele mogelijkheden om de bestaande gevoeligheid te verbeteren 
en zo een directe integratie met het HRS systeem te bereiken. 
Een grote stap voorwaarts in HRS zou de mogelijkheid zijn om absolute kwantificering 
van gemeten componenten in een HRS systeem te integreren. Dan zou bijvoorbeeld een 
kwantitatieve structuur-affiniteitsrelatie (QSAR) gemaakt kunnen worden direct op basis 
van het mengsel gesynthetiseerd met de beschreven omzettingsmethoden. ICP-MS biedt 
zich hiervoor aan omdat het heel gevoelig kan zijn en zijn respons vrijwel volledig onafhan-
kelijk is van de chemische omgeving van een atoomkern, vanwege de constant atomaire 
ionisatie en de grote verschillen tussen moleculaire bindingsenergie en atomaire ionisa-
tie-efficiëntie. Helaas kunnen de hoofdbestanddelen van organische moleculen (water-
stof, koolstof, zuurstof en stikstof) om verschillende redenen niet met LC–ICP-MS worden 
gemeten. Maar veel medicijnen bevatten halogeen- en/of zwavelatomen en er zijn zelfs 
voorbeelden welke metaalatomen bevatten. Broom en jodium konden zeer gevoelig met 
ICP-MS worden gemeten, maar dat was niet het geval bij zwavel en chloor [Hoofdstuk 5]. 
De waargenomen isobare polyatomaire verstoringen zouden met reactie/botsingscellen of 
ICP-HR-MS instrumenten kunnen worden voorkomen. Daardoor zou gevoelige kwantifice-
ring van zwavel en/of chloor bevattende verbindingen mogelijk kunnen worden. Tot nu toe 
waren de detektielimieten op het lage-resolutie ICP-MS 30 respectievelijk 200 keer te laag 
om een met HRS verenigbare kwantificering te leveren [Hoofdstuk 5]. ICP-MS is gebaseerd 
op een gelijkmatige stroom van oplosmiddel en is daarom niet geschikt om met klassieke 
oplosmiddelgradiënten gecombineerd te worden. Hoge-temperatuur LC (HTLC) biedt een 
elegante mogelijkheid om een efficiente scheiding bij constante oplosmiddelsamenstelling 
te realiseren [Hoofdstuk 5]. Daarbij is HTLC niet alleen in verband met ICP-MS interessant, 
maar het kan ook een oplossing zijn om de invloed van de oplosmiddelgradiënt in een 
post-kolom bioassay te beperken. Ook hebben lage organische oplosmiddelconcentraties 
een negatieve invloed op de ESI-MS respons, maar maakt de hoge gevoeligheid van ESI-
MS toch meestal een aantrekkelijk compromis mogelijk.
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